10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-07434

Aflac Incorporated

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Georgia			58-1167100
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
1932 Wynnton Road	Columbus,	Georgia	31999
(Address of principal executive offices)			(ZIP Code)

706.323.3431

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.10 par value per share	AFL	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  þ  Yes  ¨  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).            þ  Yes  ¨  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	þ	Accelerated filer	☐
Non-accelerated filer	¨	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes  þ  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 568,222,447 shares of the issuer's common stock were outstanding as of April 24, 2024.

Aflac Incorporated and Subsidiaries

Quarterly Report on Form 10-Q

For the Quarter Ended March 31, 2024

Table of Contents

PART I.		FINANCIAL INFORMATION:	Page
	Item 1.	Financial Statements (Unaudited)
		Consolidated Statements of Earnings    Three Months Ended March 31, 2024 and 2023	1
		Consolidated Statements of Comprehensive Income (Loss)      Three Months Ended March 31, 2024 and 2023	2
		Consolidated Balance Sheets   March 31, 2024, and December 31, 2023	3
		Consolidated Statements of Shareholders' Equity   Three Months Ended March 31, 2024 and 2023	4
		Consolidated Statements of Cash Flows   Three Months Ended March 31, 2024 and 2023	5
		Notes to the Consolidated Financial Statements	6
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	70
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	104
	Item 4.	Controls and Procedures	104
PART II.		OTHER INFORMATION:
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	105
	Item 5.	Other Information	105
	Item 6.	Exhibits	106
Glossary of Selected Terms			107

Items other than those listed above are omitted because they are not required or are not applicable.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Aflac Incorporated and Subsidiaries

Consolidated Statements of Earnings

	Three Months Ended March 31,
(In millions, except for share and per-share amounts - Unaudited)	2024		2023
Revenues:
Net earned premiums, principally supplemental health insurance	$	3,456		$	3,688
Net investment income	1,000			943
Net investment gains (losses)	951			123
Other income (loss)	29			46
Total revenues	5,436			4,800
Benefits and expenses:
Benefits and claims, excluding reserve remeasurement	2,066			2,203
Reserve remeasurement (gains) losses	(56)			(53)
Total benefits and claims, net	2,010			2,150
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs	215			205
Insurance commissions	255			280
Insurance and other expenses	739			775
Interest expense	47			48
Total acquisition and operating expenses	1,256			1,308
Total benefits and expenses	3,266			3,458
Earnings before income taxes	2,170			1,342
Income taxes	291			154
Net earnings	$	1,879		$	1,188
Net earnings per share:
Basic	$	3.27		$	1.94
Diluted	3.25			1.94
Weighted-average outstanding common shares used in   computing earnings per share (In thousands):
Basic	574,886			611,205
Diluted	577,482			613,950
Cash dividends per share	$	.50		$	.42

See the accompanying Notes to the Consolidated Financial Statements.

1

Aflac Incorporated and Subsidiaries

Consolidated Statements of Comprehensive Income (Loss)

	Three Months Ended March 31,
(In millions - Unaudited)	2024		2023
Net earnings	$	1,879		$	1,188
Other comprehensive income (loss) before income taxes:
Unrealized foreign currency translation gains (losses) during    period	(501)			(43)
Unrealized gains (losses) on fixed maturity securities:
Unrealized holding gains (losses) on fixed maturity securities    during period	103			2,578
Reclassification adjustment for (gains) losses on    fixed maturity securities included in net earnings	(168)			(57)
Unrealized gains (losses) on derivatives during period	(5)			1
Effect of changes in discount rate assumptions during period	1,348			(3,537)
Pension liability adjustment during period	2			9
Total other comprehensive income (loss) before income taxes	779			(1,049)
Income tax expense (benefit) related to items of other comprehensive    income (loss)	361			(200)
Other comprehensive income (loss), net of income taxes	418			(849)
Total comprehensive income (loss)	$	2,297		$	339

See the accompanying Notes to the Consolidated Financial Statements.

2

Aflac Incorporated and Subsidiaries

Consolidated Balance Sheets

(In millions, except for share and per-share amounts)	March 31, 2024 (Unaudited)			December 31, 2023
Assets:
Investments and cash:
Fixed maturity securities available-for-sale, at fair value (no allowance for credit losses in   2024 and 2023, amortized cost $64,838 in 2024 and $67,807 in 2023)		$	66,452		$	69,578
Fixed maturity securities available-for-sale - consolidated variable interest entities, at fair value   (amortized cost $2,756 in 2024 and $2,882 in 2023)		3,678			3,712
Fixed maturity securities held-to-maturity, at amortized cost, net of allowance   for credit losses of $5 in 2024 and $5 in 2023 (fair value $18,245 in 2024 and $19,657 in 2023)		16,689			17,819
Equity securities, at fair value		762			1,088
Commercial mortgage and other loans, net of allowance for credit losses of $232 in 2024 and $274   in 2023 (includes $9,947 in 2024 and $10,150 in 2023 of consolidated variable interest entities)		12,360			12,527
Other investments   (includes $2,443 in 2024 and $2,381 in 2023 of consolidated variable interest entities)		6,677			4,530
Cash and cash equivalents		5,098			4,306
Total investments and cash		111,716			113,560
Receivables		1,038			848
Accrued investment income		693			731
Deferred policy acquisition costs		8,819			9,132
Property and equipment, at cost less accumulated depreciation		418			445
Other		2,058			2,008
Total assets		$	124,742		$	126,724
Liabilities and shareholders’ equity:
Liabilities:
Policy liabilities:
Future policy benefits		$	77,867		$	83,718
Unpaid policy claims		344			261
Unearned premiums		1,322			1,451
Other policyholders’ funds		5,831			6,169
Total policy liabilities		85,364			91,599
Income taxes		777			154
Payables for return of cash collateral on loaned securities		3,366			1,503
Notes payable and lease obligations		7,912			7,364
Other		3,786			4,119
Total liabilities		101,205			104,739
Commitments and contingent liabilities (Note 13)
Shareholders’ equity:
Common stock of $.10 par value. In thousands: authorized 1,900,000    shares in 2024 and 2023; issued 1,356,480 shares in 2024 and 1,355,398 shares in 2023		136			136
Additional paid-in capital		2,806			2,771
Retained earnings		49,872			47,993
Accumulated other comprehensive income (loss):
Unrealized foreign currency translation gains (losses)		(4,666)			(4,069)
Unrealized gains (losses) on fixed maturity securities		1,092			1,139
Unrealized gains (losses) on derivatives		(26)			(22)
Effect of changes in discount rate assumptions		(1,495)			(2,560)
Pension liability adjustment		(7)			(8)
Treasury stock, at average cost		(24,175)			(23,395)
Total shareholders’ equity		23,537			21,985
Total liabilities and shareholders’ equity		$	124,742		$	126,724

See the accompanying Notes to the Consolidated Financial Statements.

3

Aflac Incorporated and Subsidiaries

Consolidated Statements of Shareholders’ Equity

(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2023	$	136	$	2,771	$	47,993	$	(5,520)	$	(23,395)	$	21,985
Net earnings	0		0		1,879		0		0		1,879
Unrealized foreign currency translation    gains (losses) during period, net of    income taxes	0		0		0		(597)		0		(597)
Unrealized gains (losses) on fixed maturity    securities during period, net of income    taxes and reclassification adjustments	0		0		0		(47)		0		(47)
Unrealized gains (losses) on derivatives    during period, net of income taxes	0		0		0		(4)		0		(4)
Effect of changes in discount rate assumptions    during period, net of income taxes	0		0		0		1,065		0		1,065
Pension liability adjustment during period,    net of income taxes	0		0		0		1		0		1
Dividends to shareholders (1)   ($.00 per share)	0		0		0		0		0		0
Exercise of stock options	0		4		0		0		0		4
Share-based compensation	0		18		0		0		0		18
Purchases of treasury stock	0		0		0		0		(793)		(793)
Treasury stock reissued	0		13		0		0		13		26
Balance at March 31, 2024	$	136	$	2,806	$	49,872	$	(5,102)	$	(24,175)	$	23,537

(In millions, except for per share amounts - Unaudited)	Common Stock		Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Treasury Stock		Total Shareholders' Equity
Balance at December 31, 2022	$	135	$	2,641	$	44,367	$	(6,429)	$	(20,574)	$	20,140
Net earnings	0		0		1,188		0		0		1,188
Unrealized foreign currency translation    gains (losses) during period, net of    income taxes	0		0		0		(54)		0		(54)
Unrealized gains (losses) on fixed maturity    securities during period, net of income    taxes and reclassification adjustments	0		0		0		1,991		0		1,991
Unrealized gains (losses) on derivatives    during period, net of income taxes	0		0		0		1		0		1
Effect of changes in discount rate assumptions    during period, net of income taxes	0		0		0		(2,794)		0		(2,794)
Pension liability adjustment during period,    net of income taxes	0		0		0		7		0		7
Dividends to shareholders (1)   ($.00 per share)	0		0		0		0		0		0
Exercise of stock options	0		3		0		0		0		3
Share-based compensation	0		14		0		0		0		14
Purchases of treasury stock	0		0		0		0		(732)		(732)
Treasury stock reissued	0		7		0		0		13		20
Balance at March 31, 2023	$	135	$	2,665	$	45,555	$	(7,278)	$	(21,293)	$	19,784

(1) Dividends to shareholders are recorded in the period in which they are declared.

See the accompanying Notes to the Consolidated Financial Statements.

4

Aflac Incorporated and Subsidiaries

Consolidated Statements of Cash Flows

	Three Months Ended March 31,
(In millions - Unaudited)	2024			2023
Cash flows from operating activities:
Net earnings		$	1,879		$	1,188
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Change in receivables and advance premiums		32			(34)
Capitalization of deferred policy acquisition costs		(254)			(270)
Amortization of deferred policy acquisition costs		215			205
Increase in policy liabilities		(41)			9
Change in income tax liabilities		291			154
Net investment (gains) losses		(951)			(123)
Other, net		(322)			(239)
Net cash provided (used) by operating activities		849			890
Cash flows from investing activities:
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities		2,286			949
Equity securities		267			126
Commercial mortgage and other loans		379			418
Costs of investments acquired:
Available-for-sale fixed maturity securities		(2,127)			(1,090)
Equity securities		(73)			(134)
Commercial mortgage and other loans		(251)			(315)
Other investments, net		(2,119)			(1,256)
Settlement of derivatives, net		(256)			(480)
Cash received (pledged or returned) as collateral, net		1,973			1,756
Other, net		148			(51)
Net cash provided (used) by investing activities		227			(77)
Cash flows from financing activities:
Purchases of treasury stock		(750)			(700)
Proceeds from borrowings		823			0
Dividends paid to shareholders		(278)			(248)
Change in investment-type contracts, net		(50)			(28)
Treasury stock reissued		6			2
Other, net		(7)			41
Net cash provided (used) by financing activities		(256)			(933)
Effect of exchange rate changes on cash and cash equivalents		(28)			(14)
Net change in cash and cash equivalents		792			(134)
Cash and cash equivalents, beginning of period		4,306			3,943
Cash and cash equivalents, end of period		$	5,098		$	3,809
Supplemental disclosures of cash flow information:
Income taxes paid		$	0		$	0
Interest paid		34			37
Noncash interest		13			11
Noncash real estate acquired in satisfaction of debt		35			0
Noncash financing activities:
Lease obligations		5			18
Treasury stock issued for:
Associate stock bonus		4			4
Shareholder dividend reinvestment		10			9
Share-based compensation grants		6			5

See the accompanying Notes to the Consolidated Financial Statements.

5

Aflac Incorporated and Subsidiaries

Notes to the Consolidated Financial Statements

(Interim period data - Unaudited)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd. (Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2024 and December 31, 2023, and the consolidated statements of earnings and comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2024 and 2023. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report).

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

For the three-month period ended March 31, 2023, immaterial reclassifications were made to the consolidated statement of cash flows related to investments in limited partnerships and the impact of foreign currency on policy liabilities. The impact of the reclassification related to investments in limited partnerships resulted in an increase to net cash flows provided by operating activities of $182 million with a corresponding decrease to net cash flows provided by investing activities. There was no impact to net cash flows provided by operating activities as a result of the reclassification related

6

to the impact of foreign currency on policy liabilities between the increase in policy liabilities and other, net line items within operating activities.

New Accounting Pronouncements

Accounting Pronouncements Pending Adoption

Accounting Standards Update (ASU) 2023-09 Income Taxes (Topic 740) – Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-07 Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that will add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business. 

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

2.    BUSINESS SEGMENT INFORMATION

The Company consists of two reportable insurance business segments: Aflac Japan and Aflac U.S., both of which sell supplemental health and life insurance. In addition, the Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. The Company does not allocate corporate overhead expenses to business segments.

Consistent with U.S. GAAP accounting guidance for segment reporting, the Company evaluates and manages its business segments using a financial performance measure called pretax adjusted earnings.

•Pretax adjusted earnings are adjusted revenues less benefits and adjusted expenses. The adjustments to both revenues and expenses account for certain items that are outside management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. The Company excludes income taxes related to operations to arrive at pretax adjusted earnings.

◦Adjusted revenues are U.S. GAAP total revenues excluding net investment gains and losses, except for amortized hedge costs/income related to foreign currency exposure management strategies and net interest income/expense from derivatives associated with certain investment strategies, which are reclassified from net investment gains (losses) and included in adjusted earnings as a component of adjusted net investment income when analyzing operations. 

7

◦Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company’s underlying business performance.

Aflac Japan's adjusted revenues accounted for 56% and 61% of the Company's total adjusted revenues in the three-month periods ended March 31, 2024 and 2023, respectively. The percentage of the Company's total assets attributable to Aflac Japan was 79% at March 31, 2024, compared with 80% at December 31, 2023.

Information regarding operations by reportable segment and Corporate and other, follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Revenues:
Aflac Japan:
Net earned premiums	$	1,816	$	2,170
Adjusted net investment income	648		611
Other income	9		9
Total adjusted revenue Aflac Japan	2,473		2,790
Aflac U.S.:
Net earned premiums	1,475		1,428
Adjusted net investment income	206		197
Other income	18		35
Total adjusted revenue Aflac U.S.	1,699		1,660
Corporate and other (1)	247		129
Total adjusted revenues	4,419		4,579
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Total revenues	$	5,436	$	4,800

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

8

	Three Months Ended March 31,
(In millions)	2024		2023
Pretax earnings:
Aflac Japan	$	810	$	788
Aflac U.S.	356		352
Corporate and other (1)	(3)		(7)
Pretax adjusted earnings	1,163		1,133
Other income (loss)	(2)		0
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Impact of interest from derivatives associated    with notes payable	(8)		(12)
Total earnings before income taxes	$	2,170	$	1,342
Income taxes applicable to pretax adjusted earnings	$	202	$	180
Effect of foreign currency translation on after-tax   adjusted earnings	(44)		(41)

(1)The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Assets were as follows:

(In millions)	March 31, 2024			December 31, 2023
Assets:
Aflac Japan		$	98,189		$	101,541
Aflac U.S.		21,850			21,861
Corporate and other		4,703			3,322
Total assets		$	124,742		$	126,724

9

3.     INVESTMENTS

Investment Holdings

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	21,577	$	0	$	874	$	1,811	$	20,640
Municipalities	907		0		102		59		950
Mortgage- and asset-backed securities	201		0		6		12		195
Public utilities	3,281		0		262		77		3,466
Sovereign and supranational	349		0		24		7		366
Banks/financial institutions	5,546		0		323		285		5,584
Other corporate	5,532		0		663		245		5,950
Total yen-denominated	37,393		0		2,254		2,496		37,151
U.S. dollar-denominated:
U.S. government and agencies	177		0		1		4		174
Municipalities	1,237		0		72		49		1,260
Mortgage- and asset-backed securities	2,968		0		270		48		3,190
Public utilities	3,595		0		388		136		3,847
Sovereign and supranational	95		0		33		4		124
Banks/financial institutions	2,971		0		385		41		3,315
Other corporate	19,158		0		2,635		724		21,069
Total U.S. dollar-denominated	30,201		0		3,784		1,006		32,979
Total securities available-for-sale	$	67,594	$	0	$	6,038	$	3,502	$	70,130

10

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	23,067	$	0	$	1,040	$	1,696	$	22,411
Municipalities	968		0		115		58		1,025
Mortgage- and asset-backed securities	215		0		6		11		210
Public utilities	3,757		0		325		82		4,000
Sovereign and supranational	373		0		24		7		390
Banks/financial institutions	5,896		0		320		365		5,851
Other corporate	5,898		0		699		294		6,303
Total yen-denominated	40,174		0		2,529		2,513		40,190
U.S. dollar-denominated:
U.S. government and agencies	191		0		2		4		189
Municipalities	1,246		0		65		38		1,273
Mortgage- and asset-backed securities	2,748		0		184		56		2,876
Public utilities	3,346		0		360		114		3,592
Sovereign and supranational	122		0		33		8		147
Banks/financial institutions	2,676		0		359		51		2,984
Other corporate	20,186		0		2,518		665		22,039
Total U.S. dollar-denominated	30,515		0		3,521		936		33,100
Total securities available-for-sale	$	70,689	$	0	$	6,050	$	3,449	$	73,290

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,002	$	2	$	16,000	$	1,474	$	0	$	17,474
Municipalities	248		0		248		37		0		285
Public utilities	33		0		33		3		0		36
Sovereign and supranational	394		3		391		40		0		431
Other corporate	17		0		17		2		0		19
Total yen-denominated	16,694		5		16,689		1,556		0		18,245
Total securities held-to-maturity	$	16,694	$	5	$	16,689	$	1,556	$	0	$	18,245

11

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	17,085	$	2	$	17,083	$	1,746	$	0	$	18,829
Municipalities	266		0		266		41		0		307
Public utilities	34		0		34		4		0		38
Sovereign and supranational	421		3		418		44		0		462
Other corporate	18		0		18		3		0		21
Total yen-denominated	17,824		5		17,819		1,838		0		19,657
Total securities held-to-maturity	$	17,824	$	5	$	17,819	$	1,838	$	0	$	19,657

	March 31, 2024			December 31, 2023
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	522		$	751
U.S. dollar-denominated		240			252
Other currencies		0			85
Total equity securities		$	762		$	1,088

The methods of determining the fair values of the Company's investments in fixed maturity securities and equity securities are described in Note 5.

During the first three months of 2024 and 2023, respectively, the Company did not reclassify any investments from the held-to-maturity category to the available-for-sale category.

12

Contractual and Economic Maturities

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2024, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,272		$	1,292
Due after one year through five years		6,659			7,480
Due after five years through 10 years		17,904			19,556
Due after 10 years		38,590			38,417
Mortgage- and asset-backed securities		3,169			3,385
Total fixed maturity securities available-for-sale		$	67,594		$	70,130
Held-to-maturity:
Due in one year or less		$	0		$	0
Due after one year through five years		35			36
Due after five years through 10 years		8,901			9,714
Due after 10 years		7,753			8,495
Total fixed maturity securities held-to-maturity		$	16,689		$	18,245

(1) Net of allowance for credit losses

Economic maturities are used for certain debt instruments with no stated maturity where the expected maturity date is based on the combination of features in the financial instrument such as the right to call or prepay obligations or changes in coupon rates.

Investment Concentrations

The Company's process for investing in credit-related investments begins with an independent approach to underwriting each issuer's fundamental credit quality. The Company evaluates independently those factors that it believes could influence an issuer's ability to make payments under the contractual terms of the Company's instruments. This includes a thorough analysis of a variety of items including the issuer's country of domicile (including political, legal, and financial considerations); the industry in which the issuer competes (with an analysis of industry structure, end-market dynamics, and regulation); company specific issues (such as management, assets, earnings, cash generation, and capital needs); and contractual provisions of the instrument (such as financial covenants and position in the capital structure). The Company further evaluates the investment considering broad business and portfolio management objectives, including asset/liability needs, portfolio diversification, and expected income.

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2024			December 31, 2023
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$36,641	$37,170	A+	$39,151	$40,222

(1)Japan Government Bonds (JGBs) or JGB-backed securities

13

Net Investment Gains and Losses

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	34	$	1
Gross losses from sales	(282)		(3)
Foreign currency gains (losses)	416		59
Other investments:
Gross gains (losses) from sales and redemptions	5		0
Total sales and redemptions	173		57
Equity securities	76		(3)
Credit losses:
Fixed maturity securities held-to-maturity	0		1
Commercial mortgage and other loans	(7)		(31)
Impairment losses	0		0
Loan commitments	1		3
Reinsurance recoverables and other	5		(3)
Total credit losses	(1)		(30)
Derivatives and other:
Derivative gains (losses)	(215)		17
Foreign currency gains (losses)	918		82
Total derivatives and other	703		99
Total net investment gains (losses)	$	951	$	123

The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2024 that relate to equity securities held at the March 31, 2024 reporting date were $71 million. The unrealized holding losses, net of gains, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2023 that relate to equity securities held at the March 31, 2023 reporting date were $5 million.

Unrealized Investment Gains and Losses

Effect on Shareholders’ Equity

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2024			December 31, 2023
Unrealized gains (losses) on securities available-for-sale		$	2,536		$	2,601
Deferred income taxes		(1,444)			(1,462)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	1,092		$	1,139

Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2024 and December 31, 2023, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

14

	March 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	141		$	4		$	59		$	1		$	82		$	3
Japan government and       agencies:
Yen-denominated		7,828			1,811			1,628			395			6,200			1,416
Municipalities:
U.S. dollar-denominated		662			49			9			0			653			49
Yen-denominated		277			59			31			1			246			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		754			48			304			4			450			44
Yen-denominated		54			12			1			0			53			12
Public utilities:
U.S. dollar-denominated		1,383			136			391			9			992			127
Yen-denominated		915			77			351			13			564			64
Sovereign and supranational:
U.S. dollar-denominated		14			4			0			0			14			4
Yen-denominated		55			7			0			0			55			7
Banks/financial institutions:
U.S. dollar-denominated		628			41			228			2			400			39
Yen-denominated		2,973			285			62			1			2,911			284
Other corporate:
U.S. dollar-denominated		6,196			724			1,254			36			4,942			688
Yen-denominated		1,747			245			355			9			1,392			236
Total		$	23,627		$	3,502		$	4,673		$	471		$	18,954		$	3,031

15

	December 31, 2023
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	123		$	4		$	53		$	1		$	70		$	3
Japan government and       agencies:
Yen-denominated		8,393			1,696			1,657			303			6,736			1,393
Municipalities:
U.S. dollar-denominated		703			38			31			1			672			37
Yen-denominated		301			58			34			0			267			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		925			56			340			6			585			50
Yen-denominated		58			11			0			0			58			11
Public utilities:
U.S. dollar-denominated		1,120			114			228			4			892			110
Yen-denominated		1,028			82			444			13			584			69
Sovereign and supranational:
U.S. dollar-denominated		35			8			0			0			35			8
Yen-denominated		60			7			0			0			60			7
Banks/financial institutions:
U.S. dollar-denominated		655			51			159			4			496			47
Yen-denominated		3,673			365			186			4			3,487			361
Other corporate:
U.S. dollar-denominated		6,380			665			799			19			5,581			646
Yen-denominated		1,948			294			308			9			1,640			285
Total		$	25,402		$	3,449		$	4,239		$	364		$	21,163		$	3,085

Analysis of Securities in Unrealized Loss Positions

The unrealized losses on the Company's available-for-sale securities have been primarily related to general market changes in interest rates, foreign exchange rates, and/or the levels of credit spreads rather than specific concerns with the issuer's ability to pay interest and repay principal.

For any available-for-sale securities with significant declines in fair value, the Company performs detailed analyses to identify whether the drivers of the declines are due to general market drivers, such as the recent rise in interest rates, or due to credit-related factors. Identifying the drivers of the declines in fair value helps to align and allocate the Company‘s resources to securities with real credit-related concerns that could impact ultimate collection of principal and interest. For any significant declines in fair value determined to be non-interest rate or market related, the Company performs a more focused review of the related issuers' specific credit profile.

For corporate issuers, the Company evaluates their assets, business profile including industry dynamics and competitive positioning, financial statements and other available financial data. For non-corporate issuers, the Company analyzes all sources of credit support, including issuer-specific factors. The Company utilizes information available in the public domain and, for certain private placement issuers, from consultations with the issuers directly. The Company also considers ratings from Nationally Recognized Statistical Rating Organizations (NRSROs), as well as the specific characteristics of the security it owns including seniority in the issuer's capital structure, covenant protections, or other relevant features. From these reviews, the Company evaluates the issuers' continued ability to service the Company's investment through payment of interest and principal.

16

Assuming no credit-related factors develop, unrealized gains and losses on available-for-sale securities are expected to diminish as investments near maturity. Based on its credit analysis, the Company believes that the issuers of its available-for-sale investments in the sectors shown in the table above have the ability to service their obligations to the Company. Further, the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

However, from time to time the Company identifies certain available-for-sale securities where the amortized cost basis exceeds the present value of the cash flows expected to be collected due to credit-related factors and as a result, a credit loss allowance will be estimated. Based on an evaluation of its securities currently in an unrealized loss position, the Company has determined that those securities should not have a credit loss allowance as of March 31, 2024. Refer to the Allowance for Credit Losses section below for additional information.

As of March 31, 2024 and December 31, 2023, the Company had an immaterial amount of fixed maturity securities on nonaccrual status.

Commercial Mortgage and Other Loans

The Company classifies its transitional real estate loans (TREs), commercial mortgage loans (CMLs), middle market loans (MMLs), and other loans as held-for-investment and includes them in the commercial mortgage and other loans line on the consolidated balance sheets. The Company carries them on the balance sheet at amortized cost less an estimated allowance for credit losses.

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

(In millions)	March 31, 2024				December 31, 2023
	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,768	14.0	%	$	1,807	14.1	%
Retail	335		2.7		473		3.7
Apartments/Multi-Family	2,550		20.3		2,608		20.4
Industrial	152		1.2		157		1.2
Hospitality	818		6.5		814		6.4
Other	455		3.7		255		2.0
Total transitional real estate loans	6,078		48.4		6,114		47.8
Commercial mortgage loans:
Office	356		2.8		359		2.8
Retail	254		2.0		301		2.4
Apartments/Multi-Family	583		4.6		586		4.6
Industrial	445		3.5		463		3.6
Other	15		.1		0		0.0
Total commercial mortgage loans	1,653		13.0		1,709		13.4
Middle market loans	4,586		36.4		4,677		36.5
Other loans	275		2.2		301		2.3
Total commercial mortgage and other loans	$	12,592	100.0	%	$	12,801	100.0	%
Allowance for credit losses	(232)				(274)
Total net commercial mortgage and other loans	$	12,360			$	12,527

CMLs and TREs were secured by properties entirely within the U.S. (with the largest concentrations in California (20%), Texas (15%) and Florida (12%)). MMLs are issued only to companies domiciled within the U.S. and Canada.

17

Transitional Real Estate Loans

TREs are commercial mortgage loans that are typically relatively short-term floating rate instruments secured by a first lien on the property. These loans provide funding for properties undergoing a change in their physical characteristics and/or economic profile and do not typically require any principal repayment prior to the maturity date.

As of March 31, 2024, the Company had $442 million in outstanding commitments to fund TREs. These commitments are contingent on the final underwriting and due diligence to be performed.

Commercial Mortgage Loans

CMLs are typically fixed rate loans on commercial real estate with partial repayment of principal over the life of the loan with the remaining outstanding principal being repaid upon maturity. This loan portfolio is generally considered higher quality investment grade loans.

Middle Market Loans

MMLs are typically first lien senior secured cash flow loans to small to mid-size companies for working capital, refinancing, acquisition, and recapitalization. These loans are generally considered to be below investment grade. The carrying value for MMLs included $24 million for a short-term credit facility that is reflected in other liabilities on the consolidated balance sheets at both March 31, 2024 and December 31, 2023.

As of March 31, 2024, the Company had commitments of approximately $787 million to fund future MMLs. These commitments are contingent upon the availability of MMLs that meet the Company's underwriting criteria.

Other Loans

Other loans are primarily infrastructure loans. Infrastructure loans are typically senior secured, financing operating portfolios of contracted solar and wind assets generating cash flow for loan repayment. The infrastructure loan portfolio weighted average rating is investment grade. As of March 31, 2024, the Company had commitments of approximately $5 million to fund future other loans. These commitments are contingent upon the availability of other loans that meet the Company's underwriting criteria.

Credit Quality Indicators

For TREs, the Company’s key credit quality indicators include performance of the loan and loan-to-value (LTV), which is calculated by dividing the current outstanding loan balance by the estimated property value, primarily using values at origination. Given that TREs involve properties undergoing a repositioning of their commercial profile, LTV provides the most insight into the credit risk of the loan. The Company monitors the performance of the loans periodically, but not less frequently than quarterly. The monitoring process also focuses on higher risk loans, which include those that are delinquent or for which foreclosure or deed in lieu of foreclosure is anticipated.

For CMLs, the Company’s key credit quality indicators include LTV and debt service coverage ratios (DSCR). DSCR is the most recently available net operating income of the underlying property compared to the required debt service of the loan.

For MMLs and held-to-maturity fixed maturity securities, the Company’s key credit quality indicator is credit ratings. The Company’s held-to-maturity portfolio is composed of investment grade securities that are senior unsecured instruments, while its MMLs generally have below-investment-grade ratings but are typically senior secured instruments. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

For other loans, the Company's key credit quality indicator is credit ratings. The Company monitors these credit ratings periodically, but not less frequently than quarterly.

18

The following tables present as of March 31, 2024 the amortized cost basis of TREs, CMLs, MMLs, and other loans by year of origination and credit quality indicator.

Transitional Real Estate Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	131	$	86	$	609	$	507	$	36	$	125	$	1,494
60%-69.99%	34		126		496		637		18		552		1,863
70%-79.99%	0		14		883		900		83		47		1,927
80% or greater	0		0		218		251		80		245		794
Total	$	165	$	226	$	2,206	$	2,295	$	217	$	969	$	6,078
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Commercial Mortgage Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	33	$	0	$	309	$	45	$	983	$	1,370	2.57
60%-69.99%	0		0		0		0		0		30		30		1.73
70%-79.99%	0		0		0		0		0		120		120		1.26
80% or greater	0		0		0		0		0		133		133		0.52
Total	$	0	$	33	$	0	$	309	$	45	$	1,266	$	1,653	2.30
Weighted Average DSCR	0.00		2.58		0.00		2.92		2.26		2.14
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle Market Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	17	$	45	$	123	$	54	$	64	$	77	$	380
BB	18		60		308		408		251		287		446		1,778
B	48		53		218		547		302		633		290		2,091
CCC	0		0		20		50		51		136		48		305
CC	0		0		0		0		0		10		0		10
C and lower	0		0		0		0		0		6		16		22
Total	$	66	$	130	$	591	$	1,128	$	658	$	1,136	$	877	$	4,586
Current-period gross   writeoffs:	$	0	$	0	$	0	$	27	$	0	$	23	$	0	$	50

19

Other Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	22	$	94	$	0	$	0	$	0	$	0	$	116
AA	0		0		5		5		0		0		0		10
BBB	5		68		0		0		0		0		0		73
BB	0		0		76		0		0		0		0		76
Total	$	5	$	90	$	175	$	5	$	0	$	0	$	0	$	275
Current-period gross writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Loan Modifications to Borrowers Experiencing Financial Difficulties

The Company granted certain loan modifications to borrowers experiencing financial difficulty during the first three months of 2024 and 2023. The amount, timing, and extent of modifications granted are considered in determining any credit loss allowance recorded. For the three-month period ended March 31, 2024, 3% of TREs with an amortized cost of $210 million were modified in the form of interest rate reductions and other-than-insignificant payment delays. The modifications resulted in a reduction in the weighted-average contractual interest rate from 8.3% to 6.9%. Loan modifications for the three-month period ended March 31, 2023 were immaterial.

Past Due and Nonaccrual Loans

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,152	$	97	$	829	$	926	$	6,078	$	829
Commercial mortgage loans	1,598		0		55		55		1,653		55
Middle market loans	4,560		0		26		26		4,586		26
Other loans	275		0		0		0		275		0
Total	$	11,585	$	97	$	910	$	1,007	$	12,592	$	910

(1) As of March 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2023
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,481	$	108	$	525	$	633	$	6,114	$	633
Commercial mortgage loans	1,676		33		0		33		1,709		0
Middle market loans	4,592		0		85		85		4,677		85
Other loans	301		0		0		0		301		0
Total	$	12,050	$	141	$	610	$	751	$	12,801	$	718

(1) As of December 31, 2023, there were no loans that were 90 days or more past due that continued to accrue interest.

For the three-month periods ended March 31, 2024 and March 31, 2023, the Company recognized no interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. Of these loans, TREs with an amortized cost of $383 million had no credit loss allowance as of March 31, 2024 because these loans are collateral dependent assets for which the estimated fair values of the collateral are in excess of amortized cost. As of March 31, 2024 and December 31, 2023, there were no MMLs on nonaccrual status without an allowance for credit losses.

20

Allowance for Credit Losses

The Company calculates its allowance for credit losses for held-to-maturity securities, loan receivables, loan commitments and reinsurance recoverable by grouping assets with similar risk characteristics when there is not a specific expectation of a loss for an individual asset. For held-to-maturity securities, MMLs, and MML commitments, the Company groups assets by credit ratings, industry, and country.

The Company groups CMLs and TREs and respective loan commitments by property type, property location and the property’s LTV and DSCR. On a quarterly basis, CMLs and TREs within a portfolio segment that share similar risk characteristics are pooled for calculation of credit loss allowance. On an ongoing basis, TREs, CMLs and other loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is probable), are evaluated individually for credit loss. For example, the credit loss allowance for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of the collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the credit loss allowance as a component of net investment gains (losses) in the consolidated statements of earnings.

The credit allowance for held-to-maturity fixed maturity securities and loan receivables is estimated using a probability-of-default (PD) / loss-given-default (LGD) method, discounted for the time value of money. For held-to-maturity fixed maturity securities, available-for-sale fixed maturity securities and loan receivables, the Company includes the change in present value due to the passage of time in the change in the allowance for credit losses. The Company’s methodology for estimating credit losses utilizes the contractual maturity date of the financial asset, adjusted when necessary to reflect the expected timing of repayment (such as prepayment options, renewal options, call options, or extension options). The Company applies reasonable and supportable forecasts of macroeconomic variables that impact the determination of PD / LGD over a two-year period for held-to-maturity fixed maturity securities and MMLs. The Company reverts to historical loss information over one year, following the two-year forecast period. For the CML and TRE portfolio, the Company applies reasonable and supportable forecasts of macroeconomic variables as well as national and local real-estate market factors to estimate future credit losses where the market factors revert back to historical levels over time with the period being dependent on current market conditions, projected market conditions and difference in the current and historical market levels for each factor. The Company continuously monitors the estimation methodology, due to changes in portfolio composition, changes in underwriting practices and significant events or conditions and makes adjustments as necessary.

The Company’s held-to-maturity portfolio includes Japan Government and Agency securities of $15.9 billion amortized cost as of March 31, 2024 that meet the requirements for zero-credit-loss expectation and therefore these asset classes have been excluded from the current expected credit loss measurement.

An investment in an available-for-sale security may be impaired if the fair value falls below amortized cost. The Company regularly reviews its available-for-sale portfolio for declines in fair value. The Company's available-for-sale impairment model focuses on the ultimate collection of the cash flows from its investments and whether the Company has the intent to sell or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. The determination of the amount of impairments under this model is based upon the Company's periodic evaluation and assessment of known and inherent risks associated with the respective securities. Such evaluations and assessments are revised as conditions change and new information becomes available.

When determining the Company's intention to sell a security prior to recovery of its fair value to amortized cost, the Company evaluates facts and circumstances such as, but not limited to, future cash flow needs, decisions to reposition its security portfolio, and risk profile of individual investment holdings. The Company performs ongoing analyses of its liquidity needs, which includes cash flow testing of its policy liabilities, debt maturities, projected dividend payments, and other cash flow and liquidity needs.

The Company’s methodology for estimating credit losses for available-for-sale securities utilizes the discounted cash flow model, based on past events, current market conditions and future economic conditions, as well as industry analysis and credit ratings of the securities. In addition, the Company evaluates the specific issuer’s probability of default and expected recovery of its position in the event of default based on the underlying financial condition and assets of the borrower as well as seniority and/or security of other debt holders in the issuer when developing management’s best estimate of expected cash flows.

21

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to-Maturity Securities		Available-for-Sale Securities		Total
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)
Three Months Ended March 31, 2023:
Balance at December 31, 2022	$	(54)	$	(9)	$	(129)	$	(24)	$	(7)	$	0	$	(223)
(Addition to) release of allowance for credit losses	(11)		0		(20)		3		1		0		(27)
Writeoffs, net of recoveries	0		0		0		0		0		0		0
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2023	$	(65)	$	(9)	$	(149)	$	(21)	$	(6)	$	0	$	(250)

For the three-month period ended March 31, 2024, the Company completed foreclosure or deed in lieu of foreclosure on TREs collateralized with commercial real estate properties with an amortized cost of $31 million. As a result of the excess of amortized cost over the estimated fair value of the collateral of the TREs, upon consummating the foreclosures or deed in lieu of foreclosure transactions, the Company recognized a net gain of $4 million for the three-month period ended March 31, 2024 in net investment gains (losses). The Company did not complete any foreclosure or deed in lieu of foreclosure transactions in the three-month period ended March 31, 2023. Refer to the Other Investments section below for additional information.

As of March 31, 2024, the Company identified additional TREs with an amortized cost of $601 million in anticipation of potential foreclosure or deed in lieu of foreclosure transactions. As of March 31, 2024, the Company established a credit allowance of $60 million for $598 million of loans for which the fair value of the collateral was below the amortized cost of the loans.

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2024			December 31, 2023
Other investments:
Policy loans		$	203		$	214
Short-term investments (1)		3,341			1,304
Limited partnerships (2)		2,838			2,750
Real estate owned		253			227
Other		42			35
Total other investments		$	6,677		$	4,530

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

22

Real estate owned (REO) consists of office buildings or other commercial properties obtained through foreclosure or deed in lieu of foreclosure of certain of the Company’s TREs. As of March 31, 2024, all REO was classified as held-and-used for the production of income and is carried at cost less accumulated depreciation. As of December 31, 2023, $210 million of REO was classified as held-and-used with the remaining $17 million classified as held-for-sale, which is carried at the lower of depreciated cost or fair value less cost to sell and is not further depreciated once classified as such. Depreciation expense was $1 million for the three-month period ended March 31, 2024. Additionally, as of March 31, 2024 and December 31, 2023, accumulated depreciation was $2 million and an immaterial amount, respectively.

As of March 31, 2024, the Company had $2.2 billion in outstanding commitments to fund investments in limited partnerships.

Variable Interest Entities (VIEs)

In the normal course of its activities, the Company invests in legal entities that are VIEs. The Company's debt or ownership interest in VIEs is limited to holding the equity interests and obligations issued by them. With the exception of commitments to limited partnerships and to certain loan investments made in the normal course of business, the Company has not provided any direct or contingent obligations to fund the limited activities of these VIEs or support related to the limited activities of these VIE and does not have any intention to do so in the future, nor does it have any direct or indirect financial guarantees.

The Company's risk of loss related to its interests in any of its VIEs is limited to the carrying value of the related investments, and in certain cases, to any unfunded commitments held in the VIE.

For those VIEs other than certain unit trust structures, the Company's involvement is passive in nature.

VIEs - Consolidated

The Company is the primary beneficiary of a VIE if it has

•the power to direct the activities of the VIE that most significantly impact the economic performance of the entity

and

•the obligation to absorb losses of or the right to receive benefits from the entity that could be potentially significant to the VIE.

If the Company determines that it is the VIE’s primary beneficiary, it consolidates the VIE. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company except to the extent of the unfunded commitments referenced above, as the Company’s obligation to each VIE is limited to the amount of its committed investment.

The following table presents carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	3,678		$	3,712
Commercial mortgage and other loans		9,947			10,150
Other investments (1)		2,443			2,381
Other assets (2)		57			55
Total assets of consolidated VIEs		$	16,125		$	16,298
Liabilities:
Other liabilities (2)		$	583		$	507
Total liabilities of consolidated VIEs		$	583		$	507

(1) Consists entirely of alternative investments in limited partnerships

(2) Consists entirely of derivatives

23

The Company is the sole investor in the consolidated VIEs listed in the table above. The Company invests in fixed maturity securities issued by VIEs that in turn hold U.S. dollar-denominated fixed maturity securities coupled with foreign currency swap agreements. The weighted-average lives of the Company's investments in these VIEs are very similar to the underlying collateral held by these VIEs. The activities of these VIEs are limited to holding invested assets and foreign currency swaps and utilizing the cash flows from these securities to service the VIEs' debt. Neither the Company nor any of its creditors are able to obtain the underlying collateral of these VIEs unless there is an event of default or other specified event. The Company is not a direct counterparty to the foreign currency swap contracts and has no control over them. The Company's loss exposure to these VIEs is limited to its original investment. These consolidated VIEs do not rely on outside or ongoing sources of funding to support their activities beyond the underlying collateral and foreign currency swap contracts, if applicable. The underlying collateral assets and funding of these consolidated VIEs are generally static in nature.

The Company also utilizes unit trust structures in its Aflac Japan segment to invest in various asset classes, which include CMLs, MMLs, TREs, other loans and limited partnerships. The limited partnership investments are comprised of private equity and real estate funds. The Company’s loss exposure to these VIEs is limited to its original investments, together with any unfunded portion of the Company’s commitments made in the normal course of business to fund certain loan investments and limited partnership investments, as described in the Commercial Mortgage and Other Loans and Other Investments sections of this note. Excluding these commitments, the Company does not provide financial or other support to consolidated VIEs.

VIEs - Not Consolidated

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	6,486		$	6,424
Other investments (1)		395			369
Total investments in VIEs not consolidated		$	6,881		$	6,793

(1) Consists entirely of alternative investments in limited partnerships

Certain investments in VIEs that the Company is not required to consolidate are investments that are in the form of debt obligations issued by the VIEs. These fixed maturity securities include structured securities, primarily asset-backed securities. The Company's involvement in the related VIEs is limited to that of a passive investor in asset-backed securities issued by the VIEs. The Company also invests in VIEs that are the primary financing vehicles used by their corporate sponsors to raise financing in the capital markets. The variable interests created by these VIEs are principally or solely a result of the debt instruments issued by them. The Company does not have the power to direct the activities that most significantly impact the entity's economic performance, nor does it have the obligation to absorb losses of the VIE entity or the right to receive benefits from the entity that could be significant to the entity. As such, the Company is not the primary beneficiary of these VIEs and therefore is not required to consolidate them. The Company's maximum exposure to loss on these investments is limited to the amount of the Company's investment.

The Company also holds equity investments in limited partnerships that have been determined to be VIEs. These partnerships primarily invest in private equity and real estate funds. The Company’s maximum exposure to loss on these investments is limited to the amount of its investment and any unfunded commitments. As described in the Other Investments section of this note, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to unconsolidated VIEs. The Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them. The Company classifies these investments as other investments in the consolidated balance sheets.

Securities Lending and Pledged Securities

The Company lends fixed maturity securities and, from time to time, public equity securities to financial institutions in short-term securities lending transactions. These short-term securities lending arrangements increase investment income

24

with minimal risk. The Company receives cash or other securities as collateral for such loans. The Company's securities lending policy requires that the fair value of the securities received as collateral be 102% or more of the fair value of the loaned securities and that unrestricted cash received as collateral be 100% or more of the fair value of the loaned securities. The securities loaned continue to be carried as investment assets on the Company's balance sheet during the terms of the loans and are not reported as sales. For loans involving unrestricted cash or securities as collateral, the collateral is reported as an asset with a corresponding liability for the return of the collateral. For loans where the Company receives as collateral securities that the Company is not permitted to sell or repledge, the collateral is not reflected on the consolidated financial statements.

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2024						December 31, 2023
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,542	$	2,542	$	0	$	737	$	737
Public utilities	33		0		33		19		0		19
Banks/financial institutions	148		0		148		72		0		72
Other corporate	643		0		643		675		0		675
Total borrowings	$	824	$	2,542	$	3,366	$	766	$	737	$	1,503
Gross amount of recognized liabilities for securities    lending transactions					$	3,366					$	1,503

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

In connection with securities lending, in addition to cash collateral received, the Company received from counterparties securities collateral of $4.5 billion and $4.3 billion at March 31, 2024 and December 31, 2023, respectively, which may not be sold or re-pledged, unless the counterparty is in default. Such securities collateral is not reflected on the consolidated financial statements.

The Company did not have any repurchase agreements or repurchase-to-maturity transactions outstanding as of March 31, 2024, and December 31, 2023, respectively.

Certain fixed maturity securities can be pledged as collateral as part of derivative transactions, or pledged to support state deposit requirements on certain investment programs. For additional information regarding pledged securities related to derivative transactions, see Note 4.

25

4.    DERIVATIVE INSTRUMENTS

The Company's freestanding derivative financial instruments include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency interest rate swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with variable interest entity (VIE) bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Some of the Company's derivatives are designated as cash flow hedges, fair value hedges or net investment hedges; however, other derivatives do not qualify for hedge accounting or the Company elects not to designate them as accounting hedges.

Derivative Types

Foreign currency forwards and options are executed for the Aflac Japan segment in order to hedge the currency risk on the carrying value of certain U.S. dollar-denominated investments. The average maturity of these forwards and options can change depending on factors such as market conditions and types of investments being held. In situations where the maturity of the forwards and options is shorter than the underlying investment being hedged, the Company may enter into new forwards and options near maturity of the existing derivative in order to continue hedging the underlying investment. In forward transactions, Aflac Japan agrees with another party to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. The Company also uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also executes foreign currency option transactions in a collar strategy, where Aflac Japan agrees with another party to simultaneously purchase put options and sell call options. In the purchased put transactions, Aflac Japan obtains the option to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. In the sold call transactions, Aflac Japan agrees to sell a fixed amount of yen and buy a corresponding amount of U.S. dollars at a specified future date. The combination of purchasing the put option and selling the call option results in no net premium being paid (i.e. a costless or zero-cost collar).

From time to time, the Company may also enter into foreign currency forwards and options to hedge the currency risk associated with the net investment in Aflac Japan. In these forward transactions, the Company agrees with another party to buy a fixed amount of U.S. dollars and sell a corresponding amount of yen at a specified price at a specified future date. In the option transactions, the Company may use a combination of foreign currency options to protect expected future cash flows by simultaneously purchasing yen put options (options that protect against a weakening yen) and selling yen call options (options that limit participation in a strengthening yen). The combination of these two actions create a zero-cost collar. Additionally, the Company enters into purchased options to hedge cash flows from the net investment in Aflac Japan.

The Company enters into foreign currency swaps pursuant to which it exchanges an initial principal amount in one currency for an initial principal amount of another currency, with an agreement to re-exchange the principal amounts at a future date. There may also be periodic exchanges of payments at specified intervals based on the agreed upon rates and notional amounts. Foreign currency swaps are used primarily in the consolidated VIEs in the Company's Aflac Japan portfolio to convert foreign-denominated cash flows to yen, the functional currency of Aflac Japan, in order to minimize cash flow fluctuations. The Company also uses foreign currency swaps to economically convert certain of its U.S. dollar-denominated senior note and subordinated debenture principal and interest obligations into yen-denominated obligations.

26

In order to reduce investment income volatility from its variable-rate investments, the Company enters into receive–fixed, pay–floating interest rate swaps. These derivatives are cleared and settled through a central clearinghouse.

Swaptions are used to mitigate the adverse impact resulting from significant changes in the fair value of U.S. dollar-denominated available-for-sale securities due to fluctuation in interest rates. In a payer swaption, the Company pays a premium to obtain the right, but not the obligation, to enter into a swap contract where it will pay a fixed rate and receive a floating rate. Interest rate swaption collars are combinations of two swaption positions. In order to maximize the efficiency of the collars while minimizing cost, a collar strategy is used whereby the Company purchases a long payer swaption (the Company purchases an option that allows it to enter into a swap where the Company will pay the fixed rate and receive the floating rate of the swap) and sells a short receiver swaption (the Company sells an option that provides the counterparty with the right to enter into a swap where the Company will receive the fixed rate and pay the floating rate of the swap). The combination of purchasing the long payer swaption and selling the short receiver swaption results in no net premium being paid (i.e. a costless or zero-cost collar).

Bond purchase commitments result from repackaged bond structures that are consolidated VIEs whereby there is a delay in the trade date and settlement date of the bond within the structure to ensure completion of all necessary legal agreements to support the consolidated VIE that issues the repackaged bond. Since the Company has a commitment to purchase the underlying bond at a specified price, the agreement meets the definition of a derivative where the value is derived based on the current market value of the bond compared to the fixed purchase price to be paid on the settlement date.

Derivative Balance Sheet Classification

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2024									December 31, 2023
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	4
Total cash flow hedges		18			0			5			18			0			4
Fair value hedges:
Foreign currency options		0			0			0			2,158			0			0
Total fair value hedges		0			0			0			2,158			0			0
Net investment hedge:
Foreign currency forwards		2,339			202			0			2,611			179			27
Foreign currency options		0			0			0			456			0			0
Total net investment hedge		2,339			202			0			3,067			179			27
Non-qualifying strategies:
Foreign currency swaps		1,200			24			0			1,200			31			0
Foreign currency swaps - VIE		3,417			57			578			3,417			55			503
Foreign currency forwards		0			0			0			7,402			59			477
Foreign currency options		28,715			38			69			22,557			2			0
Interest rate swaps		17,230			0			483			17,230			11			419
Total non-qualifying strategies		50,562			119			1,130			51,806			158			1,399
Total derivatives		$	52,919		$	321		$	1,135		$	57,049		$	337		$	1,430

27

Cash Flow Hedges

For certain variable-rate U.S. dollar-denominated available-for-sale securities held by Aflac Japan via consolidated VIEs, foreign currency swaps are used to swap the U.S. Dollar (USD) variable rate interest and principal payments to fixed rate Japanese Yen (JPY) interest and principal payments. The Company has designated foreign currency swaps as a hedge of the variability in cash flows of a forecasted transaction or of amounts to be received or paid related to a recognized asset (“cash flow” hedge). The remaining maximum length of time for which these cash flows are hedged is approximately three years. The derivatives in the Company's consolidated VIEs that are not designated as accounting hedges are discussed in the Non-qualifying Strategies section of this note.

Fair Value Hedges

The Company designates and accounts for certain foreign currency forwards, options, and interest rate swaptions as fair value hedges when they meet the requirements for hedge accounting. The Company recognizes gains and losses on these derivatives as well as the offsetting gain or loss on the related hedged items in current earnings.

Foreign currency forwards and options hedge the foreign currency exposure of certain U.S. dollar-denominated available-for-sale fixed-maturity investments held in Aflac Japan. The change in the fair value of the foreign currency forwards related to the changes in the difference between the spot rate and the forward price is excluded from the assessment of hedge effectiveness. The change in fair value of the foreign currency option related to the time value of the option is recognized in current earnings and is excluded from the assessment of hedge effectiveness.

Interest rate swaptions hedge the interest rate exposure of certain U.S. dollar-denominated available-for-sale securities held in Aflac Japan. For these hedging relationships, the Company excludes time value from the assessment of hedge effectiveness and recognizes changes in the intrinsic value of the swaptions in current earnings within net investment income. The change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into earnings (net investment income) over its legal term.

The following table presents the gains and losses on derivatives and the related hedged items in fair value hedges. The Company had no fair value hedges during the three-month period ending March 31, 2024.

Fair Value Hedging Relationships

(In millions)		Hedging Derivatives						Hedged Items
Hedging Derivatives	Hedged Items	Total Gains (Losses)		Gains (Losses) Excluded from Effectiveness Testing(1)		Gains (Losses) Included in Effectiveness Testing(2)		Gains (Losses)(2)		Net Investment Gains (Losses) Recognized for Fair Value Hedge
Three Months Ended March 31, 2023:
Foreign currency options	Fixed maturity securities	$	(39)	$	(39)	$	0	$	0	$	0
Total gains (losses)		$	(39)	$	(39)	$	0	$	0	$	0

(1) Gains (losses) excluded from effectiveness testing includes the forward point on foreign currency forwards and time value change on foreign currency options which are reported in the consolidated statements of earnings as net investment gains (losses). It also includes the change in the fair value of the interest rate swaptions related to the time value of the swaptions which is recognized as a component of other comprehensive income (loss).

(2) Gains and losses on foreign currency forwards and options and related hedged items are reported in the consolidated statements of earnings as net investment gains (losses). For interest rate swaptions and related hedged items, gains and losses included in the hedge assessment, premium amortization and time value amortization while the hedge items are still outstanding are reported within net investment income. The time value gains and losses for interest rate swaptions when the related hedged items are redeemed are reported in net investment gains (losses) consistent with the impact of the hedged item. For the three-month period ended March 31, 2023, gains and losses included in the hedge assessment on interest rate swaptions and related hedged items were immaterial.

28

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2024 and December 31, 2023; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2024		December 31, 2023		March 31, 2024		December 31, 2023
Fixed maturity securities		$	1,597	$	1,692	$	161	$	164

(1) The balance includes hedging adjustment on discontinued hedging relationships of $161 in 2024 and $164 in 2023.

Net Investment Hedge

The Company's investment in Aflac Japan is affected by changes in the yen/dollar exchange rate. To mitigate this exposure, the Parent Company's yen-denominated liabilities (see Note 9) have been designated as non-derivative hedges and certain foreign currency forwards and options have been designated as derivative hedges of the foreign currency exposure of the Company's net investment in Aflac Japan.

The Company's net investment hedge was effective during the three-month periods ended March 31, 2024 and 2023, respectively.

Non-qualifying Strategies

For the Company's derivative instruments in consolidated VIEs that do not qualify for hedge accounting treatment, all changes in their fair value are reported in current period earnings within net investment gains (losses). The amount of gain or loss recognized in earnings for the Company's VIEs is attributable to the derivatives in those investment structures. While the change in value of the swaps is recorded in current period earnings, the change in value of the available-for-sale fixed maturity securities associated with these swaps is recorded in other comprehensive income.

As of March 31, 2024, the Parent Company had $1.2 billion notional amount of cross-currency interest rate swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. Changes in the values of these swaps are recorded in current period earnings.

The Company uses foreign currency forwards and options to economically mitigate the currency risk of some of its U.S. dollar-denominated loan receivables and U.S. government fixed maturity securities held within the Aflac Japan segment. These arrangements are not designated as accounting hedges, as the foreign currency remeasurement of the loan receivables impacts current period earnings, and substantially offsets gains and losses from foreign currency forwards within net investment gains (losses). The Company also has certain foreign currency forwards on U.S. dollar-denominated available-for-sale securities where hedge accounting is not being applied.

The Company uses interest rate swaps to economically convert the variable rate investment income to a fixed rate on certain variable-rate investments.

29

Impact of Derivatives and Hedging Instruments

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2024										2023
(In millions)	Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)			Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	0		$	0		$	(1)			$	1
Total cash flow hedges		0			(1)		(3)		0			0			(1)		(3)		1
Fair value hedges:
Foreign currency options					0										(39)
Total fair value hedges					0										(39)
Net investment hedge:
Non-derivative hedging          instruments					0				236						0				25
Foreign currency forwards					44				145						90				29
Foreign currency options					0				0						(3)				0
Total net investment hedge					44				381						87				54
Non-qualifying strategies:
Foreign currency swaps					1										1
Foreign currency swaps - VIE					(88)										(27)
Foreign currency forwards					17										(51)
Foreign currency options					(41)										(19)
Interest rate swaps					(147)										69
Forward bond purchase          commitment - VIE					0										(3)
Total non-qualifying strategies					(258)										(30)
Total		$	0		$	(215)			$	381		$	0		$	17			$	55

(1) Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedge item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items.

(2) Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

(3) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2024, and $1 of losses during the three-month period ended March 31, 2023.

As of March 31, 2024, $5 million of deferred losses on derivative instruments recorded in accumulated other comprehensive income are expected to be reclassified into earnings during the next twelve months.

Credit Risk Assumed through Derivatives

For the foreign currency swaps associated with the Company's VIE investments for which it is the primary beneficiary, the Company bears the risk of loss due to counterparty default even though it is not a direct counterparty to those contracts.

The Company is a direct counterparty to the foreign currency swaps that it has entered into in connection with certain of its senior notes and subordinated debentures; foreign currency forwards; and foreign currency options, and therefore the Company is exposed to credit risk in the event of nonperformance by the counterparties in those contracts. The risk of counterparty default for the Company's foreign currency swaps, certain foreign currency forwards, and foreign currency options is mitigated by collateral posting requirements that counterparties to those transactions must meet.

As of March 31, 2024, all of the Company's derivative agreement counterparties were investment grade.

30

The Company engages in over-the-counter (OTC) bilateral derivative transactions directly with unaffiliated third parties under International Swaps and Derivatives Association, Inc. (ISDA) agreements and other documentation. Most of the ISDA agreements also include Credit Support Annexes (CSAs) provisions, which generally provide for two-way collateral postings at the first dollar of exposure. The Company mitigates the risk that counterparties to transactions might be unable to fulfill their contractual obligations by monitoring counterparty credit exposure and collateral value while generally requiring that collateral be posted at the outset of the transaction. In addition, a significant portion of the derivative transactions have provisions that give the counterparty the right to terminate the transaction upon a downgrade of the Company's financial strength rating. The actual amount of payments that the Company could be required to make depends on market conditions, the fair value of outstanding affected transactions, and other factors prevailing at and after the time of the downgrade.

The Company also engages in OTC cleared derivative transactions through regulated central clearing counterparties. These positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to these derivatives.

Collateral posted by the Company to third parties for derivative transactions can generally be repledged or resold by the counterparties. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position by counterparty was approximately $1.0 billion and $1.2 billion as of March 31, 2024, and December 31, 2023, respectively. If the credit-risk-related contingent features underlying these agreements had been triggered on March 31, 2024, the Company estimates that it would be required to post a maximum of $447 million of additional collateral to these derivative counterparties. The Company is generally allowed to sell or repledge collateral obtained from its derivative counterparties, although it does not typically exercise such rights. See the Offsetting tables below for collateral posted or received as of the reported balance sheet dates.

Offsetting of Financial Instruments and Derivatives

Most of the Company's derivative instruments are subject to enforceable master netting arrangements that provide for the net settlement of all derivative contracts between the Parent Company or its subsidiaries and the respective counterparty in the event of default or upon the occurrence of certain termination events. Collateral support agreements with the master netting arrangements generally provide that the Company will receive or pledge financial collateral at the first dollar of exposure.

The Company has securities lending agreements with unaffiliated financial institutions that post collateral to the Company in return for the use of its fixed maturity and public equity securities (see Note 3). When the Company has entered into securities lending agreements with the same counterparty, the agreements generally provide for net settlement in the event of default by the counterparty. This right of set-off allows the Company to keep and apply collateral received if the counterparty failed to return the securities borrowed from the Company as contractually agreed.

The tables below summarize the Company's derivatives and securities lending transactions, and as reflected in the tables, in accordance with U.S. GAAP, the Company's policy is to not offset these financial instruments in the consolidated balance sheets.

31

Offsetting of Financial Assets and Derivative Assets

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	264		$	0		$	264		$	(38)	$	(78)		$	(148)		$	0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		264			0			264			(38)		(78)			(148)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		57						57											57
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		57						57											57
Total derivative       assets		321			0			321			(38)		(78)			(148)			57
Securities lending    and similar    arrangements		3,334			0			3,334			0		0			(3,334)			0
Total		$	3,655		$	0		$	3,655		$	(38)	$	(78)		$	(3,482)		$	57

32

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	271		$	0		$	271		$	(85)	$	(53)		$	(130)		$	3
OTC - cleared		11			0			11			(11)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		282			0			282			(96)		(53)			(130)			3
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		55						55											55
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		55						55											55
Total derivative       assets		337			0			337			(96)		(53)			(130)			58
Securities lending    and similar    arrangements		1,480			0			1,480			0		0			(1,480)			0
Total		$	1,817		$	0		$	1,817		$	(96)	$	(53)		$	(1,610)		$	58

33

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	69		$	0		$	69		$	(38)	$	(31)		$	0		$	0
OTC - cleared		483			0			483			0		(27)			(456)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		552			0			552			(38)		(58)			(456)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		583						583											583
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		583						583											583
Total derivative       liabilities		1,135			0			1,135			(38)		(58)			(456)			583
Securities lending    and similar    arrangements		3,366			0			3,366			(3,334)		0			0			32
Total		$	4,501		$	0		$	4,501		$	(3,372)	$	(58)		$	(456)		$	615

34

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	504		$	0		$	504		$	(85)	$	(381)		$	(37)		$	1
OTC - cleared		419			0			419			(11)		(19)			(389)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		923			0			923			(96)		(400)			(426)			1
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		507						507											507
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		507						507											507
Total derivative       liabilities		1,430			0			1,430			(96)		(400)			(426)			508
Securities lending    and similar    arrangements		1,503			0			1,503			(1,480)		0			0			23
Total		$	2,933		$	0		$	2,933		$	(1,576)	$	(400)		$	(426)		$	531

For additional information on the Company's financial instruments, see the accompanying Notes 3 and 5 and Notes 1, 3 and 5 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

5.    FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

U.S. GAAP specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. These two types of inputs create three valuation hierarchy levels, as follows:

•Level 1 valuations reflect quoted market prices for identical assets or liabilities in active markets.

•Level 2 valuations reflect quoted market prices for similar assets or liabilities in an active market, quoted market prices for identical or similar assets or liabilities in non-active markets or model-derived valuations in which all significant valuation inputs are observable in active markets.

•Level 3 valuations reflect valuations in which one or more of the significant inputs are not observable in an active market.

35

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	19,976		$	838		$	0		$	20,814
Municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities		0			6,806			507			7,313
Sovereign and supranational		0			462			28			490
Banks/financial institutions		0			8,825			74			8,899
Other corporate		0			26,569			450			27,019
Total fixed maturity securities		19,976			48,236			1,918			70,130
Equity securities		603			0			159			762
Other investments		3,341			0			0			3,341
Cash and cash equivalents		5,098			0			0			5,098
Other assets:
Foreign currency swaps		0			81			0			81
Foreign currency forwards		0			202			0			202
Foreign currency options		0			38			0			38
Total other assets		0			321			0			321
Total assets		$	29,018		$	48,557		$	2,077		$	79,652
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	583		$	0		$	583
Foreign currency options		0			69			0			69
Interest rate swaps		0			483			0			483
Total liabilities		$	0		$	1,135		$	0		$	1,135

36

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	21,700		$	900		$	0		$	22,600
Municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities		0			7,339			253			7,592
Sovereign and supranational		0			507			30			537
Banks/financial institutions		0			8,757			78			8,835
Other corporate		0			27,694			648			28,342
Total fixed maturity securities		21,700			49,809			1,781			73,290
Equity securities		840			0			248			1,088
Other investments		1,304			0			0			1,304
Cash and cash equivalents		4,306			0			0			4,306
Other assets:
Foreign currency swaps		0			86			0			86
Foreign currency forwards		0			238			0			238
Foreign currency options		0			2			0			2
Interest rate swaps		0			11			0			11
Total other assets		0			337			0			337
Total assets		$	28,150		$	50,146		$	2,029		$	80,325
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	507		$	0		$	507
Foreign currency forwards		0			504			0			504
Interest rate swaps		0			419			0			419
Total liabilities		$	0		$	1,430		$	0		$	1,430

37

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,000		$	17,319		$	155		$	0		$	17,474
Municipalities		248			0			285			0			285
Public utilities		33			0			36			0			36
Sovereign and    supranational		391			0			431			0			431
Other corporate		17			0			19			0			19
Commercial mortgage and     other loans		12,360			0			0			12,017			12,017
Other investments (1)		42			0			42			0			42
Total assets		$	29,091		$	17,319		$	968		$	12,017		$	30,304
Liabilities:
Other policyholders’ funds		$	5,831		$	0		$	0		$	5,750		$	5,750
Notes payable    (excluding leases)		7,799			0			6,762			704			7,466
Total liabilities		$	13,630		$	0		$	6,762		$	6,454		$	13,216

(1) Excludes policy loans of $203, equity method investments of $2,838, and REO of $253, at carrying value.

38

	December 31, 2023
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	17,083		$	18,662		$	167		$	0		$	18,829
Municipalities		266			0			307			0			307
Public utilities		34			0			38			0			38
Sovereign and    supranational		418			0			462			0			462
Other corporate		18			0			21			0			21
Commercial mortgage and     other loans		12,527			0			0			12,217			12,217
Other investments (1)		35			0			35			0			35
Total assets		$	30,381		$	18,662		$	1,030		$	12,217		$	31,909
Liabilities:
Other policyholders’ funds		$	6,169		$	0		$	0		$	6,080		$	6,080
Notes payable    (excluding leases)		7,240			0			6,178			752			6,930
Total liabilities		$	13,409		$	0		$	6,178		$	6,832		$	13,010

(1) Excludes policy loans of $214, equity method investments of $2,750, and REO of $227, at carrying value.

Fair Value of Financial Instruments

Fixed maturity and equity securities

The fair values of the Company’s public fixed maturity securities are generally based on prices provided by third-party pricing vendors. The Company utilizes internally generated valuations or broker quotes for privately issued fixed maturity securities or fixed maturity securities where there is no price available from a third-party pricing vendor.

The fair values of the Company's public equity securities are generally based on price quotes, including quoted market prices readily available from independent public exchange markets or established security dealer associations. The Company determines the fair values of privately issued equity securities using the following approaches or techniques: price quotes and valuations from third-party pricing vendors, in-house valuations and non-binding price quotes the Company obtains from outside brokers.

The pricing data and market quotes the Company obtains from outside sources, including third-party pricing services, are reviewed internally for reasonableness. If a fair value appears unreasonable, the Company will re-examine the inputs and assess the reasonableness of the pricing data with the provider. Additionally, the Company may compare the inputs to relevant market indices and other performance measurements. Based on management's analysis, the valuation is confirmed or may be revised if there is evidence of a more appropriate estimate of fair value based on available market data. The Company has performed verification of the inputs and calculations in any valuation models, including independent validations and back testing, to confirm that the valuations represent reasonable estimates of fair value. For the periods presented, the Company has not adjusted the quotes or prices it obtains from the pricing services and brokers it uses.

For internally generated valuations, the Company utilizes valuation models developed by a third-party pricing vendor. The models and associated processes and controls are executed by Company personnel.

39

These models are discounted cash flow (DCF) valuation models but also use information from related markets, specifically public bond markets and the credit default swap (CDS) market, to estimate expected cash flows. The models take into consideration any unique characteristics of the securities and make various adjustments to arrive at an appropriate issuer-specific loss adjusted credit curve using the most appropriate comparable security(ies) of the issuer and issuer-specific CDS spreads. This credit curve is then used with the relevant recovery rates to estimate expected cash flows and modeling of additional features, including illiquidity adjustments, if necessary, to price the security by discounting those loss adjusted cash flows. In cases where a credit curve cannot be developed from market information for the specific issuer, the valuation methodology takes into consideration other market observable inputs, including:

•the most appropriate comparable security(ies) of a guarantor and/or parent

•CDS spreads of a guarantor and/or parent

•bonds of comparable issuers with similar characteristics such as rating, geography, or sector

•CDS spreads of an appropriate index or of comparable issuers with similar characteristics such as rating, geography, or sector

•bond indices that are comparative in rating, industry, maturity, and region.

40

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	19,976		$	505		$	0		$	20,481
Internal		0			333			0			333
Total government and agencies		19,976			838			0			20,814
Municipalities:
Third-party pricing vendor		0			1,943			0			1,943
Internal		0			267			0			267
Total municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,420			0			2,420
Internal		0			27			40			67
Broker/other		0			79			819			898
Total mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities:
Third-party pricing vendor		0			3,680			0			3,680
Internal		0			3,126			0			3,126
Broker/other		0			0			507			507
Total public utilities		0			6,806			507			7,313
Sovereign and supranational:
Third-party pricing vendor		0			125			0			125
Internal		0			337			0			337
Broker/other		0			0			28			28
Total sovereign and supranational		0			462			28			490
Banks/financial institutions:
Third-party pricing vendor		0			4,703			0			4,703
Internal		0			4,122			65			4,187
Broker/other		0			0			9			9
Total banks/financial institutions		0			8,825			74			8,899
Other corporate:
Third-party pricing vendor		0			21,282			0			21,282
Internal		0			5,277			249			5,526
Broker/other		0			10			201			211
Total other corporate		0			26,569			450			27,019
Total securities available-for-sale		$	19,976		$	48,236		$	1,918		$	70,130
Equity securities, carried at fair value:
Third-party pricing vendor		$	603		$	0		$	0		$	603
Broker/other		0			0			159			159
Total equity securities		$	603		$	0		$	159		$	762

41

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,319		$	155		$	0		$	17,474
Total government and agencies		17,319			155			0			17,474
Municipalities:
Third-party pricing vendor		0			285			0			285
Total municipalities		0			285			0			285
Public utilities:
Third-party pricing vendor		0			36			0			36
Total public utilities		0			36			0			36
Sovereign and supranational:
Third-party pricing vendor		0			213			0			213
Internal		0			218			0			218
Total sovereign and supranational		0			431			0			431
Other corporate:
Third-party pricing vendor		0			19			0			19
Total other corporate		0			19			0			19
Total securities held-to-maturity		$	17,319		$	926		$	0		$	18,245

42

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	21,692		$	808		$	0		$	22,500
Internal		0			60			0			60
Broker/other		8			32			0			40
Total government and agencies		21,700			900			0			22,600
Municipalities:
Third-party pricing vendor		0			1,426			0			1,426
Internal		0			256			0			256
Broker/other		0			616			0			616
Total municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,277			0			2,277
Internal		0			27			105			132
Broker/other		0			10			667			677
Total mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities:
Third-party pricing vendor		0			4,570			0			4,570
Internal		0			2,677			0			2,677
Broker/other		0			92			253			345
Total public utilities		0			7,339			253			7,592
Sovereign and supranational:
Third-party pricing vendor		0			118			0			118
Internal		0			330			0			330
Broker/other		0			59			30			89
Total sovereign and supranational		0			507			30			537
Banks/financial institutions:
Third-party pricing vendor		0			5,085			0			5,085
Internal		0			3,008			69			3,077
Broker/other		0			664			9			673
Total banks/financial institutions		0			8,757			78			8,835
Other corporate:
Third-party pricing vendor		0			18,088			4			18,092
Internal		0			4,210			230			4,440
Broker/other		0			5,396			414			5,810
Total other corporate		0			27,694			648			28,342
Total securities available-for-sale		$	21,700		$	49,809		$	1,781		$	73,290
Equity securities, carried at fair value:
Third-party pricing vendor		$	800		$	0		$	0		$	800
Internal		0			0			216			216
Broker/other		40			0			32			72
Total equity securities		$	840		$	0		$	248		$	1,088

43

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	18,662		$	167		$	0		$	18,829
Total government and agencies		18,662			167			0			18,829
Municipalities:
Third-party pricing vendor		0			307			0			307
Total municipalities		0			307			0			307
Public utilities:
Third-party pricing vendor		0			38			0			38
Total public utilities		0			38			0			38
Sovereign and supranational:
Third-party pricing vendor		0			226			0			226
Internal		0			236			0			236
Total sovereign and supranational		0			462			0			462
Other corporate:
Third-party pricing vendor		0			21			0			21
Total other corporate		0			21			0			21
Total securities held-to-maturity		$	18,662		$	995		$	0		$	19,657

The following is a discussion of the determination of fair value of the Company's remaining financial instruments.

Derivatives

The Company uses derivative instruments to manage the risk associated with certain assets. However, the derivative instrument may not be classified in the same fair value hierarchy level as the associated asset. The significant inputs to pricing derivatives are generally observable in the market or can be derived by observable market data. When these inputs are observable, the derivatives are classified as Level 2.

The Company uses present value techniques to value non-option based derivatives. It also uses option pricing models to value option based derivatives. Key inputs are as follows:

Instrument Type	Level 2
Interest rate derivatives	Swap yield curves Basis curves Interest rate volatility (1)
Foreign currency exchange rate derivatives - Non-VIEs (forwards, swaps and options)	Foreign currency forward rates Swap yield curves Basis curves Foreign currency spot rates Cross foreign currency basis curves Foreign currency volatility (1)
Foreign currency exchange rate derivatives - VIEs (swaps)	Foreign currency spot rates Swap yield curves Credit default swap curves Basis curves Recovery rates Foreign currency forward rates Foreign cross-currency basis curves

(1) Option-based only

44

The fair values of the foreign currency forwards and options are based on observable market inputs, therefore they are classified as Level 2.

The Parent Company has cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. Their fair values are based on observable market inputs, therefore they are classified as Level 2.

To determine the fair value of its interest rate derivatives, the Company uses inputs that are generally observable in the market or can be derived from observable market data. Interest rate swaps are cleared trades. In a cleared swap contract, the clearinghouse provides benefits to the counterparties similar to contracts listed for investment traded on an exchange since it maintains a daily margin to mitigate counterparties' credit risk. These derivatives are priced using observable inputs, accordingly, they are classified as Level 2.

For derivatives associated with VIEs where the Company is the primary beneficiary, the Company is not the direct counterparty to the swap contracts. Nevertheless, the Company has full transparency into the contracts to properly value the swaps for reporting purposes. For these derivatives, the Company utilizes valuation models developed by independent valuation analytics providers. The models are market standard DCF models and all associated processes and controls are executed by Company personnel. These models take into consideration any unique characteristics of the derivatives in determining the appropriate valuation methodology to estimate expected cash flows. The fair values of these swaps are based on observable market inputs and are classified as Level 2 within the fair value hierarchy.

For forward bond purchase commitments with VIEs, the fair value of the derivative is based on the difference in the fixed purchase price and the current market value of the related bond prior to the settlement date. Since the bond is typically a public bond with readily available pricing, the derivatives associated with the forward purchase commitment are classified as Level 2 within the fair value hierarchy.

Commercial mortgage and other loans

Commercial mortgage and other loans include TREs, CMLs, MMLs and other loans. The Company's loan receivables do not have readily determinable market prices and generally lack market liquidity. Fair values for loan receivables are determined based on the present value of expected future cash flows discounted at the applicable U.S. Treasury or floating-rate benchmark yield plus an appropriate spread that considers other risk factors, such as credit and liquidity risk. The spreads are a significant component of the pricing inputs and are generally considered unobservable. Therefore, these investments are classified as Level 3 within the fair value hierarchy.

Other investments

Other investments includes short-term investments that are measured at fair value where amortized cost approximates fair value.

Other policyholders' funds

The largest component of the other policyholders' funds liability is the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums. For this product, the Company estimates the fair value to be equal to the cash surrender value. This is analogous to the value paid to policyholders on the valuation date if they were to surrender their policy. The Company periodically checks the cash value against discounted cash flow projections for reasonableness. The Company considers its inputs for this valuation to be unobservable and have accordingly classified this valuation as Level 3.

Notes payable

The fair values of the Company's publicly issued notes payable are determined by utilizing available sources of observable inputs from third-party pricing vendors and are classified as Level 2. The fair values of the Company's yen-denominated loans approximate their carrying values and are classified as Level 3.

45

Transfers between Hierarchy Levels and Level 3 Rollforward

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales   and settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

Three Months Ended March 31, 2023
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	343	$	497	$	37	$	159	$	742	$	209	$	1,987
Net investment gains (losses) included   in earnings	0		0		0		0		0		2		2
Unrealized gains (losses) included in   other comprehensive income (loss)	3		10		0		2		30		0		45
Purchases, issuances, sales and   settlements:
Purchases	192		0		0		0		75		10		277
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(120)		(7)		0		0		(2)		0		(129)
Transfers into Level 3	0		18		0		0		0		0		18
Transfers out of Level 3	0		(168)		0		0		(92)		0		(260)
Balance, end of period	$	418	$	350	$	37	$	161	$	753	$	221	$	1,940
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	3	$	3

46

Fair Value Sensitivity

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	859	Consensus pricing	Offered quotes	85.28	-	105.35	(a)	99.24
Public utilities		507		Discounted cash flow	Credit spreads	175 bps	-	225 bps	(c)	208 bps
Sovereign and supranational		28		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		74		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		450		Discounted cash flow	Credit spreads	69 bps	-	388 bps	(c)	183 bps
Equity securities		159		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,077

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable.

December 31, 2023
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	772	Consensus pricing	Offered quotes	84.81	-	105.89	(a)	99.39
Public utilities		253		Consensus pricing	Offered quotes	94.34	-	102.99	(a)	96.46
Sovereign and supranational		30		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		78		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		648		Discounted cash flow	Credit spreads	69 bps	-	423 bps	(c)	206 bps
Equity securities		248		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,029

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable

47

The following is a discussion of the significant unobservable inputs or valuation techniques used in determining the fair value of securities classified as Level 3.

Credit Spreads

The Company holds certain assets that are of a unique, specialized, and/or securitized nature that do not trade on a regular basis in an active market, which makes their fair values difficult to estimate. Most of these assets are managed by external asset managers and the Company utilizes these managers for their expertise when evaluating various inputs used to determine the fair values for these assets, including identifying the appropriate credit or risk spread over risk-free interest rates that incorporates the unique nature or structure of the asset in the valuations. For those assets of a similar nature but not managed by external asset managers, the Company internally estimates the spreads and risk adjustments over risk-free interest rates that reflect the unique nature or structure of the asset as well as the current pricing environment and market conditions for comparable or related investments. Credit or risk spreads are an important input needed to complete the discounted cash flow analyses used to estimate an investment’s fair value. Credit or risk spreads underlying these fair values are a significant, unobservable input whose derivation is based on the Company’s evaluation of a combination of the external manager’s expertise and knowledge, the current pricing environment, and market conditions for the specific asset.

Offered Quotes

In circumstances where the Company's valuation model price is overridden because it implies a value that is not consistent with current market conditions, the Company will solicit bids from a limited number of brokers. The Company also receives unadjusted prices from brokers for certain of its mortgage and asset-backed securities. These quotes are non-binding but are reflective of valuation best estimates at that particular point in time. Offered quotes are an unobservable input in the determination of fair value of mortgage- and asset-backed securities, certain banks/financial institutions, certain other corporate, and equity securities investments.

Private Financials

The Company invests in the debt and equity securities of private companies operating in the cancer, healthtech, insurtech, finance, internet of things, big data and analytics sectors. Due to their private and often small, startup nature, these companies rely on capital provided by institutional and private equity investors for their ongoing operations. They do not have public securities that trade on a regular basis in an active market, which makes their fair values difficult to estimate. The Company values these investments on a cost basis with appropriate adjustments made based on monitoring private financial information provided by these companies. Adjustments to valuations are generally made as new funding tranches are executed or if the financial information provided significantly changes indicating the need for impairment. This private financial information is unobservable and is a significant determinant in the fair value of these corporate venture investments.

For additional information on the Company's investments and financial instruments, see the accompanying Notes 3 and 4 and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

6.     DEFERRED POLICY ACQUISITION COSTS

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

48

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	72		29		9		0		32		29		39		19		4		19		2		254
Amortization expense	(49)		(25)		(8)		(1)		(36)		(29)		(38)		(18)		(4)		(7)		0		(215)
Foreign currency translation and   other	(189)		(129)		(32)		(2)		0		0		0		0		0		0		0		(352)
Balance at March 31, 2024	$	2,805	$	1,916	$	460	$	53	$	913	$	625	$	1,337	$	437	$	86	$	184	$	3	$	8,819

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2022	$	3,035	$	2,161	$	525	$	55	$	904	$	613	$	1,304	$	418	$	88	$	135	$	1	$	9,239
Capitalization	317		123		33		8		151		125		173		84		10		61		1		1,086
Amortization expense	(184)		(105)		(34)		(3)		(138)		(113)		(141)		(66)		(12)		(24)		4		(816)
Foreign currency translation and   other	(197)		(138)		(33)		(4)		0		0		0		0		0		0		(5)		(377)
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132

The Company uses the following constant level bases to amortize deferred policy acquisition costs:

Policy Type	Constant-level Basis
Life Products (U.S.)	Face Amount
Health Products (U.S.)	Number of Policies in Force
Health & Life Products (Japan)	Units in Force

Face amount is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency.

There were no changes to the inputs, judgments, assumptions and methods used to determine amortization amounts during the three-month periods ended March 31, 2024 and 2023. For additional information on deferred policy acquisition costs, see Notes 1 and 6 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

49

7.    POLICY LIABILITIES

Future Policy Benefits

The liability for future policy benefits is determined as the present value of expected future policy benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of expected future net premiums receivable under the Company's insurance contracts. Future net premiums receivable are future gross premiums receivable under the contract multiplied by the net premium ratio (NPR).

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

50

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(46)		(52)		(19)		(5)		(18)		(10)		(48)		(14)		(4)		(8)		2
Adjusted beginning of period balance	16,406		13,988		6,239		1,064		2,612		1,728		4,368		1,179		213		901		274
Issuances	229		103		58		5		111		121		221		95		18		66		147
Interest accrual	97		77		28		4		26		16		43		11		2		9		3
Net premiums collected (1)	(369)		(290)		(226)		(26)		(117)		(99)		(139)		(58)		(10)		(37)		(8)
Foreign currency translation	(1,041)		(888)		(392)		(66)		0		0		0		0		0		0		0
Other	0		0		0		0		0		(1)		0		(1)		(1)		1		(1)
Ending balance at original discount rate	15,322		12,990		5,707		981		2,632		1,765		4,493		1,226		222		940		415
Effect of changes in discount rate assumptions	895		535		194		14		(173)		(99)		(412)		(99)		(14)		(66)		6
Balance at March 31, 2024	$	16,217	$	13,525	$	5,901	$	995	$	2,459	$	1,666	$	4,081	$	1,127	$	208	$	874	$	421
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(62)		(59)		(20)		(8)		(21)		(17)		(60)		(18)		(5)		(11)		2
Adjusted beginning of period balance	43,564		24,964		30,236		5,436		3,281		2,524		12,060		2,058		501		1,960		771
Issuances	232		105		59		7		115		128		233		99		16		70		151
Interest accrual	343		142		146		23		32		24		128		20		5		19		10
Benefit payments	(682)		(246)		(516)		(55)		(125)		(112)		(228)		(76)		(14)		(29)		(17)
Foreign currency translation	(2,757)		(1,582)		(1,909)		(345)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		1		0		1		1		0
Ending balance at original discount rate	40,700		23,383		28,016		5,066		3,303		2,564		12,194		2,101		509		2,021		915
Effect of changes in discount rate assumptions	5,689		(52)		(767)		(294)		(233)		(141)		(1,092)		(163)		(35)		(246)		15
Balance at March 31, 2024	46,389		23,331		27,249		4,772		3,070		2,423		11,102		1,938		474		1,775		930
Net liability for future policy benefits	30,172		9,806		21,348		3,777		611		757		7,021		811		266		901		509
Less: reinsurance recoverable	3,829		1,407		0		0		0		0		0		0		0		15		2
Net liability for future policy benefits after   reinsurance recoverable	$	26,343	$	8,399	$	21,348	$	3,777	$	611	$	757	$	7,021	$	811	$	266	$	886	$	507

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

51

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2022	$	19,298	$	16,714	$	7,485	$	1,256	$	2,534	$	1,635	$	4,486	$	1,220	$	211	$	724	$	110
Beginning balance at original discount rate	18,221		16,195		7,284		1,242		2,760		1,775		5,050		1,365		231		799		118
Effect of changes in cash flow assumptions	(165)		(470)		43		(12)		(16)		(51)		(494)		(142)		(9)		61		(9)
Effect of actual variances from expected    experience	(315)		(137)		(42)		(15)		(58)		(29)		(223)		(73)		(17)		(25)		(2)
Adjusted beginning of period balance	17,741		15,588		7,285		1,215		2,686		1,695		4,333		1,150		205		835		107
Issuances	1,034		418		335		26		323		376		493		249		44		181		169
Interest accrual	412		334		124		20		102		62		179		45		8		31		6
Net premiums collected (1)	(1,564)		(1,261)		(1,017)		(112)		(473)		(390)		(580)		(247)		(39)		(137)		(17)
Foreign currency translation	(1,170)		(1,038)		(469)		(80)		0		0		0		0		0		0		0
Other	(1)		(1)		0		0		(8)		(5)		(9)		(4)		(1)		(1)		7
Ending balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in discount rate assumptions	1,057		657		230		19		(142)		(86)		(342)		(86)		(11)		(56)		5
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Present value of expected future policy benefits:
Balance at December 31, 2022	$	54,766	$	27,419	$	31,954	$	5,582	$	3,098	$	2,445	$	11,489	$	2,074	$	488	$	1,526	$	622
Beginning balance at original discount rate	47,677		27,566		32,800		5,940		3,391		2,636		12,846		2,300		532		1,778		624
Effect of changes in cash flow assumptions	(147)		(507)		65		(27)		(11)		(59)		(592)		(194)		(14)		72		(13)
Effect of actual variances from expected    experience	(385)		(154)		(51)		(15)		(75)		(59)		(271)		(99)		(22)		(32)		(4)
Adjusted beginning of period balance	47,145		26,905		32,814		5,898		3,305		2,518		11,983		2,007		496		1,818		607
Issuances	1,059		432		341		32		331		392		505		258		46		185		169
Interest accrual	1,473		608		625		100		127		96		524		84		21		68		33
Benefit payments	(2,987)		(1,153)		(1,415)		(206)		(464)		(465)		(893)		(274)		(59)		(105)		(48)
Foreign currency translation	(3,064)		(1,769)		(2,109)		(380)		0		0		0		0		0		0		0
Other	0		0		0		0		3		0		1		1		2		5		8
Ending balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in discount rate assumptions	6,535		234		(525)		(266)		(193)		(119)		(830)		(133)		(28)		(207)		29
Balance at December 31, 2023	50,161		25,257		29,731		5,178		3,109		2,422		11,290		1,943		478		1,764		798
Net liability for future policy benefits	32,652		10,560		23,243		4,090		621		770		7,216		836		272		911		521
Less: reinsurance recoverable	4,135		1,521		0		0		0		0		0		0		0		15		0
Net liability for future policy benefits after    reinsurance recoverable	$	28,517	$	9,039	$	23,243	$	4,090	$	621	$	770	$	7,216	$	836	$	272	$	896	$	521

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

52

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	3.9 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.0 %	2.5 %	1.9 %	2.3 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.0	24.7	16.3	17.1	8.0	5.6	11.2	9.3	7.9	13.8	9.2

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2023
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.6 %	2.1 %	1.8 %	3.9 %	4.2 %	4.6 %	4.4 %	4.3 %	3.7 %	5.4 %
Weighted-average interest, current discount rate (1)	1.8 %	2.3 %	1.7 %	2.1 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.1	24.9	16.3	17.3	8.1	5.6	11.3	9.3	7.9	13.6	9.4

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

53

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2024			December 31, 2023
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	30,172		$	32,652
Medical and other health		9,806			10,560
Life insurance		21,348			23,243
Other		3,777			4,090
Aflac U.S.
Accident		611			621
Disability		757			770
Critical care		7,021			7,216
Hospital indemnity		811			836
Dental/vision		266			272
Life insurance		901			911
Other		509			521
Corporate and other		3,842			4,225
Deferred profit liability		1,734			1,806
Deferred reinsurance gain liability		910			1,012
Intercompany eliminations (1)		(4,598)			(5,017)
Total		$	77,867		$	83,718

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 for additional details.

Discount rates are determined using upper-medium grade (low-credit-risk) fixed-income instrument yields that reflect the duration characteristics of the liability. Locked-in discount rates are determined separately for each issue-year cohort as a single discount rate, calculated as the weighted-average of monthly upper-medium grade (low-credit-risk) fixed-income instrument forward curves in the calendar year, where the weights are the annualized premiums issued for each month of the cohort. The single discount rate for each issue-year cohort is determined by solving for a rate that produces an equivalent NPR to the forward curve and will remain unchanged after the calendar year of issue.

Discount rates are updated each reporting period and require estimation techniques (e.g., interpolation, extrapolation) for determination of points on the curve for which there is limited or no observable market data. The Company constructs a current discount rate curve separately for discounting cash flows used to calculate each of the Japan and U.S. liabilities for future policy benefits, reflective of the characteristics of the corresponding insurance liabilities, such as currency and tenor.

In the Aflac Japan segment, all long-duration insurance policies are denominated in yen. A significant portion of policies are characterized by tenors exceeding the availability of liquid market data in Japan for single-A rated (as a proxy for upper-medium grade) corporate yen-denominated debt. The discount rate curve is designed to prioritize the observable inputs where available, while past the last liquid point, the data is derived based on estimation techniques consistent with the fair value guidance in ASC 820. The Aflac Japan segment curve utilizes liquid market indices tracking publicly traded yen-denominated single-A corporate debt for the initial 10-year tenor. For the bonds within these market indices where only local ratings are available, the Company prioritizes the bonds with local ratings that are equivalent to a single-A rating based on international rating standards.

For the discount rates applicable to tenors for which the Japan single-A debt market is not liquid but there is sufficient observable market data and/or the observable market data is available for similar instruments (between 10 and 30 years), the Company estimates tenor-specific single-A credit spreads and applies them to risk-free government rates. Lastly, for the tenors where there is limited or no observable single-A or similar market data or risk-free government rates (beyond 30

54

years), the discount curve is derived by extrapolation of risk free rates beyond their last liquid point following the Smith-Wilson method and grading of the estimated forward credit spread anchored by the ultimate forward rate. The ultimate forward rate is based on the economic value-based solvency regime, which is consistent with the International Association of Insurance Supervisors (IAIS) Insurance Capital Standards (ICS) (which is expected to be introduced in Japan in 2025), and is adjusted for credit and inflation components.

For the Aflac U.S. segment where all long-duration insurance policies are denominated in U.S. dollar and substantially all have cash flow duration within 30 years, for which the U.S. upper-medium grade fixed-income market is liquid and observable, the Company uses data from a liquid fixed-income market index tracking single-A U.S. corporate debt. For the insignificant portion of the policies with cash flow tenors exceeding 30 years, the discount curve beyond that tenor is extrapolated following the Smith-Wilson method from year 30 to the same ultimate forward rate calculated for the Japan discount curve at year 60 and held constant thereafter. The use of the same ultimate rate for U.S. and Japan segments is based on the assumption of long-term global economic convergence.

For the three-month periods ended March 31, 2024 and 2023, the Company recognized $1.1 billion and $(2.8) billion in other comprehensive income (loss) net of tax, respectively, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the three-month periods ended March 31, 2024 and 2023.

For the year ended December 31, 2023, the Company recognized approximately $(460) million in other comprehensive income (loss) net of tax, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the year ended December 31, 2023.

Mortality rate assumptions are based on industry tables and adjusted for the Company's actual or expected experience where credible or appropriate. These assumptions typically vary by age, gender, and other demographic characteristics such as smoking status.

Morbidity assumptions are based on the Company's internal data and consider emerging experience. These assumptions are reflective of the coverage and benefits provided and generally vary by age, gender, duration, and any other material policyholder characteristics. In cases where a calendar-year trend is significant, future cash flow projections may include a trend adjustment.

In Japan, separate lapse assumptions are set based on actual or expected experience. These lapse and total termination rate assumptions vary by line of business and with policyholder characteristics such as duration. In the U.S., the majority of the future cash flows are modeled using total termination rates (which include both lapse and mortality) and are adjusted for actual experience. Policy provisions, such as reaching premium paid-up status, are taken into account when setting assumptions.

During the three-month periods ended March 31, 2024 and 2023, the variance of actual experience from expected experience was primarily due to favorable variances in morbidity assumptions as compared to actual experience. There were no changes to the inputs, judgments, assumptions and methods used in measuring the liability for future policy benefits during the three-month periods ended March 31, 2024 and 2023.

In 2023, the Company's annual assumption review process resulted in favorable changes to its morbidity and termination assumptions, largely due to reflecting more recent favorable U.S. morbidity experience.

55

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Net earned premiums:
Aflac Japan
Cancer	$	878	$	1,132
Medical and other health	605		689
Life insurance	339		399
Other	34		39
Aflac U.S.
Accident	325		329
Disability	333		309
Critical care	444		443
Hospital indemnity	185		184
Dental/vision	59		53
Life insurance	138		115
Other	20		10
Corporate and other	165		90
Reinsurance ceded	(69)		(104)
Total	$	3,456	$	3,688

The following table summarizes the amount of interest expense related to insurance contracts recognized in total benefits and claims, net in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Interest expense:
Aflac Japan
Cancer	$	246	$	285
Medical and other health	65		71
Life insurance	118		133
Other	19		22
Aflac U.S.
Accident	6		6
Disability	8		8
Critical care	85		87
Hospital indemnity	9		10
Dental/vision	3		3
Life insurance	10		9
Other	7		7
Total	$	576	$	641

56

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	55,096		$	61,876		$	59,169		$	66,427
Medical and other health		35,735			37,277			38,583			39,884
Life insurance		11,637			39,439			12,677			42,541
Other		1,646			6,923			1,781			7,448
Aflac U.S.
Accident		9,097			4,551			9,095			4,548
Disability		5,819			3,210			5,776			3,177
Critical care		20,008			20,712			19,886			20,626
Hospital indemnity		4,985			3,058			4,922			3,025
Dental/vision		1,161			729			1,162			726
Life insurance		2,824			3,367			2,719			3,260
Other		1,077			1,634			724			1,396
Total		$	149,085		$	182,776		$	156,494		$	193,058

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	44,795		$	46,389		$	48,363		$	50,161
Medical and other health		28,312			23,331			30,757			25,257
Life insurance		10,274			27,249			11,240			29,731
Other		1,391			4,772			1,512			5,178
Aflac U.S.
Accident		6,293			3,070			6,369			3,109
Disability		4,476			2,423			4,488			2,422
Critical care		12,295			11,102			12,417			11,290
Hospital indemnity		3,425			1,938			3,419			1,943
Dental/vision		794			474			807			478
Life insurance		1,963			1,775			1,914			1,764
Other		673			930			467			798
Total		$	114,691		$	123,453		$	121,753		$	132,131

Loss expense as a result of NPR capping for the three-month periods ended March 31, 2024 and 2023 was immaterial.

57

Other Policyholders' Funds

As of March 31, 2024 and December 31, 2023, the largest component of the other policyholders' funds liability was the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums.

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2024		December 31, 2023
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,939	$	6,423
Premiums received	29		126
Transfers from WAYS conversions	61		229
Surrenders and withdrawals	(18)		(59)
Benefit payments	(110)		(419)
Interest credited	13		53
Foreign currency translation and other	(376)		(414)
Fixed annuities account balance, end of period	5,538		5,939
Other deposit type reserves	293		230
Total	$	5,831	$	6,169

(1) Aflac Japan fixed annuities

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2024			December 31, 2023
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,538	$5,457	0.5% - 2.3%	$5,939	$5,850

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2024 and December 31, 2023.

Aflac Japan’s fixed annuities have guaranteed fixed crediting rates which results in the policyholders' funds balances being able to cover all guaranteed benefit amounts. The reserves are adequate to fully fund future benefits at any given time.

For additional information on policy liabilities, see Notes 1 and 7 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

8.    REINSURANCE

The Company periodically enters into fixed quota-share coinsurance agreements in the normal course of business, primarily to provide additional capacity for future growth, optimize capital, limit losses, and minimize exposure to significant risks. For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. For additional information on reinsurance, see Notes 1 and 8 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

58

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2024		2023
Direct earned premiums	$	3,482		$	3,738
Ceded to other companies:
Ceded Aflac Japan closed blocks	(34)			(82)
Other	(35)			(25)
Assumed from other companies:
Retrocession activities	29			34
Other	14			23
Net earned premiums	$	3,456		$	3,688
Direct benefits and claims, excluding reserve remeasurement	$	2,082		$	2,256
Ceded benefits and change in reserves for future benefits:
Ceded Aflac Japan closed blocks	(18)			(77)
Other	(15)			(27)
Assumed from other companies:
Retrocession activities	13			41
Other	4			10
Benefits and claims, excluding reserve remeasurement	$	2,066		$	2,203
Direct reserve remeasurement (gains) losses	$	(57)		$	(53)
Ceded reserve remeasurement gains (losses)	1			0
Assumed reserve remeasurement (gains) losses	0			0
Reserve remeasurement (gains) losses	$	(56)		$	(53)
Total benefits and claims, net	$	2,010		$	2,150

The Company has recorded a deferred reinsurance gain liability related to reinsurance transactions which represents ceded reserves in excess of consideration paid, or consideration received in excess of assumed reserves. The remaining deferred reinsurance gain liability of $161 million and $175 million as of March 31, 2024 and December 31, 2023, respectively, is included in future policy benefits in the consolidated balance sheets and is being amortized into income over the expected lives of the policies.

The Company has also recorded a reinsurance recoverable for reinsurance transactions. The reinsurance recoverable, which is included in other assets in the consolidated balance sheets, is reported net of allowance for credit losses and had a remaining balance of $178 million and $183 million as of March 31, 2024 and December 31, 2023, respectively. The allowance for credit losses related to the Company's reinsurance recoverable balance was $4 million and $10 million as of March 31, 2024 and December 31, 2023, respectively. The credit allowance for the reinsurance recoverable balance is estimated using a PD / LGD method and the key credit quality indicator is the credit rating of the Company’s reinsurance counterparty. The Company uses external credit ratings focused on the reinsurer’s financial strength and credit worthiness. As of March 31, 2024, the Company's reinsurance counterparties were rated A+. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

These reinsurance transactions are indemnity reinsurance that do not relieve the Company from its obligations to policyholders. In the event that the reinsurer is unable to meet its obligations, the Company remains liable for the reinsured claims.

Internal Reinsurance Transactions

Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. The inter-segment amounts associated with these internal reinsurance transactions are eliminated in consolidation.

59

9.    NOTES PAYABLE AND LEASE OBLIGATIONS

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2024			December 31, 2023
1.125% senior sustainability notes due March 2026		$	398		$	398
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		993			993
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		254			254
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		82			87
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		395			422
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			0
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		220			234
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		83			88
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		87			93
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		192			206
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		184			0
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		197			211
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		61			65
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		136			145
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		139			148
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		79			84
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		100			106
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			0
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			0
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		64			69
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		69			74
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		100			0
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		65			70
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			45
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		58			62
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		110			0
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		41			44
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		65			70
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		38			0
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		392			419
.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion) (1)		198			211
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		131			140
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		79			84
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		197			210
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		130			0
Yen-denominated loans:
Variable interest rate loan due August 2027 (.38% in 2024 and .35% in 2023,   principal amount ¥11.7 billion)		77			82
Variable interest rate loan due August 2029 (.48% in 2024 and .45% in 2023,   principal amount ¥25.3 billion)		166			178
Variable interest rate loan due August 2032 (.63% in 2024 and .60% in 2023,   principal amount ¥70.0 billion)		461			492
Finance lease obligations payable through 2030		6			6
Operating lease obligations payable through 2049		107			118
Total notes payable and lease obligations		$	7,912		$	7,364

(1) Redeemed in April 2024

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

60

In March 2024, the Parent Company issued five series of senior notes totaling ¥75.0 billion through a private placement. The first series, which totaled ¥18.3 billion, bears interest at a fixed rate of 1.600% per annum, payable semi-annually, and will mature in March 2034. The second series, which totaled ¥15.0 billion, bears interest at a fixed rate of 1.740% per annum, payable semi-annually, and will mature in March 2036. The third series, which totaled ¥16.5 billion, bears interest at a fixed rate of 1.920% per annum, payable semi-annually, and will mature in March 2039. The fourth series, which totaled ¥5.7 billion, bears interest at a fixed rate of 2.160% per annum, payable semi-annually, and will mature in March 2044. The fifth series, which totaled ¥19.5 billion, bears interest at a fixed rate of 2.400% per annum, payable semi-annually, and will mature in March 2054. These notes are redeemable at the Parent Company's option (i) in whole at any time or (ii) in part from time to time in an amount not less than 5% of the aggregate principal amount then outstanding of the notes to be redeemed.

In March 2024, the Parent Company issued three series of senior notes totaling ¥48.6 billion through a public debt offering under its U.S. shelf registration statement. The first series, which totaled ¥13.0 billion, bears interest at a fixed rate of 1.048% per annum, payable semi-annually, and will mature in March 2029. The second series, which totaled ¥27.9 billion, bears interest at a fixed rate of 1.412% per annum, payable semi-annually, and will mature in March 2031. The third series, which totaled ¥7.7 billion, bears interest at a fixed rate of 1.682% per annum, payable semi-annually, and will mature in March 2034. These notes are redeemable at the Parent Company’s option at any time, in whole but not in part, upon the occurrence of certain changes affecting U.S. taxation, as specified in the indenture governing the terms of the issuance. In addition, the notes maturing in March 2029, March 2031 and March 2034 are redeemable at the Parent Company's option, in whole or in part from time to time, on or after December 21, 2028, December 31, 2030 and September 21, 2033, respectively, at a redemption price equal to the aggregate principal amount of the applicable series to be redeemed plus accrued and unpaid interest on the principal amount to be redeemed to, but excluding, the date of redemption.

Interest expense related to the Company's notes payable, which is included in interest expense in the consolidated statements of earnings, was $46 million and $47 million for the three-month periods ended March 31, 2024 and 2023, respectively.

61

A summary of the Company's lines of credit as of March 31, 2024 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 6, 2024	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar denominated borrowings or TIBOR for Japanese yen denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 2, 2024	$250 million	$50 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 3, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac New York(1),(2)	uncommitted revolving	364 days	April 8, 2024	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than April 9, 2024	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	March 21, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(2) Renewed in April 2024 with an expiration date of April 8, 2025

(continued)

62

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	March 21, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes
Hatch Healthcare K.K.(1)	uncommitted revolving	364 days	January 2, 2025	¥900 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac Digital Services Co., Ltd.(1)	uncommitted revolving	364 days	January 2, 2025	¥600 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	July 16, 2024	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than July 17, 2024	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes

(1) Intercompany credit agreement

The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2024. No events of default or defaults occurred during the three-month period ended March 31, 2024.

For additional information, see Notes 4 and 9 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

63

10.    SHAREHOLDERS’ EQUITY

The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2024	2023
Common stock - issued:
Balance, beginning of period	1,355,398	1,354,079
Exercise of stock options and issuance of restricted shares	1,082	933
Balance, end of period	1,356,480	1,355,012
Treasury stock:
Balance, beginning of period	776,919	738,823
Purchases of treasury stock:
Share repurchase program	9,276	10,348
Other	457	347
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(212)	(239)
Exercise of stock options	(55)	(48)
Other	(183)	(171)
Balance, end of period	786,202	749,060
Shares outstanding, end of period	570,278	605,952

Outstanding share-based awards are excluded from the calculation of weighted-average shares used in the computation of basic earnings per share (EPS). The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2024	2023
Anti-dilutive share-based awards	69		164

Share Repurchase Program

During the first three months of 2024, the Company repurchased 9.3 million shares of its common stock for $750 million as part of its share repurchase program. During the first three months of 2023, the Company repurchased 10.3 million shares of its common stock for $700 million as part of its share repurchase program. As of March 31, 2024, a remaining balance of 68.5 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

64

Reclassifications from Accumulated Other Comprehensive Income

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2023
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2022		$	(3,564)		$	(702)		$	(27)		$	(2,100)		$	(36)		$	(6,429)
Other comprehensive    income (loss) before    reclassification		(54)			2,036			0			(2,794)			7			(805)
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(45)			1			0			0			(44)
Net current-period other    comprehensive    income (loss)		(54)			1,991			1			(2,794)			7			(849)
Balance at March 31, 2023		$	(3,618)		$	1,289		$	(26)		$	(4,894)		$	(29)		$	(7,278)

All amounts in the table above are net of tax.

65

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

(In millions)	Three Months Ended March 31, 2023
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	57	Net investment gains (losses)
		(12)		Tax (expense) or benefit(1)
		$	45	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	44	Net of tax

(1) Based on 21% tax rate

11.    SHARE-BASED COMPENSATION

As of March 31, 2024, the Company has outstanding share-based awards under the Aflac Incorporated Long-Term Incentive Plan (As Amended and Restated February 14, 2017), as further amended on August 9, 2022 (the Plan). Share-based awards are designed to reward employees for their long-term contributions to the Company and provide incentives for them to remain with the Company. The number and frequency of share-based awards are based on competitive practices, operating results of the Company, government regulations, and other factors.

The Plan, allows for a maximum number of shares issuable over its term of 75 million shares including 38 million shares that may be awarded in respect of awards other than options or stock appreciation rights. If any awards granted under the Plan are forfeited or are terminated before being exercised or settled for any reason other than tax forfeiture, then the shares underlying the awards will again be available under the Plan.

The Plan allows awards to Company employees for incentive stock options (ISOs), non-qualifying stock options (NQSOs), restricted stock, restricted stock units, and stock appreciation rights. Non-employee directors are eligible for grants of NQSOs, restricted stock, and stock appreciation rights. As of March 31, 2024, approximately 33.6 million shares were available for future grants under this plan. The ISOs and NQSOs have a term of 10 years, and the share-based awards generally vest upon time-based conditions or time and performance-based conditions. Time-based vesting generally occurs after three years. Performance-based vesting conditions generally include the attainment of goals related to Company financial performance. As of March 31, 2024, the only performance-based awards issued and outstanding were restricted stock awards and units.

66

Stock options and stock appreciation rights granted under the amended Plan have an exercise price of at least the fair market value of the underlying stock on the grant date and have an expiration date no later than 10 years from the grant date. Time-based restricted stock awards, restricted stock units and stock options generally vest on a ratable basis over three years. The Compensation Committee of the Board of Directors has the discretion to determine vesting schedules.

Share-based awards granted to U.S.-based grantees are settled with authorized but unissued Company stock, while those issued to Japan-based grantees are settled with treasury shares.

The following table provides information on stock options outstanding and exercisable at March 31, 2024.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		856		2.2		$	45		$	33.37
Exercisable		856		2.2		45			33.37

The Company received cash from the exercise of stock options in the amount of $5 million and $4 million during the first three months of 2024 and 2023, respectively. The tax benefit realized as a result of stock option exercises and restricted stock releases was $24 million in the first three months of 2024, compared with $17 million in the first three months of 2023.

As of March 31, 2024, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock awards and units was $74 million, of which $40 million (1.8 million shares) was related to restricted stock awards and units with a performance-based vesting condition. The Company expects to recognize these amounts over a weighted-average period of approximately 1.9 years. There are no other contractual terms covering restricted stock awards once vested.

The following table summarizes restricted stock activity during the three-month period ended March 31, 2024.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2023	2,308		$	62.96
Granted in 2024	1,213		79.75
Canceled in 2024	(7)		67.50
Vested in 2024	(1,337)		49.24
Restricted stock at March 31, 2024	2,177		$	72.33

In February 2024, the Company granted 303 thousand performance-based stock awards and units, which are contingent on the achievement of the Company's financial performance metrics and its market-based conditions. On the date of grant, the Company estimated the fair value of restricted stock awards and units with market-based conditions using a Monte Carlo simulation model. The model discounts the value of the stock at the assumed vesting date based on the risk-free interest rate. Based on estimates of actual performance versus the vesting thresholds, the calculated fair value percentage payout estimate will be updated each quarter.

The Company uses third-party analyses to assist in developing the assumptions used in, as well as calibrating, a Monte Carlo simulation model. The Company is responsible for determining the assumptions used in estimating the fair value of its share-based payment awards.

For additional information on the Company's long-term share-based compensation plans and the types of share-based awards, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report.

12.    BENEFIT PLANS

The Company has funded defined benefit plans in Japan and the U.S.; however, future benefits under the U.S. plan were frozen effective January 1, 2024. U.S. employees, including those that participated in the U.S. plan prior to the freeze, currently receive a nonelective 401(k) employer contribution.

67

The Company also maintains non-qualified, unfunded supplemental retirement plans that provide defined pension benefits in excess of limits imposed by federal tax law for certain Japanese, U.S. and former employees. However, future benefits under the Company's Supplemental Executive Retirement Plan and Retirement Plan for Senior Officers were frozen effective January 1, 2024, provided that actively employed participants may continue to accrue service toward eligibility for early retirement benefits or delayed early retirement benefits.

The Company provides certain health care benefits for eligible U.S. retired employees, their beneficiaries and covered dependents (other postretirement benefits). The health care plan is contributory and unfunded. Effective January 1, 2014, employees eligible for benefits included the following: (1) active employees whose age plus service, in years, equaled or exceeded 80 (rule of 80); (2) active employees who were age 55 or older and have met the 15 years of service requirement; (3) active employees who would meet the rule of 80 in the next five years; (4) active employees who were age 55 or older and who would meet the 15 years of service requirement within the next five years; and (5) current retirees. For certain employees and former employees, additional coverage is provided for all medical expenses for life.

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $2 million for both the three-month periods ended March 31, 2024 and 2023. Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2024			2023			2024			2023			2024			2023
Components of net periodic   benefit cost:
Service cost		$	4		$	4		$	0		$	4		$	0		$	0
Interest cost		2			2			9			11			0			0
Expected return on plan assets		(2)			(2)			(7)			(9)			0			0
Amortization of net actuarial loss		0			0			0			0			0			0
Net periodic (benefit) cost		$	4		$	4		$	2		$	6		$	0		$	0

During the three months ended March 31, 2024, Aflac Japan contributed approximately $6 million (using the weighted-average yen/dollar exchange rate for the three-month period ended March 31, 2024) to the Japanese funded defined benefit plan, and Aflac U.S. did not make a contribution to the U.S. funded defined benefit plan.

For additional information regarding the Company's Japanese and U.S. benefit plans, see Note 14 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

13.    COMMITMENTS AND CONTINGENT LIABILITIES

The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business. Members of the Company's senior legal and financial management teams review litigation and regulatory inquiries on a quarterly and annual basis. The final results of any litigation or regulatory inquiries cannot be predicted with certainty. Although some of this litigation is pending in states where large punitive damages, bearing little relation to the actual damages sustained by plaintiffs, have been awarded in recent years, the Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

See Note 3 for details on certain investment commitments.

68

Guaranty Fund Assessments

The U.S. insurance industry has a policyholder protection system that is monitored and regulated by state insurance departments. These life and health insurance guaranty associations are state entities (in all 50 states as well as Puerto Rico and the District of Columbia) created to protect policyholders of an insolvent insurance company. All insurance companies (with limited exceptions) licensed to sell life or health insurance in a state must be members of that state’s guaranty association. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business.

Guaranty fund assessments for the three-month periods ended March 31, 2024 and 2023 were immaterial.

For additional information regarding commitments and contingent liabilities, see Note 15 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

69

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

FORWARD-LOOKING INFORMATION

The Private Securities Litigation Reform Act of 1995 provides a safe harbor to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. Aflac Incorporated (the Parent Company) and its subsidiaries (collectively with the Parent Company, the Company) desire to take advantage of these provisions. This report contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by Company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as the ones listed below or similar words, as well as specific projections of future results, generally qualify as forward-looking. The Company undertakes no obligation to update such forward-looking statements.

• expect	• anticipate	• believe	• goal	• objective
• may	• should	• estimate	• intends	• projects
• will	• assumes	• potential	• target	• outlook

The Company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements:

•difficult conditions in global capital markets and the economy, including inflation

•defaults and credit downgrades of investments

•global fluctuations in interest rates and exposure to significant interest rate risk

•concentration of business in Japan

•limited availability of acceptable yen-denominated investments

•foreign currency fluctuations in the yen/dollar exchange rate

•differing interpretations applied to investment valuations

•significant valuation judgments in determination of expected credit losses recorded on the Company's investments

•decreases in the Company's financial strength or debt ratings

•decline in creditworthiness of other financial institutions

•the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners

•deviations in actual experience from pricing and reserving assumptions

•ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives

•interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality, integrity or privacy of sensitive data residing on such systems

•subsidiaries' ability to pay dividends to the Parent Company

•inherent limitations to risk management policies and procedures

•operational risks of third-party vendors

•tax rates applicable to the Company may change

•failure to comply with restrictions on policyholder privacy and information security

•extensive regulation and changes in law or regulation by governmental authorities

•competitive environment and ability to anticipate and respond to market trends

•catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events

•ability to protect the Aflac brand and the Company's reputation

•ability to effectively manage key executive succession

•changes in accounting standards

•level and outcome of litigation or regulatory inquiries

•allegations or determinations of worker misclassification in the United States

70

MD&A OVERVIEW

MD&A is intended to inform the reader about matters affecting the financial condition and results of operations of Aflac Incorporated and its subsidiaries for the three-month periods ended March 31, 2024 and 2023, respectively. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, the following discussion should be read in conjunction with the consolidated financial statements and notes that are included in the Company's annual report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report). In this MD&A, amounts may not foot due to rounding.

This MD&A is divided into the following sections:

	Page
Executive Summary	72
Results of Operations	73
Investments	89
Hedging Activities	94
Deferred Policy Acquisition Costs	97
Policy Liabilities	98
Benefit Plans	98
Policyholder Protection	98
Liquidity and Capital Resources	98
Critical Accounting Estimates	104

71

EXECUTIVE SUMMARY

Company Overview

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) provide financial protection to millions of policyholders and customers in Japan and the United States (U.S.). The Company’s principal business is supplemental health and life insurance products with the goal to provide customers the best value in supplemental insurance products in Japan and the U.S. The Company's insurance business consists of two reporting segments: Aflac Japan and Aflac U.S. The Parent Company’s primary insurance subsidiaries are Aflac Life Insurance Japan Ltd. in Japan (Aflac Japan) and American Family Life Assurance Company of Columbus (Aflac); Continental American Insurance Company (CAIC), branded as Aflac Group Insurance (AGI); American Family Life Assurance Company of New York (Aflac New York); Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS), which provides a platform for Aflac Dental and Vision in the U.S. (collectively, Aflac U.S.). The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd. (Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Performance Highlights

Total revenues were $5.4 billion in the first three months of 2024, compared with $4.8 billion in the first three months of 2023, reflecting net investment gains. Net earnings were $1.9 billion, or $3.25 per diluted share, in the first three months of 2024, compared with $1.2 billion, or $1.94 per diluted share, in the first three months of 2023.

Results in the first three months of 2024 included pretax net investment gains of $951 million, compared with pretax net investment gains of $123 million in the first three months of 2023. Net investment gains in the first three months of 2024 included an increase in credit loss allowances of $1 million; $703 million of net gains from certain derivative and foreign currency gains or losses; $76 million of net gains on equity securities; and $173 million of net gains from sales and redemptions.

The average yen/dollar exchange rate(1) for the three-month period ended March 31, 2024 was 148.67, or 11.0% weaker than the average yen/dollar exchange rate(1) of 132.30 for the same period in 2023.

Adjusted earnings(2) in the first three months of 2024 were $961 million, or $1.66 per diluted share, compared with $953 million, or $1.55 per diluted share, in the first three months of 2023. The weaker yen/dollar exchange rate negatively impacted adjusted earnings per diluted share by $.08.

In the first three months of 2024, Aflac Incorporated repurchased $750 million, or 9.3 million of its common shares. At March 31, 2024, the Company had 68.5 million remaining shares authorized for repurchase.

Shareholders’ equity was $23.5 billion, or $41.27 per share, at March 31, 2024, compared with $22.0 billion, or $38.00 per share, at December 31, 2023. Shareholders’ equity at March 31, 2024 included a cumulative decrease of $1.5 billion from the effect of changes in discount rate assumptions on insurance contracts, compared with a corresponding cumulative decrease of $2.6 billion at December 31, 2023, and a net unrealized gain on investment securities and derivatives of $1.1 billion, compared with a net unrealized gain of $1.1 billion at December 31, 2023. Shareholders’ equity at March 31, 2024 also included an unrealized foreign currency translation loss of $4.7 billion, compared with an unrealized foreign currency translation loss of $4.1 billion at December 31, 2023. The annualized return on average shareholders’ equity in the first quarter of 2024 was 33.0%.

Shareholders’ equity excluding accumulated other comprehensive income (AOCI)(2) (adjusted book value) was $28.6 billion, or $50.22 per share at March 31, 2024, compared with $27.5 billion, or $47.55 per share, at December 31, 2023. The annualized adjusted return on equity (ROE) excluding foreign currency impact(2) in the first quarter of 2024 was 14.3%.

(1) Yen/U.S. dollar exchange rates are based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

(2) See the Results of Operations section of this MD&A for a definition of this non-U.S. GAAP financial measure.

72

RESULTS OF OPERATIONS

The Company earns its revenues principally from insurance premiums and investments. The Company’s operating expenses primarily consist of insurance benefits provided and reserves established for anticipated future insurance benefits, general business expenses, commissions and other costs of selling and servicing its products. Profitability for the Company depends principally on its ability to price its insurance products at a level that enables the Company to earn a margin over the costs associated with providing benefits and administering those products. Profitability also depends on, among other items, actuarial and policyholder behavior experience on insurance products, and the Company's ability to attract and retain customer assets, generate and maintain favorable investment results, effectively deploy capital and utilize tax capacity, and manage expenses.

This document includes references to the Company’s financial performance measures which are not calculated in accordance with United States generally accepted accounting principles (U.S. GAAP) (non-U.S. GAAP). The financial measures exclude items that the Company believes may obscure the underlying fundamentals and trends in insurance operations because they tend to be driven by general economic conditions and events or related to infrequent activities not directly associated with insurance operations.

Due to the size of Aflac Japan, where the functional currency is the Japanese yen, fluctuations in the yen/dollar exchange rate can have a significant effect on reported results. In periods when the yen weakens, translating yen into dollars results in fewer dollars being reported. When the yen strengthens, translating yen into dollars results in more dollars being reported. Consequently, yen weakening has the effect of suppressing current period results in relation to the comparable prior period, while yen strengthening has the effect of magnifying current period results in relation to the comparable prior period. A significant portion of the Company’s business is conducted in yen and never converted into dollars but translated into dollars for U.S. GAAP reporting purposes, which results in foreign currency impact to earnings, cash flows and book value on a U.S. GAAP basis. Management evaluates the Company's financial performance both including and excluding the impact of foreign currency translation to monitor, respectively, cumulative currency impacts and the currency-neutral operating performance over time. The average yen/dollar exchange rate is based on the published MUFG Bank, Ltd. telegraphic transfer middle rate (TTM).

The Company defines the non-U.S. GAAP financial measures included in this document as follows:

•Adjusted earnings are adjusted revenues less benefits and adjusted expenses. Adjusted earnings per share (basic or diluted) are the adjusted earnings for the period divided by the weighted average outstanding shares (basic or diluted) for the period presented. The adjustments to both revenues and expenses account for certain items that are outside of management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. Adjusted revenues are U.S. GAAP total revenues excluding adjusted net investment gains and losses. Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company's underlying business performance. Management uses adjusted earnings and adjusted earnings per diluted share to evaluate the financial performance of the Company’s insurance operations on a consolidated basis and believes that a presentation of these financial measures is vitally important to an understanding of the underlying profitability drivers and trends of the Company’s insurance business. The most comparable U.S. GAAP financial measures for adjusted earnings and adjusted earnings per share (basic or diluted) are net earnings and net earnings per share, respectively.

•Adjusted net investment gains and losses are net investment gains and losses adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity, ii) net interest income/expense from foreign currency and interest rate derivatives associated with certain investment strategies, which are both reclassified to net investment income, and iii) the impact of interest from derivatives associated with notes payable, which is reclassified to interest expense as a component of total adjusted expenses. The Company considers adjusted net investment gains and losses important as it represents the remainder amount that is considered outside management’s control, while excluding the components that are within management’s control and are accordingly reclassified to net investment income and interest expense. The most comparable U.S. GAAP financial measure for adjusted net investment gains and losses is net investment gains and losses.

•Amortized hedge costs/income represent costs/income incurred or recognized as a result of using foreign currency derivatives to hedge certain foreign exchange risks in the Company's Japan segment or in Corporate and other. These amortized hedge costs/income are estimated at the inception of the derivatives based on the

73

specific terms of each contract and are recognized on a straight-line basis over the contractual term of the derivative. The Company believes that amortized hedge costs/income measure the periodic currency risk management costs/income related to hedging certain foreign currency exchange risks and are an important component of net investment income. There is no comparable U.S. GAAP financial measure for amortized hedge costs/income.

•Adjusted earnings excluding current period foreign currency impact are computed using the average foreign currency exchange rate for the comparable prior-year period, which eliminates fluctuations driven solely by foreign currency exchange rate changes. Adjusted earnings per diluted share excluding current period foreign currency impact is adjusted earnings excluding current period foreign currency impact divided by the weighted average outstanding diluted shares for the period presented. The Company considers adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact important because a significant portion of the Company's business is conducted in Japan and foreign exchange rates are outside management’s control; therefore, the Company believes it is important to understand the impact of translating foreign currency (primarily Japanese yen) into U.S. dollars. The most comparable U.S. GAAP financial measures for adjusted earnings excluding current period foreign currency impact and adjusted earnings per diluted share excluding current period foreign currency impact are net earnings and net earnings per share, respectively.

•Adjusted book value is the U.S. GAAP book value (representing total shareholders’ equity), less AOCI as recorded on the U.S. GAAP balance sheet. Adjusted book value per common share is adjusted book value at the period end divided by the ending outstanding common shares for the period presented. The Company considers adjusted book value and adjusted book value per common share important as they exclude AOCI, which fluctuates due to market movements that are outside management’s control. The most comparable U.S. GAAP financial measures for adjusted book value and adjusted book value per common share are total book value and total book value per common share, respectively.

•Adjusted return on equity excluding foreign currency impact is adjusted earnings excluding the current period foreign currency impact divided by average shareholders’ equity, excluding AOCI. The Company considers adjusted return on equity excluding foreign currency impact important as it excludes changes in foreign currency and components of AOCI, which fluctuate due to market movements that are outside management's control. The most comparable U.S. GAAP financial measure for adjusted return on equity excluding foreign currency impact is return on average equity (ROE) as determined using net earnings and average total shareholders’ equity.

•U.S. dollar-denominated investment income excluding foreign currency impact represents amounts excluding foreign currency impact on U.S. dollar-denominated investment income using the average foreign currency exchange rate for the comparable prior year period. The Company considers U.S. dollar-denominated investment income excluding foreign currency impact important as it eliminates the impact of foreign currency changes on the Aflac Japan segment results, which are outside management’s control. The most comparable U.S. GAAP financial measure for U.S. dollar-denominated investment income excluding foreign currency impact is the corresponding net investment income amount from the U.S. dollar denominated investments translated to yen.

74

The following table is a reconciliation of items impacting adjusted earnings and adjusted earnings per diluted share to the most directly comparable U.S. GAAP financial measures of net earnings and net earnings per diluted share, respectively.

Reconciliation of Net Earnings to Adjusted Earnings

	In Millions				Per Diluted Share
	Three Months Ended March 31,
	2024		2023		2024		2023
Net earnings	$	1,879	$	1,188	$	3.25	$	1.94
Items impacting net earnings:
Adjusted net investment (gains) losses (1)	(1,009)		(209)		(1.75)		(.34)
Other and non-recurring (income) loss	2		0		.00		.00
Income tax (benefit) expense on items excluded from adjusted earning	89		(26)		.15		(.04)
Adjusted earnings	961		953		1.66		1.55
Current period foreign currency impact (2)	44		N/A		.08		N/A
Adjusted earnings excluding current period foreign currency impact	$	1,005	$	953	$	1.74	$	1.55

(1) See reconciliation of net investment (gains) losses to adjusted net investment (gains) losses below.

(2) Prior period foreign currency impact reflected as “N/A” to isolate change for current period only.

Reconciling Items

Net Investment Gains and Losses

Reconciliation of Net Investment (Gains) Losses to Adjusted Net Investment (Gains) Losses

	Three Months Ended March 31,
(In millions)	2024		2023
Net investment (gains) losses	$	(951)	$	(123)
Items impacting net investment (gains) losses:
Amortized hedge costs	(6)		(58)
Amortized hedge income	28		29
Net interest income (expense) from derivatives associated   with certain investment strategies	(88)		(69)
Impact of interest from derivatives associated with notes payable	8		12
Adjusted net investment (gains) losses	$	(1,009)	$	(209)

The Company's investment strategy is to invest primarily in fixed maturity securities to provide a reliable stream of investment income, which is one of the drivers of the Company’s profitability. This investment strategy incorporates asset-liability matching (ALM) to align the expected cash flows of the portfolio to the needs of the Company's liability structure. The Company does not purchase securities with the intent of generating investment gains or losses. However, investment gains and losses may be realized as a result of changes in the financial markets and the creditworthiness of specific issuers, tax planning strategies, and/or general portfolio management and rebalancing. The realization of investment gains and losses is independent of the underwriting and administration of the Company's insurance products.

Net investment gains and losses excluded from adjusted earnings include the following:

•Securities Transactions

•Credit Losses

•Changes in the Fair Value of Equity Securities

•Certain Derivative and Foreign Currency Activities.

75

Securities Transactions, Credit Losses and Changes in the Fair Value of Equity Securities

Securities transactions include gains and losses from sales and redemptions of investments where the amount received is different from the amortized cost of the investment. Credit losses include losses for held-to-maturity fixed maturity securities, available-for-sale fixed maturity securities, loan receivables, loan commitments and reinsurance recoverables. Changes in the fair value of equity securities are the result of gains or losses driven by fluctuations in market prices.

Certain Derivative and Foreign Currency Activities

The Company's derivative activities include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency interest rate swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with variable interest entity (VIE) bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Gains and losses are recognized as a result of valuing these derivatives, net of the effects of hedge accounting. The Company also excludes from adjusted earnings the accounting impacts of remeasurement associated with changes in the foreign currency exchange rate.

For additional information regarding net investment gains and losses, including details of reported amounts for the periods presented, see Notes 3 and 4 of the Notes to the Consolidated Financial Statements.

Other and Non-recurring Items

The U.S. insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. The system can result in periodic charges to the Company as a result of insolvencies/bankruptcies that occur with other companies in the life insurance industry. Some states permit member insurers to recover assessments paid through full or partial premium tax offsets. These charges neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, but result from external situations not controlled by the Company. The Company excludes any charges associated with U.S. guaranty fund assessments and the corresponding tax benefit or expense from adjusted earnings.

In Japan, the government also requires the insurance industry to contribute to a policyholder protection corporation that provides funds for the policyholders of insolvent insurers; however, these costs are calculated and administered differently than in the U.S. In Japan, these costs are not directly related to specific insolvencies or bankruptcies, but are rather a regular operational cost for an insurance company. Based on this structure, the Company does not remove the Japan policyholder protection expenses from adjusted earnings.

The Company considers the costs associated with the early redemption of its debt to be unrelated to the underlying fundamentals and trends in its insurance operations. Additionally, these costs are driven by changes in interest rates subsequent to the issuance of the debt, and the Company considers these interest rate changes to represent economic conditions not directly associated with its insurance operations.

76

Income Taxes

The Company's combined U.S. and Japanese effective income tax rate on pretax earnings was 13.4% for the three-month period ended March 31, 2024, compared with 11.5% for the same period in 2023. The combined effective tax rate differs from the U.S. statutory rate primarily due to historic and solar tax credits and the exclusion of foreign currency translation gains and losses held in the Delaware Statutory Trust. For additional information, see the Critical Accounting Estimates - Income Taxes section of Item 7. MD&A in the 2023 Annual Report.

The Company expects that its effective tax rate on adjusted earnings for future periods will be approximately 20%. The effective tax rate continues to be subject to future tax law changes both in the U.S. and in foreign jurisdictions. See the risk factor entitled "Tax rates applicable to the Company may change" in Item 1A. Risk Factors of the 2023 Annual Report for more information.

Foreign Currency Translation

Aflac Japan’s premiums and a significant portion of its investment income are received in yen, and its claims and most expenses are paid in yen. Aflac Japan purchases yen-denominated assets and U.S. dollar-denominated assets, which may be hedged to yen, to support yen-denominated policy liabilities. Yen-denominated income statement accounts are translated to U.S. dollars using the weighted average Japanese yen/U.S. dollar foreign exchange rate for the reporting period, except realized gains and losses on securities transactions which are translated at the exchange rate on the trade date of each transaction. Yen-denominated balance sheet accounts are translated to U.S. dollars using the spot Japanese yen/U.S. dollar foreign exchange rate at the end of the reporting period.

Reconciliation of Book Value to Adjusted Book Value

The following table is a reconciliation of items impacting adjusted book value and adjusted book value per diluted share to the most directly comparable U.S. GAAP financial measures of book value and book value per diluted share, respectively.

(In millions, except for share and per-share amounts)	March 31, 2024			December 31, 2023
U.S. GAAP book value		$	23,537		$	21,985
Items impacting U.S. GAAP book value:
Unrealized foreign currency translation gains (losses)		(4,666)			(4,069)
Unrealized gains (losses) on securities and derivatives		1,066			1,117
Effect of changes in discount rate assumptions		(1,495)			(2,560)
Pension liability adjustment		(7)			(8)
Total accumulated other comprehensive income		(5,102)			(5,520)
Adjusted book value		$	28,639		$	27,505
Number of shares outstanding at end of period		570,278			578,479
U.S. GAAP book value per common share		$	41.27		$	38.00
Items impacting U.S. GAAP book value per common share:
Unrealized foreign currency translation gains (losses) per common share		(8.18)			(7.03)
Unrealized gains (losses) on securities and derivatives per common share		1.87			1.93
Effect of changes in discount rate assumptions per common share		(2.62)			(4.43)
Pension liability adjustment per common share		(.01)			(.01)
Total accumulated other comprehensive income per common share		(8.95)			(9.54)
Adjusted book value per common share		$	50.22		$	47.55

77

Reconciliation of Return on Equity to Adjusted Return on Equity

(Excluding the Impact of Foreign Currency)

The following table is a reconciliation of items impacting adjusted return on equity excluding the impact of foreign currency to the most directly comparable U.S. GAAP financial measure of return on equity for the three-month periods ended March 31.

	2024		2023
U.S. GAAP return on equity - net earnings (1)	33.0	%	23.8	%
Impact of excluding unrealized foreign currency translation gains (losses)	(5.1)		(3.2)
Impact of excluding unrealized gains (losses) on securities and derivatives	1.3		.2
Impact of excluding effect of changes in discount rate assumptions	(2.4)		(3.1)
Impact of excluding pension liability adjustment	.0		.0
Impact of excluding accumulated other comprehensive income	(6.2)		(6.1)
U.S. GAAP return on equity less accumulated other comprehensive income	26.8		17.7
Differences between adjusted earnings and net earnings (2)	(13.1)		(3.5)
Adjusted return on equity - reported	13.7		14.2
Impact of foreign currency (3)	(.6)		N/A
Adjusted return on equity, excluding impact of foreign currency	14.3		14.2

(1) U.S. GAAP return on equity is calculated by dividing net earnings (annualized) by average shareholders' equity.

(2) See separate reconciliation of net earnings to adjusted earnings above.

(3) Impact of foreign currency is calculated by restating all foreign currency components of the income statement to the weighted average foreign currency exchange rate for the comparable prior year period. The impact is the difference of the restated adjusted earnings compared to reported adjusted earnings. For comparative purposes, only current period income is restated using the weighted average prior period exchange rate, which eliminates the foreign currency impact for the current period. This allows for equal comparison of this financial measure.

RESULTS OF OPERATIONS BY SEGMENT

U.S. GAAP financial reporting requires that a company report financial and descriptive information about operating segments in its annual and interim period financial statements. Furthermore, the Company is required to report a measure of segment profit or loss, certain revenue and expense items, and segment assets. The Company's insurance business consists of two segments: Aflac Japan and Aflac U.S. Aflac Japan is the principal contributor to consolidated earnings. In addition, the Parent Company, other business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. See Item 1. Business in the 2023 Annual Report for a summary of each segment's products and distribution channels.

Consistent with U.S. GAAP guidance for segment reporting, pretax adjusted earnings is the Company's U.S. GAAP measure of segment performance. The Company believes that a presentation of this measure is vitally important to an understanding of the underlying profitability drivers and trends of its business. Additional performance measures used to evaluate the financial condition and performance of the Company's segments are listed below.

•Operating Ratios

•New Annualized Premium Sales

•New Money Yield

•Return on Average Invested Assets

•Average Weekly Producer

•Premium Persistency

For additional information on the Company’s performance measures included in this MD&A, see the Glossary of Selected Terms found directly following Part II. Other Information. See Note 2 of the Notes to the Consolidated Financial Statements for the reconciliation of segment results to the Company's consolidated U.S. GAAP results and additional information.

78

AFLAC JAPAN SEGMENT

Aflac Japan Pretax Adjusted Earnings

Changes in Aflac Japan’s pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac Japan.

Aflac Japan Summary of Operating Results

	In Dollars						In Yen
	Three Months Ended March 31,						Three Months Ended March 31,
(In millions of dollars and billions of yen)	2024			2023			2024			2023
Net earned premiums	$	1,816		$	2,170		¥	270		¥	287
Net investment income: (1)
Yen-denominated investment income	231			263			34			35
U.S. dollar-denominated investment income	424			407			63			54
Net investment income	655			669			97			89
Amortized hedge costs related to certain foreign currency   exposure management strategies	6			58			1			8
Adjusted net investment income	648			611			97			81
Other income (loss)	9			9			1			1
Total adjusted revenues	2,473			2,790			368			369
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	1,243			1,466			185			194
Reserve remeasurement (gains) losses	(26)			(13)			(4)			(2)
Total benefits and claims, net	1,217			1,453			181			192
Adjusted expenses:
Amortization of deferred policy acquisition costs	83			85			12			11
Insurance commissions	114			138			17			18
Insurance and other expenses	248			326			37			43
Total adjusted expenses	445			549			66			73
Total benefits and adjusted expenses	1,663			2,002			247			265
Pretax adjusted earnings	$	810		$	788		¥	121		¥	104
Weighted-average yen/dollar exchange rate	148.67			132.30			—			—
Percentage change over previous period
Net earned premiums	(16.3)		%	(17.3)		%	(6.0)		%	(5.9)		%
Adjusted net investment income	6.1			(10.1)			19.3			2.4
Total adjusted revenues	(11.4)			(15.8)			(.4)			(4.1)
Total benefits and claims, net	(16.2)			(18.3)			(5.9)			(7.1)
Adjusted expenses	(18.9)			(17.3)			(8.9)			(5.8)
Pretax adjusted earnings	2.8			(9.4)			15.6			3.2

(1) Net interest income/expense from derivatives associated with certain investment strategies of $(79) and $(62) for the three-month periods ended March 31, 2024 and 2023, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

For the three-month period ended March 31, 2024, operating results in yen terms compared to the same period in the previous year were as follows:

•Net earned premiums decreased primarily due to approximately ¥8 billion related to the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2023 and approximately ¥6 billion in limited-pay products reaching premium paid-up status.

•Adjusted net investment income increased primarily due to lower hedge costs of ¥7 billion, the weakening of the yen of ¥6 billion, higher variable net investment income of ¥5 billion and higher fixed rate income of ¥3 billion, partially offset by lower floating rate income due to the increase in loans on nonaccrual status.

79

•Total adjusted revenues decreased slightly primarily due to the decrease in net earned premiums mostly offset by the increase in adjusted net investment income.

•Total benefits and claims decreased primarily due to the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2023.

•Total adjusted expenses decreased primarily due to the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2023 as well as expense control efforts.

•Pretax adjusted earnings increased primarily due to the decrease in both total benefits and claims and total adjusted expenses.

Annualized premiums in force decreased 3.8% to ¥1.23 trillion as of March 31, 2024, compared with ¥1.28 trillion as of March 31, 2023. The decrease in annualized premiums in force in yen was driven primarily by limited-pay products reaching premium paid-up status. Annualized premiums in force, translated into dollars at respective period-end exchange rates, were $8.1 billion at March 31, 2024, compared with $9.6 billion at March 31, 2023. As of March 31, 2024, Aflac Japan exceeded 22 million individual policies in force in Japan, with more than 14 million cancer policies in force in Japan.

Aflac Japan's investment portfolios include U.S. dollar-denominated securities and reverse-dual currency securities (yen-denominated debt securities with dollar coupon payments). In years when the yen strengthens in relation to the dollar, translating Aflac Japan's U.S. dollar-denominated investment income into yen lowers growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms. In years when the yen weakens, translating U.S. dollar-denominated investment income into yen magnifies growth rates for net investment income, total adjusted revenues, and pretax adjusted earnings in yen terms.

The following table illustrates the effect of translating Aflac Japan’s U.S. dollar-denominated investment income and related items into yen by comparing certain segment results with those that would have been reported had foreign currency exchange rates remained unchanged from the comparable period in the prior year. Amounts excluding foreign currency impact on U.S. dollar-denominated investment income were determined using the average foreign currency exchange rate for the comparable prior year period. See non-U.S. GAAP financial measures defined above.

Aflac Japan Percentage Changes Over Previous Period

(Yen Operating Results)

For the Periods Ended March 31,

	Including Foreign Currency Changes				Excluding Foreign Currency Changes
	Three Months					Three Months
	2024		2023			2024		2023
Adjusted net investment income	19.3	%	2.4	%		10.7	%	(5.9)	%
Total adjusted revenues	(.4)		(4.1)			(2.3)		(5.8)
Pretax adjusted earnings	15.6		3.2			9.3		(3.0)

80

The following table presents a summary of operating ratios in yen terms for Aflac Japan followed by a discussion of the significant drivers of changes in operating ratios in yen compared to the same period in the previous year.

	Three Months Ended March 31,
Ratios to total adjusted revenues:	2024		2023
Total benefits and claims, net	49.2	%	52.1	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	3.3		3.1
Insurance commissions	4.6		4.9
Insurance and other expenses	10.0		11.7
Total adjusted expenses	18.0		19.7
Pretax adjusted earnings	32.8		28.2
Ratios to total premiums:
Total benefits and claims, net	67.0	%	67.0	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	4.6		3.9

For the three-month period ended March 31, 2024, the total benefits and claims to total premiums ratio was flat. The total adjusted expense ratio decreased in the three-month period ended March 31, 2024 primarily due to the decrease in total adjusted expenses associated with the internal reinsurance transaction with Aflac Re established in the fourth quarter of 2023 as well as expense control efforts. In total, the pretax adjusted profit margin increased in the three-month period ended March 31, 2024 primarily due to the lower expense ratio and a slight offsetting decrease in total adjusted revenues.

The following table presents Aflac Japan's premium persistency on a 12-month rolling basis as of March 31.

	2024		2023
Premium persistency	93.4	%	93.9	%

Aflac Japan Sales

The following table presents Aflac Japan’s new annualized premium sales for the periods ended March 31.

	In Dollars						In Yen
	Three Months						Three Months
(In millions of dollars and billions of yen)	2024			2023			2024			2023
New annualized premium sales	$	84		$	100		¥	12.5		¥	13.2
Increase (decrease) over prior period	(15.5)		%	(3.2)		%	(5.1)		%	10.8		%

The decrease in new annualized premium sales on a yen basis in the first quarter of 2024 was primarily due to a decrease in the sales of first sector products.

81

The following table details the contributions to Aflac Japan's new annualized premium sales by major insurance product for the periods ended March 31.

	Three Months
	2024		2023
Cancer	63.2	%	59.9	%
Medical and other health:
Medical	21.1		20.8
Income support	.3		.6
Life insurance:
Traditional life (1)	8.1		7.3
WAYS	5.3		8.9
Child endowment	.3		.6
Other	1.7		1.9
Total	100.0	%	100.0	%

(1) Includes term and whole life

The foundation of Aflac Japan's product portfolio has been, and continues to be, third sector products, which include cancer, medical, income support and other products. With continued cost pressure on Japan’s health care system, the Company expects the need for third sector products will continue to rise in the future and that the medical and cancer insurance products Aflac Japan provides will continue to be an important part of its product portfolio. Moreover, in November 2022, Aflac Japan refreshed its first sector savings-type products WAYS and Child Endowment and began to actively promote sales of these products after having curtailed sales of both products beginning in 2013. The refreshment of these first sector products position Aflac Japan for potential future long-term sales opportunities by marketing these products to a younger demographic as well as potential cross-selling opportunities of Aflac Japan's third sector products.

Sales of Aflac Japan cancer insurance products in the Japan Post Group channel experienced a material decline beginning in August 2019. Japan Post Group resumed proactive sales of cancer insurance policies in April 2021 and Aflac Japan continues to strengthen the strategic alliance. In April 2023, Japan Post Group began selling Aflac Japan's new cancer insurance product that was first launched in other channels in August 2022.

Aflac Japan continues to promote digital and web-based sales to groups and use of its system that enables smart device-based insurance application by allowing the customer and an Aflac Japan operator to see the same screen through their smart devices. Further, Aflac Japan continues to utilize its virtual sales tool that enables online consultations and policy applications to be completed entirely online.

The following table details the contributions to Aflac Japan's new annualized premium sales by agency type for the three-month periods ended March 31.

	2024		2023
Independent corporate and individual	48.9	%	50.9	%
Affiliated corporate (1)	48.0		45.4
Bank	3.1		3.7
Total	100.0	%	100.0	%

(1) Includes Japan Post Group, Dai-ichi Life and Daido Life

During the three-month period ended March 31, 2024, Aflac Japan recruited 12 new sales agencies. At March 31, 2024, Aflac Japan was represented by approximately 6,900 sales agencies, with approximately 113,000 licensed sales associates employed by those agencies. The number of sales agencies has declined in recent years due to Aflac Japan's focus on supporting agencies with strong management frameworks, high productivity and more producing agents.

At March 31, 2024, Aflac Japan had agreements to sell its products at 360 banks, approximately 90% of the total number of banks in Japan.

82

Aflac Japan Investments

The level of investment income in yen is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, the effect of yen/dollar exchange rates on U.S. dollar-denominated investment income, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac Japan invests in yen and U.S. dollar-denominated investments. Yen-denominated investments primarily consist of Japan Government Bonds (JGBs), public and private fixed maturity securities and public equity securities. Aflac Japan's U.S. dollar-denominated investments include fixed maturity investments, loan receivables, and growth assets, including alternative investments in limited partnerships or similar investment vehicles. Aflac Japan invests in both publicly traded and privately originated U.S. dollar-denominated investment-grade and below-investment-grade fixed maturity securities and loan receivables, and has entered into foreign currency forwards and options to hedge the currency risk on the fair value of a portion of the U.S. dollar investments.

The following table details the investment purchases for Aflac Japan.

	Three Months Ended March 31,
(In millions)	2024		2023
Yen-denominated:
Fixed maturity securities:
Japan government and agencies	$	0	$	151
Private placements	67		273
Other fixed maturity securities	66		0
Equity securities	87		123
Commercial mortgage and other loans:
Other loans	0		77
Other investments	7		6
Total yen-denominated	$	227	$	630
U.S. dollar-denominated:
Fixed maturity securities:
Other fixed maturity securities	$	1,548	$	376
Infrastructure debt	60		0
Collateralized loan obligations	27		0
Commercial mortgage and other loans:
Transitional real estate loans	22		53
Middle market loans	142		150
Other investments	62		137
Total U.S. dollar-denominated	$	1,861	$	716
Total Aflac Japan purchases	$	2,088	$	1,346

See the Investments section of this MD&A for further discussion of these investment programs, and see Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report for more information regarding loans and loan receivables.

83

The following table presents the results of Aflac Japan’s investment yields for the periods ended March 31.

	Three Months
	2024			2023
Total purchases for the period (in millions) (1)	$	2,019		$	1,203
New money yield (1),(2)	5.57		%	5.18		%
Return on average invested assets (3)	3.14			2.57
Portfolio book yield, including U.S. dollar-denominated investments, end of period (1),(2)	3.24		%	3.13		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses, external management fees and amortized hedge costs

(3) Net of investment expenses and amortized hedge costs, year-to-date number reflected on a quarterly average basis

The increase in the Aflac Japan new money yield in the three-month period ended March 31, 2024 was primarily due to higher allocations to higher yielding asset classes. See Notes 3, 4 and 5 of the Notes to the Consolidated Financial Statements and the Investments and Hedging Activities sections of this MD&A for additional information on the Company's investments and hedging strategies.

AFLAC U.S. SEGMENT

Aflac U.S. Pretax Adjusted Earnings

Changes in Aflac U.S. pretax adjusted earnings and profit margins are primarily affected by morbidity, mortality, expenses, persistency and investment yields. The following table presents a summary of operating results for Aflac U.S.

Aflac U.S. Summary of Operating Results

	Three Months Ended March 31,
(In millions)	2024			2023
Net earned premiums	$	1,475		$	1,428
Adjusted net investment income (1)	206			197
Other income	18			35
Total adjusted revenues	1,699			1,660
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	715			691
Reserve remeasurement (gains) losses	(30)			(40)
Total benefits and claims, net	686			651
Adjusted expenses:
Amortization of deferred policy acquisition costs	132			119
Insurance commissions	141			142
Insurance and other expenses	384			395
Total adjusted expenses	658			657
Total benefits and adjusted expenses	1,343			1,308
Pretax adjusted earnings	$	356		$	352
Percentage change over previous period:
Net earned premiums	3.3		%	1.1		%
Adjusted net investment income	4.6			7.1
Total adjusted revenues	2.3			1.3
Total benefits and claims, net	5.4			(2.3)
Adjusted expenses	.2			2.7
Pretax adjusted earnings	1.1			5.7

(1) Net interest income/expense from derivatives associated with certain investment strategies of $(9) and $(7) for the three-month periods ended March 31, 2024 and 2023, respectively, have been reclassified from net investment gains (losses) and included in adjusted earnings as a component of net investment income.

84

For the three-month period ended March 31, 2024, operating results compared to the same period in the previous year were as follows:

•Net earned premiums increased primarily due to higher net earned premiums from growth initiatives including group life and disability, network dental and vision, and consumer markets businesses.

•Adjusted net investment income increased primarily due to higher variable income, higher short-term income and higher yielding asset classes.

•Total adjusted revenues increased primarily due to the increase in net earned premiums.

•Total benefits and claims increased primarily due to growth of group life and disability and lower remeasurement gains reflecting actual experience.

•Total adjusted expenses increased slightly primarily due to higher deferred policy acquisition costs amortization and an offsetting decrease in insurance and other expenses.

•Pretax adjusted earnings increased primarily due to higher net earned premiums.

Annualized premiums in force increased 3.1% to $6.2 billion at March 31, 2024, compared with $6.0 billion at March 31, 2023.

The following table presents a summary of operating ratios for Aflac U.S. followed by a discussion of the significant drivers of changes in operating ratios compared to the same period in the previous year.

	Three Months Ended March 31,
Ratios to total adjusted revenues:	2024		2023
Total benefits and claims	40.4	%	39.2	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	7.8		7.2
Insurance commissions	8.3		8.6
Insurance and other expenses	22.6		23.8
Total adjusted expenses	38.7		39.6
Pretax adjusted earnings	21.0		21.2
Ratios to total premiums:
Total benefits and claims	46.5	%	45.6	%
Adjusted expenses:
Amortization of deferred policy acquisition costs	8.9		8.3

For the three-month period ended March 31, 2024, the total benefits and claims to total premiums ratio increased primarily due to lower remeasurement gains. The total adjusted expense ratio decreased in the three-month period ended March 31, 2024 primarily due to higher total adjusted revenues. In total, the pretax adjusted profit margin decreased slightly in the three-month period ended March 31, 2024 primarily due to the higher total benefits and claims to total adjusted revenues ratio.

The following table presents premium persistency for Aflac U.S. on a 12-month rolling basis as of March 31.

	2024		2023
Premium persistency	78.7	%	77.9	%

Aflac U.S. Sales

The following table presents Aflac's U.S. new annualized premium sales for the periods ended March 31.

	Three Months
(In millions)	2024			2023
New annualized premium sales	$	298		$	315
Increase (decrease) over prior period	(5.2)		%	5.3		%

85

The decrease in new annualized premium sales for Aflac U.S. in the first quarter of 2024 reflects continued strong underwriting discipline.

The following table details the contributions to Aflac's U.S. new annualized premium sales by major insurance product category for the periods ended March 31.

	Three Months
	2024		2023
Accident	22.5	%	23.5	%
Disability	23.0		25.2
Critical care(1)	22.1		20.5
Hospital indemnity	15.1		15.9
Dental/vision	6.5		6.6
Life	10.8		8.3
Total	100.0	%	100.0	%

(1) Includes cancer, critical illness, and hospital intensive care products

In the first quarter of 2024, the Aflac U.S. sales force included an average of approximately 5,800 U.S. agents, including brokers, who were actively producing business on a weekly basis. The Company believes that this average weekly producer equivalent metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity.

As previously reported in the 2023 Annual Report, in July 2023, the U.S. Department of Labor, U.S. Department of the Treasury and U.S. Department of Health and Human Services (the tri-agencies) issued a proposed joint rule that, as written, could have potentially imposed significant limitations on the structure of benefits for hospital indemnity and other fixed indemnity plans, including those sold by Aflac U.S. However, on March 28, 2024, the tri-agencies released the final regulations requiring expanded disclosures to consumers for hospital and fixed indemnity insurance. The final regulations, which become effective June 17, 2024, did not include the proposals relating to the regulation and tax treatment of hospital and fixed indemnity insurance. As such, the implementation of the final regulations is not anticipated to have a material impact on Aflac U.S. sales.

Aflac U.S. Investments

The level of investment income is affected by available cash flow from operations, the timing of investing the cash flow, yields on new investments, and other factors.

As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments, loan receivables, and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. invests in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loan receivables.

86

The following table details the investment purchases for Aflac U.S.

	Three Months Ended March 31,
(In millions)	2024		2023
Fixed maturity securities:
Other fixed maturity securities	$	401	$	209
Infrastructure debt	24		0
Collateralized loan obligations	3		0
Equity securities	12		0
Commercial mortgage and other loans:
Transitional real estate loans	7		14
Middle market loans	72		19
Other investments	7		15
Total Aflac U.S. Purchases	$	526	$	257

See Note 3 of the Notes to the Consolidated Financial Statements and Notes 1 and 3 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report for more information regarding loans and loans receivables.

The following table presents the results of Aflac's U.S. investment yields for the periods ended March 31.

	Three Months
	2024			2023
Total purchases for period (in millions) (1)	$	519		$	242
New money yield (1),(2)	6.66		%	7.01		%
Return on average invested assets (3)	4.87			4.74
Portfolio book yield, end of period (1),(2)	5.57		%	5.46		%

(1) Includes fixed maturity securities, commercial mortgage and other loans, equity securities, and excludes alternative investments in limited partnerships

(2) Reported on a gross yield basis; excludes investment expenses and external management fees

(3) Net of investment expenses, year-to-date number reflected on a quarterly average basis

The decrease in the Aflac U.S. new money yield in the three-month period ended March 31, 2024 was primarily due to higher allocations to lower yielding asset classes. See Notes 3 and 5 of the Notes to the Consolidated Financial Statements and the Investments section of this MD&A for additional information on the Company's investments.

87

CORPORATE AND OTHER

Changes in the pretax adjusted earnings of Corporate and other are primarily affected by internal reinsurance activity and net investment income. The following table presents a summary of operating results for Corporate and other.

Corporate and Other Summary of Operating Results

	Three Months Ended March 31,
(In millions)	2024			2023
Net earned premiums	$	165		$	91
Net investment income (loss) (1)	51			7
Amortized hedge income related to certain foreign currency   management strategies	28			29
Adjusted net investment income	79			36
Other income	3			2
Total adjusted revenues	247			129
Benefits and claims:
Benefits and claims, excluding reserve remeasurement	108			46
Reserve remeasurement (gains) losses	(1)			0
Total benefits and claims, net	107			46
Adjusted expenses:
Interest expense	36			33
Other adjusted expenses	107			57
Total adjusted expenses	143			90
Total benefits and adjusted expenses	250			136
Pretax adjusted earnings	$	(3)		$	(7)
Percentage change over previous period:
Net earned premiums	81.3		%	122.0		%
Adjusted net investment income	119.4			140.0
Total adjusted revenues	91.5			74.3
Total benefits and claims, net	132.6			24.3
Total adjusted expenses	58.9			12.5
Pretax adjusted earnings	57.1			83.3

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 of the Notes to the Consolidated Financial Statements for additional information on these investments.

For the three-month period ended March 31, 2024, operating results compared to the same period in the previous year were as follows:

•Net earned premiums and total benefits and claims increased primarily due to higher reinsurance activity resulting from agreements established in the fourth quarter of 2023.

•Adjusted net investment income increased due to higher Aflac Re consolidated investment income of $23 million primarily due to a higher volume of assets as part of the reinsurance agreements established in the fourth quarter of 2023 and $19 million due to a lower volume of federal historic rehabilitation and solar tax credit investments, with offsetting tax benefits recognized as a corresponding lower income tax expense.

•Total adjusted revenues increased due to higher net earned premiums and higher adjusted net investment income.

•Total adjusted expenses increased primarily due to the higher reinsurance activity of $37 million as well as an increase in other general operating expenses.

•Pretax adjusted earnings increased due to higher total adjusted revenues partially offset by the higher total benefits and adjusted expenses.

88

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

INVESTMENTS

The Company’s investment strategy utilizes disciplined asset and liability management while seeking long-term risk-adjusted investment returns and the delivery of stable income within regulatory and capital objectives, and preserving shareholder value. In attempting to optimally balance these objectives, the Company seeks to maintain on behalf of Aflac Japan a diversified portfolio of yen-denominated investment assets, a U.S. dollar-denominated investment portfolio hedged back to yen and a portfolio of unhedged U.S. dollar-denominated assets. As part of the Company's portfolio management and asset allocation process, Aflac U.S. invests in fixed maturity investments and growth assets, including public equity securities and alternative investments in limited partnerships. Aflac U.S. invests in both publicly traded and privately originated investment-grade and below-investment-grade fixed maturity securities and loans.

For additional information concerning the Company's investments, see Notes 3, 4, and 5 of the Notes to the Consolidated Financial Statements.

The following tables detail investments by segment.

Investment Securities by Segment

	March 31, 2024
(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available-for-sale, fixed maturity securities,    at fair value	$	52,100	$	12,833	$	5,197	$	70,130
Held-to-maturity, fixed maturity securities,    at amortized cost (1)	16,689		0		0		16,689
Equity securities	494		2		266		762
Commercial mortgage and other loans:
Transitional real estate loans (1)	4,750		1,018		196		5,964
Commercial mortgage loans (1)	1,015		619		0		1,634
Middle market loans (1)	4,002		485		0		4,487
Other loans (1)	178		82		15		275
Other investments:
Policy loans	174		29		0		203
Short-term investments (2)	2,318		238		785		3,341
Limited partnerships	2,422		265		151		2,838
Real estate owned	205		48		0		253
Other	0		42		0		42
Investment in affiliate (3)	0		403		(403)		0
Total investments	84,347		16,064		6,207		106,618
Cash and cash equivalents	1,467		603		3,028		5,098
Total investments and cash	$	85,814	$	16,667	$	9,235	$	111,716

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

89

	December 31, 2023
(In millions)	Aflac Japan		Aflac U.S.		Corporate and Other		Total
Available-for-sale, fixed maturity securities,    at fair value	$	54,983	$	12,884	$	5,423	$	73,290
Held-to-maturity, fixed maturity securities,    at amortized cost (1)	17,819		0		0		17,819
Equity securities	720		2		366		1,088
Commercial mortgage and other loans:
Transitional real estate loans (1)	4,795		1,011		192		5,998
Commercial mortgage loans (1)	1,075		622		0		1,697
Middle market loans (1)	4,095		436		0		4,531
Other loans (1)	185		101		15		301
Other investments:
Policy loans	186		28		0		214
Short-term investments (2)	347		204		753		1,304
Limited partnerships	2,360		258		132		2,750
Real estate owned	180		47		0		227
Other	0		35		0		35
Investment in affiliate (3)	0		439		(439)		0
Total investments	86,745		16,067		6,442		109,254
Cash and cash equivalents	1,861		651		1,794		4,306
Total investments and cash	$	88,606	$	16,718	$	8,236	$	113,560

(1) Net of allowance for credit losses

(2) Includes securities lending collateral

(3) For consolidated reporting, Aflac U.S.'s investment in Aflac Re is eliminated in Corporate and other

The Company has invested in a variety of commercial mortgage loans (CMLs) and other loans including transitional real estate loans (TREs). The Company's TRE and CML investments are collateralized by commercial real estate, including some office properties. The Company considers these investments to be well diversified by geography and among property types. Further, the Company believes that the portfolio is generally well positioned with exposures concentrated in high quality underlying properties with institutional investors who are experienced in managing their assets during periods of market volatility.

While generally resilient, the Company's investments in TREs and CMLs have been affected by conditions in the commercial real estate market, with a greater impact on mortgages secured by office properties. The Company invested in certain TREs and CMLs that are currently in default of interest or maturity payments. The Company works with the affected borrowers to resolve specific situations through loan continuance with potential modifications, or through the process of foreclosure or deed in lieu of foreclosure. Since the third quarter of 2023, the Company has taken possession, through foreclosure or deed in lieu of foreclosure, of certain commercial real estate properties, which secured defaulted loans. Properties acquired by the Company through foreclosure and deed in lieu of foreclosure are reported as real estate owned (REO) in other investments in the Company's consolidated balance sheets.

The Company utilizes third-party asset managers to source, underwrite and manage each loan, as well as any resulting REO. The Company closely monitors the activities of these managers. In the event that a loan workout is necessary, the Company believes these external managers have the experience and resources to manage the process to maximize recovery.

The Company also monitors its commercial mortgage and other loan investments internally on an ongoing basis, including a review of loans' credit quality indicators and payment status as current, past due, restructured or under foreclosure. See Note 3 of the Notes to the Consolidated Financial Statements for further information concerning credit quality indicators, information on loans that are on nonaccrual status, and REO obtained through foreclosure or deed in lieu of foreclosure. See also Item 1A. Risk Factors of the 2023 Annual Report for a discussion of risk factors associated with the Company's investments.

90

The ratings of the Company's securities referenced in the table below are based on the ratings designations provided by major rating organizations such as Moody's, Standard & Poor's and Fitch or, if not rated, are determined based on the Company's internal analysis of such securities. When the ratings issued by the rating agencies differ, the Company utilizes the second lowest rating when three or more rating agency ratings are available or the lowest rating when only two rating agency ratings are available.

The distributions of fixed maturity securities the Company owns, by credit rating, were as follows:

Composition of Fixed Maturity Securities by Credit Rating

		March 31, 2024						December 31, 2023
	Amortized Cost			Fair       Value			Amortized Cost			Fair       Value
AAA		1.6	%		1.7	%		1.6	%		1.6	%
AA		6.1			6.3			5.7			5.9
A		67.7			66.4			68.1			67.2
BBB		23.1			23.9			22.9			23.5
BB or lower		1.5			1.7			1.7			1.8
Total		100.0	%		100.0	%		100.0	%		100.0	%

As of March 31, 2024, the Company's direct and indirect exposure to securities in its investment portfolio that were guaranteed by third parties was immaterial both individually and in the aggregate.

The following table presents the 10 largest unrealized loss positions in the Company's portfolio as of March 31, 2024.

(In millions)	Credit Rating		Amortized Cost			Fair Value			Unrealized Loss
KLM Royal Dutch Airlines		B		$	128		$	99		$	(29)
Urban Renaissance Agency		A		161			132			(29)
JP Morgan Chase and Co.		A		206			183			(23)
Prologis LP		A		152			130			(22)
Alphabet Inc.		AA		85			67			(18)
Salesforce Inc		A		94			77			(17)
BASF		A		66			49			(17)
Nippon Prologis REIT Inc.		A		66			49			(17)
Citigroup Inc		A		153			137			(16)
Banco de Chile		A		132			116			(16)

Generally, declines in fair values can be a result of changes in interest rates, yen/dollar exchange rate, and changes in net spreads driven by a broad market move or a change in the issuer's underlying credit quality. The Company believes these issuers have the ability to continue making timely payments of principal and interest. See the Unrealized Investment Gains and Losses section in Note 3 of the Notes to the Consolidated Financial Statements for further discussions of unrealized losses related to financial institutions and other corporate investments.

Below-Investment-Grade Securities

The Company's portfolio of below-investment-grade securities includes debt securities purchased while the issuer was rated investment grade plus other loans and bonds purchased as part of an allocation to that segment of the market. The following is the Company's below-investment-grade exposure.

91

Below-Investment-Grade Investments

	March 31, 2024
(In millions)	Par Value		Amortized Cost (1)		Fair Value		Unrealized Gain (Loss)
Investcorp Capital Limited	$	228	$	228	$	228	$	0
Commerzbank	165		134		189		55
Telecom Italia SpA	132		132		171		39
KLM Royal Dutch Airlines	132		128		99		(29)
IKB Deutsche Industriebank AG	86		44		71		27
Generalitat de Catalunya	53		22		52		30
National Gas Co. Trinidad & Tobago	52		50		48		(2)
Hawaiian Electric Industries Inc	35		35		28		(7)
VTTI B.V.	20		20		19		(1)
Commonwealth of the Bahamas	18		17		14		(3)
Other Issuers	23		25		24		(1)
Subtotal (2)	944		835		943		108
High yield corporate bonds	583		459		543		84
Middle market loans	4,237		4,108		4,077		(31)
Grand Total	$	5,764	$	5,402	$	5,563	$	161

(1) Net of allowance for credit losses

(2) Securities initially purchased as investment grade, but have subsequently been downgraded to below investment grade

The Company maintains an allocation to higher yielding corporate bonds within the Aflac Japan and Aflac U.S. portfolios. Most of these securities were rated below-investment-grade at the time of purchase, but the Company also purchased several that were rated investment grade which, because of market pricing, offer yields commensurate with below-investment-grade risk profiles. The objective of this allocation was to enhance the Company's yield on invested assets and further diversify credit risk. All investments in this program must have a minimum rating at purchase of low BB using the Company's above described rating methodology and are managed by the Company's internal credit portfolio management team.

The Company invests in middle market loans primarily to U.S. corporate borrowers, most of which have below-investment-grade ratings. The objectives of this program include enhancing the yield on invested assets, achieving further diversification of credit risk, and mitigating the risk of rising interest rates and hedge costs through the acquisition of floating rate assets.

92

Fixed Maturity Securities by Sector

The Company maintains diversification in investments by sector to avoid concentrations to any one sector, thus managing exposure risk. The following table shows the distribution of fixed maturities by sector classification.

	March 31, 2024
(In millions)	Amortized Cost (1)		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		% of Total
Government and agencies	$	37,754	$	2,349	$	(1,815)	$	38,288	44.8	%
Municipalities	2,392		211		(108)		2,495		2.8
Mortgage- and asset-backed securities	3,169		276		(60)		3,385		3.8
Public utilities	6,909		653		(213)		7,349		8.2
Electric	5,704		532		(139)		6,096		6.8
Natural Gas	665		76		(37)		705		.8
Other	540		45		(37)		548		.6
Sovereign and supranational	835		97		(11)		921		1.1
Banks/financial institutions	8,517		708		(326)		8,899		10.1
Banking	4,895		460		(178)		5,177		5.8
Insurance	1,816		160		(54)		1,923		2.2
Other	1,806		88		(94)		1,799		2.1
Other corporate	24,707		3,300		(969)		27,038		29.2
Basic Industry	2,121		342		(90)		2,373		2.5
Capital Goods	3,011		352		(133)		3,229		3.6
Communications	2,653		480		(46)		3,087		3.1
Consumer Cyclical	1,945		233		(39)		2,139		2.3
Consumer Non-Cyclical	5,740		735		(248)		6,227		6.8
Energy	2,195		444		(38)		2,601		2.6
Other	1,094		95		(66)		1,124		1.3
Technology	3,153		269		(157)		3,265		3.7
Transportation	2,795		350		(152)		2,993		3.3
Total fixed maturity securities	$	84,283	$	7,594	$	(3,502)	$	88,375	100.0	%

(1) Net of allowance for credit losses

Securities by Type of Issuance

The Company has investments in both publicly and privately issued securities. The Company's ability to sell either type of security is a function of overall market liquidity which is impacted by, among other things, the amount of outstanding securities of a particular issuer or issuance, trading history of the issue or issuer, overall market conditions, and idiosyncratic events affecting the specific issue or issuer.

93

The following table details investment securities by type of issuance.

Investment Securities by Type of Issuance 

		March 31, 2024						December 31, 2023
(In millions)	Amortized Cost (1)			Fair    Value			Amortized Cost (1)			Fair   Value
Publicly issued securities:
Fixed maturity securities		$	68,958		$	71,961		$	72,218		$	75,622
Equity securities		597			597			838			838
Total publicly issued		69,555			72,558			73,056			76,460
Privately issued securities: (2)
Fixed maturity securities (3)		15,325			16,414			16,290			17,325
Equity securities		165			165			250			250
Total privately issued		15,490			16,579			16,540			17,575
Total investment securities		$	85,045		$	89,137		$	89,596		$	94,035

(1) Net of allowance for credit losses

(2) Primarily consists of securities owned by Aflac Japan

(3) Excludes Rule 144A securities

The following table details the Company's reverse-dual currency securities.

Reverse-Dual Currency Securities(1)

(Amortized cost, in millions)	March 31, 2024				December 31, 2023
Privately issued reverse-dual currency securities		$	3,507			$	3,740
Publicly issued collateral structured as reverse-dual currency securities		1,154				1,232
Total reverse-dual currency securities		$	4,661			$	4,972
Reverse-dual currency securities as a percentage of total investment    securities		5.5		%		5.5		%

(1) Principal payments in yen and interest payments in dollars

Aflac Japan has a portfolio of privately issued securities to better match liability characteristics and secure higher yields than those available on Japanese government or other public corporate bonds. Aflac Japan’s investments in yen-denominated privately issued securities consist primarily of non-Japanese issuers, are rated investment grade at purchase and have longer maturities, thereby allowing the Company to improve asset/liability matching and overall investment returns. These securities are generally either privately negotiated arrangements or issued under medium-term note programs and have standard documentation commensurate with credit ratings of the issuer, except when internal credit analysis indicates that additional protective and/or event-risk covenants were required. Many of these investments have protective covenants appropriate to the specific investment. These may include a prohibition of certain activities by the borrower, maintenance of certain financial measures, and specific conditions impacting the payment of the Company's notes.

HEDGING ACTIVITIES

The Company uses derivative contracts to hedge foreign currency exchange rate risk and interest rate risk. The Company uses various strategies, including derivatives, to manage these risks. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the 2023 Annual Report for more information about market risk and the Company’s use of derivatives.

94

Derivatives are designed to reduce risk on an economic basis while minimizing the impact on financial results. The Company’s derivatives programs vary depending on the type of risk being hedged. See Note 4 of the Notes to the Consolidated Financial Statements for:

•A description of the Company's derivatives, hedging strategies and underlying risk exposure.

•Information about the notional amount and fair market value of the Company's derivatives.

•The unrealized and realized gains and losses impact on adjusted earnings of derivatives in cash flow, fair value, net investments in foreign operations, or non-qualifying hedging relationships.

Foreign Currency Exchange Rate Risk Hedge Program

The Company has deployed the following hedging strategies to mitigate exposure to foreign currency exchange rate risk:

•Aflac Japan hedges U.S. dollar-denominated investments back to yen (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•Aflac Japan maintains certain unhedged U.S. dollar-denominated securities, which serve as an economic currency hedge of a portion of the Company's investment in Aflac Japan (see Aflac Japan’s U.S. Dollar-Denominated Hedge Program below).

•The Parent Company designates yen-denominated liabilities (notes payable and loans) as non-derivative hedging instruments and designates certain foreign currency forwards and options as derivative hedges of the Company’s net investment in Aflac Japan (see Enterprise Corporate Hedging Program below).

•The Parent Company enters into forward and option contracts to accomplish a dual objective of hedging foreign currency exchange rate risk related to dividend payments by its subsidiary, ALIJ, and reducing enterprise-wide hedge costs (see Enterprise Corporate Hedging Program below).

The following table presents metrics related to Aflac Japan's U.S. dollar-denominated hedge program and the Parent Company's enterprise corporate hedging program, including associated amortized hedge costs/income, for the periods ended March 31. See the Results of Operations section of this MD&A for the Company's definition of amortized hedge costs/income.

	Three Months
	2024	2023
Aflac Japan:
FX Forwards
FX forward (sell USD, buy yen) notional at end of period (in billions) (1)	$0.0	$3.7
Amortized hedge income (cost) for period (in millions)	$2	$(39)
FX Options
FX option notional at the end of period (in billions) (1)	$24.7	$13.5
Amortized hedge income (cost) for period (in millions)	$(8)	$(19)
Corporate and other (Parent Company):
FX Forwards
FX forward (buy USD, sell yen) notional at end of period (in billions) (1)	$2.3	$5.0
Amortized hedge income (cost) for period (in millions)	$28	$31
FX Options
FX option notional at the end of period (in billions) (1)	$0.0	$2.2
Amortized hedge income (cost) for period (in millions)	$0	$(2)

(1) Notional is reported net of any offsetting positions within Aflac Japan or the Parent Company, respectively.

Amortized hedge costs/income can fluctuate based upon many factors, including the derivative notional amount, the length of time of the derivative contract, changes in both U.S. and Japan interest rates, and supply and demand for dollar funding. Amortized hedge costs/income have fluctuated in recent periods due to changes in the previously mentioned factors.

95

Aflac Japan’s U.S. Dollar-Denominated Hedge Program (U.S. Dollar Program)

Aflac Japan buys U.S. dollar-denominated investments, typically corporate bonds, and hedges them back to yen with foreign currency forwards and options to hedge foreign currency exchange rate risk. This economically creates yen assets that match yen liabilities during the life of the derivative and provides favorable capital treatment under the Japan solvency margin ratio (SMR) calculations. The currency risk being hedged is generally based on fair value of hedged investments. The following table summarizes the U.S. dollar-denominated investments held by Aflac Japan.

	March 31, 2024				December 31, 2023
(In millions)	Amortized Cost (1)		Fair Value		Amortized Cost (1)		Fair Value
Available-for-sale securities:
Fixed maturity securities	$	10,729	$	13,056	$	10,924	$	12,918
Equity securities	22		22		22		22
Commercial mortgage and other loans:
Transitional real estate loans (floating rate)	4,750		4,656		4,795		4,829
Commercial mortgage and other loans	1,015		881		1,075		948
Middle market loans (floating rate)	4,002		3,972		4,095		4,065
Other loans	110		108		112		111
Other investments	4,358		4,358		2,361		2,361
Total U.S. Dollar Program	24,986		27,053		23,384		25,254
Available-for-sale securities:
Fixed maturity securities - economically converted to yen	1,948		2,848		2,081		2,902
Total U.S. dollar-denominated investments in Aflac Japan	$	26,934	$	29,901	$	25,465	$	28,156

(1) Net of allowance for credit losses

The U.S. Dollar Program includes all U.S. dollar-denominated investments in Aflac Japan other than the investments in certain consolidated VIEs where the instrument is economically converted to yen as a result of a derivative in the consolidated VIE. The Company uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also maintains a collar program on a portion of its U.S. Dollar Program to mitigate against more extreme moves in foreign exchange and therefore support SMR. As of March 31, 2024, some of the Company's foreign currency options hedging Aflac Japan's U.S. dollar-denominated assets were in-the-money.

As of March 31, 2024, the fair value of Aflac Japan's unhedged U.S. dollar-denominated portfolio was $338 million (excluding certain U.S. dollar-denominated assets shown in the table above as a result of consolidation that have been economically converted to yen using derivatives).

Foreign exchange derivatives used for hedging are periodically settled, which results in cash receipt or payment at maturity or early termination. The following table presents the settlements associated with the Company's currency derivatives used for hedging Aflac Japan’s U.S. dollar-denominated investments.

	Three Months Ended March 31,
(In millions)	2024			2023
Net cash inflows (outflows)		$	(411)		$	(579)

Enterprise Corporate Hedging Program

The Company has designated certain yen-denominated liabilities and foreign currency forwards and options of the Parent Company as accounting hedges of its net investment in Aflac Japan. The Company's consolidated yen-denominated net asset position was partially hedged at $6.6 billion as of March 31, 2024, with hedging instruments comprised of $4.3 billion of yen-denominated debt and $2.3 billion of foreign currency forwards and options, compared with $6.8 billion as of December 31, 2023, with hedging instruments comprised of $3.7 billion of yen-denominated debt and $3.1 billion of foreign currency forwards and options.

96

The Company makes its accounting designation of net investment hedge at the beginning of each quarter. If the total of the designated Parent Company non-derivative and derivative notional is equal to or less than the Company's net investment in Aflac Japan, the hedge is deemed to be effective, and the currency exchange effect on the yen-denominated liabilities and the change in estimated fair value of the derivatives are reported in the unrealized foreign currency component of other comprehensive income. The Company's net investment hedge was effective during the three-month periods ended March 31, 2024 and 2023, respectively. For additional information on the Company's net investment hedging strategy, see Note 4 of the Notes to the Consolidated Financial Statements.

In order to economically mitigate risks associated with the enterprise-wide exposure to the yen and the level and volatility of hedge costs, the Parent Company enters into foreign currency forward and option contracts. By buying U.S. dollars and selling yen, the Parent Company is effectively lowering its overall economic exposure to the yen, while Aflac Japan's U.S. dollar exposure remains reduced as a result of Aflac Japan's U.S. Dollar Program that economically creates yen assets. Among other objectives, this strategy is intended to offset the enterprise-wide amortized hedge costs by generating amortized hedge income. This activity is reported in Corporate and other. The Company continually evaluates the program’s efficacy.

As part of the Company’s internal reinsurance platform, Aflac Re enters into foreign currency forwards with the Parent Company, and may enter into such forwards with third parties, to economically manage the currency mismatch between Aflac Re's assets, which are mostly denominated in U.S. dollars, and liabilities, which are mostly denominated in yen, in order to support and optimize Bermuda Monetary Authority (BMA) capital requirements. For additional information on the Company's internal reinsurance platform, see Note 8 of the Notes to the Consolidated Financial Statements and the Liquidity and Capital Resources section of this MD&A and Note 8 of the Notes to Consolidated Financial Statements in the 2023 Annual Report.

Interest Rate Risk Hedge Program

Aflac Japan and Aflac U.S. use interest rate swaps from time to time to mitigate the risk of investment income volatility for certain variable-rate investments. Additionally, to manage interest rate risk associated with its U.S. dollar-denominated investments held by Aflac Japan, from time to time the Company utilizes interest rate swaptions.

For additional discussion of the risks associated with the foreign currency exposure refer to the Currency Risk section in Item 7A., Quantitative and Qualitative Disclosures about Market Risk, and Item 1A, specifically to the Risk Factors titled “The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and “Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity" in the 2023 Annual Report.

See Note 4 of the Notes to the Consolidated Financial Statements for additional information on the Company's hedging activities.

DEFERRED POLICY ACQUISITION COSTS

The following table presents deferred policy acquisition costs (DAC) by segment.

(In millions)	March 31, 2024			December 31, 2023			% Change
Aflac Japan		$	5,234		$	5,559		(5.8)	%	(1)
Aflac U.S.		3,585			3,573			.3
Total		$	8,819		$	9,132		(3.4)	%

(1) Aflac Japan’s deferred policy acquisition costs increased .5% in yen during the three months ended March 31, 2024.

See Note 6 of the Notes to the Consolidated Financial Statements for additional information on the Company's deferred policy acquisition costs.

97

POLICY LIABILITIES

The following table presents policy liabilities by segment.

(In millions)	March 31, 2024			December 31, 2023			% Change
Aflac Japan		$	75,080		$	81,167		(7.5)	%	(1)
Aflac U.S.		11,366			11,600			(2.0)
Corporate and other		3,655			3,979			(8.1)
Intercompany eliminations(2)		(4,737)			(5,147)			(8.0)
Total		$	85,364		$	91,599		(6.8)	%

(1) Aflac Japan’s policy liabilities decreased 1.3% in yen during the three months ended March 31, 2024.

(2) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture of a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

See Note 7 of the Notes to the Consolidated Financial Statements for additional information on the Company's policy liabilities.

BENEFIT PLANS

Aflac Japan and Aflac U.S. have various benefit plans. For additional information on the Company's Japanese and U.S. plans, see Note 12 of the Notes to the Consolidated Financial Statements and Note 14 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

POLICYHOLDER PROTECTION

Policyholder Protection Corporation

The Japanese insurance industry has a policyholder protection system that provides funds for the policyholders of insolvent insurers. Legislation enacted regarding the framework of the Life Insurance Policyholder Protection Corporation (LIPPC) included government fiscal measures supporting the LIPPC. In March 2022, Japan's Diet passed legislation that extended the government's fiscal support of the LIPPC through March 2027. In March 2022, the LIPPC reached the required balance for the total life industry of ¥400 billion as specified by its Articles of Incorporation. As a result, additional contributions are not expected to be required unless the balance is reduced due to payments made by the LIPPC to the policyholders of insolvent insurers. Accordingly, Aflac Japan did not recognize an expense for LIPPC assessments for the three-month periods ended March 31, 2024 and 2023.

Guaranty Fund Assessments

Under U.S. state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business. The amount of the guaranty fund assessment that an insurer is assessed is based on its proportionate share of premiums in that state. Guaranty fund assessments for the three-month periods ended March 31, 2024 and 2023 were immaterial.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to the ability to generate sufficient cash resources to meet the payment obligations of the Company. Capital refers to the long-term financial resources available to support the operations of the businesses, fund business growth and provide for an ability to withstand adverse circumstances. Financial leverage (leverage) refers to an investment strategy of using debt to increase the potential ROE. The Company targets and actively manages liquidity, capital and leverage in the context of a number of considerations, including:

•business investment and growth needs

•strategic growth objectives

•financial flexibility and obligations

•capital support for hedging activity

•a constantly evolving business and economic environment

•a balanced approach to capital allocation and shareholder deployment.

98

The governance framework supporting liquidity, capital, and leverage includes global senior management and board committees that review and approve all significant capital related decisions.

The Company's cash and cash equivalents include unrestricted cash on hand, money market instruments, and other debt instruments with a maturity of 90 days or less when purchased, all of which have minimal market, settlement or other risk exposure. The target minimum amount for the Parent Company’s cash and cash equivalents is approximately $1.8 billion to provide a capital buffer and liquidity support at the holding company. The Company remains committed to prudent liquidity and capital management. At March 31, 2024, the Company held $5.1 billion in cash and cash equivalents for stress conditions, which includes the Parent Company's target minimum amount of $1.8 billion.

Aflac Japan and Aflac U.S. generate cash flows from their operations and provide the primary sources of liquidity to the Parent Company through management fees and dividends, with Aflac Japan being the largest contributor. The primary uses of cash by the Parent Company are shareholder dividends, the repurchase of its common stock, interest on its outstanding indebtedness and operating expenses.

The following table presents the amounts provided to the Parent Company for the three-month periods ended March 31.

Liquidity Provided by Subsidiaries to Parent Company

(In millions)	2024		2023
Management fees paid by subsidiaries	$	41	$	38
Dividends declared or paid by subsidiaries	658		780

The following table details Aflac Japan remittances, which are included in the totals above, for the three-month periods ended March 31.

Aflac Japan Remittances 

(In millions of dollars and billions of yen)	2024		2023
Aflac Japan management fees paid to Parent Company	$	17	$	16
Aflac Japan dividends declared or paid to Parent Company (in dollars)	433		505
Aflac Japan dividends declared or paid to Parent Company (in yen)	¥	63.9	¥	67.3

The Company intends to maintain higher than historical levels of liquidity and capital at the Parent Company for stress conditions and with the goals of addressing the Company’s hedge costs and related potential need for collateral and mitigating against long-term weakening of the Japanese yen. Further, the Company plans to continue to maintain a population of unhedged U.S. dollar-denominated investments at Aflac Japan and to consider whether the amount of such investments should be increased or decreased relative to the Company’s view of economic equity surplus in Aflac Japan in light of potentially rising hedge costs and other factors. See the Hedging Activities subsection of this MD&A for additional information.

The Company believes that its balance of cash and cash equivalents and cash generated by operations will be sufficient to satisfy both its short-term and long-term cash requirements and plans for cash, including material cash requirements from known contractual obligations and returning capital to shareholders through share repurchases and dividends. For additional information, see the Liquidity and Capital Resources section of Item 7. MD&A in the 2023 Annual Report.

In addition to cash and cash equivalents, the Company also maintains credit facilities, both intercompany and with external partners, and a number of other available tools to support liquidity needs on a global basis. In September 2021, the Parent Company filed a shelf registration statement with the SEC that allows the Company to issue an indefinite amount of debt securities, in one or more series, from time to time until September 2024. The Company believes outside sources for additional debt and equity capital, if needed, will continue to be available. The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2024. For additional information, see Note 9 of the Notes to the Consolidated Financial Statements.

As part of enterprise-wide capital management and optimization, the Company also utilizes the intercompany reinsurance platform to execute internal reinsurance transactions with Aflac Re. For additional information, see Note 8 of the Notes to the Consolidated Financial Statements.

99

The Company's consolidated financial statements convey its financing arrangements during the periods presented. The Company has not engaged in material intra-period short-term financings during the periods presented that are not otherwise reported in its balance sheet or disclosed therein. As of March 31, 2024, the Company had no material letters of credit, standby letters of credit, guarantees or standby repurchase obligations. The Company has not entered into transactions involving the transfer of financial assets with an obligation to repurchase financial assets that have been accounted for as a sale under applicable accounting standards, including securities lending transactions. See Notes 3 and 4 of the Notes to the Consolidated Financial Statements and Notes 1, 3, and 4 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report for more information on the Company's securities lending and derivative activities. See Note 15 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report for information on material unconditional purchase obligations that are not recorded on the Company's balance sheet. With the exception of disclosed activities in those referenced footnotes and the Risk Factors in the 2023 Annual Report entitled, "The Company is exposed to foreign currency fluctuations in the yen/dollar exchange rate" and "Lack of availability of acceptable yen-denominated investments could adversely affect the Company's results of operations, financial position or liquidity," the Company is not aware of any trend, demand, commitment, event or uncertainty that would reasonably result in its liquidity increasing or decreasing by a material amount.

Consolidated Cash Flows

The Company consistently generates positive cash flows from operations, and has the ability to adjust cash flow management from other sources of liquidity including reinvestment cash flows and selling investments in order to meet short-term cash needs.

The Company translates cash flows for Aflac Japan’s yen-denominated items into U.S. dollars using weighted-average exchange rates. In periods when the yen weakens, translating yen into dollars causes fewer dollars to be reported. When the yen strengthens, translating yen into dollars causes more dollars to be reported.

The following table summarizes consolidated cash flows by activity for the three-month periods ended March 31.

(In millions)	2024		2023
Operating activities	$	849	$	890
Investing activities	227		(77)
Financing activities	(256)		(933)
Exchange effect on cash and cash equivalents	(28)		(14)
Net change in cash and cash equivalents	$	792	$	(134)

Operating Activities

The principal cash inflows for the Company's insurance activities come from insurance premiums and investment income. The principal cash outflows are the result of policy claims, operating expenses, income tax, as well as interest expense. As a result of policyholder aging, claims payments are expected to gradually increase over the life of a policy. Therefore, future policy benefit reserves are accumulated in the early years of a policy and are designed to help fund future claims payments.

The Company expects its future cash flows from premiums and investment portfolios to be sufficient to meet its cash needs for benefits and expenses.

Investing Activities

The Company's investment objectives provide for liquidity primarily through the purchase of publicly traded investment-grade debt securities. Prudent portfolio management dictates that the Company attempts to match the duration of its assets with the duration of its liabilities. Currently, when the Company's fixed maturity securities mature, the proceeds may be reinvested at a yield below that required for the accretion of policy benefit liabilities on policies issued in earlier years. However, the long-term nature of the Company's business and its strong cash flows provide the Company with the ability to minimize the effect of mismatched durations and/or yields identified by various asset adequacy analyses. From time to time or when market opportunities arise, the Company disposes of selected fixed maturity securities that are available-for-sale to improve the duration matching of assets and liabilities, improve future investment yields, and/or re-balance its portfolio. As a result, dispositions before maturity can vary significantly from year to year.

100

As part of its overall corporate strategy, the Company has committed $400 million to Aflac Ventures, LLC (Aflac Ventures), as opportunities emerge. As of March 31, 2024, of the $400 million committed, approximately $282 million has been deployed. Aflac Ventures is a subsidiary of Aflac Global Ventures, LLC (Aflac Global Ventures) which is reported in Corporate and other. The central mission of Aflac Global Ventures is to support the organic growth and business development needs of Aflac Japan and Aflac U.S. with an emphasis on digital applications designed to improve the customer experience, gain efficiencies, and develop new markets in an effort to enhance and defend long-term shareholder value. Investments are included in equity securities or the other investments line in the consolidated balance sheets.

As part of an arrangement with Federal Home Loan Bank of Atlanta (FHLB), Aflac U.S. obtains low-cost funding from FHLB supported by acceptable forms of collateral pledged by Aflac U.S. In the first three months of 2024, Aflac U.S. borrowed and repaid $111 million under this program. As of March 31, 2024, Aflac U.S. had outstanding borrowings of $652 million reported in its balance sheet.

See Note 3 of the Notes to the Consolidated Financial Statements for details on certain investment commitments.

Financing Activities

Cash flows from financing activities consist primarily of share repurchases, dividends to shareholders and, from time to time, debt issuances and redemptions.

In March 2024, the Parent Company issued five series of senior notes totaling ¥75.0 billion through a private placement. The first series, which totaled ¥18.3 billion, bears interest at a fixed rate of 1.600% per annum, payable semi-annually, and will mature in March 2034. The second series, which totaled ¥15.0 billion, bears interest at a fixed rate of 1.740% per annum, payable semi-annually, and will mature in March 2036. The third series, which totaled ¥16.5 billion, bears interest at a fixed rate of 1.920% per annum, payable semi-annually, and will mature in March 2039. The fourth series, which totaled ¥5.7 billion, bears interest at a fixed rate of 2.160% per annum, payable semi-annually, and will mature in March 2044. The fifth series, which totaled ¥19.5 billion, bears interest at a fixed rate of 2.400% per annum, payable semi-annually, and will mature in March 2054. These notes are redeemable at the Parent Company's option (i) in whole at any time or (ii) in part from time to time in an amount not less than 5% of the aggregate principal amount then outstanding of the notes to be redeemed.

In March 2024, the Parent Company issued three series of senior notes totaling ¥48.6 billion through a public debt offering under its U.S. shelf registration statement. The first series, which totaled ¥13.0 billion, bears interest at a fixed rate of 1.048% per annum, payable semi-annually, and will mature in March 2029. The second series, which totaled ¥27.9 billion, bears interest at a fixed rate of 1.412% per annum, payable semi-annually, and will mature in March 2031. The third series, which totaled ¥7.7 billion, bears interest at a fixed rate of 1.682% per annum, payable semi-annually, and will mature in March 2034. These notes are redeemable at the Parent Company’s option at any time, in whole but not in part, upon the occurrence of certain changes affecting U.S. taxation, as specified in the indenture governing the terms of the issuance. In addition, the notes maturing in March 2029, March 2031 and March 2034 are redeemable at the Parent Company's option, in whole or in part from time to time, on or after December 21, 2028, December 31, 2030 and September 21, 2033, respectively, at a redemption price equal to the aggregate principal amount of the applicable series to be redeemed plus accrued and unpaid interest on the principal amount to be redeemed to, but excluding, the date of redemption.

Cash returned to shareholders through treasury stock purchases and dividends was $1.0 billion during the three-month period ended March 31, 2024, compared with $948 million during the three-month period ended March 31, 2023.

The following tables present a summary of treasury stock activity during the three-month periods ended March 31.

Treasury Stock Purchased

(In millions of dollars and thousands of shares)	2024		2023
Treasury stock purchases	$	750	$	700
Number of shares purchased:
Share repurchase program	9,276		10,348
Other	457		347
Total shares purchased	9,733		10,695

101

Treasury Stock Issued

(In millions of dollars and thousands of shares)	2024		2023
Stock issued from treasury:
Cash financing	$	6	$	2
Noncash financing	20		18
Total stock issued from treasury	$	26	$	20
Number of shares issued	450		458

As of March 31, 2024, a remaining balance of 68.5 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

Cash dividends paid to shareholders were $.50 per share in the first quarter of 2024, compared with $.42 per share in the first quarter of 2023. The following table presents the dividend activity for the three-month periods ended March 31.

(In millions)	2024		2023
Dividends paid in cash	$	278	$	248
Dividends through issuance of treasury shares	10		9
Total dividends to shareholders	$	288	$	257

In April 2024, the board of directors declared the second quarter cash dividend of $.50 per share, an increase of 19.0% compared with the same period in 2023. The dividend is payable on June 3, 2024 to shareholders of record at the close of business on May 22, 2024.

Regulatory Restrictions

Aflac Japan

Aflac Japan is required to meet certain financial criteria as governed by Japanese corporate law in order to provide dividends to the Parent Company. Under these criteria, dividend capacity at the Japan subsidiary is basically defined as total equity excluding common stock and capital reserves (representing statutorily required amounts in Japan) but reduced for net after-tax unrealized losses on available-for-sale securities. These dividend capacity requirements are generally aligned with the SMR. Japan's Financial Services Agency (FSA) maintains its own solvency standard which is quantified through the SMR. Aflac Japan's SMR is sensitive to interest rate, credit spread, and foreign exchange rate changes; therefore, the Company continues to evaluate alternatives for reducing this sensitivity, including the reduction of subsidiary dividends paid to the Parent Company and Parent Company capital contributions. In the event of a rapid change in market risk conditions causing SMR to decline, the Company has a senior unsecured revolving credit facility in the amount of ¥100 billion as a capital contingency plan. Additionally, subject to market conditions, the Company expects that it could take action to enter into derivatives on unhedged U.S. dollar-denominated investments with foreign currency options or forwards or execute additional internal reinsurance transactions with Aflac Re. See Notes 8 and 9 of the Notes to the Consolidated Financial Statements for additional information.

The Company has already undertaken various measures to mitigate the sensitivity of Aflac Japan's SMR. For example, the Company employs policy reserve matching (PRM) investment strategies, which is a Japan-specific accounting treatment that reduces SMR interest rate sensitivity since PRM-designated investments are carried at amortized cost consistent with corresponding liabilities. In order for a PRM-designated asset to be held at amortized cost, there are certain criteria that must be maintained. The primary criterion relates to maintaining the duration of designated assets and liabilities within a specified tolerance range. If the duration difference is not maintained within the specified range without rebalancing, then a certain portion of the assets must be reclassified as available-for-sale and held at fair value with any associated unrealized gain or loss recorded in surplus. To rebalance, assets may need to be sold in order to maintain the duration with the specified range, resulting in realizing a gain or loss from the sale. For U.S. GAAP, PRM investments are categorized as available-for-sale. The Company also uses foreign currency derivatives to hedge a portion of its U.S. dollar-denominated investments. See Notes 3, 4 and 8 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report for additional information on the Company's investment strategies, hedging activities, and reinsurance, respectively.

102

As of March 31, 2024, Aflac Japan's SMR remains high and reflects a strong capital and surplus position. The Company is committed to maintaining strong capital levels, consistent with maintaining current insurance financial strength and credit ratings.

The FSA is considering the introduction of an economic value-based solvency regime based on the Insurance Capital Standards (ICS) for insurance companies in Japan. The FSA continues to conduct field testing with insurance companies in Japan for the purpose of investigating the impact of the introduction of such regulations. Final specifications are expected to be decided in 2024, and a new capital regime to replace the current solvency regime is expected to be introduced in Aflac Japan's 2025 fiscal year.

Aflac U.S.

A life insurance company’s statutory capital and surplus is determined according to rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. Statutory accounting rules are different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency. The continued long-term growth of the Company's business may require increases in the statutory capital and surplus of its insurance operations. The Company's insurance operations may secure additional statutory capital through various sources, such as internally generated statutory earnings, reduced dividends paid to the Parent Company, capital contributions by the Parent Company from funds generated through debt or equity offerings, or reinsurance transactions. The NAIC’s Risk-based capital (RBC) formula is used by insurance regulators to help identify inadequately capitalized insurance companies. The RBC formula quantifies insurance risk, business risk, asset risk and interest rate risk by weighing the types and mixtures of risks inherent in the insurer’s operations. As of March 31, 2024, Aflac U.S.'s combined RBC ratio remains high and reflects a strong capital and surplus position.

Aflac, CAIC and TOIC are domiciled in Nebraska and are subject to its regulations. The maximum amount of dividends that can be paid to the Parent Company by Aflac, CAIC and TOIC without prior approval of Nebraska's director of insurance is the greater of the net income from operations, which excludes net investment gains, for the previous year determined under statutory accounting principles, or 10% of statutory capital and surplus as of the previous year-end. Dividends declared by Aflac during 2024 in excess of $1.1 billion would be considered extraordinary and require such approval. Similar laws apply in New York, the domiciliary jurisdiction of Aflac New York.

Corporate and Other

Aflac Re is licensed by the BMA as a long-term insurer and is subject to the Bermuda Insurance Act of 1978 (Bermuda Insurance Act). Aflac Re is required to file an annual return for its Bermuda Solvency Capital Requirement (BSCR) which utilizes an Economic Balance Sheet (EBS) framework to determine Aflac Re’s Enhanced Capital Requirement (ECR). Aflac Re is also subject to a Minimum Margin of Solvency (MMS) related to its statutory financial statements. The MMS is equal to the greater of $500,000, 1.5% of the total statutory assets, or 25% of ECR.

Under the Bermuda Insurance Act, Aflac Re is prohibited from paying dividends in an amount that exceeds 25% of the prior year's statutory capital and surplus without an affidavit stating that Aflac Re will continue to meet its solvency margin. Further, Aflac Re may not reduce its total statutory capital by 15% or more without prior regulatory approval. Additionally, Aflac Re is not permitted to pay any dividends that would cause Aflac Re to fail to meet its minimum capital requirements.

Other

For information regarding commitments and contingent liabilities, see Note 13 of the Notes to the Consolidated Financial Statements.

Additional Information

Investors should note that the Company announces material financial information in its SEC filings, press releases and public conference calls. In accordance with SEC guidance, the Company may also use the Investor Relations section of the Company's website (http://investors.aflac.com) to communicate with investors about the Company. It is possible that the financial and other information the Company posts there could be deemed to be material information. The information on the Company's website is not part of this document. Further, the Company's references to website URLs are intended to be inactive textual references only.

103

CRITICAL ACCOUNTING ESTIMATES

The Company prepares its financial statements in accordance with U.S. GAAP. These principles are established primarily by the Financial Accounting Standards Board (FASB). In this MD&A, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards Codification™ (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The estimates that the Company deems to be most critical to an understanding of its results of operations and financial condition are those related to the valuation of investments and derivatives, DAC, liabilities for future policy benefits, and income taxes. The preparation and evaluation of these critical accounting estimates involve the use of various assumptions developed from management’s analyses and judgments. Calculations of DAC and the liability for future policy benefits require the use of estimates based on actuarial valuation techniques. The application of these critical accounting estimates determines the values at which 93% of the Company's assets and 78% of its liabilities are reported as of March 31, 2024, and thus has a direct effect on net earnings and shareholders’ equity. Subsequent experience or use of other assumptions could produce significantly different results.

There have been no changes in the items the Company has identified as critical accounting estimates during the three-month period ended March 31, 2024. For additional information, see the Critical Accounting Estimates section of Item 7. MD&A included in the 2023 Annual Report.

New Accounting Pronouncements

For information on new accounting pronouncements and the impact, if any, on the Company's financial position or results of operations, see Note 1 of the Notes to the Consolidated Financial Statements.

Item 3.Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed primarily to the following types of market risks: currency risk, interest rate risk, credit risk and equity risk. The Company regularly monitors its market risks and uses a variety of strategies to manage its exposure to these market risks. A description of the Company's market risk exposures may be found under “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A, of the 2023 Annual Report. There have been no material changes to the Company's market risk exposures from the market risk exposures previously disclosed in the 2023 Annual Report.

Item 4.Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this quarterly report (the Evaluation Date). Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the first fiscal quarter of 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

104

PART II. OTHER INFORMATION

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

During the first three months of 2024, the Parent Company repurchased shares of its common stock as follows:

Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 - January 31	0		$	0.00	0	77,745,381
February 1 - February 29	5,308,570		78.58		4,859,803	72,885,578
March 1 - March 31	4,424,657		83.34		4,416,656	68,468,922
Total	9,733,227	(1)	$	80.75	9,276,459	68,468,922	(2)

(1) During the first three months of 2024, 456,768 shares were purchased in connection with income tax withholding obligations related to the vesting of restricted-share-based awards during the period.

(2) The total remaining shares available for purchase at March 31, 2024, are related to a 100,000,000 share repurchase authorization by the board of directors announced in November 2022.

Item 5.    Other Information

Insider Trading Arrangements

During the first quarter of 2024, no directors or executive officers adopted or terminated a contract, instruction or written plan for the purchase or sale of the Company's securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement as defined in Regulation S-K Item 408(c).

105

Item 6.    Exhibits

(a)	EXHIBIT INDEX
	3.0	-	Articles of Incorporation, as amended – incorporated by reference from Form 10-Q for June 30, 2008, Exhibit 3.0.
	3.1	-	Bylaws of Aflac Incorporated, as amended and restated – incorporated by reference from Form 8-K dated November 17, 2023, Exhibit 3.1.
	4.1	-	Thirty-Eighth Supplemental Indenture, dated as of March 21, 2024, between Aflac Incorporated and The Bank of New York Mellon Trust Company, N.A., as trustee (including the form of 1.048% Senior Note due 2029) – incorporated by reference from Form 8-K dated March 21, 2024, Exhibit 4.1.
	4.2	-	Thirty-Ninth Supplemental Indenture, dated as of March 21, 2024, between Aflac Incorporated and The Bank of New York Mellon Trust Company, N.A., as trustee (including the form of 1.412% Senior Note due 2031) – incorporated by reference from Form 8-K dated March 21, 2024, Exhibit 4.2.
	4.3	-	Fortieth Supplemental Indenture, dated as of March 21, 2024, between Aflac Incorporated and The Bank of New York Mellon Trust Company, N.A., as trustee (including the form of 1.682% Senior Note due 2034) – incorporated by reference from Form 8-K dated March 21, 2024, Exhibit 4.3.
	31.1	-	Certification of CEO dated May 2, 2024, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	31.2	-	Certification of CFO dated May 2, 2024, required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.
	32	-	Certification of CEO and CFO dated May 2, 2024, pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.INS	-	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
	101.SCH	-	Inline XBRL Taxonomy Extension Schema.
	101.CAL	-	Inline XBRL Taxonomy Extension Calculation Linkbase.
	101.DEF	-	Inline XBRL Taxonomy Extension Definition Linkbase.
	101.LAB	-	Inline XBRL Taxonomy Extension Label Linkbase.
	101.PRE	-	Inline XBRL Taxonomy Extension Presentation Linkbase.
	104	-	Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101.

106

Glossary of Selected Terms

Throughout this Quarterly Report on Form 10-Q, the Company may use certain performance metrics and other terms which are defined below.

Adjusted Net Investment Income - Net Investment Income adjusted for i) amortized hedge cost/income related to foreign currency exposure management strategies and certain derivative activity and ii) net interest income/expense from foreign currency and interest rate derivatives associated with certain investment strategies, which are reclassified from net investment gains and losses to net investment income. The Company considers adjusted net investment income important because it provides a more comprehensive understanding of the costs and income associated with the Company's investments and related hedging strategies. The metric is used in segment reporting as a component of segment profitability.

Affiliated Corporate Agency – Agency in Japan directly affiliated with a specific corporation that sells insurance policies primarily to its employees.

Annualized Premiums in Force – The amount of gross premium that a policyholder must pay over a full year in order to keep coverage. The growth of net earned premiums (defined below) is directly affected by the change in premiums in force and by the change in weighted-average yen/dollar exchange rates.

Average Weekly Producer – The total number of writing agents who have produced greater than $0.00 during the production week - excluding any manual adjustments - divided by the number of weeks in the time period. The Company believes this metric allows sales management to monitor progress and needs, as well as serve as a leading indicator of future production capacity.

Capital Buffer – Established dollar amount of liquidity at the Parent Company reserved for injecting capital into the insurance entities or general liquidity support for general expenses at the Parent Company.

Earnings Per Basic Share – Net earnings divided by weighted-average number of shares outstanding for the period.

Earnings Per Diluted Share – Net earnings divided by the weighted-average number of shares outstanding for the period plus the weighted-average shares for the dilutive effect of share-based awards outstanding.

Group Insurance – Insurance issued to a group, such as an employer or trade association, that covers employees or association members and their dependents through certificates of coverage.

Individual Insurance – Insurance issued to an individual with the policy designed to cover that person and his or her dependents.

In force Policies – A count of policies that are active contracts at the end of a period.

Liquidity Support – Internally defined and established dollar amount of liquidity reserved for supporting potential collateral and settlements of derivatives at the Parent Company.

Net Investment Income – The income derived from interest and dividends on invested assets, after deducting investment expenses.

Net Earned Premiums – is a financial measure that appears on the Company's consolidated statements of earnings and in its segment reporting. This measure reflects collected or due premiums that have been earned ratably on policies in force during the reporting period, reduced by premiums that have been ceded to third parties and increased by premiums assumed through reinsurance.

New Annualized Premium Sales – (sometimes referred to as new sales or sales) An operating measure that is not reflected on the Company's financial statements. New annualized premium sales generally represent annual premiums on policies and riders the Company sold and incremental increases from policy conversions that would be collected over a 12-month period assuming the policies remain in force for that entire period. For Aflac Japan, new annualized premium sales are determined by applications submitted during the reporting period. For Aflac U.S., new annualized premium sales are determined by applications that are issued during the reporting period. Policy conversions are defined as the positive difference in the annualized premium when a policy upgrades in the current reporting period. The Company believes that this metric is a key indicator of the Company's future source of earnings.

New Money Yield – Gross yields earned on purchases of fixed maturities, loan receivables, and equities. Purchases exclude capitalized interest, securities lending/repurchase agreements, short-term/cash activity, and alternatives. New money yield for equities is based on the assumed dividend yield at the time of purchase. The new money yield for Aflac Japan excludes the impact of any derivatives and associated amortized hedge costs associated with USD-denominated investments. Management uses this metric as a leading indicator of future investment earning potential.

Operating Ratios – Used to evaluate the Company's financial condition and profitability. Examples include: (1) Ratios to total adjusted revenues, which present expenses as a percentage of total revenues and (2) Ratios to total premium, including benefit ratio.

107

Premium Persistency – Percentage of premiums remaining in force at the end of a period, usually one year, and presented on a trailing 12-month basis. For example, 95% persistency would mean that 95% of the premiums in force at the beginning of the period were still in force at the end of the period. The Company believes that this metric is a key driver of in force levels, which is a key measure of the size of the Company's business and future sources of earnings.

Pretax Adjusted Earnings – Earnings as adjusted earnings before the application of income taxes. This measure is used in the Company's segment reporting.

Pretax Adjusted Profit Margin – Adjusted earnings divided by adjusted revenues, before taxes are applied. This measure is used in the Company's segment reporting.

Return on Average Invested Assets – Net investment income as a percentage of average invested assets during the period. Management uses this metric to demonstrate how the Company's actual net investment income results represent an overall return on the portfolio to provide a more comparative metric as the size of the Company's investment portfolio changes over time.

Risk-based Capital (RBC) Ratio – Statutory adjusted capital divided by statutory required capital. This insurance ratio is based on rules prescribed by the National Association of Insurance Commissioners (NAIC) and provides an indication of the amount of statutory capital the insurance company maintains, relative to the inherent risks in the insurer’s operations.

Solvency Margin Ratio (SMR) – Solvency margin total divided by one half of the risk total. This insurance ratio is prescribed by the Japan Financial Services Agency (FSA) and is used for all life insurance companies in Japan to measure the adequacy of the company’s ability to pay policyholder claims in the event actual risks exceed expected levels.

Statutory Earnings – Earnings determined according to accounting rules prescribed by the National Association of Insurance Commissioners (NAIC), as modified by the insurance department in the insurance company’s state of domicile. These statutory accounting rules are different from U.S. GAAP and are intended to emphasize policyholder protection and company solvency.

Weighted-Average Foreign Currency Exchange Rate – Japan segment operating earnings for the period (excluding hedge costs) in yen divided by Japan segment operating earnings for the period (excluding hedge costs) in dollars. Management uses this metric to evaluate and determine consolidated results on foreign currency effective basis.

108

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Aflac Incorporated
May 2, 2024	/s/ Max K. Brodén
	(Max K. Brodén)
	Executive Vice President; Chief Financial Officer
May 2, 2024	/s/ Robin L. Blackmon
	(Robin L. Blackmon)
	Senior Vice President, Financial Services; Chief Accounting Officer

109

EX-31.1

Aflac Incorporated 1st Quarter 2024 Form 10-Q

EXHIBIT 31.1

Certification of Chief Executive Officer

I, Daniel P. Amos, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Aflac Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 2, 2024	/s/ Daniel P. Amos
		Daniel P. Amos
		Chairman and Chief Executive Officer

EX-31.2

Aflac Incorporated 1st Quarter 2024 Form 10-Q

EXHIBIT 31.2

Certification of Chief Financial Officer

I, Max K. Brodén, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Aflac Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	May 2, 2024	/s/ Max K. Brodén
		Max K. Brodén
		Executive Vice President, Chief Financial Officer

EX-32

Aflac Incorporated 1st Quarter 2024 Form 10-Q

EXHIBIT 32

Certification of CEO and CFO Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Aflac Incorporated (the “Company”) for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Daniel P. Amos, as Chief Executive Officer of the Company, and Max K. Brodén, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Daniel P. Amos
Name:	Daniel P. Amos
Title:	Chief Executive Officer
Date:	May 2, 2024

/s/ Max K. Brodén
Name:	Max K. Brodén
Title:	Chief Financial Officer
Date:	May 2, 2024

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	Apr. 24, 2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-07434
Entity Registrant Name	Aflac Incorporated
Entity Incorporation, State or Country Code	GA
Entity Tax Identification Number	58-1167100
Entity Address, Address Line One	1932 Wynnton Road
Entity Address, City or Town	Columbus,
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	31999
City Area Code	706.
Local Phone Number	323.3431
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		568,222,447
Amendment Flag	false
Entity Central Index Key	0000004977
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
NEW YORK STOCK EXCHANGE, INC.
Title of 12(b) Security	Common Stock, $.10 par value per share
Trading Symbol	AFL
Security Exchange Name	NYSE

XML

Consolidated Statements of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net earned premiums, principally supplemental health insurance	$ 3,456	$ 3,688
Net investment income	1,000	943
Net investment gains (losses)	951	123
Other income (loss)	29	46
Total revenues	5,436	4,800
Benefits and expenses:
Benefits and claims, excluding reserve remeasurement	2,066	2,203
Reserve remeasurement (gains) losses	(56)	(53)
Total benefits and claims, net	2,010	2,150
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs	215	205
Insurance commissions	255	280
Insurance and other expenses	739	775
Interest expense	47	48
Total acquisition and operating expenses	1,256	1,308
Total benefits and expenses	3,266	3,458
Earnings before income taxes	2,170	1,342
Income taxes	291	154
Net earnings	$ 1,879	$ 1,188
Net earnings per share:
Basic (in dollars per share)	$ 3.27	$ 1.94
Diluted (in dollars per share)	$ 3.25	$ 1.94
Weighted-average outstanding common shares used in computing earnings per share (In thousands):
Basic (in shares)	574,886	611,205
Diluted (in shares)	577,482	613,950
Cash dividends per share	$ 0.50	$ 0.42

XML

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,879	$ 1,188
Other comprehensive income (loss) before income taxes:
Unrealized foreign currency translation gains (losses) during period	(501)	(43)
Unrealized gains (losses) on fixed maturity securities:
Unrealized holding gains (losses) on fixed maturity securities during period	103	2,578
Reclassification adjustment for (gains) losses on fixed maturity securities included in net earnings	(168)	(57)
Unrealized gains (losses) on derivatives during period	(5)	1
Effect of changes in discount rate assumptions during period	1,348	(3,537)
Pension liability adjustment during period	2	9
Total other comprehensive income (loss) before income taxes	779	(1,049)
Income tax expense (benefit) related to items of other comprehensive income (loss)	361	(200)
Other comprehensive income (loss), net of income taxes	418	(849)
Total comprehensive income (loss)	$ 2,297	$ 339

XML

Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2024		Dec. 31, 2023
Investments and cash:
Fixed maturity securities, available-for-sale		$ 70,130		$ 73,290
Fixed maturity securities, held-to-maturity		16,689	[1]	17,819
Equity securities		762		1,088
Commercial mortgage and other loans		12,360		12,527
Other investments		6,677		4,530
Cash and cash equivalents		5,098		4,306
Total investments and cash		111,716		113,560
Receivables		1,038		848
Accrued investment income		693		731
Deferred policy acquisition costs		8,819		9,132
Property and equipment, at cost less accumulated depreciation		418		445
Other		2,058		2,008
Total assets		124,742		126,724
Policy liabilities:
Future policy benefits		77,867		83,718
Unpaid policy claims		344		261
Unearned premiums		1,322		1,451
Other policyholders’ funds		5,831		6,169
Total policy liabilities		85,364		91,599
Income taxes		777		154
Payables for return of cash collateral on loaned securities		3,366		1,503
Notes payable and lease obligations		7,912		7,364
Other		3,786		4,119
Total liabilities		101,205		104,739
Commitments and contingent liabilities (Note 13)
Shareholders’ equity:
Common stock of $.10 par value. In thousands: authorized 1,900,000 shares in 2024 and 2023; issued 1,356,480 shares in 2024 and 1,355,398 shares in 2023		136		136
Additional paid-in capital		2,806		2,771
Retained earnings		49,872		47,993
Accumulated other comprehensive income (loss):
Unrealized foreign currency translation gains (losses)		(4,666)		(4,069)
Unrealized gains (losses) on fixed maturity securities		1,092		1,139
Unrealized gains (losses) on derivatives		(26)		(22)
Effect of changes in discount rate assumptions		(1,495)		(2,560)
Pension liability adjustment		(7)		(8)
Treasury stock, at average cost		(24,175)		(23,395)
Total shareholders’ equity		23,537		21,985
Total liabilities and shareholders’ equity		124,742		126,724
Consolidated Entity Excluding Variable Interest Entities (VIE)
Investments and cash:
Fixed maturity securities, available-for-sale		66,452		69,578
Variable Interest Entity, Consolidated
Investments and cash:
Fixed maturity securities, available-for-sale		3,678		3,712
Commercial mortgage and other loans		9,947		10,150
Other investments	[2]	2,443		2,381
Total assets		16,125		16,298
Policy liabilities:
Total liabilities		$ 583		$ 507

[1] Net of allowance for credit losses

[2] Consists entirely of alternative investments in limited partnerships

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Fixed maturity securities, available-for-sale, allowance for credit losses		$ 0	$ 0
Fixed maturity securities, available-for-sale, amortized cost		67,594	70,689
Fixed maturity securities, held-to-maturity, allowance for credit losses		5	5
Fixed maturity securities, held-to-maturity, fair value		18,245	19,657
Commercial mortgage and other loans, allowance for credit losses		232	274
Commercial mortgage and other loans		12,360	12,527
Other investments		$ 6,677	$ 4,530
Common stock, par value (in dollars per share)		$ 0.10	$ 0.10
Common stock, shares authorized (in shares)		1,900,000	1,900,000
Common stock, shares issued (in shares)		1,356,480	1,355,398
Consolidated Entity Excluding Variable Interest Entities (VIE)
Fixed maturity securities, available-for-sale, allowance for credit losses		$ 0	$ 0
Fixed maturity securities, available-for-sale, amortized cost		64,838	67,807
Variable Interest Entity, Consolidated
Fixed maturity securities, available-for-sale, amortized cost		2,756	2,882
Commercial mortgage and other loans		9,947	10,150
Other investments	[1]	$ 2,443	$ 2,381

[1] Consists entirely of alternative investments in limited partnerships

XML

Consolidated Statements of Shareholders' Equity - USD ($) $ in Millions		Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock
Balance, beginning of period at Dec. 31, 2022		$ 20,140	$ 135	$ 2,641	$ 44,367	$ (6,429)	$ (20,574)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings		1,188	0	0	1,188	0	0
Unrealized foreign currency translation gains (losses) during period, net of income taxes		(54)	0	0	0	(54)	0
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments		1,991	0	0	0	1,991	0
Unrealized gains (losses) on derivatives during period, net of income taxes		1	0	0	0	1	0
Effect of changes in discount rate assumptions during period, net of income taxes		(2,794)	0	0	0	(2,794)	0
Pension liability adjustment during period, net of income taxes		7	0	0	0	7	0
Dividends to shareholders	[1]	0	0	0	0	0	0
Exercise of stock options		3	0	3	0	0	0
Share-based compensation		14	0	14	0	0	0
Purchases of treasury stock		(732)	0	0	0	0	(732)
Treasury stock reissued		20	0	7	0	0	13
Balance, end of period at Mar. 31, 2023		19,784	135	2,665	45,555	(7,278)	(21,293)
Balance, beginning of period at Dec. 31, 2022		20,140	135	2,641	44,367	(6,429)	(20,574)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of changes in discount rate assumptions during period, net of income taxes						(460)
Balance, end of period at Dec. 31, 2023		21,985	136	2,771	47,993	(5,520)	(23,395)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings		1,879	0	0	1,879	0	0
Unrealized foreign currency translation gains (losses) during period, net of income taxes		(597)	0	0	0	(597)	0
Unrealized gains (losses) on fixed maturity securities during period, net of income taxes and reclassification adjustments		(47)	0	0	0	(47)	0
Unrealized gains (losses) on derivatives during period, net of income taxes		(4)	0	0	0	(4)	0
Effect of changes in discount rate assumptions during period, net of income taxes		1,065	0	0	0	1,065	0
Pension liability adjustment during period, net of income taxes		1	0	0	0	1	0
Dividends to shareholders	[1]	0	0	0	0	0	0
Exercise of stock options		4	0	4	0	0	0
Share-based compensation		18	0	18	0	0	0
Purchases of treasury stock		(793)	0	0	0	0	(793)
Treasury stock reissued		26	0	13	0	0	13
Balance, end of period at Mar. 31, 2024		$ 23,537	$ 136	$ 2,806	$ 49,872	$ (5,102)	$ (24,175)

[1] Dividends to shareholders are recorded in the period in which they are declared.

XML

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Retained Earnings
Dividends to shareholders (in dollars per share)	$ 0.00	$ 0.00

XML

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net earnings	$ 1,879	$ 1,188
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities
Change in receivables and advance premiums	32	(34)
Capitalization of deferred policy acquisition costs	(254)	(270)
Amortization of deferred policy acquisition costs	215	205	$ 816
Increase in policy liabilities	(41)	9
Change in income tax liabilities	291	154
Net investment (gains) losses	(951)	(123)
Other, net	(322)	(239)
Net cash provided (used) by operating activities	849	890
Proceeds from investments sold or matured:
Available-for-sale fixed maturity securities	2,286	949
Equity securities	267	126
Commercial mortgage and other loans	379	418
Costs of investments acquired:
Available-for-sale fixed maturity securities	(2,127)	(1,090)
Equity securities	(73)	(134)
Commercial mortgage and other loans	(251)	(315)
Other investments, net	(2,119)	(1,256)
Settlement of derivatives, net	(256)	(480)
Cash received (pledged or returned) as collateral, net	1,973	1,756
Other, net	148	(51)
Net cash provided (used) by investing activities	227	(77)
Cash flows from financing activities:
Purchases of treasury stock	(750)	(700)
Proceeds from borrowings	823	0
Dividends paid to shareholders	(278)	(248)
Change in investment-type contracts, net	(50)	(28)
Treasury stock reissued	6	2
Other, net	(7)	41
Net cash provided (used) by financing activities	(256)	(933)
Effect of exchange rate changes on cash and cash equivalents	(28)	(14)
Net change in cash and cash equivalents	792	(134)
Cash and cash equivalents, beginning of period	4,306	3,943	3,943
Cash and cash equivalents, end of period	5,098	3,809	$ 4,306
Supplemental disclosures of cash flow information:
Income taxes paid	0	0
Interest paid	34	37
Noncash interest	13	11
Noncash real estate acquired in satisfaction of debt	35	0
Noncash financing activities:
Lease obligations	5	18
Associate stock bonus
Treasury stock issued for:
Treasury stock issued	4	4
Shareholder dividend reinvestment
Treasury stock issued for:
Treasury stock issued	10	9
Share-based compensation grants
Treasury stock issued for:
Treasury stock issued	$ 6	$ 5

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd. (Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2024 and December 31, 2023, and the consolidated statements of earnings and comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2024 and 2023. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report).

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

For the three-month period ended March 31, 2023, immaterial reclassifications were made to the consolidated statement of cash flows related to investments in limited partnerships and the impact of foreign currency on policy liabilities. The impact of the reclassification related to investments in limited partnerships resulted in an increase to net cash flows provided by operating activities of $182 million with a corresponding decrease to net cash flows provided by investing activities. There was no impact to net cash flows provided by operating activities as a result of the reclassification related

to the impact of foreign currency on policy liabilities between the increase in policy liabilities and other, net line items within operating activities.

New Accounting Pronouncements

Accounting Pronouncements Pending Adoption

Accounting Standards Update (ASU) 2023-09 Income Taxes (Topic 740) – Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-07 Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that will add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business. 

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

The Company consists of two reportable insurance business segments: Aflac Japan and Aflac U.S., both of which sell supplemental health and life insurance. In addition, the Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re, and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other. The Company does not allocate corporate overhead expenses to business segments.

Consistent with U.S. GAAP accounting guidance for segment reporting, the Company evaluates and manages its business segments using a financial performance measure called pretax adjusted earnings.

•Pretax adjusted earnings are adjusted revenues less benefits and adjusted expenses. The adjustments to both revenues and expenses account for certain items that are outside management’s control because they tend to be driven by general economic conditions and events or are related to infrequent activities not directly associated with insurance operations. The Company excludes income taxes related to operations to arrive at pretax adjusted earnings.

◦Adjusted revenues are U.S. GAAP total revenues excluding net investment gains and losses, except for amortized hedge costs/income related to foreign currency exposure management strategies and net interest income/expense from derivatives associated with certain investment strategies, which are reclassified from net investment gains (losses) and included in adjusted earnings as a component of adjusted net investment income when analyzing operations. 

◦Adjusted expenses are U.S. GAAP total acquisition and operating expenses including the impact of interest from derivatives associated with notes payable but excluding any non-recurring or other items not associated with the normal course of the Company’s insurance operations and that do not reflect the Company’s underlying business performance.

Aflac Japan's adjusted revenues accounted for 56% and 61% of the Company's total adjusted revenues in the three-month periods ended March 31, 2024 and 2023, respectively. The percentage of the Company's total assets attributable to Aflac Japan was 79% at March 31, 2024, compared with 80% at December 31, 2023.

Information regarding operations by reportable segment and Corporate and other, follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Revenues:
Aflac Japan:
Net earned premiums	$	1,816	$	2,170
Adjusted net investment income	648		611
Other income	9		9
Total adjusted revenue Aflac Japan	2,473		2,790
Aflac U.S.:
Net earned premiums	1,475		1,428
Adjusted net investment income	206		197
Other income	18		35
Total adjusted revenue Aflac U.S.	1,699		1,660
Corporate and other (1)	247		129
Total adjusted revenues	4,419		4,579
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Total revenues	$	5,436	$	4,800

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

	Three Months Ended March 31,
(In millions)	2024		2023
Pretax earnings:
Aflac Japan	$	810	$	788
Aflac U.S.	356		352
Corporate and other (1)	(3)		(7)
Pretax adjusted earnings	1,163		1,133
Other income (loss)	(2)		0
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Impact of interest from derivatives associated    with notes payable	(8)		(12)
Total earnings before income taxes	$	2,170	$	1,342
Income taxes applicable to pretax adjusted earnings	$	202	$	180
Effect of foreign currency translation on after-tax   adjusted earnings	(44)		(41)

(1)The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Assets were as follows:

(In millions)	March 31, 2024			December 31, 2023
Assets:
Aflac Japan		$	98,189		$	101,541
Aflac U.S.		21,850			21,861
Corporate and other		4,703			3,322
Total assets		$	124,742		$	126,724

XML

INVESTMENTS

3 Months Ended

Mar. 31, 2024

Investments [Abstract]

INVESTMENTS

INVESTMENTS

Investment Holdings

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	21,577	$	0	$	874	$	1,811	$	20,640
Municipalities	907		0		102		59		950
Mortgage- and asset-backed securities	201		0		6		12		195
Public utilities	3,281		0		262		77		3,466
Sovereign and supranational	349		0		24		7		366
Banks/financial institutions	5,546		0		323		285		5,584
Other corporate	5,532		0		663		245		5,950
Total yen-denominated	37,393		0		2,254		2,496		37,151
U.S. dollar-denominated:
U.S. government and agencies	177		0		1		4		174
Municipalities	1,237		0		72		49		1,260
Mortgage- and asset-backed securities	2,968		0		270		48		3,190
Public utilities	3,595		0		388		136		3,847
Sovereign and supranational	95		0		33		4		124
Banks/financial institutions	2,971		0		385		41		3,315
Other corporate	19,158		0		2,635		724		21,069
Total U.S. dollar-denominated	30,201		0		3,784		1,006		32,979
Total securities available-for-sale	$	67,594	$	0	$	6,038	$	3,502	$	70,130

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	23,067	$	0	$	1,040	$	1,696	$	22,411
Municipalities	968		0		115		58		1,025
Mortgage- and asset-backed securities	215		0		6		11		210
Public utilities	3,757		0		325		82		4,000
Sovereign and supranational	373		0		24		7		390
Banks/financial institutions	5,896		0		320		365		5,851
Other corporate	5,898		0		699		294		6,303
Total yen-denominated	40,174		0		2,529		2,513		40,190
U.S. dollar-denominated:
U.S. government and agencies	191		0		2		4		189
Municipalities	1,246		0		65		38		1,273
Mortgage- and asset-backed securities	2,748		0		184		56		2,876
Public utilities	3,346		0		360		114		3,592
Sovereign and supranational	122		0		33		8		147
Banks/financial institutions	2,676		0		359		51		2,984
Other corporate	20,186		0		2,518		665		22,039
Total U.S. dollar-denominated	30,515		0		3,521		936		33,100
Total securities available-for-sale	$	70,689	$	0	$	6,050	$	3,449	$	73,290

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,002	$	2	$	16,000	$	1,474	$	0	$	17,474
Municipalities	248		0		248		37		0		285
Public utilities	33		0		33		3		0		36
Sovereign and supranational	394		3		391		40		0		431
Other corporate	17		0		17		2		0		19
Total yen-denominated	16,694		5		16,689		1,556		0		18,245
Total securities held-to-maturity	$	16,694	$	5	$	16,689	$	1,556	$	0	$	18,245

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	17,085	$	2	$	17,083	$	1,746	$	0	$	18,829
Municipalities	266		0		266		41		0		307
Public utilities	34		0		34		4		0		38
Sovereign and supranational	421		3		418		44		0		462
Other corporate	18		0		18		3		0		21
Total yen-denominated	17,824		5		17,819		1,838		0		19,657
Total securities held-to-maturity	$	17,824	$	5	$	17,819	$	1,838	$	0	$	19,657

	March 31, 2024			December 31, 2023
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	522		$	751
U.S. dollar-denominated		240			252
Other currencies		0			85
Total equity securities		$	762		$	1,088

The methods of determining the fair values of the Company's investments in fixed maturity securities and equity securities are described in Note 5.

During the first three months of 2024 and 2023, respectively, the Company did not reclassify any investments from the held-to-maturity category to the available-for-sale category.

Contractual and Economic Maturities

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2024, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,272		$	1,292
Due after one year through five years		6,659			7,480
Due after five years through 10 years		17,904			19,556
Due after 10 years		38,590			38,417
Mortgage- and asset-backed securities		3,169			3,385
Total fixed maturity securities available-for-sale		$	67,594		$	70,130
Held-to-maturity:
Due in one year or less		$	0		$	0
Due after one year through five years		35			36
Due after five years through 10 years		8,901			9,714
Due after 10 years		7,753			8,495
Total fixed maturity securities held-to-maturity		$	16,689		$	18,245

(1) Net of allowance for credit losses

Economic maturities are used for certain debt instruments with no stated maturity where the expected maturity date is based on the combination of features in the financial instrument such as the right to call or prepay obligations or changes in coupon rates.

Investment Concentrations

The Company's process for investing in credit-related investments begins with an independent approach to underwriting each issuer's fundamental credit quality. The Company evaluates independently those factors that it believes could influence an issuer's ability to make payments under the contractual terms of the Company's instruments. This includes a thorough analysis of a variety of items including the issuer's country of domicile (including political, legal, and financial considerations); the industry in which the issuer competes (with an analysis of industry structure, end-market dynamics, and regulation); company specific issues (such as management, assets, earnings, cash generation, and capital needs); and contractual provisions of the instrument (such as financial covenants and position in the capital structure). The Company further evaluates the investment considering broad business and portfolio management objectives, including asset/liability needs, portfolio diversification, and expected income.

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2024			December 31, 2023
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$36,641	$37,170	A+	$39,151	$40,222

(1)Japan Government Bonds (JGBs) or JGB-backed securities

Net Investment Gains and Losses

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	34	$	1
Gross losses from sales	(282)		(3)
Foreign currency gains (losses)	416		59
Other investments:
Gross gains (losses) from sales and redemptions	5		0
Total sales and redemptions	173		57
Equity securities	76		(3)
Credit losses:
Fixed maturity securities held-to-maturity	0		1
Commercial mortgage and other loans	(7)		(31)
Impairment losses	0		0
Loan commitments	1		3
Reinsurance recoverables and other	5		(3)
Total credit losses	(1)		(30)
Derivatives and other:
Derivative gains (losses)	(215)		17
Foreign currency gains (losses)	918		82
Total derivatives and other	703		99
Total net investment gains (losses)	$	951	$	123

The unrealized holding gains, net of losses, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2024 that relate to equity securities held at the March 31, 2024 reporting date were $71 million. The unrealized holding losses, net of gains, recorded as a component of net investment gains and losses for the three-month period ended March 31, 2023 that relate to equity securities held at the March 31, 2023 reporting date were $5 million.

Unrealized Investment Gains and Losses

Effect on Shareholders’ Equity

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2024			December 31, 2023
Unrealized gains (losses) on securities available-for-sale		$	2,536		$	2,601
Deferred income taxes		(1,444)			(1,462)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	1,092		$	1,139

Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2024 and December 31, 2023, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

	March 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	141		$	4		$	59		$	1		$	82		$	3
Japan government and       agencies:
Yen-denominated		7,828			1,811			1,628			395			6,200			1,416
Municipalities:
U.S. dollar-denominated		662			49			9			0			653			49
Yen-denominated		277			59			31			1			246			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		754			48			304			4			450			44
Yen-denominated		54			12			1			0			53			12
Public utilities:
U.S. dollar-denominated		1,383			136			391			9			992			127
Yen-denominated		915			77			351			13			564			64
Sovereign and supranational:
U.S. dollar-denominated		14			4			0			0			14			4
Yen-denominated		55			7			0			0			55			7
Banks/financial institutions:
U.S. dollar-denominated		628			41			228			2			400			39
Yen-denominated		2,973			285			62			1			2,911			284
Other corporate:
U.S. dollar-denominated		6,196			724			1,254			36			4,942			688
Yen-denominated		1,747			245			355			9			1,392			236
Total		$	23,627		$	3,502		$	4,673		$	471		$	18,954		$	3,031

	December 31, 2023
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	123		$	4		$	53		$	1		$	70		$	3
Japan government and       agencies:
Yen-denominated		8,393			1,696			1,657			303			6,736			1,393
Municipalities:
U.S. dollar-denominated		703			38			31			1			672			37
Yen-denominated		301			58			34			0			267			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		925			56			340			6			585			50
Yen-denominated		58			11			0			0			58			11
Public utilities:
U.S. dollar-denominated		1,120			114			228			4			892			110
Yen-denominated		1,028			82			444			13			584			69
Sovereign and supranational:
U.S. dollar-denominated		35			8			0			0			35			8
Yen-denominated		60			7			0			0			60			7
Banks/financial institutions:
U.S. dollar-denominated		655			51			159			4			496			47
Yen-denominated		3,673			365			186			4			3,487			361
Other corporate:
U.S. dollar-denominated		6,380			665			799			19			5,581			646
Yen-denominated		1,948			294			308			9			1,640			285
Total		$	25,402		$	3,449		$	4,239		$	364		$	21,163		$	3,085

Analysis of Securities in Unrealized Loss Positions

The unrealized losses on the Company's available-for-sale securities have been primarily related to general market changes in interest rates, foreign exchange rates, and/or the levels of credit spreads rather than specific concerns with the issuer's ability to pay interest and repay principal.

For any available-for-sale securities with significant declines in fair value, the Company performs detailed analyses to identify whether the drivers of the declines are due to general market drivers, such as the recent rise in interest rates, or due to credit-related factors. Identifying the drivers of the declines in fair value helps to align and allocate the Company‘s resources to securities with real credit-related concerns that could impact ultimate collection of principal and interest. For any significant declines in fair value determined to be non-interest rate or market related, the Company performs a more focused review of the related issuers' specific credit profile.

For corporate issuers, the Company evaluates their assets, business profile including industry dynamics and competitive positioning, financial statements and other available financial data. For non-corporate issuers, the Company analyzes all sources of credit support, including issuer-specific factors. The Company utilizes information available in the public domain and, for certain private placement issuers, from consultations with the issuers directly. The Company also considers ratings from Nationally Recognized Statistical Rating Organizations (NRSROs), as well as the specific characteristics of the security it owns including seniority in the issuer's capital structure, covenant protections, or other relevant features. From these reviews, the Company evaluates the issuers' continued ability to service the Company's investment through payment of interest and principal.

Assuming no credit-related factors develop, unrealized gains and losses on available-for-sale securities are expected to diminish as investments near maturity. Based on its credit analysis, the Company believes that the issuers of its available-for-sale investments in the sectors shown in the table above have the ability to service their obligations to the Company. Further, the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

However, from time to time the Company identifies certain available-for-sale securities where the amortized cost basis exceeds the present value of the cash flows expected to be collected due to credit-related factors and as a result, a credit loss allowance will be estimated. Based on an evaluation of its securities currently in an unrealized loss position, the Company has determined that those securities should not have a credit loss allowance as of March 31, 2024. Refer to the Allowance for Credit Losses section below for additional information.

As of March 31, 2024 and December 31, 2023, the Company had an immaterial amount of fixed maturity securities on nonaccrual status.

Commercial Mortgage and Other Loans

The Company classifies its transitional real estate loans (TREs), commercial mortgage loans (CMLs), middle market loans (MMLs), and other loans as held-for-investment and includes them in the commercial mortgage and other loans line on the consolidated balance sheets. The Company carries them on the balance sheet at amortized cost less an estimated allowance for credit losses.

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

(In millions)	March 31, 2024				December 31, 2023
	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,768	14.0	%	$	1,807	14.1	%
Retail	335		2.7		473		3.7
Apartments/Multi-Family	2,550		20.3		2,608		20.4
Industrial	152		1.2		157		1.2
Hospitality	818		6.5		814		6.4
Other	455		3.7		255		2.0
Total transitional real estate loans	6,078		48.4		6,114		47.8
Commercial mortgage loans:
Office	356		2.8		359		2.8
Retail	254		2.0		301		2.4
Apartments/Multi-Family	583		4.6		586		4.6
Industrial	445		3.5		463		3.6
Other	15		.1		0		0.0
Total commercial mortgage loans	1,653		13.0		1,709		13.4
Middle market loans	4,586		36.4		4,677		36.5
Other loans	275		2.2		301		2.3
Total commercial mortgage and other loans	$	12,592	100.0	%	$	12,801	100.0	%
Allowance for credit losses	(232)				(274)
Total net commercial mortgage and other loans	$	12,360			$	12,527

CMLs and TREs were secured by properties entirely within the U.S. (with the largest concentrations in California (20%), Texas (15%) and Florida (12%)). MMLs are issued only to companies domiciled within the U.S. and Canada.

Transitional Real Estate Loans

TREs are commercial mortgage loans that are typically relatively short-term floating rate instruments secured by a first lien on the property. These loans provide funding for properties undergoing a change in their physical characteristics and/or economic profile and do not typically require any principal repayment prior to the maturity date.

As of March 31, 2024, the Company had $442 million in outstanding commitments to fund TREs. These commitments are contingent on the final underwriting and due diligence to be performed.

Commercial Mortgage Loans

CMLs are typically fixed rate loans on commercial real estate with partial repayment of principal over the life of the loan with the remaining outstanding principal being repaid upon maturity. This loan portfolio is generally considered higher quality investment grade loans.

Middle Market Loans

MMLs are typically first lien senior secured cash flow loans to small to mid-size companies for working capital, refinancing, acquisition, and recapitalization. These loans are generally considered to be below investment grade. The carrying value for MMLs included $24 million for a short-term credit facility that is reflected in other liabilities on the consolidated balance sheets at both March 31, 2024 and December 31, 2023.

As of March 31, 2024, the Company had commitments of approximately $787 million to fund future MMLs. These commitments are contingent upon the availability of MMLs that meet the Company's underwriting criteria.

Other Loans

Other loans are primarily infrastructure loans. Infrastructure loans are typically senior secured, financing operating portfolios of contracted solar and wind assets generating cash flow for loan repayment. The infrastructure loan portfolio weighted average rating is investment grade. As of March 31, 2024, the Company had commitments of approximately $5 million to fund future other loans. These commitments are contingent upon the availability of other loans that meet the Company's underwriting criteria.

Credit Quality Indicators

For TREs, the Company’s key credit quality indicators include performance of the loan and loan-to-value (LTV), which is calculated by dividing the current outstanding loan balance by the estimated property value, primarily using values at origination. Given that TREs involve properties undergoing a repositioning of their commercial profile, LTV provides the most insight into the credit risk of the loan. The Company monitors the performance of the loans periodically, but not less frequently than quarterly. The monitoring process also focuses on higher risk loans, which include those that are delinquent or for which foreclosure or deed in lieu of foreclosure is anticipated.

For CMLs, the Company’s key credit quality indicators include LTV and debt service coverage ratios (DSCR). DSCR is the most recently available net operating income of the underlying property compared to the required debt service of the loan.

For MMLs and held-to-maturity fixed maturity securities, the Company’s key credit quality indicator is credit ratings. The Company’s held-to-maturity portfolio is composed of investment grade securities that are senior unsecured instruments, while its MMLs generally have below-investment-grade ratings but are typically senior secured instruments. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

For other loans, the Company's key credit quality indicator is credit ratings. The Company monitors these credit ratings periodically, but not less frequently than quarterly.

The following tables present as of March 31, 2024 the amortized cost basis of TREs, CMLs, MMLs, and other loans by year of origination and credit quality indicator.

Transitional Real Estate Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	131	$	86	$	609	$	507	$	36	$	125	$	1,494
60%-69.99%	34		126		496		637		18		552		1,863
70%-79.99%	0		14		883		900		83		47		1,927
80% or greater	0		0		218		251		80		245		794
Total	$	165	$	226	$	2,206	$	2,295	$	217	$	969	$	6,078
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Commercial Mortgage Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	33	$	0	$	309	$	45	$	983	$	1,370	2.57
60%-69.99%	0		0		0		0		0		30		30		1.73
70%-79.99%	0		0		0		0		0		120		120		1.26
80% or greater	0		0		0		0		0		133		133		0.52
Total	$	0	$	33	$	0	$	309	$	45	$	1,266	$	1,653	2.30
Weighted Average DSCR	0.00		2.58		0.00		2.92		2.26		2.14
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle Market Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	17	$	45	$	123	$	54	$	64	$	77	$	380
BB	18		60		308		408		251		287		446		1,778
B	48		53		218		547		302		633		290		2,091
CCC	0		0		20		50		51		136		48		305
CC	0		0		0		0		0		10		0		10
C and lower	0		0		0		0		0		6		16		22
Total	$	66	$	130	$	591	$	1,128	$	658	$	1,136	$	877	$	4,586
Current-period gross   writeoffs:	$	0	$	0	$	0	$	27	$	0	$	23	$	0	$	50

Other Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	22	$	94	$	0	$	0	$	0	$	0	$	116
AA	0		0		5		5		0		0		0		10
BBB	5		68		0		0		0		0		0		73
BB	0		0		76		0		0		0		0		76
Total	$	5	$	90	$	175	$	5	$	0	$	0	$	0	$	275
Current-period gross writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Loan Modifications to Borrowers Experiencing Financial Difficulties

The Company granted certain loan modifications to borrowers experiencing financial difficulty during the first three months of 2024 and 2023. The amount, timing, and extent of modifications granted are considered in determining any credit loss allowance recorded. For the three-month period ended March 31, 2024, 3% of TREs with an amortized cost of $210 million were modified in the form of interest rate reductions and other-than-insignificant payment delays. The modifications resulted in a reduction in the weighted-average contractual interest rate from 8.3% to 6.9%. Loan modifications for the three-month period ended March 31, 2023 were immaterial.

Past Due and Nonaccrual Loans

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,152	$	97	$	829	$	926	$	6,078	$	829
Commercial mortgage loans	1,598		0		55		55		1,653		55
Middle market loans	4,560		0		26		26		4,586		26
Other loans	275		0		0		0		275		0
Total	$	11,585	$	97	$	910	$	1,007	$	12,592	$	910

(1) As of March 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2023
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,481	$	108	$	525	$	633	$	6,114	$	633
Commercial mortgage loans	1,676		33		0		33		1,709		0
Middle market loans	4,592		0		85		85		4,677		85
Other loans	301		0		0		0		301		0
Total	$	12,050	$	141	$	610	$	751	$	12,801	$	718

(1) As of December 31, 2023, there were no loans that were 90 days or more past due that continued to accrue interest.

For the three-month periods ended March 31, 2024 and March 31, 2023, the Company recognized no interest income for TREs, CMLs, MMLs, or other loans on nonaccrual status. Of these loans, TREs with an amortized cost of $383 million had no credit loss allowance as of March 31, 2024 because these loans are collateral dependent assets for which the estimated fair values of the collateral are in excess of amortized cost. As of March 31, 2024 and December 31, 2023, there were no MMLs on nonaccrual status without an allowance for credit losses.

Allowance for Credit Losses

The Company calculates its allowance for credit losses for held-to-maturity securities, loan receivables, loan commitments and reinsurance recoverable by grouping assets with similar risk characteristics when there is not a specific expectation of a loss for an individual asset. For held-to-maturity securities, MMLs, and MML commitments, the Company groups assets by credit ratings, industry, and country.

The Company groups CMLs and TREs and respective loan commitments by property type, property location and the property’s LTV and DSCR. On a quarterly basis, CMLs and TREs within a portfolio segment that share similar risk characteristics are pooled for calculation of credit loss allowance. On an ongoing basis, TREs, CMLs and other loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is probable), are evaluated individually for credit loss. For example, the credit loss allowance for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of the collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the credit loss allowance as a component of net investment gains (losses) in the consolidated statements of earnings.

The credit allowance for held-to-maturity fixed maturity securities and loan receivables is estimated using a probability-of-default (PD) / loss-given-default (LGD) method, discounted for the time value of money. For held-to-maturity fixed maturity securities, available-for-sale fixed maturity securities and loan receivables, the Company includes the change in present value due to the passage of time in the change in the allowance for credit losses. The Company’s methodology for estimating credit losses utilizes the contractual maturity date of the financial asset, adjusted when necessary to reflect the expected timing of repayment (such as prepayment options, renewal options, call options, or extension options). The Company applies reasonable and supportable forecasts of macroeconomic variables that impact the determination of PD / LGD over a two-year period for held-to-maturity fixed maturity securities and MMLs. The Company reverts to historical loss information over one year, following the two-year forecast period. For the CML and TRE portfolio, the Company applies reasonable and supportable forecasts of macroeconomic variables as well as national and local real-estate market factors to estimate future credit losses where the market factors revert back to historical levels over time with the period being dependent on current market conditions, projected market conditions and difference in the current and historical market levels for each factor. The Company continuously monitors the estimation methodology, due to changes in portfolio composition, changes in underwriting practices and significant events or conditions and makes adjustments as necessary.

The Company’s held-to-maturity portfolio includes Japan Government and Agency securities of $15.9 billion amortized cost as of March 31, 2024 that meet the requirements for zero-credit-loss expectation and therefore these asset classes have been excluded from the current expected credit loss measurement.

An investment in an available-for-sale security may be impaired if the fair value falls below amortized cost. The Company regularly reviews its available-for-sale portfolio for declines in fair value. The Company's available-for-sale impairment model focuses on the ultimate collection of the cash flows from its investments and whether the Company has the intent to sell or if it is more likely than not the Company would be required to sell the security prior to recovery of its amortized cost. The determination of the amount of impairments under this model is based upon the Company's periodic evaluation and assessment of known and inherent risks associated with the respective securities. Such evaluations and assessments are revised as conditions change and new information becomes available.

When determining the Company's intention to sell a security prior to recovery of its fair value to amortized cost, the Company evaluates facts and circumstances such as, but not limited to, future cash flow needs, decisions to reposition its security portfolio, and risk profile of individual investment holdings. The Company performs ongoing analyses of its liquidity needs, which includes cash flow testing of its policy liabilities, debt maturities, projected dividend payments, and other cash flow and liquidity needs.

The Company’s methodology for estimating credit losses for available-for-sale securities utilizes the discounted cash flow model, based on past events, current market conditions and future economic conditions, as well as industry analysis and credit ratings of the securities. In addition, the Company evaluates the specific issuer’s probability of default and expected recovery of its position in the event of default based on the underlying financial condition and assets of the borrower as well as seniority and/or security of other debt holders in the issuer when developing management’s best estimate of expected cash flows.

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to-Maturity Securities		Available-for-Sale Securities		Total
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)
Three Months Ended March 31, 2023:
Balance at December 31, 2022	$	(54)	$	(9)	$	(129)	$	(24)	$	(7)	$	0	$	(223)
(Addition to) release of allowance for credit losses	(11)		0		(20)		3		1		0		(27)
Writeoffs, net of recoveries	0		0		0		0		0		0		0
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2023	$	(65)	$	(9)	$	(149)	$	(21)	$	(6)	$	0	$	(250)

For the three-month period ended March 31, 2024, the Company completed foreclosure or deed in lieu of foreclosure on TREs collateralized with commercial real estate properties with an amortized cost of $31 million. As a result of the excess of amortized cost over the estimated fair value of the collateral of the TREs, upon consummating the foreclosures or deed in lieu of foreclosure transactions, the Company recognized a net gain of $4 million for the three-month period ended March 31, 2024 in net investment gains (losses). The Company did not complete any foreclosure or deed in lieu of foreclosure transactions in the three-month period ended March 31, 2023. Refer to the Other Investments section below for additional information.

As of March 31, 2024, the Company identified additional TREs with an amortized cost of $601 million in anticipation of potential foreclosure or deed in lieu of foreclosure transactions. As of March 31, 2024, the Company established a credit allowance of $60 million for $598 million of loans for which the fair value of the collateral was below the amortized cost of the loans.

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2024			December 31, 2023
Other investments:
Policy loans		$	203		$	214
Short-term investments (1)		3,341			1,304
Limited partnerships (2)		2,838			2,750
Real estate owned		253			227
Other		42			35
Total other investments		$	6,677		$	4,530

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

The Parent Company invests in partnerships that specialize in rehabilitating historic structures or the installation of solar equipment in order to receive federal historic rehabilitation and solar tax credits. These investments are classified as limited partnerships and included in other investments in the consolidated balance sheets. The change in value of each investment is recorded as a reduction to net investment income. Tax credits generated by these investments are recorded as an income tax benefit in the consolidated statements of earnings.

Real estate owned (REO) consists of office buildings or other commercial properties obtained through foreclosure or deed in lieu of foreclosure of certain of the Company’s TREs. As of March 31, 2024, all REO was classified as held-and-used for the production of income and is carried at cost less accumulated depreciation. As of December 31, 2023, $210 million of REO was classified as held-and-used with the remaining $17 million classified as held-for-sale, which is carried at the lower of depreciated cost or fair value less cost to sell and is not further depreciated once classified as such. Depreciation expense was $1 million for the three-month period ended March 31, 2024. Additionally, as of March 31, 2024 and December 31, 2023, accumulated depreciation was $2 million and an immaterial amount, respectively.

As of March 31, 2024, the Company had $2.2 billion in outstanding commitments to fund investments in limited partnerships.

Variable Interest Entities (VIEs)

In the normal course of its activities, the Company invests in legal entities that are VIEs. The Company's debt or ownership interest in VIEs is limited to holding the equity interests and obligations issued by them. With the exception of commitments to limited partnerships and to certain loan investments made in the normal course of business, the Company has not provided any direct or contingent obligations to fund the limited activities of these VIEs or support related to the limited activities of these VIE and does not have any intention to do so in the future, nor does it have any direct or indirect financial guarantees.

The Company's risk of loss related to its interests in any of its VIEs is limited to the carrying value of the related investments, and in certain cases, to any unfunded commitments held in the VIE.

For those VIEs other than certain unit trust structures, the Company's involvement is passive in nature.

VIEs - Consolidated

The Company is the primary beneficiary of a VIE if it has

•the power to direct the activities of the VIE that most significantly impact the economic performance of the entity

and

•the obligation to absorb losses of or the right to receive benefits from the entity that could be potentially significant to the VIE.

If the Company determines that it is the VIE’s primary beneficiary, it consolidates the VIE. Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company except to the extent of the unfunded commitments referenced above, as the Company’s obligation to each VIE is limited to the amount of its committed investment.

The following table presents carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	3,678		$	3,712
Commercial mortgage and other loans		9,947			10,150
Other investments (1)		2,443			2,381
Other assets (2)		57			55
Total assets of consolidated VIEs		$	16,125		$	16,298
Liabilities:
Other liabilities (2)		$	583		$	507
Total liabilities of consolidated VIEs		$	583		$	507

(1) Consists entirely of alternative investments in limited partnerships

(2) Consists entirely of derivatives

The Company is the sole investor in the consolidated VIEs listed in the table above. The Company invests in fixed maturity securities issued by VIEs that in turn hold U.S. dollar-denominated fixed maturity securities coupled with foreign currency swap agreements. The weighted-average lives of the Company's investments in these VIEs are very similar to the underlying collateral held by these VIEs. The activities of these VIEs are limited to holding invested assets and foreign currency swaps and utilizing the cash flows from these securities to service the VIEs' debt. Neither the Company nor any of its creditors are able to obtain the underlying collateral of these VIEs unless there is an event of default or other specified event. The Company is not a direct counterparty to the foreign currency swap contracts and has no control over them. The Company's loss exposure to these VIEs is limited to its original investment. These consolidated VIEs do not rely on outside or ongoing sources of funding to support their activities beyond the underlying collateral and foreign currency swap contracts, if applicable. The underlying collateral assets and funding of these consolidated VIEs are generally static in nature.

The Company also utilizes unit trust structures in its Aflac Japan segment to invest in various asset classes, which include CMLs, MMLs, TREs, other loans and limited partnerships. The limited partnership investments are comprised of private equity and real estate funds. The Company’s loss exposure to these VIEs is limited to its original investments, together with any unfunded portion of the Company’s commitments made in the normal course of business to fund certain loan investments and limited partnership investments, as described in the Commercial Mortgage and Other Loans and Other Investments sections of this note. Excluding these commitments, the Company does not provide financial or other support to consolidated VIEs.

VIEs - Not Consolidated

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	6,486		$	6,424
Other investments (1)		395			369
Total investments in VIEs not consolidated		$	6,881		$	6,793

(1) Consists entirely of alternative investments in limited partnerships

Certain investments in VIEs that the Company is not required to consolidate are investments that are in the form of debt obligations issued by the VIEs. These fixed maturity securities include structured securities, primarily asset-backed securities. The Company's involvement in the related VIEs is limited to that of a passive investor in asset-backed securities issued by the VIEs. The Company also invests in VIEs that are the primary financing vehicles used by their corporate sponsors to raise financing in the capital markets. The variable interests created by these VIEs are principally or solely a result of the debt instruments issued by them. The Company does not have the power to direct the activities that most significantly impact the entity's economic performance, nor does it have the obligation to absorb losses of the VIE entity or the right to receive benefits from the entity that could be significant to the entity. As such, the Company is not the primary beneficiary of these VIEs and therefore is not required to consolidate them. The Company's maximum exposure to loss on these investments is limited to the amount of the Company's investment.

The Company also holds equity investments in limited partnerships that have been determined to be VIEs. These partnerships primarily invest in private equity and real estate funds. The Company’s maximum exposure to loss on these investments is limited to the amount of its investment and any unfunded commitments. As described in the Other Investments section of this note, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to unconsolidated VIEs. The Company is not the primary beneficiary of these VIEs and is therefore not required to consolidate them. The Company classifies these investments as other investments in the consolidated balance sheets.

Securities Lending and Pledged Securities

The Company lends fixed maturity securities and, from time to time, public equity securities to financial institutions in short-term securities lending transactions. These short-term securities lending arrangements increase investment income

with minimal risk. The Company receives cash or other securities as collateral for such loans. The Company's securities lending policy requires that the fair value of the securities received as collateral be 102% or more of the fair value of the loaned securities and that unrestricted cash received as collateral be 100% or more of the fair value of the loaned securities. The securities loaned continue to be carried as investment assets on the Company's balance sheet during the terms of the loans and are not reported as sales. For loans involving unrestricted cash or securities as collateral, the collateral is reported as an asset with a corresponding liability for the return of the collateral. For loans where the Company receives as collateral securities that the Company is not permitted to sell or repledge, the collateral is not reflected on the consolidated financial statements.

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2024						December 31, 2023
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,542	$	2,542	$	0	$	737	$	737
Public utilities	33		0		33		19		0		19
Banks/financial institutions	148		0		148		72		0		72
Other corporate	643		0		643		675		0		675
Total borrowings	$	824	$	2,542	$	3,366	$	766	$	737	$	1,503
Gross amount of recognized liabilities for securities    lending transactions					$	3,366					$	1,503

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

In connection with securities lending, in addition to cash collateral received, the Company received from counterparties securities collateral of $4.5 billion and $4.3 billion at March 31, 2024 and December 31, 2023, respectively, which may not be sold or re-pledged, unless the counterparty is in default. Such securities collateral is not reflected on the consolidated financial statements.

The Company did not have any repurchase agreements or repurchase-to-maturity transactions outstanding as of March 31, 2024, and December 31, 2023, respectively.

Certain fixed maturity securities can be pledged as collateral as part of derivative transactions, or pledged to support state deposit requirements on certain investment programs. For additional information regarding pledged securities related to derivative transactions, see Note 4.

XML

DERIVATIVE INSTRUMENTS

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS

The Company's freestanding derivative financial instruments include:

•foreign currency forwards and options used in hedging foreign exchange risk on U.S. dollar-denominated investments in Aflac Japan's portfolio, with options used on a standalone basis and/or in a collar strategy;

•foreign currency forwards and options used to economically hedge certain portions of forecasted cash flows denominated in yen and hedge the Company's long term exposure to a weakening yen;

•cross-currency interest rate swaps, also referred to as foreign currency swaps, associated with certain senior notes and subordinated debentures;

•foreign currency swaps that are associated with variable interest entity (VIE) bond purchase commitments, and investments in special-purpose entities, including VIEs where the Company is the primary beneficiary;

•interest rate swaps used to economically hedge interest rate fluctuations in certain variable-rate investments;

•interest rate swaptions used to hedge changes in the fair value associated with interest rate fluctuations for certain U.S. dollar-denominated available-for-sale fixed-maturity securities; and

•bond purchase commitments at the inception of investments in consolidated VIEs.

Some of the Company's derivatives are designated as cash flow hedges, fair value hedges or net investment hedges; however, other derivatives do not qualify for hedge accounting or the Company elects not to designate them as accounting hedges.

Derivative Types

Foreign currency forwards and options are executed for the Aflac Japan segment in order to hedge the currency risk on the carrying value of certain U.S. dollar-denominated investments. The average maturity of these forwards and options can change depending on factors such as market conditions and types of investments being held. In situations where the maturity of the forwards and options is shorter than the underlying investment being hedged, the Company may enter into new forwards and options near maturity of the existing derivative in order to continue hedging the underlying investment. In forward transactions, Aflac Japan agrees with another party to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. The Company also uses one-sided foreign currency put options to mitigate the settlement risk on U.S. dollar-denominated assets related to extreme foreign currency rate changes. From time to time, Aflac Japan also executes foreign currency option transactions in a collar strategy, where Aflac Japan agrees with another party to simultaneously purchase put options and sell call options. In the purchased put transactions, Aflac Japan obtains the option to buy a fixed amount of yen and sell a corresponding amount of U.S. dollars at a specified future date. In the sold call transactions, Aflac Japan agrees to sell a fixed amount of yen and buy a corresponding amount of U.S. dollars at a specified future date. The combination of purchasing the put option and selling the call option results in no net premium being paid (i.e. a costless or zero-cost collar).

From time to time, the Company may also enter into foreign currency forwards and options to hedge the currency risk associated with the net investment in Aflac Japan. In these forward transactions, the Company agrees with another party to buy a fixed amount of U.S. dollars and sell a corresponding amount of yen at a specified price at a specified future date. In the option transactions, the Company may use a combination of foreign currency options to protect expected future cash flows by simultaneously purchasing yen put options (options that protect against a weakening yen) and selling yen call options (options that limit participation in a strengthening yen). The combination of these two actions create a zero-cost collar. Additionally, the Company enters into purchased options to hedge cash flows from the net investment in Aflac Japan.

The Company enters into foreign currency swaps pursuant to which it exchanges an initial principal amount in one currency for an initial principal amount of another currency, with an agreement to re-exchange the principal amounts at a future date. There may also be periodic exchanges of payments at specified intervals based on the agreed upon rates and notional amounts. Foreign currency swaps are used primarily in the consolidated VIEs in the Company's Aflac Japan portfolio to convert foreign-denominated cash flows to yen, the functional currency of Aflac Japan, in order to minimize cash flow fluctuations. The Company also uses foreign currency swaps to economically convert certain of its U.S. dollar-denominated senior note and subordinated debenture principal and interest obligations into yen-denominated obligations.

In order to reduce investment income volatility from its variable-rate investments, the Company enters into receive–fixed, pay–floating interest rate swaps. These derivatives are cleared and settled through a central clearinghouse.

Swaptions are used to mitigate the adverse impact resulting from significant changes in the fair value of U.S. dollar-denominated available-for-sale securities due to fluctuation in interest rates. In a payer swaption, the Company pays a premium to obtain the right, but not the obligation, to enter into a swap contract where it will pay a fixed rate and receive a floating rate. Interest rate swaption collars are combinations of two swaption positions. In order to maximize the efficiency of the collars while minimizing cost, a collar strategy is used whereby the Company purchases a long payer swaption (the Company purchases an option that allows it to enter into a swap where the Company will pay the fixed rate and receive the floating rate of the swap) and sells a short receiver swaption (the Company sells an option that provides the counterparty with the right to enter into a swap where the Company will receive the fixed rate and pay the floating rate of the swap). The combination of purchasing the long payer swaption and selling the short receiver swaption results in no net premium being paid (i.e. a costless or zero-cost collar).

Bond purchase commitments result from repackaged bond structures that are consolidated VIEs whereby there is a delay in the trade date and settlement date of the bond within the structure to ensure completion of all necessary legal agreements to support the consolidated VIE that issues the repackaged bond. Since the Company has a commitment to purchase the underlying bond at a specified price, the agreement meets the definition of a derivative where the value is derived based on the current market value of the bond compared to the fixed purchase price to be paid on the settlement date.

Derivative Balance Sheet Classification

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2024									December 31, 2023
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	4
Total cash flow hedges		18			0			5			18			0			4
Fair value hedges:
Foreign currency options		0			0			0			2,158			0			0
Total fair value hedges		0			0			0			2,158			0			0
Net investment hedge:
Foreign currency forwards		2,339			202			0			2,611			179			27
Foreign currency options		0			0			0			456			0			0
Total net investment hedge		2,339			202			0			3,067			179			27
Non-qualifying strategies:
Foreign currency swaps		1,200			24			0			1,200			31			0
Foreign currency swaps - VIE		3,417			57			578			3,417			55			503
Foreign currency forwards		0			0			0			7,402			59			477
Foreign currency options		28,715			38			69			22,557			2			0
Interest rate swaps		17,230			0			483			17,230			11			419
Total non-qualifying strategies		50,562			119			1,130			51,806			158			1,399
Total derivatives		$	52,919		$	321		$	1,135		$	57,049		$	337		$	1,430

Cash Flow Hedges

For certain variable-rate U.S. dollar-denominated available-for-sale securities held by Aflac Japan via consolidated VIEs, foreign currency swaps are used to swap the U.S. Dollar (USD) variable rate interest and principal payments to fixed rate Japanese Yen (JPY) interest and principal payments. The Company has designated foreign currency swaps as a hedge of the variability in cash flows of a forecasted transaction or of amounts to be received or paid related to a recognized asset (“cash flow” hedge). The remaining maximum length of time for which these cash flows are hedged is approximately three years. The derivatives in the Company's consolidated VIEs that are not designated as accounting hedges are discussed in the Non-qualifying Strategies section of this note.

Fair Value Hedges

The Company designates and accounts for certain foreign currency forwards, options, and interest rate swaptions as fair value hedges when they meet the requirements for hedge accounting. The Company recognizes gains and losses on these derivatives as well as the offsetting gain or loss on the related hedged items in current earnings.

Foreign currency forwards and options hedge the foreign currency exposure of certain U.S. dollar-denominated available-for-sale fixed-maturity investments held in Aflac Japan. The change in the fair value of the foreign currency forwards related to the changes in the difference between the spot rate and the forward price is excluded from the assessment of hedge effectiveness. The change in fair value of the foreign currency option related to the time value of the option is recognized in current earnings and is excluded from the assessment of hedge effectiveness.

Interest rate swaptions hedge the interest rate exposure of certain U.S. dollar-denominated available-for-sale securities held in Aflac Japan. For these hedging relationships, the Company excludes time value from the assessment of hedge effectiveness and recognizes changes in the intrinsic value of the swaptions in current earnings within net investment income. The change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into earnings (net investment income) over its legal term.

The following table presents the gains and losses on derivatives and the related hedged items in fair value hedges. The Company had no fair value hedges during the three-month period ending March 31, 2024.

Fair Value Hedging Relationships

(In millions)		Hedging Derivatives						Hedged Items
Hedging Derivatives	Hedged Items	Total Gains (Losses)		Gains (Losses) Excluded from Effectiveness Testing(1)		Gains (Losses) Included in Effectiveness Testing(2)		Gains (Losses)(2)		Net Investment Gains (Losses) Recognized for Fair Value Hedge
Three Months Ended March 31, 2023:
Foreign currency options	Fixed maturity securities	$	(39)	$	(39)	$	0	$	0	$	0
Total gains (losses)		$	(39)	$	(39)	$	0	$	0	$	0

(1) Gains (losses) excluded from effectiveness testing includes the forward point on foreign currency forwards and time value change on foreign currency options which are reported in the consolidated statements of earnings as net investment gains (losses). It also includes the change in the fair value of the interest rate swaptions related to the time value of the swaptions which is recognized as a component of other comprehensive income (loss).

(2) Gains and losses on foreign currency forwards and options and related hedged items are reported in the consolidated statements of earnings as net investment gains (losses). For interest rate swaptions and related hedged items, gains and losses included in the hedge assessment, premium amortization and time value amortization while the hedge items are still outstanding are reported within net investment income. The time value gains and losses for interest rate swaptions when the related hedged items are redeemed are reported in net investment gains (losses) consistent with the impact of the hedged item. For the three-month period ended March 31, 2023, gains and losses included in the hedge assessment on interest rate swaptions and related hedged items were immaterial.

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2024 and December 31, 2023; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2024		December 31, 2023		March 31, 2024		December 31, 2023
Fixed maturity securities		$	1,597	$	1,692	$	161	$	164

(1) The balance includes hedging adjustment on discontinued hedging relationships of $161 in 2024 and $164 in 2023.

Net Investment Hedge

The Company's investment in Aflac Japan is affected by changes in the yen/dollar exchange rate. To mitigate this exposure, the Parent Company's yen-denominated liabilities (see Note 9) have been designated as non-derivative hedges and certain foreign currency forwards and options have been designated as derivative hedges of the foreign currency exposure of the Company's net investment in Aflac Japan.

The Company's net investment hedge was effective during the three-month periods ended March 31, 2024 and 2023, respectively.

Non-qualifying Strategies

For the Company's derivative instruments in consolidated VIEs that do not qualify for hedge accounting treatment, all changes in their fair value are reported in current period earnings within net investment gains (losses). The amount of gain or loss recognized in earnings for the Company's VIEs is attributable to the derivatives in those investment structures. While the change in value of the swaps is recorded in current period earnings, the change in value of the available-for-sale fixed maturity securities associated with these swaps is recorded in other comprehensive income.

As of March 31, 2024, the Parent Company had $1.2 billion notional amount of cross-currency interest rate swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. Changes in the values of these swaps are recorded in current period earnings.

The Company uses foreign currency forwards and options to economically mitigate the currency risk of some of its U.S. dollar-denominated loan receivables and U.S. government fixed maturity securities held within the Aflac Japan segment. These arrangements are not designated as accounting hedges, as the foreign currency remeasurement of the loan receivables impacts current period earnings, and substantially offsets gains and losses from foreign currency forwards within net investment gains (losses). The Company also has certain foreign currency forwards on U.S. dollar-denominated available-for-sale securities where hedge accounting is not being applied.

The Company uses interest rate swaps to economically convert the variable rate investment income to a fixed rate on certain variable-rate investments.

Impact of Derivatives and Hedging Instruments

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2024										2023
(In millions)	Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)			Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	0		$	0		$	(1)			$	1
Total cash flow hedges		0			(1)		(3)		0			0			(1)		(3)		1
Fair value hedges:
Foreign currency options					0										(39)
Total fair value hedges					0										(39)
Net investment hedge:
Non-derivative hedging          instruments					0				236						0				25
Foreign currency forwards					44				145						90				29
Foreign currency options					0				0						(3)				0
Total net investment hedge					44				381						87				54
Non-qualifying strategies:
Foreign currency swaps					1										1
Foreign currency swaps - VIE					(88)										(27)
Foreign currency forwards					17										(51)
Foreign currency options					(41)										(19)
Interest rate swaps					(147)										69
Forward bond purchase          commitment - VIE					0										(3)
Total non-qualifying strategies					(258)										(30)
Total		$	0		$	(215)			$	381		$	0		$	17			$	55

(1) Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedge item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items.

(2) Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

(3) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2024, and $1 of losses during the three-month period ended March 31, 2023.

As of March 31, 2024, $5 million of deferred losses on derivative instruments recorded in accumulated other comprehensive income are expected to be reclassified into earnings during the next twelve months.

Credit Risk Assumed through Derivatives

For the foreign currency swaps associated with the Company's VIE investments for which it is the primary beneficiary, the Company bears the risk of loss due to counterparty default even though it is not a direct counterparty to those contracts.

The Company is a direct counterparty to the foreign currency swaps that it has entered into in connection with certain of its senior notes and subordinated debentures; foreign currency forwards; and foreign currency options, and therefore the Company is exposed to credit risk in the event of nonperformance by the counterparties in those contracts. The risk of counterparty default for the Company's foreign currency swaps, certain foreign currency forwards, and foreign currency options is mitigated by collateral posting requirements that counterparties to those transactions must meet.

As of March 31, 2024, all of the Company's derivative agreement counterparties were investment grade.

The Company engages in over-the-counter (OTC) bilateral derivative transactions directly with unaffiliated third parties under International Swaps and Derivatives Association, Inc. (ISDA) agreements and other documentation. Most of the ISDA agreements also include Credit Support Annexes (CSAs) provisions, which generally provide for two-way collateral postings at the first dollar of exposure. The Company mitigates the risk that counterparties to transactions might be unable to fulfill their contractual obligations by monitoring counterparty credit exposure and collateral value while generally requiring that collateral be posted at the outset of the transaction. In addition, a significant portion of the derivative transactions have provisions that give the counterparty the right to terminate the transaction upon a downgrade of the Company's financial strength rating. The actual amount of payments that the Company could be required to make depends on market conditions, the fair value of outstanding affected transactions, and other factors prevailing at and after the time of the downgrade.

The Company also engages in OTC cleared derivative transactions through regulated central clearing counterparties. These positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to these derivatives.

Collateral posted by the Company to third parties for derivative transactions can generally be repledged or resold by the counterparties. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position by counterparty was approximately $1.0 billion and $1.2 billion as of March 31, 2024, and December 31, 2023, respectively. If the credit-risk-related contingent features underlying these agreements had been triggered on March 31, 2024, the Company estimates that it would be required to post a maximum of $447 million of additional collateral to these derivative counterparties. The Company is generally allowed to sell or repledge collateral obtained from its derivative counterparties, although it does not typically exercise such rights. See the Offsetting tables below for collateral posted or received as of the reported balance sheet dates.

Offsetting of Financial Instruments and Derivatives

Most of the Company's derivative instruments are subject to enforceable master netting arrangements that provide for the net settlement of all derivative contracts between the Parent Company or its subsidiaries and the respective counterparty in the event of default or upon the occurrence of certain termination events. Collateral support agreements with the master netting arrangements generally provide that the Company will receive or pledge financial collateral at the first dollar of exposure.

The Company has securities lending agreements with unaffiliated financial institutions that post collateral to the Company in return for the use of its fixed maturity and public equity securities (see Note 3). When the Company has entered into securities lending agreements with the same counterparty, the agreements generally provide for net settlement in the event of default by the counterparty. This right of set-off allows the Company to keep and apply collateral received if the counterparty failed to return the securities borrowed from the Company as contractually agreed.

The tables below summarize the Company's derivatives and securities lending transactions, and as reflected in the tables, in accordance with U.S. GAAP, the Company's policy is to not offset these financial instruments in the consolidated balance sheets.

Offsetting of Financial Assets and Derivative Assets

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	264		$	0		$	264		$	(38)	$	(78)		$	(148)		$	0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		264			0			264			(38)		(78)			(148)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		57						57											57
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		57						57											57
Total derivative       assets		321			0			321			(38)		(78)			(148)			57
Securities lending    and similar    arrangements		3,334			0			3,334			0		0			(3,334)			0
Total		$	3,655		$	0		$	3,655		$	(38)	$	(78)		$	(3,482)		$	57

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	271		$	0		$	271		$	(85)	$	(53)		$	(130)		$	3
OTC - cleared		11			0			11			(11)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		282			0			282			(96)		(53)			(130)			3
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		55						55											55
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		55						55											55
Total derivative       assets		337			0			337			(96)		(53)			(130)			58
Securities lending    and similar    arrangements		1,480			0			1,480			0		0			(1,480)			0
Total		$	1,817		$	0		$	1,817		$	(96)	$	(53)		$	(1,610)		$	58

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	69		$	0		$	69		$	(38)	$	(31)		$	0		$	0
OTC - cleared		483			0			483			0		(27)			(456)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		552			0			552			(38)		(58)			(456)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		583						583											583
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		583						583											583
Total derivative       liabilities		1,135			0			1,135			(38)		(58)			(456)			583
Securities lending    and similar    arrangements		3,366			0			3,366			(3,334)		0			0			32
Total		$	4,501		$	0		$	4,501		$	(3,372)	$	(58)		$	(456)		$	615

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	504		$	0		$	504		$	(85)	$	(381)		$	(37)		$	1
OTC - cleared		419			0			419			(11)		(19)			(389)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		923			0			923			(96)		(400)			(426)			1
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		507						507											507
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		507						507											507
Total derivative       liabilities		1,430			0			1,430			(96)		(400)			(426)			508
Securities lending    and similar    arrangements		1,503			0			1,503			(1,480)		0			0			23
Total		$	2,933		$	0		$	2,933		$	(1,576)	$	(400)		$	(426)		$	531

For additional information on the Company's financial instruments, see the accompanying Notes 3 and 5 and Notes 1, 3 and 5 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair Value Hierarchy

U.S. GAAP specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. These two types of inputs create three valuation hierarchy levels, as follows:

•Level 1 valuations reflect quoted market prices for identical assets or liabilities in active markets.

•Level 2 valuations reflect quoted market prices for similar assets or liabilities in an active market, quoted market prices for identical or similar assets or liabilities in non-active markets or model-derived valuations in which all significant valuation inputs are observable in active markets.

•Level 3 valuations reflect valuations in which one or more of the significant inputs are not observable in an active market.

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	19,976		$	838		$	0		$	20,814
Municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities		0			6,806			507			7,313
Sovereign and supranational		0			462			28			490
Banks/financial institutions		0			8,825			74			8,899
Other corporate		0			26,569			450			27,019
Total fixed maturity securities		19,976			48,236			1,918			70,130
Equity securities		603			0			159			762
Other investments		3,341			0			0			3,341
Cash and cash equivalents		5,098			0			0			5,098
Other assets:
Foreign currency swaps		0			81			0			81
Foreign currency forwards		0			202			0			202
Foreign currency options		0			38			0			38
Total other assets		0			321			0			321
Total assets		$	29,018		$	48,557		$	2,077		$	79,652
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	583		$	0		$	583
Foreign currency options		0			69			0			69
Interest rate swaps		0			483			0			483
Total liabilities		$	0		$	1,135		$	0		$	1,135

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	21,700		$	900		$	0		$	22,600
Municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities		0			7,339			253			7,592
Sovereign and supranational		0			507			30			537
Banks/financial institutions		0			8,757			78			8,835
Other corporate		0			27,694			648			28,342
Total fixed maturity securities		21,700			49,809			1,781			73,290
Equity securities		840			0			248			1,088
Other investments		1,304			0			0			1,304
Cash and cash equivalents		4,306			0			0			4,306
Other assets:
Foreign currency swaps		0			86			0			86
Foreign currency forwards		0			238			0			238
Foreign currency options		0			2			0			2
Interest rate swaps		0			11			0			11
Total other assets		0			337			0			337
Total assets		$	28,150		$	50,146		$	2,029		$	80,325
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	507		$	0		$	507
Foreign currency forwards		0			504			0			504
Interest rate swaps		0			419			0			419
Total liabilities		$	0		$	1,430		$	0		$	1,430

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,000		$	17,319		$	155		$	0		$	17,474
Municipalities		248			0			285			0			285
Public utilities		33			0			36			0			36
Sovereign and    supranational		391			0			431			0			431
Other corporate		17			0			19			0			19
Commercial mortgage and     other loans		12,360			0			0			12,017			12,017
Other investments (1)		42			0			42			0			42
Total assets		$	29,091		$	17,319		$	968		$	12,017		$	30,304
Liabilities:
Other policyholders’ funds		$	5,831		$	0		$	0		$	5,750		$	5,750
Notes payable    (excluding leases)		7,799			0			6,762			704			7,466
Total liabilities		$	13,630		$	0		$	6,762		$	6,454		$	13,216

(1) Excludes policy loans of $203, equity method investments of $2,838, and REO of $253, at carrying value.

	December 31, 2023
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	17,083		$	18,662		$	167		$	0		$	18,829
Municipalities		266			0			307			0			307
Public utilities		34			0			38			0			38
Sovereign and    supranational		418			0			462			0			462
Other corporate		18			0			21			0			21
Commercial mortgage and     other loans		12,527			0			0			12,217			12,217
Other investments (1)		35			0			35			0			35
Total assets		$	30,381		$	18,662		$	1,030		$	12,217		$	31,909
Liabilities:
Other policyholders’ funds		$	6,169		$	0		$	0		$	6,080		$	6,080
Notes payable    (excluding leases)		7,240			0			6,178			752			6,930
Total liabilities		$	13,409		$	0		$	6,178		$	6,832		$	13,010

(1) Excludes policy loans of $214, equity method investments of $2,750, and REO of $227, at carrying value.

Fair Value of Financial Instruments

Fixed maturity and equity securities

The fair values of the Company’s public fixed maturity securities are generally based on prices provided by third-party pricing vendors. The Company utilizes internally generated valuations or broker quotes for privately issued fixed maturity securities or fixed maturity securities where there is no price available from a third-party pricing vendor.

The fair values of the Company's public equity securities are generally based on price quotes, including quoted market prices readily available from independent public exchange markets or established security dealer associations. The Company determines the fair values of privately issued equity securities using the following approaches or techniques: price quotes and valuations from third-party pricing vendors, in-house valuations and non-binding price quotes the Company obtains from outside brokers.

The pricing data and market quotes the Company obtains from outside sources, including third-party pricing services, are reviewed internally for reasonableness. If a fair value appears unreasonable, the Company will re-examine the inputs and assess the reasonableness of the pricing data with the provider. Additionally, the Company may compare the inputs to relevant market indices and other performance measurements. Based on management's analysis, the valuation is confirmed or may be revised if there is evidence of a more appropriate estimate of fair value based on available market data. The Company has performed verification of the inputs and calculations in any valuation models, including independent validations and back testing, to confirm that the valuations represent reasonable estimates of fair value. For the periods presented, the Company has not adjusted the quotes or prices it obtains from the pricing services and brokers it uses.

For internally generated valuations, the Company utilizes valuation models developed by a third-party pricing vendor. The models and associated processes and controls are executed by Company personnel.

These models are discounted cash flow (DCF) valuation models but also use information from related markets, specifically public bond markets and the credit default swap (CDS) market, to estimate expected cash flows. The models take into consideration any unique characteristics of the securities and make various adjustments to arrive at an appropriate issuer-specific loss adjusted credit curve using the most appropriate comparable security(ies) of the issuer and issuer-specific CDS spreads. This credit curve is then used with the relevant recovery rates to estimate expected cash flows and modeling of additional features, including illiquidity adjustments, if necessary, to price the security by discounting those loss adjusted cash flows. In cases where a credit curve cannot be developed from market information for the specific issuer, the valuation methodology takes into consideration other market observable inputs, including:

•the most appropriate comparable security(ies) of a guarantor and/or parent

•CDS spreads of a guarantor and/or parent

•bonds of comparable issuers with similar characteristics such as rating, geography, or sector

•CDS spreads of an appropriate index or of comparable issuers with similar characteristics such as rating, geography, or sector

•bond indices that are comparative in rating, industry, maturity, and region.

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	19,976		$	505		$	0		$	20,481
Internal		0			333			0			333
Total government and agencies		19,976			838			0			20,814
Municipalities:
Third-party pricing vendor		0			1,943			0			1,943
Internal		0			267			0			267
Total municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,420			0			2,420
Internal		0			27			40			67
Broker/other		0			79			819			898
Total mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities:
Third-party pricing vendor		0			3,680			0			3,680
Internal		0			3,126			0			3,126
Broker/other		0			0			507			507
Total public utilities		0			6,806			507			7,313
Sovereign and supranational:
Third-party pricing vendor		0			125			0			125
Internal		0			337			0			337
Broker/other		0			0			28			28
Total sovereign and supranational		0			462			28			490
Banks/financial institutions:
Third-party pricing vendor		0			4,703			0			4,703
Internal		0			4,122			65			4,187
Broker/other		0			0			9			9
Total banks/financial institutions		0			8,825			74			8,899
Other corporate:
Third-party pricing vendor		0			21,282			0			21,282
Internal		0			5,277			249			5,526
Broker/other		0			10			201			211
Total other corporate		0			26,569			450			27,019
Total securities available-for-sale		$	19,976		$	48,236		$	1,918		$	70,130
Equity securities, carried at fair value:
Third-party pricing vendor		$	603		$	0		$	0		$	603
Broker/other		0			0			159			159
Total equity securities		$	603		$	0		$	159		$	762

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,319		$	155		$	0		$	17,474
Total government and agencies		17,319			155			0			17,474
Municipalities:
Third-party pricing vendor		0			285			0			285
Total municipalities		0			285			0			285
Public utilities:
Third-party pricing vendor		0			36			0			36
Total public utilities		0			36			0			36
Sovereign and supranational:
Third-party pricing vendor		0			213			0			213
Internal		0			218			0			218
Total sovereign and supranational		0			431			0			431
Other corporate:
Third-party pricing vendor		0			19			0			19
Total other corporate		0			19			0			19
Total securities held-to-maturity		$	17,319		$	926		$	0		$	18,245

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	21,692		$	808		$	0		$	22,500
Internal		0			60			0			60
Broker/other		8			32			0			40
Total government and agencies		21,700			900			0			22,600
Municipalities:
Third-party pricing vendor		0			1,426			0			1,426
Internal		0			256			0			256
Broker/other		0			616			0			616
Total municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,277			0			2,277
Internal		0			27			105			132
Broker/other		0			10			667			677
Total mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities:
Third-party pricing vendor		0			4,570			0			4,570
Internal		0			2,677			0			2,677
Broker/other		0			92			253			345
Total public utilities		0			7,339			253			7,592
Sovereign and supranational:
Third-party pricing vendor		0			118			0			118
Internal		0			330			0			330
Broker/other		0			59			30			89
Total sovereign and supranational		0			507			30			537
Banks/financial institutions:
Third-party pricing vendor		0			5,085			0			5,085
Internal		0			3,008			69			3,077
Broker/other		0			664			9			673
Total banks/financial institutions		0			8,757			78			8,835
Other corporate:
Third-party pricing vendor		0			18,088			4			18,092
Internal		0			4,210			230			4,440
Broker/other		0			5,396			414			5,810
Total other corporate		0			27,694			648			28,342
Total securities available-for-sale		$	21,700		$	49,809		$	1,781		$	73,290
Equity securities, carried at fair value:
Third-party pricing vendor		$	800		$	0		$	0		$	800
Internal		0			0			216			216
Broker/other		40			0			32			72
Total equity securities		$	840		$	0		$	248		$	1,088

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	18,662		$	167		$	0		$	18,829
Total government and agencies		18,662			167			0			18,829
Municipalities:
Third-party pricing vendor		0			307			0			307
Total municipalities		0			307			0			307
Public utilities:
Third-party pricing vendor		0			38			0			38
Total public utilities		0			38			0			38
Sovereign and supranational:
Third-party pricing vendor		0			226			0			226
Internal		0			236			0			236
Total sovereign and supranational		0			462			0			462
Other corporate:
Third-party pricing vendor		0			21			0			21
Total other corporate		0			21			0			21
Total securities held-to-maturity		$	18,662		$	995		$	0		$	19,657

The following is a discussion of the determination of fair value of the Company's remaining financial instruments.

Derivatives

The Company uses derivative instruments to manage the risk associated with certain assets. However, the derivative instrument may not be classified in the same fair value hierarchy level as the associated asset. The significant inputs to pricing derivatives are generally observable in the market or can be derived by observable market data. When these inputs are observable, the derivatives are classified as Level 2.

The Company uses present value techniques to value non-option based derivatives. It also uses option pricing models to value option based derivatives. Key inputs are as follows:

Instrument Type	Level 2
Interest rate derivatives	Swap yield curves Basis curves Interest rate volatility (1)
Foreign currency exchange rate derivatives - Non-VIEs (forwards, swaps and options)	Foreign currency forward rates Swap yield curves Basis curves Foreign currency spot rates Cross foreign currency basis curves Foreign currency volatility (1)
Foreign currency exchange rate derivatives - VIEs (swaps)	Foreign currency spot rates Swap yield curves Credit default swap curves Basis curves Recovery rates Foreign currency forward rates Foreign cross-currency basis curves

(1) Option-based only

The fair values of the foreign currency forwards and options are based on observable market inputs, therefore they are classified as Level 2.

The Parent Company has cross-currency swap agreements related to certain of its U.S. dollar-denominated senior notes to effectively convert a portion of the interest on the notes from U.S. dollar to Japanese yen. Their fair values are based on observable market inputs, therefore they are classified as Level 2.

To determine the fair value of its interest rate derivatives, the Company uses inputs that are generally observable in the market or can be derived from observable market data. Interest rate swaps are cleared trades. In a cleared swap contract, the clearinghouse provides benefits to the counterparties similar to contracts listed for investment traded on an exchange since it maintains a daily margin to mitigate counterparties' credit risk. These derivatives are priced using observable inputs, accordingly, they are classified as Level 2.

For derivatives associated with VIEs where the Company is the primary beneficiary, the Company is not the direct counterparty to the swap contracts. Nevertheless, the Company has full transparency into the contracts to properly value the swaps for reporting purposes. For these derivatives, the Company utilizes valuation models developed by independent valuation analytics providers. The models are market standard DCF models and all associated processes and controls are executed by Company personnel. These models take into consideration any unique characteristics of the derivatives in determining the appropriate valuation methodology to estimate expected cash flows. The fair values of these swaps are based on observable market inputs and are classified as Level 2 within the fair value hierarchy.

For forward bond purchase commitments with VIEs, the fair value of the derivative is based on the difference in the fixed purchase price and the current market value of the related bond prior to the settlement date. Since the bond is typically a public bond with readily available pricing, the derivatives associated with the forward purchase commitment are classified as Level 2 within the fair value hierarchy.

Commercial mortgage and other loans

Commercial mortgage and other loans include TREs, CMLs, MMLs and other loans. The Company's loan receivables do not have readily determinable market prices and generally lack market liquidity. Fair values for loan receivables are determined based on the present value of expected future cash flows discounted at the applicable U.S. Treasury or floating-rate benchmark yield plus an appropriate spread that considers other risk factors, such as credit and liquidity risk. The spreads are a significant component of the pricing inputs and are generally considered unobservable. Therefore, these investments are classified as Level 3 within the fair value hierarchy.

Other investments

Other investments includes short-term investments that are measured at fair value where amortized cost approximates fair value.

Other policyholders' funds

The largest component of the other policyholders' funds liability is the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums. For this product, the Company estimates the fair value to be equal to the cash surrender value. This is analogous to the value paid to policyholders on the valuation date if they were to surrender their policy. The Company periodically checks the cash value against discounted cash flow projections for reasonableness. The Company considers its inputs for this valuation to be unobservable and have accordingly classified this valuation as Level 3.

Notes payable

The fair values of the Company's publicly issued notes payable are determined by utilizing available sources of observable inputs from third-party pricing vendors and are classified as Level 2. The fair values of the Company's yen-denominated loans approximate their carrying values and are classified as Level 3.

Transfers between Hierarchy Levels and Level 3 Rollforward

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales   and settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

Three Months Ended March 31, 2023
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	343	$	497	$	37	$	159	$	742	$	209	$	1,987
Net investment gains (losses) included   in earnings	0		0		0		0		0		2		2
Unrealized gains (losses) included in   other comprehensive income (loss)	3		10		0		2		30		0		45
Purchases, issuances, sales and   settlements:
Purchases	192		0		0		0		75		10		277
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(120)		(7)		0		0		(2)		0		(129)
Transfers into Level 3	0		18		0		0		0		0		18
Transfers out of Level 3	0		(168)		0		0		(92)		0		(260)
Balance, end of period	$	418	$	350	$	37	$	161	$	753	$	221	$	1,940
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	3	$	3

Fair Value Sensitivity

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	859	Consensus pricing	Offered quotes	85.28	-	105.35	(a)	99.24
Public utilities		507		Discounted cash flow	Credit spreads	175 bps	-	225 bps	(c)	208 bps
Sovereign and supranational		28		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		74		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		450		Discounted cash flow	Credit spreads	69 bps	-	388 bps	(c)	183 bps
Equity securities		159		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,077

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable.

December 31, 2023
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	772	Consensus pricing	Offered quotes	84.81	-	105.89	(a)	99.39
Public utilities		253		Consensus pricing	Offered quotes	94.34	-	102.99	(a)	96.46
Sovereign and supranational		30		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		78		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		648		Discounted cash flow	Credit spreads	69 bps	-	423 bps	(c)	206 bps
Equity securities		248		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,029

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable

The following is a discussion of the significant unobservable inputs or valuation techniques used in determining the fair value of securities classified as Level 3.

Credit Spreads

The Company holds certain assets that are of a unique, specialized, and/or securitized nature that do not trade on a regular basis in an active market, which makes their fair values difficult to estimate. Most of these assets are managed by external asset managers and the Company utilizes these managers for their expertise when evaluating various inputs used to determine the fair values for these assets, including identifying the appropriate credit or risk spread over risk-free interest rates that incorporates the unique nature or structure of the asset in the valuations. For those assets of a similar nature but not managed by external asset managers, the Company internally estimates the spreads and risk adjustments over risk-free interest rates that reflect the unique nature or structure of the asset as well as the current pricing environment and market conditions for comparable or related investments. Credit or risk spreads are an important input needed to complete the discounted cash flow analyses used to estimate an investment’s fair value. Credit or risk spreads underlying these fair values are a significant, unobservable input whose derivation is based on the Company’s evaluation of a combination of the external manager’s expertise and knowledge, the current pricing environment, and market conditions for the specific asset.

Offered Quotes

In circumstances where the Company's valuation model price is overridden because it implies a value that is not consistent with current market conditions, the Company will solicit bids from a limited number of brokers. The Company also receives unadjusted prices from brokers for certain of its mortgage and asset-backed securities. These quotes are non-binding but are reflective of valuation best estimates at that particular point in time. Offered quotes are an unobservable input in the determination of fair value of mortgage- and asset-backed securities, certain banks/financial institutions, certain other corporate, and equity securities investments.

Private Financials

The Company invests in the debt and equity securities of private companies operating in the cancer, healthtech, insurtech, finance, internet of things, big data and analytics sectors. Due to their private and often small, startup nature, these companies rely on capital provided by institutional and private equity investors for their ongoing operations. They do not have public securities that trade on a regular basis in an active market, which makes their fair values difficult to estimate. The Company values these investments on a cost basis with appropriate adjustments made based on monitoring private financial information provided by these companies. Adjustments to valuations are generally made as new funding tranches are executed or if the financial information provided significantly changes indicating the need for impairment. This private financial information is unobservable and is a significant determinant in the fair value of these corporate venture investments.

For additional information on the Company's investments and financial instruments, see the accompanying Notes 3 and 4 and Notes 1, 3 and 4 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

DEFERRED POLICY ACQUISITION COSTS

3 Months Ended

Mar. 31, 2024

Insurance [Abstract]

DEFERRED POLICY ACQUISITION COSTS

DEFERRED POLICY ACQUISITION COSTS

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	72		29		9		0		32		29		39		19		4		19		2		254
Amortization expense	(49)		(25)		(8)		(1)		(36)		(29)		(38)		(18)		(4)		(7)		0		(215)
Foreign currency translation and   other	(189)		(129)		(32)		(2)		0		0		0		0		0		0		0		(352)
Balance at March 31, 2024	$	2,805	$	1,916	$	460	$	53	$	913	$	625	$	1,337	$	437	$	86	$	184	$	3	$	8,819

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2022	$	3,035	$	2,161	$	525	$	55	$	904	$	613	$	1,304	$	418	$	88	$	135	$	1	$	9,239
Capitalization	317		123		33		8		151		125		173		84		10		61		1		1,086
Amortization expense	(184)		(105)		(34)		(3)		(138)		(113)		(141)		(66)		(12)		(24)		4		(816)
Foreign currency translation and   other	(197)		(138)		(33)		(4)		0		0		0		0		0		0		(5)		(377)
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132

The Company uses the following constant level bases to amortize deferred policy acquisition costs:

Policy Type	Constant-level Basis
Life Products (U.S.)	Face Amount
Health Products (U.S.)	Number of Policies in Force
Health & Life Products (Japan)	Units in Force

Face amount is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency.

There were no changes to the inputs, judgments, assumptions and methods used to determine amortization amounts during the three-month periods ended March 31, 2024 and 2023. For additional information on deferred policy acquisition costs, see Notes 1 and 6 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

POLICY LIABILITIES

3 Months Ended

Mar. 31, 2024

Insurance Loss Reserves [Abstract]

POLICY LIABILITIES

POLICY LIABILITIES

Future Policy Benefits

The liability for future policy benefits is determined as the present value of expected future policy benefits to be paid to or on the behalf of policyholders and certain related expenses less the present value of expected future net premiums receivable under the Company's insurance contracts. Future net premiums receivable are future gross premiums receivable under the contract multiplied by the net premium ratio (NPR).

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(46)		(52)		(19)		(5)		(18)		(10)		(48)		(14)		(4)		(8)		2
Adjusted beginning of period balance	16,406		13,988		6,239		1,064		2,612		1,728		4,368		1,179		213		901		274
Issuances	229		103		58		5		111		121		221		95		18		66		147
Interest accrual	97		77		28		4		26		16		43		11		2		9		3
Net premiums collected (1)	(369)		(290)		(226)		(26)		(117)		(99)		(139)		(58)		(10)		(37)		(8)
Foreign currency translation	(1,041)		(888)		(392)		(66)		0		0		0		0		0		0		0
Other	0		0		0		0		0		(1)		0		(1)		(1)		1		(1)
Ending balance at original discount rate	15,322		12,990		5,707		981		2,632		1,765		4,493		1,226		222		940		415
Effect of changes in discount rate assumptions	895		535		194		14		(173)		(99)		(412)		(99)		(14)		(66)		6
Balance at March 31, 2024	$	16,217	$	13,525	$	5,901	$	995	$	2,459	$	1,666	$	4,081	$	1,127	$	208	$	874	$	421
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(62)		(59)		(20)		(8)		(21)		(17)		(60)		(18)		(5)		(11)		2
Adjusted beginning of period balance	43,564		24,964		30,236		5,436		3,281		2,524		12,060		2,058		501		1,960		771
Issuances	232		105		59		7		115		128		233		99		16		70		151
Interest accrual	343		142		146		23		32		24		128		20		5		19		10
Benefit payments	(682)		(246)		(516)		(55)		(125)		(112)		(228)		(76)		(14)		(29)		(17)
Foreign currency translation	(2,757)		(1,582)		(1,909)		(345)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		1		0		1		1		0
Ending balance at original discount rate	40,700		23,383		28,016		5,066		3,303		2,564		12,194		2,101		509		2,021		915
Effect of changes in discount rate assumptions	5,689		(52)		(767)		(294)		(233)		(141)		(1,092)		(163)		(35)		(246)		15
Balance at March 31, 2024	46,389		23,331		27,249		4,772		3,070		2,423		11,102		1,938		474		1,775		930
Net liability for future policy benefits	30,172		9,806		21,348		3,777		611		757		7,021		811		266		901		509
Less: reinsurance recoverable	3,829		1,407		0		0		0		0		0		0		0		15		2
Net liability for future policy benefits after   reinsurance recoverable	$	26,343	$	8,399	$	21,348	$	3,777	$	611	$	757	$	7,021	$	811	$	266	$	886	$	507

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2022	$	19,298	$	16,714	$	7,485	$	1,256	$	2,534	$	1,635	$	4,486	$	1,220	$	211	$	724	$	110
Beginning balance at original discount rate	18,221		16,195		7,284		1,242		2,760		1,775		5,050		1,365		231		799		118
Effect of changes in cash flow assumptions	(165)		(470)		43		(12)		(16)		(51)		(494)		(142)		(9)		61		(9)
Effect of actual variances from expected    experience	(315)		(137)		(42)		(15)		(58)		(29)		(223)		(73)		(17)		(25)		(2)
Adjusted beginning of period balance	17,741		15,588		7,285		1,215		2,686		1,695		4,333		1,150		205		835		107
Issuances	1,034		418		335		26		323		376		493		249		44		181		169
Interest accrual	412		334		124		20		102		62		179		45		8		31		6
Net premiums collected (1)	(1,564)		(1,261)		(1,017)		(112)		(473)		(390)		(580)		(247)		(39)		(137)		(17)
Foreign currency translation	(1,170)		(1,038)		(469)		(80)		0		0		0		0		0		0		0
Other	(1)		(1)		0		0		(8)		(5)		(9)		(4)		(1)		(1)		7
Ending balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in discount rate assumptions	1,057		657		230		19		(142)		(86)		(342)		(86)		(11)		(56)		5
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Present value of expected future policy benefits:
Balance at December 31, 2022	$	54,766	$	27,419	$	31,954	$	5,582	$	3,098	$	2,445	$	11,489	$	2,074	$	488	$	1,526	$	622
Beginning balance at original discount rate	47,677		27,566		32,800		5,940		3,391		2,636		12,846		2,300		532		1,778		624
Effect of changes in cash flow assumptions	(147)		(507)		65		(27)		(11)		(59)		(592)		(194)		(14)		72		(13)
Effect of actual variances from expected    experience	(385)		(154)		(51)		(15)		(75)		(59)		(271)		(99)		(22)		(32)		(4)
Adjusted beginning of period balance	47,145		26,905		32,814		5,898		3,305		2,518		11,983		2,007		496		1,818		607
Issuances	1,059		432		341		32		331		392		505		258		46		185		169
Interest accrual	1,473		608		625		100		127		96		524		84		21		68		33
Benefit payments	(2,987)		(1,153)		(1,415)		(206)		(464)		(465)		(893)		(274)		(59)		(105)		(48)
Foreign currency translation	(3,064)		(1,769)		(2,109)		(380)		0		0		0		0		0		0		0
Other	0		0		0		0		3		0		1		1		2		5		8
Ending balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in discount rate assumptions	6,535		234		(525)		(266)		(193)		(119)		(830)		(133)		(28)		(207)		29
Balance at December 31, 2023	50,161		25,257		29,731		5,178		3,109		2,422		11,290		1,943		478		1,764		798
Net liability for future policy benefits	32,652		10,560		23,243		4,090		621		770		7,216		836		272		911		521
Less: reinsurance recoverable	4,135		1,521		0		0		0		0		0		0		0		15		0
Net liability for future policy benefits after    reinsurance recoverable	$	28,517	$	9,039	$	23,243	$	4,090	$	621	$	770	$	7,216	$	836	$	272	$	896	$	521

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	3.9 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.0 %	2.5 %	1.9 %	2.3 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.0	24.7	16.3	17.1	8.0	5.6	11.2	9.3	7.9	13.8	9.2

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2023
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.6 %	2.1 %	1.8 %	3.9 %	4.2 %	4.6 %	4.4 %	4.3 %	3.7 %	5.4 %
Weighted-average interest, current discount rate (1)	1.8 %	2.3 %	1.7 %	2.1 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.1	24.9	16.3	17.3	8.1	5.6	11.3	9.3	7.9	13.6	9.4

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2024			December 31, 2023
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	30,172		$	32,652
Medical and other health		9,806			10,560
Life insurance		21,348			23,243
Other		3,777			4,090
Aflac U.S.
Accident		611			621
Disability		757			770
Critical care		7,021			7,216
Hospital indemnity		811			836
Dental/vision		266			272
Life insurance		901			911
Other		509			521
Corporate and other		3,842			4,225
Deferred profit liability		1,734			1,806
Deferred reinsurance gain liability		910			1,012
Intercompany eliminations (1)		(4,598)			(5,017)
Total		$	77,867		$	83,718

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 for additional details.

Discount rates are determined using upper-medium grade (low-credit-risk) fixed-income instrument yields that reflect the duration characteristics of the liability. Locked-in discount rates are determined separately for each issue-year cohort as a single discount rate, calculated as the weighted-average of monthly upper-medium grade (low-credit-risk) fixed-income instrument forward curves in the calendar year, where the weights are the annualized premiums issued for each month of the cohort. The single discount rate for each issue-year cohort is determined by solving for a rate that produces an equivalent NPR to the forward curve and will remain unchanged after the calendar year of issue.

Discount rates are updated each reporting period and require estimation techniques (e.g., interpolation, extrapolation) for determination of points on the curve for which there is limited or no observable market data. The Company constructs a current discount rate curve separately for discounting cash flows used to calculate each of the Japan and U.S. liabilities for future policy benefits, reflective of the characteristics of the corresponding insurance liabilities, such as currency and tenor.

In the Aflac Japan segment, all long-duration insurance policies are denominated in yen. A significant portion of policies are characterized by tenors exceeding the availability of liquid market data in Japan for single-A rated (as a proxy for upper-medium grade) corporate yen-denominated debt. The discount rate curve is designed to prioritize the observable inputs where available, while past the last liquid point, the data is derived based on estimation techniques consistent with the fair value guidance in ASC 820. The Aflac Japan segment curve utilizes liquid market indices tracking publicly traded yen-denominated single-A corporate debt for the initial 10-year tenor. For the bonds within these market indices where only local ratings are available, the Company prioritizes the bonds with local ratings that are equivalent to a single-A rating based on international rating standards.

For the discount rates applicable to tenors for which the Japan single-A debt market is not liquid but there is sufficient observable market data and/or the observable market data is available for similar instruments (between 10 and 30 years), the Company estimates tenor-specific single-A credit spreads and applies them to risk-free government rates. Lastly, for the tenors where there is limited or no observable single-A or similar market data or risk-free government rates (beyond 30

years), the discount curve is derived by extrapolation of risk free rates beyond their last liquid point following the Smith-Wilson method and grading of the estimated forward credit spread anchored by the ultimate forward rate. The ultimate forward rate is based on the economic value-based solvency regime, which is consistent with the International Association of Insurance Supervisors (IAIS) Insurance Capital Standards (ICS) (which is expected to be introduced in Japan in 2025), and is adjusted for credit and inflation components.

For the Aflac U.S. segment where all long-duration insurance policies are denominated in U.S. dollar and substantially all have cash flow duration within 30 years, for which the U.S. upper-medium grade fixed-income market is liquid and observable, the Company uses data from a liquid fixed-income market index tracking single-A U.S. corporate debt. For the insignificant portion of the policies with cash flow tenors exceeding 30 years, the discount curve beyond that tenor is extrapolated following the Smith-Wilson method from year 30 to the same ultimate forward rate calculated for the Japan discount curve at year 60 and held constant thereafter. The use of the same ultimate rate for U.S. and Japan segments is based on the assumption of long-term global economic convergence.

For the three-month periods ended March 31, 2024 and 2023, the Company recognized $1.1 billion and $(2.8) billion in other comprehensive income (loss) net of tax, respectively, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the three-month periods ended March 31, 2024 and 2023.

For the year ended December 31, 2023, the Company recognized approximately $(460) million in other comprehensive income (loss) net of tax, due to changes in the future policy benefits estimate from updating the discount rate assumptions. There were no changes to the methods used to determine the discount rates during the year ended December 31, 2023.

Mortality rate assumptions are based on industry tables and adjusted for the Company's actual or expected experience where credible or appropriate. These assumptions typically vary by age, gender, and other demographic characteristics such as smoking status.

Morbidity assumptions are based on the Company's internal data and consider emerging experience. These assumptions are reflective of the coverage and benefits provided and generally vary by age, gender, duration, and any other material policyholder characteristics. In cases where a calendar-year trend is significant, future cash flow projections may include a trend adjustment.

In Japan, separate lapse assumptions are set based on actual or expected experience. These lapse and total termination rate assumptions vary by line of business and with policyholder characteristics such as duration. In the U.S., the majority of the future cash flows are modeled using total termination rates (which include both lapse and mortality) and are adjusted for actual experience. Policy provisions, such as reaching premium paid-up status, are taken into account when setting assumptions.

During the three-month periods ended March 31, 2024 and 2023, the variance of actual experience from expected experience was primarily due to favorable variances in morbidity assumptions as compared to actual experience. There were no changes to the inputs, judgments, assumptions and methods used in measuring the liability for future policy benefits during the three-month periods ended March 31, 2024 and 2023.

In 2023, the Company's annual assumption review process resulted in favorable changes to its morbidity and termination assumptions, largely due to reflecting more recent favorable U.S. morbidity experience.

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Net earned premiums:
Aflac Japan
Cancer	$	878	$	1,132
Medical and other health	605		689
Life insurance	339		399
Other	34		39
Aflac U.S.
Accident	325		329
Disability	333		309
Critical care	444		443
Hospital indemnity	185		184
Dental/vision	59		53
Life insurance	138		115
Other	20		10
Corporate and other	165		90
Reinsurance ceded	(69)		(104)
Total	$	3,456	$	3,688

The following table summarizes the amount of interest expense related to insurance contracts recognized in total benefits and claims, net in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Interest expense:
Aflac Japan
Cancer	$	246	$	285
Medical and other health	65		71
Life insurance	118		133
Other	19		22
Aflac U.S.
Accident	6		6
Disability	8		8
Critical care	85		87
Hospital indemnity	9		10
Dental/vision	3		3
Life insurance	10		9
Other	7		7
Total	$	576	$	641

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	55,096		$	61,876		$	59,169		$	66,427
Medical and other health		35,735			37,277			38,583			39,884
Life insurance		11,637			39,439			12,677			42,541
Other		1,646			6,923			1,781			7,448
Aflac U.S.
Accident		9,097			4,551			9,095			4,548
Disability		5,819			3,210			5,776			3,177
Critical care		20,008			20,712			19,886			20,626
Hospital indemnity		4,985			3,058			4,922			3,025
Dental/vision		1,161			729			1,162			726
Life insurance		2,824			3,367			2,719			3,260
Other		1,077			1,634			724			1,396
Total		$	149,085		$	182,776		$	156,494		$	193,058

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	44,795		$	46,389		$	48,363		$	50,161
Medical and other health		28,312			23,331			30,757			25,257
Life insurance		10,274			27,249			11,240			29,731
Other		1,391			4,772			1,512			5,178
Aflac U.S.
Accident		6,293			3,070			6,369			3,109
Disability		4,476			2,423			4,488			2,422
Critical care		12,295			11,102			12,417			11,290
Hospital indemnity		3,425			1,938			3,419			1,943
Dental/vision		794			474			807			478
Life insurance		1,963			1,775			1,914			1,764
Other		673			930			467			798
Total		$	114,691		$	123,453		$	121,753		$	132,131

Loss expense as a result of NPR capping for the three-month periods ended March 31, 2024 and 2023 was immaterial.

Other Policyholders' Funds

As of March 31, 2024 and December 31, 2023, the largest component of the other policyholders' funds liability was the Company's annuity line of business in Aflac Japan. The Company's annuities have fixed benefits and premiums.

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2024		December 31, 2023
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,939	$	6,423
Premiums received	29		126
Transfers from WAYS conversions	61		229
Surrenders and withdrawals	(18)		(59)
Benefit payments	(110)		(419)
Interest credited	13		53
Foreign currency translation and other	(376)		(414)
Fixed annuities account balance, end of period	5,538		5,939
Other deposit type reserves	293		230
Total	$	5,831	$	6,169

(1) Aflac Japan fixed annuities

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2024			December 31, 2023
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,538	$5,457	0.5% - 2.3%	$5,939	$5,850

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2024 and December 31, 2023.

Aflac Japan’s fixed annuities have guaranteed fixed crediting rates which results in the policyholders' funds balances being able to cover all guaranteed benefit amounts. The reserves are adequate to fully fund future benefits at any given time.

For additional information on policy liabilities, see Notes 1 and 7 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

REINSURANCE

3 Months Ended

Mar. 31, 2024

Reinsurance Disclosures [Abstract]

REINSURANCE

REINSURANCE

The Company periodically enters into fixed quota-share coinsurance agreements in the normal course of business, primarily to provide additional capacity for future growth, optimize capital, limit losses, and minimize exposure to significant risks. For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. For additional information on reinsurance, see Notes 1 and 8 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2024		2023
Direct earned premiums	$	3,482		$	3,738
Ceded to other companies:
Ceded Aflac Japan closed blocks	(34)			(82)
Other	(35)			(25)
Assumed from other companies:
Retrocession activities	29			34
Other	14			23
Net earned premiums	$	3,456		$	3,688
Direct benefits and claims, excluding reserve remeasurement	$	2,082		$	2,256
Ceded benefits and change in reserves for future benefits:
Ceded Aflac Japan closed blocks	(18)			(77)
Other	(15)			(27)
Assumed from other companies:
Retrocession activities	13			41
Other	4			10
Benefits and claims, excluding reserve remeasurement	$	2,066		$	2,203
Direct reserve remeasurement (gains) losses	$	(57)		$	(53)
Ceded reserve remeasurement gains (losses)	1			0
Assumed reserve remeasurement (gains) losses	0			0
Reserve remeasurement (gains) losses	$	(56)		$	(53)
Total benefits and claims, net	$	2,010		$	2,150

The Company has recorded a deferred reinsurance gain liability related to reinsurance transactions which represents ceded reserves in excess of consideration paid, or consideration received in excess of assumed reserves. The remaining deferred reinsurance gain liability of $161 million and $175 million as of March 31, 2024 and December 31, 2023, respectively, is included in future policy benefits in the consolidated balance sheets and is being amortized into income over the expected lives of the policies.

The Company has also recorded a reinsurance recoverable for reinsurance transactions. The reinsurance recoverable, which is included in other assets in the consolidated balance sheets, is reported net of allowance for credit losses and had a remaining balance of $178 million and $183 million as of March 31, 2024 and December 31, 2023, respectively. The allowance for credit losses related to the Company's reinsurance recoverable balance was $4 million and $10 million as of March 31, 2024 and December 31, 2023, respectively. The credit allowance for the reinsurance recoverable balance is estimated using a PD / LGD method and the key credit quality indicator is the credit rating of the Company’s reinsurance counterparty. The Company uses external credit ratings focused on the reinsurer’s financial strength and credit worthiness. As of March 31, 2024, the Company's reinsurance counterparties were rated A+. The Company monitors the credit ratings periodically, but not less frequently than quarterly.

These reinsurance transactions are indemnity reinsurance that do not relieve the Company from its obligations to policyholders. In the event that the reinsurer is unable to meet its obligations, the Company remains liable for the reinsured claims.

Internal Reinsurance Transactions

Aflac Re is a Bermuda domiciled insurer that reinsures certain policies issued by ALIJ. The inter-segment amounts associated with these internal reinsurance transactions are eliminated in consolidation.

XML

NOTES PAYABLE AND LEASE OBLIGATIONS

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

NOTES PAYABLE AND LEASE OBLIGATIONS

NOTES PAYABLE AND LEASE OBLIGATIONS

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2024			December 31, 2023
1.125% senior sustainability notes due March 2026		$	398		$	398
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		993			993
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		254			254
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		82			87
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		395			422
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			0
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		220			234
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		83			88
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		87			93
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		192			206
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		184			0
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		197			211
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		61			65
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		136			145
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		139			148
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		79			84
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		100			106
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			0
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			0
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		64			69
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		69			74
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		100			0
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		65			70
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			45
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		58			62
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		110			0
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		41			44
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		65			70
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		38			0
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		392			419
.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion) (1)		198			211
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		131			140
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		79			84
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		197			210
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		130			0
Yen-denominated loans:
Variable interest rate loan due August 2027 (.38% in 2024 and .35% in 2023,   principal amount ¥11.7 billion)		77			82
Variable interest rate loan due August 2029 (.48% in 2024 and .45% in 2023,   principal amount ¥25.3 billion)		166			178
Variable interest rate loan due August 2032 (.63% in 2024 and .60% in 2023,   principal amount ¥70.0 billion)		461			492
Finance lease obligations payable through 2030		6			6
Operating lease obligations payable through 2049		107			118
Total notes payable and lease obligations		$	7,912		$	7,364

(1) Redeemed in April 2024

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

In March 2024, the Parent Company issued five series of senior notes totaling ¥75.0 billion through a private placement. The first series, which totaled ¥18.3 billion, bears interest at a fixed rate of 1.600% per annum, payable semi-annually, and will mature in March 2034. The second series, which totaled ¥15.0 billion, bears interest at a fixed rate of 1.740% per annum, payable semi-annually, and will mature in March 2036. The third series, which totaled ¥16.5 billion, bears interest at a fixed rate of 1.920% per annum, payable semi-annually, and will mature in March 2039. The fourth series, which totaled ¥5.7 billion, bears interest at a fixed rate of 2.160% per annum, payable semi-annually, and will mature in March 2044. The fifth series, which totaled ¥19.5 billion, bears interest at a fixed rate of 2.400% per annum, payable semi-annually, and will mature in March 2054. These notes are redeemable at the Parent Company's option (i) in whole at any time or (ii) in part from time to time in an amount not less than 5% of the aggregate principal amount then outstanding of the notes to be redeemed.

In March 2024, the Parent Company issued three series of senior notes totaling ¥48.6 billion through a public debt offering under its U.S. shelf registration statement. The first series, which totaled ¥13.0 billion, bears interest at a fixed rate of 1.048% per annum, payable semi-annually, and will mature in March 2029. The second series, which totaled ¥27.9 billion, bears interest at a fixed rate of 1.412% per annum, payable semi-annually, and will mature in March 2031. The third series, which totaled ¥7.7 billion, bears interest at a fixed rate of 1.682% per annum, payable semi-annually, and will mature in March 2034. These notes are redeemable at the Parent Company’s option at any time, in whole but not in part, upon the occurrence of certain changes affecting U.S. taxation, as specified in the indenture governing the terms of the issuance. In addition, the notes maturing in March 2029, March 2031 and March 2034 are redeemable at the Parent Company's option, in whole or in part from time to time, on or after December 21, 2028, December 31, 2030 and September 21, 2033, respectively, at a redemption price equal to the aggregate principal amount of the applicable series to be redeemed plus accrued and unpaid interest on the principal amount to be redeemed to, but excluding, the date of redemption.

Interest expense related to the Company's notes payable, which is included in interest expense in the consolidated statements of earnings, was $46 million and $47 million for the three-month periods ended March 31, 2024 and 2023, respectively.

A summary of the Company's lines of credit as of March 31, 2024 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 6, 2024	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar denominated borrowings or TIBOR for Japanese yen denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 2, 2024	$250 million	$50 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 3, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac New York(1),(2)	uncommitted revolving	364 days	April 8, 2024	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than April 9, 2024	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	March 21, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(2) Renewed in April 2024 with an expiration date of April 8, 2025

(continued)

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	March 21, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes
Hatch Healthcare K.K.(1)	uncommitted revolving	364 days	January 2, 2025	¥900 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac Digital Services Co., Ltd.(1)	uncommitted revolving	364 days	January 2, 2025	¥600 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	July 16, 2024	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than July 17, 2024	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes

(1) Intercompany credit agreement

The Company was in compliance with all of the covenants of its notes payable and lines of credit at March 31, 2024. No events of default or defaults occurred during the three-month period ended March 31, 2024.

For additional information, see Notes 4 and 9 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

SHAREHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2024

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' EQUITY

SHAREHOLDERS’ EQUITY

The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2024	2023
Common stock - issued:
Balance, beginning of period	1,355,398	1,354,079
Exercise of stock options and issuance of restricted shares	1,082	933
Balance, end of period	1,356,480	1,355,012
Treasury stock:
Balance, beginning of period	776,919	738,823
Purchases of treasury stock:
Share repurchase program	9,276	10,348
Other	457	347
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(212)	(239)
Exercise of stock options	(55)	(48)
Other	(183)	(171)
Balance, end of period	786,202	749,060
Shares outstanding, end of period	570,278	605,952

Outstanding share-based awards are excluded from the calculation of weighted-average shares used in the computation of basic earnings per share (EPS). The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2024	2023
Anti-dilutive share-based awards	69		164

Share Repurchase Program

During the first three months of 2024, the Company repurchased 9.3 million shares of its common stock for $750 million as part of its share repurchase program. During the first three months of 2023, the Company repurchased 10.3 million shares of its common stock for $700 million as part of its share repurchase program. As of March 31, 2024, a remaining balance of 68.5 million shares of the Company's common stock was available for purchase under share repurchase authorizations by its board of directors.

Reclassifications from Accumulated Other Comprehensive Income

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2023
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2022		$	(3,564)		$	(702)		$	(27)		$	(2,100)		$	(36)		$	(6,429)
Other comprehensive    income (loss) before    reclassification		(54)			2,036			0			(2,794)			7			(805)
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(45)			1			0			0			(44)
Net current-period other    comprehensive    income (loss)		(54)			1,991			1			(2,794)			7			(849)
Balance at March 31, 2023		$	(3,618)		$	1,289		$	(26)		$	(4,894)		$	(29)		$	(7,278)

All amounts in the table above are net of tax.

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

(In millions)	Three Months Ended March 31, 2023
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	57	Net investment gains (losses)
		(12)		Tax (expense) or benefit(1)
		$	45	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	44	Net of tax

(1) Based on 21% tax rate

XML

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION

As of March 31, 2024, the Company has outstanding share-based awards under the Aflac Incorporated Long-Term Incentive Plan (As Amended and Restated February 14, 2017), as further amended on August 9, 2022 (the Plan). Share-based awards are designed to reward employees for their long-term contributions to the Company and provide incentives for them to remain with the Company. The number and frequency of share-based awards are based on competitive practices, operating results of the Company, government regulations, and other factors.

The Plan, allows for a maximum number of shares issuable over its term of 75 million shares including 38 million shares that may be awarded in respect of awards other than options or stock appreciation rights. If any awards granted under the Plan are forfeited or are terminated before being exercised or settled for any reason other than tax forfeiture, then the shares underlying the awards will again be available under the Plan.

The Plan allows awards to Company employees for incentive stock options (ISOs), non-qualifying stock options (NQSOs), restricted stock, restricted stock units, and stock appreciation rights. Non-employee directors are eligible for grants of NQSOs, restricted stock, and stock appreciation rights. As of March 31, 2024, approximately 33.6 million shares were available for future grants under this plan. The ISOs and NQSOs have a term of 10 years, and the share-based awards generally vest upon time-based conditions or time and performance-based conditions. Time-based vesting generally occurs after three years. Performance-based vesting conditions generally include the attainment of goals related to Company financial performance. As of March 31, 2024, the only performance-based awards issued and outstanding were restricted stock awards and units.

Stock options and stock appreciation rights granted under the amended Plan have an exercise price of at least the fair market value of the underlying stock on the grant date and have an expiration date no later than 10 years from the grant date. Time-based restricted stock awards, restricted stock units and stock options generally vest on a ratable basis over three years. The Compensation Committee of the Board of Directors has the discretion to determine vesting schedules.

Share-based awards granted to U.S.-based grantees are settled with authorized but unissued Company stock, while those issued to Japan-based grantees are settled with treasury shares.

The following table provides information on stock options outstanding and exercisable at March 31, 2024.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		856		2.2		$	45		$	33.37
Exercisable		856		2.2		45			33.37

The Company received cash from the exercise of stock options in the amount of $5 million and $4 million during the first three months of 2024 and 2023, respectively. The tax benefit realized as a result of stock option exercises and restricted stock releases was $24 million in the first three months of 2024, compared with $17 million in the first three months of 2023.

As of March 31, 2024, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock awards and units was $74 million, of which $40 million (1.8 million shares) was related to restricted stock awards and units with a performance-based vesting condition. The Company expects to recognize these amounts over a weighted-average period of approximately 1.9 years. There are no other contractual terms covering restricted stock awards once vested.

The following table summarizes restricted stock activity during the three-month period ended March 31, 2024.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2023	2,308		$	62.96
Granted in 2024	1,213		79.75
Canceled in 2024	(7)		67.50
Vested in 2024	(1,337)		49.24
Restricted stock at March 31, 2024	2,177		$	72.33

In February 2024, the Company granted 303 thousand performance-based stock awards and units, which are contingent on the achievement of the Company's financial performance metrics and its market-based conditions. On the date of grant, the Company estimated the fair value of restricted stock awards and units with market-based conditions using a Monte Carlo simulation model. The model discounts the value of the stock at the assumed vesting date based on the risk-free interest rate. Based on estimates of actual performance versus the vesting thresholds, the calculated fair value percentage payout estimate will be updated each quarter.

The Company uses third-party analyses to assist in developing the assumptions used in, as well as calibrating, a Monte Carlo simulation model. The Company is responsible for determining the assumptions used in estimating the fair value of its share-based payment awards.

For additional information on the Company's long-term share-based compensation plans and the types of share-based awards, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report.

XML

BENEFIT PLANS

3 Months Ended

Mar. 31, 2024

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

BENEFIT PLANS

BENEFIT PLANS

The Company has funded defined benefit plans in Japan and the U.S.; however, future benefits under the U.S. plan were frozen effective January 1, 2024. U.S. employees, including those that participated in the U.S. plan prior to the freeze, currently receive a nonelective 401(k) employer contribution.

The Company also maintains non-qualified, unfunded supplemental retirement plans that provide defined pension benefits in excess of limits imposed by federal tax law for certain Japanese, U.S. and former employees. However, future benefits under the Company's Supplemental Executive Retirement Plan and Retirement Plan for Senior Officers were frozen effective January 1, 2024, provided that actively employed participants may continue to accrue service toward eligibility for early retirement benefits or delayed early retirement benefits.

The Company provides certain health care benefits for eligible U.S. retired employees, their beneficiaries and covered dependents (other postretirement benefits). The health care plan is contributory and unfunded. Effective January 1, 2014, employees eligible for benefits included the following: (1) active employees whose age plus service, in years, equaled or exceeded 80 (rule of 80); (2) active employees who were age 55 or older and have met the 15 years of service requirement; (3) active employees who would meet the rule of 80 in the next five years; (4) active employees who were age 55 or older and who would meet the 15 years of service requirement within the next five years; and (5) current retirees. For certain employees and former employees, additional coverage is provided for all medical expenses for life.

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $2 million for both the three-month periods ended March 31, 2024 and 2023. Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2024			2023			2024			2023			2024			2023
Components of net periodic   benefit cost:
Service cost		$	4		$	4		$	0		$	4		$	0		$	0
Interest cost		2			2			9			11			0			0
Expected return on plan assets		(2)			(2)			(7)			(9)			0			0
Amortization of net actuarial loss		0			0			0			0			0			0
Net periodic (benefit) cost		$	4		$	4		$	2		$	6		$	0		$	0

During the three months ended March 31, 2024, Aflac Japan contributed approximately $6 million (using the weighted-average yen/dollar exchange rate for the three-month period ended March 31, 2024) to the Japanese funded defined benefit plan, and Aflac U.S. did not make a contribution to the U.S. funded defined benefit plan.

For additional information regarding the Company's Japanese and U.S. benefit plans, see Note 14 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

COMMITMENTS AND CONTINGENT LIABILITIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

COMMITMENTS AND CONTINGENT LIABILITIES

The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business. Members of the Company's senior legal and financial management teams review litigation and regulatory inquiries on a quarterly and annual basis. The final results of any litigation or regulatory inquiries cannot be predicted with certainty. Although some of this litigation is pending in states where large punitive damages, bearing little relation to the actual damages sustained by plaintiffs, have been awarded in recent years, the Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

See Note 3 for details on certain investment commitments.

Guaranty Fund Assessments

The U.S. insurance industry has a policyholder protection system that is monitored and regulated by state insurance departments. These life and health insurance guaranty associations are state entities (in all 50 states as well as Puerto Rico and the District of Columbia) created to protect policyholders of an insolvent insurance company. All insurance companies (with limited exceptions) licensed to sell life or health insurance in a state must be members of that state’s guaranty association. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business.

Guaranty fund assessments for the three-month periods ended March 31, 2024 and 2023 were immaterial.

For additional information regarding commitments and contingent liabilities, see Note 15 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net earnings	$ 1,879	$ 1,188

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Basis of Presentation

Description of Business

Aflac Incorporated (the Parent Company) and its subsidiaries (collectively, the Company) primarily sell supplemental health and life insurance in Japan and the United States (U.S.). The Company's insurance business is marketed and administered through Aflac Life Insurance Japan Ltd. (ALIJ) in Japan and through American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS) in the U.S. The Company’s operations consist of two reportable business segments: Aflac Japan, which includes ALIJ, and Aflac U.S., which includes Aflac, Aflac New York, CAIC, TOIC and ABS. Aflac New York is a wholly owned subsidiary of Aflac. Most of the Aflac U.S. policies are individually underwritten and marketed through independent agents. With the exception of dental and vision products administered by ABS, and certain group life insurance products, Aflac U.S. markets and administers group products through CAIC, branded as Aflac Group Insurance. Additionally, Aflac U.S. markets its consumer markets products through TOIC. The Company's insurance operations in the U.S. and Japan service the two markets for the Company's insurance business. The Parent Company, other operating business units that are not individually reportable, reinsurance activities, including internal reinsurance activity with Aflac Re Bermuda Ltd. (Aflac Re), and other business activities not included in Aflac Japan or Aflac U.S., as well as intercompany eliminations, are included in Corporate and other.

Basis of Presentation

The Company prepares its financial statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP). These principles are established primarily by the Financial Accounting Standards Board (FASB). In these Notes to the Consolidated Financial Statements, references to U.S. GAAP issued by the FASB are derived from the FASB Accounting Standards CodificationTM (ASC). The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates based on currently available information when recording transactions resulting from business operations. The most significant items on the Company's balance sheet that involve a greater degree of accounting estimates and actuarial determinations subject to changes in the future are the valuation of investments and derivatives, deferred policy acquisition costs (DAC), liabilities for future policy benefits and income taxes. These accounting estimates and actuarial determinations are sensitive to market conditions, investment yields, interest rates, mortality, morbidity, commission and other acquisition expenses and terminations by policyholders. As additional information becomes available, or actual amounts are determinable, the recorded estimates are revised and reflected in the consolidated financial statements. Although some variability is inherent in these estimates, the Company believes the amounts provided are reasonable and reflective of the best estimates of management.

The unaudited consolidated financial statements include the accounts of the Parent Company, its subsidiaries and those entities required to be consolidated under applicable accounting standards. All material intercompany accounts and transactions have been eliminated.

In the opinion of management, the accompanying unaudited consolidated financial statements of the Company contain all adjustments, consisting of normal recurring accruals, which are necessary to fairly present the consolidated balance sheets as of March 31, 2024 and December 31, 2023, and the consolidated statements of earnings and comprehensive income (loss), shareholders' equity and cash flows for the three-month periods ended March 31, 2024 and 2023. Results of operations for interim periods are not necessarily indicative of results for the entire year. As a result, these financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 (2023 Annual Report).

Reclassifications

Reclassifications: Certain reclassifications have been made to prior-year amounts to conform to current-year reporting classifications. These reclassifications had no impact on net earnings or total shareholders' equity.

For the three-month period ended March 31, 2023, immaterial reclassifications were made to the consolidated statement of cash flows related to investments in limited partnerships and the impact of foreign currency on policy liabilities. The impact of the reclassification related to investments in limited partnerships resulted in an increase to net cash flows provided by operating activities of $182 million with a corresponding decrease to net cash flows provided by investing activities. There was no impact to net cash flows provided by operating activities as a result of the reclassification related

to the impact of foreign currency on policy liabilities between the increase in policy liabilities and other, net line items within operating activities.

New Accounting Pronouncements

New Accounting Pronouncements

Accounting Pronouncements Pending Adoption

Accounting Standards Update (ASU) 2023-09 Income Taxes (Topic 740) – Improvements to Income Tax Disclosures

In December 2023, the FASB issued amendments that require enhanced income tax disclosures including (1) disclosure of specific categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures.

The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

ASU 2023-07 Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued amendments that will add certain segment disclosures related to significant segment expenses and require that a public entity disclose the title and position of the Chief Operating Decision Maker (CODM) and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance has no impact on the Company’s financial position or results of operations. The Company is evaluating the impact of adoption on its disclosures.

Recent accounting guidance not discussed above is not applicable, did not have, or is not expected to have a material impact to the Company's business. 

For additional information on new accounting pronouncements and recent accounting guidance and their impact, if any, on the Company's financial position, results of operations or disclosures, see Note 1 of the Notes to the Consolidated Financial Statements in the 2023 Annual Report.

XML

BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated

Information regarding operations by reportable segment and Corporate and other, follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Revenues:
Aflac Japan:
Net earned premiums	$	1,816	$	2,170
Adjusted net investment income	648		611
Other income	9		9
Total adjusted revenue Aflac Japan	2,473		2,790
Aflac U.S.:
Net earned premiums	1,475		1,428
Adjusted net investment income	206		197
Other income	18		35
Total adjusted revenue Aflac U.S.	1,699		1,660
Corporate and other (1)	247		129
Total adjusted revenues	4,419		4,579
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Total revenues	$	5,436	$	4,800

(1) The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Reconciliation of Adjusted Profit (Loss) from Segments to Consolidated

	Three Months Ended March 31,
(In millions)	2024		2023
Pretax earnings:
Aflac Japan	$	810	$	788
Aflac U.S.	356		352
Corporate and other (1)	(3)		(7)
Pretax adjusted earnings	1,163		1,133
Other income (loss)	(2)		0
Net investment gains (losses)	951		123
Reconciling items:
Amortized hedge costs	6		58
Amortized hedge income	(28)		(29)
Net interest (income) expense from derivatives    associated with certain investment strategies	88		69
Impact of interest from derivatives associated    with notes payable	(8)		(12)
Total earnings before income taxes	$	2,170	$	1,342
Income taxes applicable to pretax adjusted earnings	$	202	$	180
Effect of foreign currency translation on after-tax   adjusted earnings	(44)		(41)

(1)The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

Reconciliation of Assets from Segment to Consolidated

Assets were as follows:

(In millions)	March 31, 2024			December 31, 2023
Assets:
Aflac Japan		$	98,189		$	101,541
Aflac U.S.		21,850			21,861
Corporate and other		4,703			3,322
Total assets		$	124,742		$	126,724

XML

INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Available-for-Sale Debt Securities

The amortized cost and allowance for credit losses for the Company's investments in fixed maturity securities and the fair values of these investments as well as the fair value of the Company's investments in equity securities are shown in the following tables.

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	21,577	$	0	$	874	$	1,811	$	20,640
Municipalities	907		0		102		59		950
Mortgage- and asset-backed securities	201		0		6		12		195
Public utilities	3,281		0		262		77		3,466
Sovereign and supranational	349		0		24		7		366
Banks/financial institutions	5,546		0		323		285		5,584
Other corporate	5,532		0		663		245		5,950
Total yen-denominated	37,393		0		2,254		2,496		37,151
U.S. dollar-denominated:
U.S. government and agencies	177		0		1		4		174
Municipalities	1,237		0		72		49		1,260
Mortgage- and asset-backed securities	2,968		0		270		48		3,190
Public utilities	3,595		0		388		136		3,847
Sovereign and supranational	95		0		33		4		124
Banks/financial institutions	2,971		0		385		41		3,315
Other corporate	19,158		0		2,635		724		21,069
Total U.S. dollar-denominated	30,201		0		3,784		1,006		32,979
Total securities available-for-sale	$	67,594	$	0	$	6,038	$	3,502	$	70,130

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities available-for-sale, carried at fair   value through other comprehensive income:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	23,067	$	0	$	1,040	$	1,696	$	22,411
Municipalities	968		0		115		58		1,025
Mortgage- and asset-backed securities	215		0		6		11		210
Public utilities	3,757		0		325		82		4,000
Sovereign and supranational	373		0		24		7		390
Banks/financial institutions	5,896		0		320		365		5,851
Other corporate	5,898		0		699		294		6,303
Total yen-denominated	40,174		0		2,529		2,513		40,190
U.S. dollar-denominated:
U.S. government and agencies	191		0		2		4		189
Municipalities	1,246		0		65		38		1,273
Mortgage- and asset-backed securities	2,748		0		184		56		2,876
Public utilities	3,346		0		360		114		3,592
Sovereign and supranational	122		0		33		8		147
Banks/financial institutions	2,676		0		359		51		2,984
Other corporate	20,186		0		2,518		665		22,039
Total U.S. dollar-denominated	30,515		0		3,521		936		33,100
Total securities available-for-sale	$	70,689	$	0	$	6,050	$	3,449	$	73,290

Held-to-maturity Securities

	March 31, 2024
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	16,002	$	2	$	16,000	$	1,474	$	0	$	17,474
Municipalities	248		0		248		37		0		285
Public utilities	33		0		33		3		0		36
Sovereign and supranational	394		3		391		40		0		431
Other corporate	17		0		17		2		0		19
Total yen-denominated	16,694		5		16,689		1,556		0		18,245
Total securities held-to-maturity	$	16,694	$	5	$	16,689	$	1,556	$	0	$	18,245

	December 31, 2023
(In millions)	Amortized Cost		Allowance for Credit Losses		Net Carrying Amount		Gross Unrealized Gains		Gross Unrealized Losses		Fair   Value
Securities held-to-maturity, carried at   amortized cost:
Fixed maturity securities:
Yen-denominated:
Japan government and agencies	$	17,085	$	2	$	17,083	$	1,746	$	0	$	18,829
Municipalities	266		0		266		41		0		307
Public utilities	34		0		34		4		0		38
Sovereign and supranational	421		3		418		44		0		462
Other corporate	18		0		18		3		0		21
Total yen-denominated	17,824		5		17,819		1,838		0		19,657
Total securities held-to-maturity	$	17,824	$	5	$	17,819	$	1,838	$	0	$	19,657

Equity securities, FV-NI

	March 31, 2024			December 31, 2023
(In millions)	Fair Value			Fair Value
Equity securities, carried at fair value through net earnings:
Equity securities:
Yen-denominated		$	522		$	751
U.S. dollar-denominated		240			252
Other currencies		0			85
Total equity securities		$	762		$	1,088

Investments Classified by Contractual Maturity Date

The contractual and economic maturities of the Company's investments in fixed maturity securities at March 31, 2024, were as follows:

(In millions)	Amortized Cost (1)			Fair Value
Available-for-sale:
Due in one year or less		$	1,272		$	1,292
Due after one year through five years		6,659			7,480
Due after five years through 10 years		17,904			19,556
Due after 10 years		38,590			38,417
Mortgage- and asset-backed securities		3,169			3,385
Total fixed maturity securities available-for-sale		$	67,594		$	70,130
Held-to-maturity:
Due in one year or less		$	0		$	0
Due after one year through five years		35			36
Due after five years through 10 years		8,901			9,714
Due after 10 years		7,753			8,495
Total fixed maturity securities held-to-maturity		$	16,689		$	18,245

(1) Net of allowance for credit losses

Investment Exposures Exceeding Ten Percent Shareholders Equity

Investment exposures that individually exceeded 10% of shareholders' equity were as follows:

	March 31, 2024			December 31, 2023
(In millions)	Credit Rating	Amortized Cost	Fair Value	Credit Rating	Amortized Cost	Fair Value
Japan National Government(1)	A+	$36,641	$37,170	A+	$39,151	$40,222

(1)Japan Government Bonds (JGBs) or JGB-backed securities

Gain (Loss) on Investments

Information regarding pretax net gains and losses from investments is as follows:

	Three Months Ended March 31,
(In millions)	2024		2023
Net investment gains (losses):
Sales and redemptions:
Fixed maturity securities available-for-sale:
Gross gains from sales	$	34	$	1
Gross losses from sales	(282)		(3)
Foreign currency gains (losses)	416		59
Other investments:
Gross gains (losses) from sales and redemptions	5		0
Total sales and redemptions	173		57
Equity securities	76		(3)
Credit losses:
Fixed maturity securities held-to-maturity	0		1
Commercial mortgage and other loans	(7)		(31)
Impairment losses	0		0
Loan commitments	1		3
Reinsurance recoverables and other	5		(3)
Total credit losses	(1)		(30)
Derivatives and other:
Derivative gains (losses)	(215)		17
Foreign currency gains (losses)	918		82
Total derivatives and other	703		99
Total net investment gains (losses)	$	951	$	123

Net Effect on Shareholders' Equity of Unrealized Gains and Losses from Investment Securities

The net effect on shareholders’ equity of unrealized gains and losses from fixed maturity securities was as follows:

(In millions)	March 31, 2024			December 31, 2023
Unrealized gains (losses) on securities available-for-sale		$	2,536		$	2,601
Deferred income taxes		(1,444)			(1,462)
Shareholders’ equity, unrealized gains (losses) on fixed maturity securities		$	1,092		$	1,139

Investments Gross Unrealized Loss Aging

The following tables show the fair values and gross unrealized losses of the Company's available-for-sale investments for the periods ended March 31, 2024 and December 31, 2023, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position.

	March 31, 2024
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	141		$	4		$	59		$	1		$	82		$	3
Japan government and       agencies:
Yen-denominated		7,828			1,811			1,628			395			6,200			1,416
Municipalities:
U.S. dollar-denominated		662			49			9			0			653			49
Yen-denominated		277			59			31			1			246			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		754			48			304			4			450			44
Yen-denominated		54			12			1			0			53			12
Public utilities:
U.S. dollar-denominated		1,383			136			391			9			992			127
Yen-denominated		915			77			351			13			564			64
Sovereign and supranational:
U.S. dollar-denominated		14			4			0			0			14			4
Yen-denominated		55			7			0			0			55			7
Banks/financial institutions:
U.S. dollar-denominated		628			41			228			2			400			39
Yen-denominated		2,973			285			62			1			2,911			284
Other corporate:
U.S. dollar-denominated		6,196			724			1,254			36			4,942			688
Yen-denominated		1,747			245			355			9			1,392			236
Total		$	23,627		$	3,502		$	4,673		$	471		$	18,954		$	3,031

	December 31, 2023
	Total						Less than 12 months						12 months or longer
(In millions)	Fair Value			Unrealized Losses			Fair Value			Unrealized Losses			Fair Value			Unrealized Losses
Fixed maturity securities available-    for-sale:
U.S. government and       agencies:
U.S. dollar-denominated		$	123		$	4		$	53		$	1		$	70		$	3
Japan government and       agencies:
Yen-denominated		8,393			1,696			1,657			303			6,736			1,393
Municipalities:
U.S. dollar-denominated		703			38			31			1			672			37
Yen-denominated		301			58			34			0			267			58
Mortgage- and asset-     backed securities:
U.S. dollar-denominated		925			56			340			6			585			50
Yen-denominated		58			11			0			0			58			11
Public utilities:
U.S. dollar-denominated		1,120			114			228			4			892			110
Yen-denominated		1,028			82			444			13			584			69
Sovereign and supranational:
U.S. dollar-denominated		35			8			0			0			35			8
Yen-denominated		60			7			0			0			60			7
Banks/financial institutions:
U.S. dollar-denominated		655			51			159			4			496			47
Yen-denominated		3,673			365			186			4			3,487			361
Other corporate:
U.S. dollar-denominated		6,380			665			799			19			5,581			646
Yen-denominated		1,948			294			308			9			1,640			285
Total		$	25,402		$	3,449		$	4,239		$	364		$	21,163		$	3,085

Composition of the Carrying Value for Commercial Mortgage and Other Loans by Property Type

The following table reflects the composition of the carrying value for commercial mortgage and other loans by property type as of the periods presented.

(In millions)	March 31, 2024				December 31, 2023
	Amortized Cost		% of Total		Amortized Cost		% of Total
Commercial Mortgage and other loans:
Transitional real estate loans:
Office	$	1,768	14.0	%	$	1,807	14.1	%
Retail	335		2.7		473		3.7
Apartments/Multi-Family	2,550		20.3		2,608		20.4
Industrial	152		1.2		157		1.2
Hospitality	818		6.5		814		6.4
Other	455		3.7		255		2.0
Total transitional real estate loans	6,078		48.4		6,114		47.8
Commercial mortgage loans:
Office	356		2.8		359		2.8
Retail	254		2.0		301		2.4
Apartments/Multi-Family	583		4.6		586		4.6
Industrial	445		3.5		463		3.6
Other	15		.1		0		0.0
Total commercial mortgage loans	1,653		13.0		1,709		13.4
Middle market loans	4,586		36.4		4,677		36.5
Other loans	275		2.2		301		2.3
Total commercial mortgage and other loans	$	12,592	100.0	%	$	12,801	100.0	%
Allowance for credit losses	(232)				(274)
Total net commercial mortgage and other loans	$	12,360			$	12,527

Financing Receivable Nonaccrual

The following tables present an aging of past due and nonaccrual loans at amortized cost, before allowance for credit losses, as of the periods presented.

	March 31, 2024
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,152	$	97	$	829	$	926	$	6,078	$	829
Commercial mortgage loans	1,598		0		55		55		1,653		55
Middle market loans	4,560		0		26		26		4,586		26
Other loans	275		0		0		0		275		0
Total	$	11,585	$	97	$	910	$	1,007	$	12,592	$	910

(1) As of March 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

	December 31, 2023
(In millions)	Current		Less Than 90 Days Past Due		90 Days or More  Past Due(1)		Total Past Due		Total Loans		Nonaccrual Status
Transitional real estate loans	$	5,481	$	108	$	525	$	633	$	6,114	$	633
Commercial mortgage loans	1,676		33		0		33		1,709		0
Middle market loans	4,592		0		85		85		4,677		85
Other loans	301		0		0		0		301		0
Total	$	12,050	$	141	$	610	$	751	$	12,801	$	718

(1) As of December 31, 2023, there were no loans that were 90 days or more past due that continued to accrue interest.

Allowance for Loan Losses by Portfolio Segment

The following table presents the roll forward of the allowance for credit losses by portfolio segment for loans and by accounting classification for securities.

(In millions)	Transitional Real Estate Loans		Commercial Mortgage Loans		Middle Market Loans		Other Loans and Loan Commitments		Held-to-Maturity Securities		Available-for-Sale Securities		Total
Three Months Ended March 31, 2024:
Balance at December 31, 2023	$	(112)	$	(16)	$	(146)	$	(16)	$	(5)	$	0	$	(295)
(Addition to) release of allowance for credit losses	(2)		(3)		(3)		1		0		0		(7)
Writeoffs, net of recoveries	0		0		50		0		0		0		50
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2024	$	(114)	$	(19)	$	(99)	$	(15)	$	(5)	$	0	$	(252)
Three Months Ended March 31, 2023:
Balance at December 31, 2022	$	(54)	$	(9)	$	(129)	$	(24)	$	(7)	$	0	$	(223)
(Addition to) release of allowance for credit losses	(11)		0		(20)		3		1		0		(27)
Writeoffs, net of recoveries	0		0		0		0		0		0		0
Change in foreign exchange	0		0		0		0		0		0		0
Balance at March 31, 2023	$	(65)	$	(9)	$	(149)	$	(21)	$	(6)	$	0	$	(250)

Other Investments

The table below reflects the composition of the carrying value for other investments as of the periods presented.

(In millions)	March 31, 2024			December 31, 2023
Other investments:
Policy loans		$	203		$	214
Short-term investments (1)		3,341			1,304
Limited partnerships (2)		2,838			2,750
Real estate owned		253			227
Other		42			35
Total other investments		$	6,677		$	4,530

(1) Includes securities lending collateral

(2) Includes tax credit investments and asset classes such as private equity and real estate funds

Securities Lending Transactions Accounted for as Secured Borrowings

Details of collateral by loaned security type and remaining maturity of the agreements were as follows:

Securities Lending Transactions Accounted for as Secured Borrowings
Remaining Contractual Maturity of the Agreements
	March 31, 2024						December 31, 2023
(In millions)	Overnight and Continuous(1)		Up to 30 days		Total		Overnight and Continuous(1)		Up to 30 days		Total
Securities lending   transactions:
Fixed maturity securities:
Japan government and agencies	$	0	$	2,542	$	2,542	$	0	$	737	$	737
Public utilities	33		0		33		19		0		19
Banks/financial institutions	148		0		148		72		0		72
Other corporate	643		0		643		675		0		675
Total borrowings	$	824	$	2,542	$	3,366	$	766	$	737	$	1,503
Gross amount of recognized liabilities for securities    lending transactions					$	3,366					$	1,503

(1) The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

Variable Interest Entity, Consolidated

Investments in Variable Interest Entities

The following table presents carrying value and balance sheet caption in which the assets and liabilities of consolidated VIEs are reported.

Investments in Consolidated Variable Interest Entities

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	3,678		$	3,712
Commercial mortgage and other loans		9,947			10,150
Other investments (1)		2,443			2,381
Other assets (2)		57			55
Total assets of consolidated VIEs		$	16,125		$	16,298
Liabilities:
Other liabilities (2)		$	583		$	507
Total liabilities of consolidated VIEs		$	583		$	507

(1) Consists entirely of alternative investments in limited partnerships

(2) Consists entirely of derivatives

Variable Interest Entity, Not Consolidated

Investments in Variable Interest Entities

The table below reflects the carrying value and balance sheet caption in which the Company's investments in VIEs that are not consolidated are reported.

Investments in Variable Interest Entities Not Consolidated

(In millions)	March 31, 2024			December 31, 2023
Assets:
Fixed maturity securities, available-for-sale		$	6,486		$	6,424
Other investments (1)		395			369
Total investments in VIEs not consolidated		$	6,881		$	6,793

(1) Consists entirely of alternative investments in limited partnerships

Transitional real estate loans

Financing Receivable Credit Quality Indicators

Transitional Real Estate Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total
Loan-to-Value Ratio:
0%-59.99%	$	131	$	86	$	609	$	507	$	36	$	125	$	1,494
60%-69.99%	34		126		496		637		18		552		1,863
70%-79.99%	0		14		883		900		83		47		1,927
80% or greater	0		0		218		251		80		245		794
Total	$	165	$	226	$	2,206	$	2,295	$	217	$	969	$	6,078
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Commercial mortgage loans

Financing Receivable Credit Quality Indicators

Commercial Mortgage Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Total		Weighted-Average DSCR
Loan-to-Value Ratio:
0%-59.99%	$	0	$	33	$	0	$	309	$	45	$	983	$	1,370	2.57
60%-69.99%	0		0		0		0		0		30		30		1.73
70%-79.99%	0		0		0		0		0		120		120		1.26
80% or greater	0		0		0		0		0		133		133		0.52
Total	$	0	$	33	$	0	$	309	$	45	$	1,266	$	1,653	2.30
Weighted Average DSCR	0.00		2.58		0.00		2.92		2.26		2.14
Current-period gross   writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0

Middle market loans

Financing Receivable Credit Quality Indicators

Middle Market Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
BBB	$	0	$	17	$	45	$	123	$	54	$	64	$	77	$	380
BB	18		60		308		408		251		287		446		1,778
B	48		53		218		547		302		633		290		2,091
CCC	0		0		20		50		51		136		48		305
CC	0		0		0		0		0		10		0		10
C and lower	0		0		0		0		0		6		16		22
Total	$	66	$	130	$	591	$	1,128	$	658	$	1,136	$	877	$	4,586
Current-period gross   writeoffs:	$	0	$	0	$	0	$	27	$	0	$	23	$	0	$	50

Other loans

Financing Receivable Credit Quality Indicators

Other Loans
(In millions)	2024		2023		2022		2021		2020		Prior		Revolving Loans		Total
Credit Ratings:
A	$	0	$	22	$	94	$	0	$	0	$	0	$	0	$	116
AA	0		0		5		5		0		0		0		10
BBB	5		68		0		0		0		0		0		73
BB	0		0		76		0		0		0		0		76
Total	$	5	$	90	$	175	$	5	$	0	$	0	$	0	$	275
Current-period gross writeoffs:	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0

XML

DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The table below summarizes the balance sheet classification of the Company's derivative fair value amounts, as well as the gross asset and liability fair value amounts. The fair value amounts presented do not include income accruals. Derivative assets are included in other assets, while derivative liabilities are included in other liabilities within the Company’s consolidated balance sheets. The notional amount of derivative contracts represents the basis upon which pay or receive amounts are calculated and are not reflective of exposure or credit risk.

		March 31, 2024									December 31, 2023
(In millions)				Asset Derivatives			Liability Derivatives						Asset Derivatives			Liability Derivatives
Hedge Designation/ Derivative   Type	Notional Amount			Fair Value			Fair Value			Notional Amount			Fair Value			Fair Value
Cash flow hedges:
Foreign currency swaps - VIE		$	18		$	0		$	5		$	18		$	0		$	4
Total cash flow hedges		18			0			5			18			0			4
Fair value hedges:
Foreign currency options		0			0			0			2,158			0			0
Total fair value hedges		0			0			0			2,158			0			0
Net investment hedge:
Foreign currency forwards		2,339			202			0			2,611			179			27
Foreign currency options		0			0			0			456			0			0
Total net investment hedge		2,339			202			0			3,067			179			27
Non-qualifying strategies:
Foreign currency swaps		1,200			24			0			1,200			31			0
Foreign currency swaps - VIE		3,417			57			578			3,417			55			503
Foreign currency forwards		0			0			0			7,402			59			477
Foreign currency options		28,715			38			69			22,557			2			0
Interest rate swaps		17,230			0			483			17,230			11			419
Total non-qualifying strategies		50,562			119			1,130			51,806			158			1,399
Total derivatives		$	52,919		$	321		$	1,135		$	57,049		$	337		$	1,430

Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location

The following table presents the gains and losses on derivatives and the related hedged items in fair value hedges. The Company had no fair value hedges during the three-month period ending March 31, 2024.

Fair Value Hedging Relationships

(In millions)		Hedging Derivatives						Hedged Items
Hedging Derivatives	Hedged Items	Total Gains (Losses)		Gains (Losses) Excluded from Effectiveness Testing(1)		Gains (Losses) Included in Effectiveness Testing(2)		Gains (Losses)(2)		Net Investment Gains (Losses) Recognized for Fair Value Hedge
Three Months Ended March 31, 2023:
Foreign currency options	Fixed maturity securities	$	(39)	$	(39)	$	0	$	0	$	0
Total gains (losses)		$	(39)	$	(39)	$	0	$	0	$	0

(1) Gains (losses) excluded from effectiveness testing includes the forward point on foreign currency forwards and time value change on foreign currency options which are reported in the consolidated statements of earnings as net investment gains (losses). It also includes the change in the fair value of the interest rate swaptions related to the time value of the swaptions which is recognized as a component of other comprehensive income (loss).

(2) Gains and losses on foreign currency forwards and options and related hedged items are reported in the consolidated statements of earnings as net investment gains (losses). For interest rate swaptions and related hedged items, gains and losses included in the hedge assessment, premium amortization and time value amortization while the hedge items are still outstanding are reported within net investment income. The time value gains and losses for interest rate swaptions when the related hedged items are redeemed are reported in net investment gains (losses) consistent with the impact of the hedged item. For the three-month period ended March 31, 2023, gains and losses included in the hedge assessment on interest rate swaptions and related hedged items were immaterial.

Schedule of Interest Rate Fair Value Hedges Hedged Items

The following table shows the carrying amounts of assets designated and qualifying as hedged items in fair value hedges of interest rate risk and the related cumulative hedge adjustment included in the carrying amount. The Company had no fair value hedges of interest rate risk as of March 31, 2024 and December 31, 2023; therefore, the amounts presented in the table below are related to previous fair value hedges of interest rate risk that were discontinued.

(In millions)	Carrying Amount of the Hedged Assets/(Liabilities)(1)					Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)
		March 31, 2024		December 31, 2023		March 31, 2024		December 31, 2023
Fixed maturity securities		$	1,597	$	1,692	$	161	$	164

(1) The balance includes hedging adjustment on discontinued hedging relationships of $161 in 2024 and $164 in 2023.

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The following table summarizes the impact to earnings and other comprehensive income (loss) from all derivatives and hedging instruments.

	Three Months Ended March 31,
	2024										2023
(In millions)	Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)			Net Investment Income(1)			Net Investment Gains (Losses)				Other Comprehensive Income (Loss)(2)
Qualifying hedges:
Cash flow hedges:
Foreign currency swaps - VIE		$	0		$	(1)			$	0		$	0		$	(1)			$	1
Total cash flow hedges		0			(1)		(3)		0			0			(1)		(3)		1
Fair value hedges:
Foreign currency options					0										(39)
Total fair value hedges					0										(39)
Net investment hedge:
Non-derivative hedging          instruments					0				236						0				25
Foreign currency forwards					44				145						90				29
Foreign currency options					0				0						(3)				0
Total net investment hedge					44				381						87				54
Non-qualifying strategies:
Foreign currency swaps					1										1
Foreign currency swaps - VIE					(88)										(27)
Foreign currency forwards					17										(51)
Foreign currency options					(41)										(19)
Interest rate swaps					(147)										69
Forward bond purchase          commitment - VIE					0										(3)
Total non-qualifying strategies					(258)										(30)
Total		$	0		$	(215)			$	381		$	0		$	17			$	55

(1) Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedge item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items.

(2) Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

(3) Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2024, and $1 of losses during the three-month period ended March 31, 2023.

Offsetting Assets

Offsetting of Financial Assets and Derivative Assets

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	264		$	0		$	264		$	(38)	$	(78)		$	(148)		$	0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		264			0			264			(38)		(78)			(148)			0
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		57						57											57
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		57						57											57
Total derivative       assets		321			0			321			(38)		(78)			(148)			57
Securities lending    and similar    arrangements		3,334			0			3,334			0		0			(3,334)			0
Total		$	3,655		$	0		$	3,655		$	(38)	$	(78)		$	(3,482)		$	57

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Assets			Gross Amount Offset in Balance Sheet			Net Amount of Assets Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Received			Net Amount
Derivative   assets:
Derivative       assets subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	271		$	0		$	271		$	(85)	$	(53)		$	(130)		$	3
OTC - cleared		11			0			11			(11)		0			0			0
Total derivative       assets subject to a       master netting       agreement or       offsetting       arrangement		282			0			282			(96)		(53)			(130)			3
Derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		55						55											55
Total derivative       assets not subject       to a master netting       agreement or       offsetting       arrangement		55						55											55
Total derivative       assets		337			0			337			(96)		(53)			(130)			58
Securities lending    and similar    arrangements		1,480			0			1,480			0		0			(1,480)			0
Total		$	1,817		$	0		$	1,817		$	(96)	$	(53)		$	(1,610)		$	58

Offsetting Liabilities

Offsetting of Financial Liabilities and Derivative Liabilities

March 31, 2024
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	69		$	0		$	69		$	(38)	$	(31)		$	0		$	0
OTC - cleared		483			0			483			0		(27)			(456)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		552			0			552			(38)		(58)			(456)			0
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		583						583											583
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		583						583											583
Total derivative       liabilities		1,135			0			1,135			(38)		(58)			(456)			583
Securities lending    and similar    arrangements		3,366			0			3,366			(3,334)		0			0			32
Total		$	4,501		$	0		$	4,501		$	(3,372)	$	(58)		$	(456)		$	615

December 31, 2023
										Gross Amounts Not Offset in Balance Sheet
(In millions)	Gross Amount of Recognized Liabilities			Gross Amount Offset in Balance Sheet			Net Amount of Liabilities Presented  in Balance Sheet			Financial Instruments			Securities Collateral		Cash Collateral Pledged			Net Amount
Derivative   liabilities:
Derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement
OTC - bilateral		$	504		$	0		$	504		$	(85)	$	(381)		$	(37)		$	1
OTC - cleared		419			0			419			(11)		(19)			(389)			0
Total derivative       liabilities subject       to a master netting       agreement or       offsetting       arrangement		923			0			923			(96)		(400)			(426)			1
Derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement
OTC - bilateral		507						507											507
Total derivative       liabilities not       subject to a       master netting       agreement or       offsetting       arrangement		507						507											507
Total derivative       liabilities		1,430			0			1,430			(96)		(400)			(426)			508
Securities lending    and similar    arrangements		1,503			0			1,503			(1,480)		0			0			23
Total		$	2,933		$	0		$	2,933		$	(1,576)	$	(400)		$	(426)		$	531

XML

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Hierarchy, Assets and Liabilities Measured on Recurring Basis

The following tables present the fair value hierarchy levels of the Company's assets and liabilities that are measured and carried at fair value on a recurring basis.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	19,976		$	838		$	0		$	20,814
Municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities		0			6,806			507			7,313
Sovereign and supranational		0			462			28			490
Banks/financial institutions		0			8,825			74			8,899
Other corporate		0			26,569			450			27,019
Total fixed maturity securities		19,976			48,236			1,918			70,130
Equity securities		603			0			159			762
Other investments		3,341			0			0			3,341
Cash and cash equivalents		5,098			0			0			5,098
Other assets:
Foreign currency swaps		0			81			0			81
Foreign currency forwards		0			202			0			202
Foreign currency options		0			38			0			38
Total other assets		0			321			0			321
Total assets		$	29,018		$	48,557		$	2,077		$	79,652
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	583		$	0		$	583
Foreign currency options		0			69			0			69
Interest rate swaps		0			483			0			483
Total liabilities		$	0		$	1,135		$	0		$	1,135

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities available-for-sale, carried at   fair value:
Fixed maturity securities:
Government and agencies		$	21,700		$	900		$	0		$	22,600
Municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities		0			7,339			253			7,592
Sovereign and supranational		0			507			30			537
Banks/financial institutions		0			8,757			78			8,835
Other corporate		0			27,694			648			28,342
Total fixed maturity securities		21,700			49,809			1,781			73,290
Equity securities		840			0			248			1,088
Other investments		1,304			0			0			1,304
Cash and cash equivalents		4,306			0			0			4,306
Other assets:
Foreign currency swaps		0			86			0			86
Foreign currency forwards		0			238			0			238
Foreign currency options		0			2			0			2
Interest rate swaps		0			11			0			11
Total other assets		0			337			0			337
Total assets		$	28,150		$	50,146		$	2,029		$	80,325
Liabilities:
Other liabilities:
Foreign currency swaps		$	0		$	507		$	0		$	507
Foreign currency forwards		0			504			0			504
Interest rate swaps		0			419			0			419
Total liabilities		$	0		$	1,430		$	0		$	1,430

Fair Value Hierarchy Levels of Assets and Liabilities Carried at Cost or Amortized Cost

The following tables present the carrying amount and fair value categorized by fair value hierarchy level for the Company's financial instruments that are not carried at fair value.

	March 31, 2024
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,     carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	16,000		$	17,319		$	155		$	0		$	17,474
Municipalities		248			0			285			0			285
Public utilities		33			0			36			0			36
Sovereign and    supranational		391			0			431			0			431
Other corporate		17			0			19			0			19
Commercial mortgage and     other loans		12,360			0			0			12,017			12,017
Other investments (1)		42			0			42			0			42
Total assets		$	29,091		$	17,319		$	968		$	12,017		$	30,304
Liabilities:
Other policyholders’ funds		$	5,831		$	0		$	0		$	5,750		$	5,750
Notes payable    (excluding leases)		7,799			0			6,762			704			7,466
Total liabilities		$	13,630		$	0		$	6,762		$	6,454		$	13,216

(1) Excludes policy loans of $203, equity method investments of $2,838, and REO of $253, at carrying value.

	December 31, 2023
(In millions)	Carrying Value			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Assets:
Securities held-to-maturity,    carried at amortized cost:
Fixed maturity securities:
Government and agencies		$	17,083		$	18,662		$	167		$	0		$	18,829
Municipalities		266			0			307			0			307
Public utilities		34			0			38			0			38
Sovereign and    supranational		418			0			462			0			462
Other corporate		18			0			21			0			21
Commercial mortgage and     other loans		12,527			0			0			12,217			12,217
Other investments (1)		35			0			35			0			35
Total assets		$	30,381		$	18,662		$	1,030		$	12,217		$	31,909
Liabilities:
Other policyholders’ funds		$	6,169		$	0		$	0		$	6,080		$	6,080
Notes payable    (excluding leases)		7,240			0			6,178			752			6,930
Total liabilities		$	13,409		$	0		$	6,178		$	6,832		$	13,010

(1) Excludes policy loans of $214, equity method investments of $2,750, and REO of $227, at carrying value.

Fair Value Assets Available-For-Sale Securities Carried Primary Pricing Sources

The following tables present the pricing sources for the fair values of the Company's fixed maturity and equity securities.

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	19,976		$	505		$	0		$	20,481
Internal		0			333			0			333
Total government and agencies		19,976			838			0			20,814
Municipalities:
Third-party pricing vendor		0			1,943			0			1,943
Internal		0			267			0			267
Total municipalities		0			2,210			0			2,210
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,420			0			2,420
Internal		0			27			40			67
Broker/other		0			79			819			898
Total mortgage- and asset-backed securities		0			2,526			859			3,385
Public utilities:
Third-party pricing vendor		0			3,680			0			3,680
Internal		0			3,126			0			3,126
Broker/other		0			0			507			507
Total public utilities		0			6,806			507			7,313
Sovereign and supranational:
Third-party pricing vendor		0			125			0			125
Internal		0			337			0			337
Broker/other		0			0			28			28
Total sovereign and supranational		0			462			28			490
Banks/financial institutions:
Third-party pricing vendor		0			4,703			0			4,703
Internal		0			4,122			65			4,187
Broker/other		0			0			9			9
Total banks/financial institutions		0			8,825			74			8,899
Other corporate:
Third-party pricing vendor		0			21,282			0			21,282
Internal		0			5,277			249			5,526
Broker/other		0			10			201			211
Total other corporate		0			26,569			450			27,019
Total securities available-for-sale		$	19,976		$	48,236		$	1,918		$	70,130
Equity securities, carried at fair value:
Third-party pricing vendor		$	603		$	0		$	0		$	603
Broker/other		0			0			159			159
Total equity securities		$	603		$	0		$	159		$	762

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair Value
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	21,692		$	808		$	0		$	22,500
Internal		0			60			0			60
Broker/other		8			32			0			40
Total government and agencies		21,700			900			0			22,600
Municipalities:
Third-party pricing vendor		0			1,426			0			1,426
Internal		0			256			0			256
Broker/other		0			616			0			616
Total municipalities		0			2,298			0			2,298
Mortgage- and asset-backed securities:
Third-party pricing vendor		0			2,277			0			2,277
Internal		0			27			105			132
Broker/other		0			10			667			677
Total mortgage- and asset-backed securities		0			2,314			772			3,086
Public utilities:
Third-party pricing vendor		0			4,570			0			4,570
Internal		0			2,677			0			2,677
Broker/other		0			92			253			345
Total public utilities		0			7,339			253			7,592
Sovereign and supranational:
Third-party pricing vendor		0			118			0			118
Internal		0			330			0			330
Broker/other		0			59			30			89
Total sovereign and supranational		0			507			30			537
Banks/financial institutions:
Third-party pricing vendor		0			5,085			0			5,085
Internal		0			3,008			69			3,077
Broker/other		0			664			9			673
Total banks/financial institutions		0			8,757			78			8,835
Other corporate:
Third-party pricing vendor		0			18,088			4			18,092
Internal		0			4,210			230			4,440
Broker/other		0			5,396			414			5,810
Total other corporate		0			27,694			648			28,342
Total securities available-for-sale		$	21,700		$	49,809		$	1,781		$	73,290
Equity securities, carried at fair value:
Third-party pricing vendor		$	800		$	0		$	0		$	800
Internal		0			0			216			216
Broker/other		40			0			32			72
Total equity securities		$	840		$	0		$	248		$	1,088

Fair Value Assets Held-To-Maturity Securities Primary Pricing Sources

	March 31, 2024
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	17,319		$	155		$	0		$	17,474
Total government and agencies		17,319			155			0			17,474
Municipalities:
Third-party pricing vendor		0			285			0			285
Total municipalities		0			285			0			285
Public utilities:
Third-party pricing vendor		0			36			0			36
Total public utilities		0			36			0			36
Sovereign and supranational:
Third-party pricing vendor		0			213			0			213
Internal		0			218			0			218
Total sovereign and supranational		0			431			0			431
Other corporate:
Third-party pricing vendor		0			19			0			19
Total other corporate		0			19			0			19
Total securities held-to-maturity		$	17,319		$	926		$	0		$	18,245

	December 31, 2023
(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Total Fair  Value
Securities held-to-maturity, carried at amortized cost:
Fixed maturity securities:
Government and agencies:
Third-party pricing vendor		$	18,662		$	167		$	0		$	18,829
Total government and agencies		18,662			167			0			18,829
Municipalities:
Third-party pricing vendor		0			307			0			307
Total municipalities		0			307			0			307
Public utilities:
Third-party pricing vendor		0			38			0			38
Total public utilities		0			38			0			38
Sovereign and supranational:
Third-party pricing vendor		0			226			0			226
Internal		0			236			0			236
Total sovereign and supranational		0			462			0			462
Other corporate:
Third-party pricing vendor		0			21			0			21
Total other corporate		0			21			0			21
Total securities held-to-maturity		$	18,662		$	995		$	0		$	19,657

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The following tables present the changes in fair value of the Company's investments carried at fair value classified as Level 3.

Three Months Ended March 31, 2024
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	772	$	253	$	30	$	78	$	648	$	248	$	2,029
Net investment gains (losses) included   in earnings	1		0		0		0		0		(5)		(4)
Unrealized gains (losses) included in   other comprehensive income (loss)	(4)		(10)		(2)		(4)		1		0		(19)
Purchases, issuances, sales   and settlements:
Purchases	118		60		0		5		37		0		220
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(28)		(22)		0		(5)		(3)		(84)		(142)
Transfers into Level 3	0		226		0		0		0		0		226
Transfers out of Level 3	0		0		0		0		(233)		0		(233)
Balance, end of period	$	859	$	507	$	28	$	74	$	450	$	159	$	2,077
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	1	$	0	$	0	$	0	$	0	$	(3)	$	(2)

Three Months Ended March 31, 2023
	Fixed Maturity Securities										Equity Securities
(In millions)	Mortgage- and Asset- Backed Securities		Public Utilities		Sovereign and Supranational		Banks/ Financial Institutions		Other Corporate				Total
Balance, beginning of period	$	343	$	497	$	37	$	159	$	742	$	209	$	1,987
Net investment gains (losses) included   in earnings	0		0		0		0		0		2		2
Unrealized gains (losses) included in   other comprehensive income (loss)	3		10		0		2		30		0		45
Purchases, issuances, sales and   settlements:
Purchases	192		0		0		0		75		10		277
Issuances	0		0		0		0		0		0		0
Sales	0		0		0		0		0		0		0
Settlements	(120)		(7)		0		0		(2)		0		(129)
Transfers into Level 3	0		18		0		0		0		0		18
Transfers out of Level 3	0		(168)		0		0		(92)		0		(260)
Balance, end of period	$	418	$	350	$	37	$	161	$	753	$	221	$	1,940
Changes in unrealized gains   (losses) relating to Level 3 assets   and liabilities still held at the end   of the period included in earnings	$	0	$	0	$	0	$	0	$	0	$	3	$	3

Fair Value Measurement Inputs and Valuation Techniques

Level 3 Significant Unobservable Input Sensitivity

The following tables summarize the significant unobservable inputs used in the valuation of the Company's Level 3 investments carried at fair value. Included in the tables are the inputs or range of possible inputs that have an effect on the overall valuation of the financial instruments.

March 31, 2024
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	859	Consensus pricing	Offered quotes	85.28	-	105.35	(a)	99.24
Public utilities		507		Discounted cash flow	Credit spreads	175 bps	-	225 bps	(c)	208 bps
Sovereign and supranational		28		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		74		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		450		Discounted cash flow	Credit spreads	69 bps	-	388 bps	(c)	183 bps
Equity securities		159		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,077

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable.

December 31, 2023
(In millions)	Fair Value			Valuation Technique(s)	Unobservable Input	Range				Weighted Average
Assets:
Securities available-for-sale, carried at fair value:
Fixed maturity securities:
Mortgage- and asset-backed securities		$	772	Consensus pricing	Offered quotes	84.81	-	105.89	(a)	99.39
Public utilities		253		Consensus pricing	Offered quotes	94.34	-	102.99	(a)	96.46
Sovereign and supranational		30		Consensus pricing	Offered quotes	N/A			(b)	N/A
Banks/financial institutions		78		Discounted cash flow	Credit spreads	N/A			(b)	N/A
Other corporate		648		Discounted cash flow	Credit spreads	69 bps	-	423 bps	(c)	206 bps
Equity securities		248		Adjusted cost	Private financials	N/A			(d)	N/A
Total assets		$	2,029

(a) Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

(b) Category represents a single security; range not applicable.

(c) Actual or equivalent credit spreads in basis points.

(d) Prices do not utilize credit spreads; therefore, range is not applicable

XML

DEFERRED POLICY ACQUISITION COSTS (Tables)

3 Months Ended

Mar. 31, 2024

Insurance [Abstract]

Schedule Of Deferred Policy Acquisition Costs

The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type.

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132
Capitalization	72		29		9		0		32		29		39		19		4		19		2		254
Amortization expense	(49)		(25)		(8)		(1)		(36)		(29)		(38)		(18)		(4)		(7)		0		(215)
Foreign currency translation and   other	(189)		(129)		(32)		(2)		0		0		0		0		0		0		0		(352)
Balance at March 31, 2024	$	2,805	$	1,916	$	460	$	53	$	913	$	625	$	1,337	$	437	$	86	$	184	$	3	$	8,819

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other		Total
Deferred policy acquisition costs:
Balance at December 31, 2022	$	3,035	$	2,161	$	525	$	55	$	904	$	613	$	1,304	$	418	$	88	$	135	$	1	$	9,239
Capitalization	317		123		33		8		151		125		173		84		10		61		1		1,086
Amortization expense	(184)		(105)		(34)		(3)		(138)		(113)		(141)		(66)		(12)		(24)		4		(816)
Foreign currency translation and   other	(197)		(138)		(33)		(4)		0		0		0		0		0		0		(5)		(377)
Balance at December 31, 2023	$	2,971	$	2,041	$	491	$	56	$	917	$	625	$	1,336	$	436	$	86	$	172	$	1	$	9,132

XML

POLICY LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2024

Insurance Loss Reserves [Abstract]

Schedule of Changes in Present Value of Expected Net Premiums and Expected Future Policy Benefits

The following tables present the changes in the present value of expected future net premiums and the present value of expected future policy benefits by reporting segment and disaggregated by product type. The present value of expected future net premiums and the present value of expected future policy benefits are presented gross of internal and external ceded reinsurance.

	March 31, 2024
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Beginning balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(46)		(52)		(19)		(5)		(18)		(10)		(48)		(14)		(4)		(8)		2
Adjusted beginning of period balance	16,406		13,988		6,239		1,064		2,612		1,728		4,368		1,179		213		901		274
Issuances	229		103		58		5		111		121		221		95		18		66		147
Interest accrual	97		77		28		4		26		16		43		11		2		9		3
Net premiums collected (1)	(369)		(290)		(226)		(26)		(117)		(99)		(139)		(58)		(10)		(37)		(8)
Foreign currency translation	(1,041)		(888)		(392)		(66)		0		0		0		0		0		0		0
Other	0		0		0		0		0		(1)		0		(1)		(1)		1		(1)
Ending balance at original discount rate	15,322		12,990		5,707		981		2,632		1,765		4,493		1,226		222		940		415
Effect of changes in discount rate assumptions	895		535		194		14		(173)		(99)		(412)		(99)		(14)		(66)		6
Balance at March 31, 2024	$	16,217	$	13,525	$	5,901	$	995	$	2,459	$	1,666	$	4,081	$	1,127	$	208	$	874	$	421
Present value of expected future policy benefits:
Balance at December 31, 2023	$	50,161	$	25,257	$	29,731	$	5,178	$	3,109	$	2,422	$	11,290	$	1,943	$	478	$	1,764	$	798
Beginning balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in cash flow assumptions	0		0		0		0		0		0		0		0		0		0		0
Effect of actual variances from expected    experience	(62)		(59)		(20)		(8)		(21)		(17)		(60)		(18)		(5)		(11)		2
Adjusted beginning of period balance	43,564		24,964		30,236		5,436		3,281		2,524		12,060		2,058		501		1,960		771
Issuances	232		105		59		7		115		128		233		99		16		70		151
Interest accrual	343		142		146		23		32		24		128		20		5		19		10
Benefit payments	(682)		(246)		(516)		(55)		(125)		(112)		(228)		(76)		(14)		(29)		(17)
Foreign currency translation	(2,757)		(1,582)		(1,909)		(345)		0		0		0		0		0		0		0
Other	0		0		0		0		0		0		1		0		1		1		0
Ending balance at original discount rate	40,700		23,383		28,016		5,066		3,303		2,564		12,194		2,101		509		2,021		915
Effect of changes in discount rate assumptions	5,689		(52)		(767)		(294)		(233)		(141)		(1,092)		(163)		(35)		(246)		15
Balance at March 31, 2024	46,389		23,331		27,249		4,772		3,070		2,423		11,102		1,938		474		1,775		930
Net liability for future policy benefits	30,172		9,806		21,348		3,777		611		757		7,021		811		266		901		509
Less: reinsurance recoverable	3,829		1,407		0		0		0		0		0		0		0		15		2
Net liability for future policy benefits after   reinsurance recoverable	$	26,343	$	8,399	$	21,348	$	3,777	$	611	$	757	$	7,021	$	811	$	266	$	886	$	507

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

	December 31, 2023
	Aflac Japan								Aflac U.S.
(In millions)	Cancer		Medical and Other Health		Life Insurance		Other		Accident		Disability		Critical Care		Hospital Indemnity		Dental/Vision		Life Insurance		Other
Present value of expected future net premiums:
Balance at December 31, 2022	$	19,298	$	16,714	$	7,485	$	1,256	$	2,534	$	1,635	$	4,486	$	1,220	$	211	$	724	$	110
Beginning balance at original discount rate	18,221		16,195		7,284		1,242		2,760		1,775		5,050		1,365		231		799		118
Effect of changes in cash flow assumptions	(165)		(470)		43		(12)		(16)		(51)		(494)		(142)		(9)		61		(9)
Effect of actual variances from expected    experience	(315)		(137)		(42)		(15)		(58)		(29)		(223)		(73)		(17)		(25)		(2)
Adjusted beginning of period balance	17,741		15,588		7,285		1,215		2,686		1,695		4,333		1,150		205		835		107
Issuances	1,034		418		335		26		323		376		493		249		44		181		169
Interest accrual	412		334		124		20		102		62		179		45		8		31		6
Net premiums collected (1)	(1,564)		(1,261)		(1,017)		(112)		(473)		(390)		(580)		(247)		(39)		(137)		(17)
Foreign currency translation	(1,170)		(1,038)		(469)		(80)		0		0		0		0		0		0		0
Other	(1)		(1)		0		0		(8)		(5)		(9)		(4)		(1)		(1)		7
Ending balance at original discount rate	16,452		14,040		6,258		1,069		2,630		1,738		4,416		1,193		217		909		272
Effect of changes in discount rate assumptions	1,057		657		230		19		(142)		(86)		(342)		(86)		(11)		(56)		5
Balance at December 31, 2023	$	17,509	$	14,697	$	6,488	$	1,088	$	2,488	$	1,652	$	4,074	$	1,107	$	206	$	853	$	277
Present value of expected future policy benefits:
Balance at December 31, 2022	$	54,766	$	27,419	$	31,954	$	5,582	$	3,098	$	2,445	$	11,489	$	2,074	$	488	$	1,526	$	622
Beginning balance at original discount rate	47,677		27,566		32,800		5,940		3,391		2,636		12,846		2,300		532		1,778		624
Effect of changes in cash flow assumptions	(147)		(507)		65		(27)		(11)		(59)		(592)		(194)		(14)		72		(13)
Effect of actual variances from expected    experience	(385)		(154)		(51)		(15)		(75)		(59)		(271)		(99)		(22)		(32)		(4)
Adjusted beginning of period balance	47,145		26,905		32,814		5,898		3,305		2,518		11,983		2,007		496		1,818		607
Issuances	1,059		432		341		32		331		392		505		258		46		185		169
Interest accrual	1,473		608		625		100		127		96		524		84		21		68		33
Benefit payments	(2,987)		(1,153)		(1,415)		(206)		(464)		(465)		(893)		(274)		(59)		(105)		(48)
Foreign currency translation	(3,064)		(1,769)		(2,109)		(380)		0		0		0		0		0		0		0
Other	0		0		0		0		3		0		1		1		2		5		8
Ending balance at original discount rate	43,626		25,023		30,256		5,444		3,302		2,541		12,120		2,076		506		1,971		769
Effect of changes in discount rate assumptions	6,535		234		(525)		(266)		(193)		(119)		(830)		(133)		(28)		(207)		29
Balance at December 31, 2023	50,161		25,257		29,731		5,178		3,109		2,422		11,290		1,943		478		1,764		798
Net liability for future policy benefits	32,652		10,560		23,243		4,090		621		770		7,216		836		272		911		521
Less: reinsurance recoverable	4,135		1,521		0		0		0		0		0		0		0		15		0
Net liability for future policy benefits after    reinsurance recoverable	$	28,517	$	9,039	$	23,243	$	4,090	$	621	$	770	$	7,216	$	836	$	272	$	896	$	521

(1) Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

Schedule of Weighted-Average Interest Rate and Liability for Future Policy Benefit

The following tables present the weighted-average interest rates and weighted-average liability duration (calculated using the original discount rate) by reporting segment and disaggregated by product type.

	March 31, 2024
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.5 %	2.1 %	1.8 %	3.9 %	4.3 %	4.6 %	4.5 %	4.3 %	3.8 %	5.4 %
Weighted-average interest, current discount rate (1)	2.0 %	2.5 %	1.9 %	2.3 %	5.3 %	5.2 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.0	24.7	16.3	17.1	8.0	5.6	11.2	9.3	7.9	13.8	9.2

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

	December 31, 2023
	Aflac Japan				Aflac U.S.
	Cancer	Medical and Other Health	Life Insurance	Other	Accident	Disability	Critical Care	Hospital Indemnity	Dental/Vision	Life Insurance	Other
Weighted-average interest, original discount rate (1)	3.9 %	2.6 %	2.1 %	1.8 %	3.9 %	4.2 %	4.6 %	4.4 %	4.3 %	3.7 %	5.4 %
Weighted-average interest, current discount rate (1)	1.8 %	2.3 %	1.7 %	2.1 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %	5.3 %
Weighted-average liability duration (years)	13.1	24.9	16.3	17.3	8.1	5.6	11.3	9.3	7.9	13.6	9.4

(1) The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

Reconciliation of Future Policy Benefits

The following table presents a reconciliation of the disaggregated rollforwards above to the ending future policy benefits presented in the consolidated balance sheets. The deferred profit liability for limited-payment contracts and the deferred reinsurance gain liability are presented together with the liability for future policy benefits in the consolidated balance sheets and have been included as reconciling items in the table below.

(In millions)	March 31, 2024			December 31, 2023
Balances included in future policy benefits rollforward:
Aflac Japan
Cancer		$	30,172		$	32,652
Medical and other health		9,806			10,560
Life insurance		21,348			23,243
Other		3,777			4,090
Aflac U.S.
Accident		611			621
Disability		757			770
Critical care		7,021			7,216
Hospital indemnity		811			836
Dental/vision		266			272
Life insurance		901			911
Other		509			521
Corporate and other		3,842			4,225
Deferred profit liability		1,734			1,806
Deferred reinsurance gain liability		910			1,012
Intercompany eliminations (1)		(4,598)			(5,017)
Total		$	77,867		$	83,718

(1) Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 for additional details.

Summary of Net Earned Premiums Recognized

The following table summarizes the amount of net earned premiums recognized in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Net earned premiums:
Aflac Japan
Cancer	$	878	$	1,132
Medical and other health	605		689
Life insurance	339		399
Other	34		39
Aflac U.S.
Accident	325		329
Disability	333		309
Critical care	444		443
Hospital indemnity	185		184
Dental/vision	59		53
Life insurance	138		115
Other	20		10
Corporate and other	165		90
Reinsurance ceded	(69)		(104)
Total	$	3,456	$	3,688

Summary of Interest Expense Related to Insurance Contracts Recognized

The following table summarizes the amount of interest expense related to insurance contracts recognized in total benefits and claims, net in the consolidated statements of earnings by reporting segment and disaggregated by product type.

	Three Months Ended March 31,
(In millions)	2024		2023
Interest expense:
Aflac Japan
Cancer	$	246	$	285
Medical and other health	65		71
Life insurance	118		133
Other	19		22
Aflac U.S.
Accident	6		6
Disability	8		8
Critical care	85		87
Hospital indemnity	9		10
Dental/vision	3		3
Life insurance	10		9
Other	7		7
Total	$	576	$	641

Summary of Undiscounted and Discounted Expected Future Gross Premiums and Future Benefits and Expenses

The following tables summarize the amount of undiscounted expected future gross premiums and expected future policy benefits and expenses and discounted (discounted at the current period discount rate) expected future gross premiums and expected future policy benefits and expenses by reporting segment and disaggregated by product type. These tables are presented gross of internal and external ceded reinsurance. Future gross premiums represent the expected amount of future premiums to be received. For limited-payment policies, the premiums are collected over a shorter period than the policy term over which benefits are provided. As a result, once the policy reaches premium paid-up status, the future gross premiums can be significantly less than the future benefit payments. Further, benefits and expenses are generally greater in the later years of a policy. These are the primary factors that result in future gross premiums lower than future benefit and expense payments for certain lines of business of the Company.

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Undiscounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	55,096		$	61,876		$	59,169		$	66,427
Medical and other health		35,735			37,277			38,583			39,884
Life insurance		11,637			39,439			12,677			42,541
Other		1,646			6,923			1,781			7,448
Aflac U.S.
Accident		9,097			4,551			9,095			4,548
Disability		5,819			3,210			5,776			3,177
Critical care		20,008			20,712			19,886			20,626
Hospital indemnity		4,985			3,058			4,922			3,025
Dental/vision		1,161			729			1,162			726
Life insurance		2,824			3,367			2,719			3,260
Other		1,077			1,634			724			1,396
Total		$	149,085		$	182,776		$	156,494		$	193,058

	March 31, 2024						December 31, 2023
(In millions)	Gross Premiums			Benefits and Expenses			Gross Premiums			Benefits and Expenses
Discounted expected future gross premiums   and expected future policy benefits and expenses:
Aflac Japan
Cancer		$	44,795		$	46,389		$	48,363		$	50,161
Medical and other health		28,312			23,331			30,757			25,257
Life insurance		10,274			27,249			11,240			29,731
Other		1,391			4,772			1,512			5,178
Aflac U.S.
Accident		6,293			3,070			6,369			3,109
Disability		4,476			2,423			4,488			2,422
Critical care		12,295			11,102			12,417			11,290
Hospital indemnity		3,425			1,938			3,419			1,943
Dental/vision		794			474			807			478
Life insurance		1,963			1,775			1,914			1,764
Other		673			930			467			798
Total		$	114,691		$	123,453		$	121,753		$	132,131

Schedule of Changes in Other Policyholders' Funds

The following table presents the changes in other policyholders’ funds.

(In millions)	March 31, 2024		December 31, 2023
Other policyholders' funds:
Fixed annuities account balance, beginning of period (1)	$	5,939	$	6,423
Premiums received	29		126
Transfers from WAYS conversions	61		229
Surrenders and withdrawals	(18)		(59)
Benefit payments	(110)		(419)
Interest credited	13		53
Foreign currency translation and other	(376)		(414)
Fixed annuities account balance, end of period	5,538		5,939
Other deposit type reserves	293		230
Total	$	5,831	$	6,169

(1) Aflac Japan fixed annuities

Schedule of Other Policyholders' Funds by Guaranteed Crediting Rates

The following table presents other policyholders’ funds balances by range of guaranteed crediting rates.

	March 31, 2024			December 31, 2023
(In millions)	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value	Range of Guaranteed Minimum Crediting Rates (2)	At Guaranteed Minimum	Cash Surrender Value
Fixed annuities (1)	0.5% - 2.2%	$5,538	$5,457	0.5% - 2.3%	$5,939	$5,850

(1) Aflac Japan fixed annuities

(2) Weighted-average crediting rate of 1.5% at March 31, 2024 and December 31, 2023.

XML

REINSURANCE (Tables)

3 Months Ended

Mar. 31, 2024

Reinsurance Disclosures [Abstract]

Effects of Reinsurance

The following table reconciles direct earned premiums, direct benefits and claims, excluding reserve remeasurement gains and losses, and reserve remeasurement gains and losses to net amounts after the effect of reinsurance.

	Three Months Ended March 31,
(In millions)	2024		2023
Direct earned premiums	$	3,482		$	3,738
Ceded to other companies:
Ceded Aflac Japan closed blocks	(34)			(82)
Other	(35)			(25)
Assumed from other companies:
Retrocession activities	29			34
Other	14			23
Net earned premiums	$	3,456		$	3,688
Direct benefits and claims, excluding reserve remeasurement	$	2,082		$	2,256
Ceded benefits and change in reserves for future benefits:
Ceded Aflac Japan closed blocks	(18)			(77)
Other	(15)			(27)
Assumed from other companies:
Retrocession activities	13			41
Other	4			10
Benefits and claims, excluding reserve remeasurement	$	2,066		$	2,203
Direct reserve remeasurement (gains) losses	$	(57)		$	(53)
Ceded reserve remeasurement gains (losses)	1			0
Assumed reserve remeasurement (gains) losses	0			0
Reserve remeasurement (gains) losses	$	(56)		$	(53)
Total benefits and claims, net	$	2,010		$	2,150

XML

NOTES PAYABLE AND LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

A summary of notes payable and lease obligations follows:

(In millions)	March 31, 2024			December 31, 2023
1.125% senior sustainability notes due March 2026		$	398		$	398
2.875% senior notes due October 2026		299			299
3.60% senior notes due April 2030		993			993
6.90% senior notes due December 2039		221			221
6.45% senior notes due August 2040		254			254
4.00% senior notes due October 2046		394			394
4.750% senior notes due January 2049		542			542
Yen-denominated senior notes and subordinated debentures:
.300% senior notes due September 2025 (principal amount ¥12.4 billion)		82			87
.932% senior notes due January 2027 (principal amount ¥60.0 billion)		395			422
1.048% senior notes due March 2029 (principal amount ¥13.0 billion)		86			0
1.075% senior notes due September 2029 (principal amount ¥33.4 billion)		220			234
.500% senior notes due December 2029 (principal amount ¥12.6 billion)		83			88
.550% senior notes due March 2030 (principal amount ¥13.3 billion)		87			93
1.159% senior notes due October 2030 (principal amount ¥29.3 billion)		192			206
1.412% senior notes due March 2031 (principal amount ¥27.9 billion)		184			0
.633% senior notes due April 2031 (principal amount ¥30.0 billion)		197			211
.843% senior notes due December 2031 (principal amount ¥9.3 billion)		61			65
.750% senior notes due March 2032 (principal amount ¥20.7 billion)		136			145
1.320% senior notes due December 2032 (principal amount ¥21.1 billion)		139			148
.844% senior notes due April 2033 (principal amount ¥12.0 billion)		79			84
1.488% senior notes due October 2033 (principal amount ¥15.2 billion)		100			106
1.682% senior notes due March 2034 (principal amount ¥7.7 billion)		51			0
1.600% senior notes due March 2034 (principal amount ¥18.3 billion)		122			0
.934% senior notes due December 2034 (principal amount ¥9.8 billion)		64			69
.830% senior notes due March 2035 (principal amount ¥10.6 billion)		69			74
1.740% senior notes due March 2036 (principal amount ¥15.0 billion)		100			0
1.039% senior notes due April 2036 (principal amount ¥10.0 billion)		65			70
1.594% senior notes due September 2037 (principal amount ¥6.5 billion)		43			45
1.750% senior notes due October 2038 (principal amount ¥8.9 billion)		58			62
1.920% senior notes due March 2039 (principal amount ¥16.5 billion)		110			0
1.122% senior notes due December 2039 (principal amount ¥6.3 billion)		41			44
1.264% senior notes due April 2041 (principal amount ¥10.0 billion)		65			70
2.160% senior notes due March 2044 (principal amount ¥5.7 billion)		38			0
2.108% subordinated debentures due October 2047 (principal amount ¥60.0 billion)		392			419
.963% subordinated bonds due April 2049 (principal amount ¥30.0 billion) (1)		198			211
1.560% senior notes due April 2051 (principal amount ¥20.0 billion)		131			140
2.144% senior notes due September 2052 (principal amount ¥12.0 billion)		79			84
1.958% subordinated bonds due December 2053 (principal amount ¥30.0 billion)		197			210
2.400% senior notes due March 2054 (principal amount ¥19.5 billion)		130			0
Yen-denominated loans:
Variable interest rate loan due August 2027 (.38% in 2024 and .35% in 2023,   principal amount ¥11.7 billion)		77			82
Variable interest rate loan due August 2029 (.48% in 2024 and .45% in 2023,   principal amount ¥25.3 billion)		166			178
Variable interest rate loan due August 2032 (.63% in 2024 and .60% in 2023,   principal amount ¥70.0 billion)		461			492
Finance lease obligations payable through 2030		6			6
Operating lease obligations payable through 2049		107			118
Total notes payable and lease obligations		$	7,912		$	7,364

(1) Redeemed in April 2024

Amounts in the table above are reported net of debt issuance costs and issuance premiums or discounts, if applicable, that are being amortized over the life of the notes.

Schedule of Line of Credit Facilities

A summary of the Company's lines of credit as of March 31, 2024 follows:

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
Aflac Incorporated and Aflac	uncommitted bilateral	364 days	December 6, 2024	$100 million	$0 million	The rate quoted by the bank and agreed upon at the time of borrowing	Up to 3 months	None	General corporate purposes
Aflac Incorporated	unsecured revolving	5 years	May 9, 2027, or the date commitments are terminated pursuant to an event of default	¥100.0 billion	¥0.0 billion	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period	No later than May 10, 2027	.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	unsecured revolving	5 years	November 15, 2027, or the date commitments are terminated pursuant to an event of default	$1.0 billion	$0.0 billion	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar denominated borrowings or TIBOR for Japanese yen denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin	No later than November 15, 2027	.08% to .20%, depending on the Parent Company's debt ratings as of the date of determination	General corporate purposes, including a capital contingency plan for the operations of the Parent Company
Aflac Incorporated and Aflac	uncommitted bilateral	None specified	None specified	$50 million	$0 million	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%	Up to 3 months	None	General corporate purposes
Aflac(1)	uncommitted revolving	364 days	December 2, 2024	$250 million	$50 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than December 3, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 1)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac Incorporated(1) (Tranche 2)	uncommitted revolving	364 days	November 25, 2024	¥50.0 billion	¥0.0 billion	Three-month yen TIBOR plus 75 basis points per annum	No later than November 26, 2024	None	General corporate purposes
Aflac New York(1),(2)	uncommitted revolving	364 days	April 8, 2024	$25 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than April 9, 2024	None	General corporate purposes
CAIC(1)	uncommitted revolving	364 days	March 21, 2025	$15 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes

(1) Intercompany credit agreement

(2) Renewed in April 2024 with an expiration date of April 8, 2025

(continued)

Borrower(s)	Type	Term	Expiration Date	Capacity	Amount Outstanding	Interest Rate on Borrowed Amount	Maturity Period	Commitment Fee	Business Purpose
TOIC(1)	uncommitted revolving	364 days	March 21, 2025	$0.3 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than March 24, 2025	None	General corporate purposes
Hatch Healthcare K.K.(1)	uncommitted revolving	364 days	January 2, 2025	¥900 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac Digital Services Co., Ltd.(1)	uncommitted revolving	364 days	January 2, 2025	¥600 million	¥0 million	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period	No later than January 3, 2025	None	General corporate purposes
Aflac GI Holdings LLC(1)	uncommitted revolving	364 days	July 16, 2024	$30 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum	No later than July 17, 2024	None	General corporate purposes
Aflac Incorporated(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes
Aflac Re(1)	uncommitted revolving	364 days	January 2, 2025	$400 million	$0 million	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings	No later than January 3, 2025	None	General corporate purposes

(1) Intercompany credit agreement

XML

SHAREHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

Stockholders' Equity Note [Abstract]

Schedule of Common Stock Outstanding Roll Forward

The following table is a reconciliation of the number of shares of the Company's common stock for the three-month periods ended March 31.

(In thousands of shares)	2024	2023
Common stock - issued:
Balance, beginning of period	1,355,398	1,354,079
Exercise of stock options and issuance of restricted shares	1,082	933
Balance, end of period	1,356,480	1,355,012
Treasury stock:
Balance, beginning of period	776,919	738,823
Purchases of treasury stock:
Share repurchase program	9,276	10,348
Other	457	347
Dispositions of treasury stock:
Shares issued to AFL Stock Plan	(212)	(239)
Exercise of stock options	(55)	(48)
Other	(183)	(171)
Balance, end of period	786,202	749,060
Shares outstanding, end of period	570,278	605,952

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table presents the approximate number of share-based awards to purchase shares, on a weighted-average basis, that were considered to be anti-dilutive and were excluded from the calculation of diluted EPS for the following periods.

	Three Months Ended March 31,
(In thousands)	2024	2023
Anti-dilutive share-based awards	69		164

Changes in Accumulated Other Comprehensive Income (Loss)

The tables below are reconciliations of accumulated other comprehensive income by component for the following periods.

Changes in Accumulated Other Comprehensive Income

Three Months Ended March 31, 2024
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2023		$	(4,069)		$	1,139		$	(22)		$	(2,560)		$	(8)		$	(5,520)
Other comprehensive    income (loss) before    reclassification		(597)			86			(5)			1,065			1			550
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(133)			1			0			0			(132)
Net current-period other    comprehensive    income (loss)		(597)			(47)			(4)			1,065			1			418
Balance at March 31, 2024		$	(4,666)		$	1,092		$	(26)		$	(1,495)		$	(7)		$	(5,102)

All amounts in the table above are net of tax.

Three Months Ended March 31, 2023
(In millions)	Unrealized Foreign Currency Translation Gains (Losses)			Unrealized Gains (Losses) on Fixed Maturity Securities			Unrealized Gains (Losses) on Derivatives			Effect of Changes in Discount Rate Assumptions			Pension Liability Adjustment			Total
Balance at December 31, 2022		$	(3,564)		$	(702)		$	(27)		$	(2,100)		$	(36)		$	(6,429)
Other comprehensive    income (loss) before    reclassification		(54)			2,036			0			(2,794)			7			(805)
Amounts reclassified from    accumulated other    comprehensive income   (loss)		0			(45)			1			0			0			(44)
Net current-period other    comprehensive    income (loss)		(54)			1,991			1			(2,794)			7			(849)
Balance at March 31, 2023		$	(3,618)		$	1,289		$	(26)		$	(4,894)		$	(29)		$	(7,278)

All amounts in the table above are net of tax.

Reclassification Out Of Accumulated Other Comprehensive Income

The tables below summarize the amounts reclassified from each component of accumulated other comprehensive income into net earnings for the following periods.

Reclassifications Out of Accumulated Other Comprehensive Income

(In millions)	Three Months Ended March 31, 2024
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	168	Net investment gains (losses)
		(35)		Tax (expense) or benefit(1)
		$	133	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	132	Net of tax

(1) Based on 21% tax rate

(In millions)	Three Months Ended March 31, 2023
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statements of Earnings
Unrealized gains (losses) on available-for-sale    securities		$	57	Net investment gains (losses)
		(12)		Tax (expense) or benefit(1)
		$	45	Net of tax
Unrealized gains (losses) on derivatives		$	(1)	Net investment gains (losses)
		0		Tax (expense) or benefit(1)
		$	(1)	Net of tax
Total reclassifications for the period		$	44	Net of tax

(1) Based on 21% tax rate

XML

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stock Options Outstanding and Exercisable

The following table provides information on stock options outstanding and exercisable at March 31, 2024.

	Stock Option Shares (in thousands)		Weighted-Average Remaining Term (in years)		Aggregate Intrinsic Value (in millions)			Weighted-Average Exercise Price Per Share
Outstanding		856		2.2		$	45		$	33.37
Exercisable		856		2.2		45			33.37

Schedule of Nonvested Restricted Stock Units Activity

The following table summarizes restricted stock activity during the three-month period ended March 31, 2024.

(In thousands of shares)	Shares	Weighted-Average Grant-Date Fair Value Per Share
Restricted stock at December 31, 2023	2,308		$	62.96
Granted in 2024	1,213		79.75
Canceled in 2024	(7)		67.50
Vested in 2024	(1,337)		49.24
Restricted stock at March 31, 2024	2,177		$	72.33

XML

BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2024

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Schedule of Net Benefit Costs

Pension and other postretirement benefit expenses are included in acquisition and operating expenses in the consolidated statements of earnings, which includes other components of net periodic pension cost and postretirement costs (other than service costs) of $2 million for both the three-month periods ended March 31, 2024 and 2023. Total net periodic benefit cost includes the following components:

	Three Months Ended March 31,
	Pension Benefits												Other
	Japan						U.S.						Postretirement Benefits
(In millions)	2024			2023			2024			2023			2024			2023
Components of net periodic   benefit cost:
Service cost		$	4		$	4		$	0		$	4		$	0		$	0
Interest cost		2			2			9			11			0			0
Expected return on plan assets		(2)			(2)			(7)			(9)			0			0
Amortization of net actuarial loss		0			0			0			0			0			0
Net periodic (benefit) cost		$	4		$	4		$	2		$	6		$	0		$	0

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)
Significant Accounting Policies [Line Items]
Number of reportable insurance business segments | segment	2
Net cash provided (used) by operating activities	$ 849	$ 890
Net cash provided (used) by investing activities	$ 227	(77)
Revision of prior period, reclassification, adjustment
Significant Accounting Policies [Line Items]
Net cash provided (used) by operating activities		182
Net cash provided (used) by investing activities		$ (182)

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Revenues (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums		$ 3,456	$ 3,688
Net investment income		1,000	943
Other income		29	46
Total revenues		5,436	4,800
Net investment gains (losses)		951	123
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues		4,419	4,579
Segment Reconciling Items
Segment Reporting, Revenue Reconciling Item [Line Items]
Amortized hedge costs		6	58
Amortized hedge income		(28)	(29)
Net interest (income) expense from from derivatives associated with certain investment strategies		88	69
Aflac Japan | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums		1,816	2,170
Net investment income		648	611
Other income		9	9
Total revenues		2,473	2,790
Aflac U.S. | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Net earned premiums		1,475	1,428
Net investment income		206	197
Other income		18	35
Total revenues		1,699	1,660
Corporate and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Change in value of federal historic rehabilitation and solar tax credit investments		(32)	(51)
Federal historic rehabilitation and solar tax credits, amount		33	52
Corporate and other | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	[1]	$ 247	$ 129

[1] The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Pretax Earnings (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Other income (loss)		$ (2)	$ 0
Net investment gains (losses)		951	123
Earnings before income taxes		2,170	1,342
Income taxes applicable to pretax adjusted earnings		202	180
Effect of foreign currency translation on after-tax adjusted earnings		(44)	(41)
Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Pretax adjusted earnings		1,163	1,133
Segment Reconciling Items
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Amortized hedge costs		6	58
Amortized hedge income		(28)	(29)
Net interest (income) expense from from derivatives associated with certain investment strategies		88	69
Impact of interest from derivatives associated with notes payable		(8)	(12)
Aflac Japan | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Pretax adjusted earnings		810	788
Aflac U.S. | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Pretax adjusted earnings		356	352
Corporate and other
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Change in value of federal historic rehabilitation and solar tax credit investments		(32)	(51)
Federal historic rehabilitation and solar tax credits, amount		33	52
Corporate and other | Operating Segments
Segment Reporting, Reconciling Item for Adjusted Profit (Loss) from Segment to Consolidated [Line Items]
Pretax adjusted earnings	[1]	$ (3)	$ (7)

[1] The change in value of federal historic rehabilitation and solar investments in partnerships of $32 and $51 for the three-month periods ended March 31, 2024, and 2023, respectively, is included as a reduction to net investment income. Tax credits on these investments of $33 and $52 for the three-month periods ended March 31, 2024, and 2023, respectively, have been recorded as an income tax benefit in the consolidated statements of earnings. See Note 3 for additional information on these investments.

XML

BUSINESS SEGMENT INFORMATION - Operations by Segment - Assets (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 124,742	$ 126,724
Aflac Japan
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	98,189	101,541
Aflac U.S.
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	21,850	21,861
Corporate and other
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 4,703	$ 3,322

XML

BUSINESS SEGMENT INFORMATION - Additional Information (Details) - segment	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Number of reportable insurance business segments	2
Aflac Japan
Segment Reporting Information [Line Items]
Percentage of the Company's total revenues	56.00%	61.00%
Percentage of the Company's total assets	79.00%		80.00%

XML

INVESTMENTS - Available-for-sale Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 67,594	$ 70,689
Allowance for Credit Losses	0	0	$ 0	$ 0
Gross Unrealized Gains	6,038	6,050
Gross Unrealized Losses	3,502	3,449
Fair   Value	70,130	73,290
Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	37,393	40,174
Allowance for Credit Losses	0	0
Gross Unrealized Gains	2,254	2,529
Gross Unrealized Losses	2,496	2,513
Fair   Value	37,151	40,190
Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	30,201	30,515
Allowance for Credit Losses	0	0
Gross Unrealized Gains	3,784	3,521
Gross Unrealized Losses	1,006	936
Fair   Value	32,979	33,100
Japan government and agencies | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	21,577	23,067
Allowance for Credit Losses	0	0
Gross Unrealized Gains	874	1,040
Gross Unrealized Losses	1,811	1,696
Fair   Value	20,640	22,411
Municipalities
Debt Securities, Available-for-sale [Line Items]
Fair   Value	2,210	2,298
Municipalities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	907	968
Allowance for Credit Losses	0	0
Gross Unrealized Gains	102	115
Gross Unrealized Losses	59	58
Fair   Value	950	1,025
Municipalities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,237	1,246
Allowance for Credit Losses	0	0
Gross Unrealized Gains	72	65
Gross Unrealized Losses	49	38
Fair   Value	1,260	1,273
Mortgage- and asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Fair   Value	3,385	3,086
Mortgage- and asset-backed securities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	201	215
Allowance for Credit Losses	0	0
Gross Unrealized Gains	6	6
Gross Unrealized Losses	12	11
Fair   Value	195	210
Mortgage- and asset-backed securities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,968	2,748
Allowance for Credit Losses	0	0
Gross Unrealized Gains	270	184
Gross Unrealized Losses	48	56
Fair   Value	3,190	2,876
Public utilities
Debt Securities, Available-for-sale [Line Items]
Fair   Value	7,313	7,592
Public utilities | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,281	3,757
Allowance for Credit Losses	0	0
Gross Unrealized Gains	262	325
Gross Unrealized Losses	77	82
Fair   Value	3,466	4,000
Public utilities | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	3,595	3,346
Allowance for Credit Losses	0	0
Gross Unrealized Gains	388	360
Gross Unrealized Losses	136	114
Fair   Value	3,847	3,592
Sovereign and supranational
Debt Securities, Available-for-sale [Line Items]
Fair   Value	490	537
Sovereign and supranational | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	349	373
Allowance for Credit Losses	0	0
Gross Unrealized Gains	24	24
Gross Unrealized Losses	7	7
Fair   Value	366	390
Sovereign and supranational | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	95	122
Allowance for Credit Losses	0	0
Gross Unrealized Gains	33	33
Gross Unrealized Losses	4	8
Fair   Value	124	147
Banks/financial institutions
Debt Securities, Available-for-sale [Line Items]
Fair   Value	8,899	8,835
Banks/financial institutions | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,546	5,896
Allowance for Credit Losses	0	0
Gross Unrealized Gains	323	320
Gross Unrealized Losses	285	365
Fair   Value	5,584	5,851
Banks/financial institutions | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,971	2,676
Allowance for Credit Losses	0	0
Gross Unrealized Gains	385	359
Gross Unrealized Losses	41	51
Fair   Value	3,315	2,984
Other corporate
Debt Securities, Available-for-sale [Line Items]
Fair   Value	27,019	28,342
Other corporate | Yen-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,532	5,898
Allowance for Credit Losses	0	0
Gross Unrealized Gains	663	699
Gross Unrealized Losses	245	294
Fair   Value	5,950	6,303
Other corporate | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	19,158	20,186
Allowance for Credit Losses	0	0
Gross Unrealized Gains	2,635	2,518
Gross Unrealized Losses	724	665
Fair   Value	21,069	22,039
U.S. government and agencies | Dollar-denominated
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	177	191
Allowance for Credit Losses	0	0
Gross Unrealized Gains	1	2
Gross Unrealized Losses	4	4
Fair   Value	$ 174	$ 189

XML

INVESTMENTS - Held-to-Maturity Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2024		Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$ 16,694		$ 17,824
Allowance for Credit Loss	5		5	$ 6	$ 7
Total fixed maturity securities, held-to- maturity, amortized cost	16,689	[1]	17,819
Gross Unrealized Gains	1,556		1,838
Gross Unrealized Losses	0		0
Fair   Value	18,245		19,657
Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	16,694		17,824
Allowance for Credit Loss	5		5
Total fixed maturity securities, held-to- maturity, amortized cost	16,689		17,819
Gross Unrealized Gains	1,556		1,838
Gross Unrealized Losses	0		0
Fair   Value	18,245		19,657
Japan government and agencies | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	16,002		17,085
Allowance for Credit Loss	2		2
Total fixed maturity securities, held-to- maturity, amortized cost	16,000		17,083
Gross Unrealized Gains	1,474		1,746
Gross Unrealized Losses	0		0
Fair   Value	17,474		18,829
Municipalities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	248		266
Fair   Value	285		307
Municipalities | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	248		266
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	248		266
Gross Unrealized Gains	37		41
Gross Unrealized Losses	0		0
Fair   Value	285		307
Public utilities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	33		34
Fair   Value	36		38
Public utilities | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	33		34
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	33		34
Gross Unrealized Gains	3		4
Gross Unrealized Losses	0		0
Fair   Value	36		38
Sovereign and supranational
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	391		418
Fair   Value	431		462
Sovereign and supranational | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	394		421
Allowance for Credit Loss	3		3
Total fixed maturity securities, held-to- maturity, amortized cost	391		418
Gross Unrealized Gains	40		44
Gross Unrealized Losses	0		0
Fair   Value	431		462
Other corporate
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	17		18
Fair   Value	19		21
Other corporate | Yen-denominated
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	17		18
Allowance for Credit Loss	0		0
Total fixed maturity securities, held-to- maturity, amortized cost	17		18
Gross Unrealized Gains	2		3
Gross Unrealized Losses	0		0
Fair   Value	$ 19		$ 21

[1] Net of allowance for credit losses

XML

INVESTMENTS - Equity Securities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Equity Securities, FV-NI [Line Items]
Equity securities	$ 762	$ 1,088
Yen-denominated
Equity Securities, FV-NI [Line Items]
Equity securities	522	751
Dollar-denominated
Equity Securities, FV-NI [Line Items]
Equity securities	240	252
Other currencies
Equity Securities, FV-NI [Line Items]
Equity securities	$ 0	$ 85

XML

INVESTMENTS - Contractual and Economic Maturities of Investments in Fixed Maturities (Detail) - USD ($) $ in Millions		Mar. 31, 2024		Dec. 31, 2023
Available for sale:
Due in one year or less	[1]	$ 1,272
Due after one year through five years	[1]	6,659
Due after five years through 10 years	[1]	17,904
Due after 10 years	[1]	38,590
Mortgage- and asset-backed securities	[1]	3,169
Total fixed maturity securities, available-for-sale, amortized cost	[1]	67,594
Held to maturity:
Due in one year or less	[1]	0
Due after one year through five years	[1]	35
Due after five years through 10 years	[1]	8,901
Due after 10 years	[1]	7,753
Total fixed maturity securities, held-to- maturity, amortized cost		16,689	[1]	$ 17,819
Available for sale:
Due in one year or less		1,292
Due after one year through five years		7,480
Due after five years through 10 years		19,556
Due after 10 years		38,417
Mortgage- and asset-backed securities		3,385
Fair Value		70,130		73,290
Held to maturity:
Due in one year or less		0
Due after one year through five years		36
Due after five years through 10 years		9,714
Due after 10 years		8,495
Fair Value		$ 18,245		$ 19,657

[1] Net of allowance for credit losses

XML

INVESTMENTS - Investment Exposures Individually Exceeded 10% of Shareholders' Equity (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Credit Rating	[1]	A+	A+
Investment, Type [Extensible Enumeration]		Japan National Government [Member]	Japan National Government [Member]	[1]
Amortized Cost	[1]	$ 36,641	$ 39,151
Fair Value	[1]	$ 37,170	$ 40,222

[1] Japan Government Bonds (JGBs) or JGB-backed securities

XML

INVESTMENTS - Information Regarding Pretax Net Gains and Losses From Investments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Gain (Loss) on Securities [Line Items]
Gross gains (losses) from sales and redemptions	$ 5	$ 0
Net investment gains (losses)	951	123
Credit losses:
Fixed maturity securities held-to-maturity	0	1
Commercial mortgage and other loans	(7)	(31)
Impairment losses	0	0
Loan commitments	1	3
Reinsurance recoverables and other	5	(3)
Total credit losses	(1)	(30)
Derivatives and other:
Derivative gains (losses)	(215)	17
Foreign currency gains (losses)	918	82
Fixed maturity securities
Gain (Loss) on Securities [Line Items]
Gross gains from sales	34	1
Gross losses from sales	(282)	(3)
Foreign currency gains (losses)	416	59
Debt Securities, Financing Receivables, and Other Investments
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	173	57
Equity securities
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	76	(3)
Derivatives and other
Gain (Loss) on Securities [Line Items]
Net investment gains (losses)	$ 703	$ 99

XML

INVESTMENTS - Net Effect on Shareholders' Equity of Unrealized Gains and Losses from Investment Securities (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Investments [Abstract]
Unrealized gains (losses) on securities available-for-sale	$ 2,536	$ 2,601
Deferred income taxes	(1,444)	(1,462)
Unrealized gains (losses) on fixed maturity securities	$ 1,092	$ 1,139

XML

INVESTMENTS - Fair Value and Gross Unrealized Losses for Securities That Have Been in Continuous Unrealized Loss Position (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	$ 23,627	$ 25,402
Total Unrealized Losses	3,502	3,449
Less than 12 months Fair Value	4,673	4,239
Less than 12 months Unrealized Losses	471	364
12 months or Longer Fair Value	18,954	21,163
12 months or Longer Unrealized Losses	3,031	3,085
Dollar-denominated | U.S. government and agencies
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	141	123
Total Unrealized Losses	4	4
Less than 12 months Fair Value	59	53
Less than 12 months Unrealized Losses	1	1
12 months or Longer Fair Value	82	70
12 months or Longer Unrealized Losses	3	3
Dollar-denominated | Municipalities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	662	703
Total Unrealized Losses	49	38
Less than 12 months Fair Value	9	31
Less than 12 months Unrealized Losses	0	1
12 months or Longer Fair Value	653	672
12 months or Longer Unrealized Losses	49	37
Dollar-denominated | Mortgage- and asset-backed securities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	754	925
Total Unrealized Losses	48	56
Less than 12 months Fair Value	304	340
Less than 12 months Unrealized Losses	4	6
12 months or Longer Fair Value	450	585
12 months or Longer Unrealized Losses	44	50
Dollar-denominated | Public utilities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	1,383	1,120
Total Unrealized Losses	136	114
Less than 12 months Fair Value	391	228
Less than 12 months Unrealized Losses	9	4
12 months or Longer Fair Value	992	892
12 months or Longer Unrealized Losses	127	110
Dollar-denominated | Sovereign and supranational
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	14	35
Total Unrealized Losses	4	8
Less than 12 months Fair Value	0	0
Less than 12 months Unrealized Losses	0	0
12 months or Longer Fair Value	14	35
12 months or Longer Unrealized Losses	4	8
Dollar-denominated | Banks/financial institutions
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	628	655
Total Unrealized Losses	41	51
Less than 12 months Fair Value	228	159
Less than 12 months Unrealized Losses	2	4
12 months or Longer Fair Value	400	496
12 months or Longer Unrealized Losses	39	47
Dollar-denominated | Other corporate
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	6,196	6,380
Total Unrealized Losses	724	665
Less than 12 months Fair Value	1,254	799
Less than 12 months Unrealized Losses	36	19
12 months or Longer Fair Value	4,942	5,581
12 months or Longer Unrealized Losses	688	646
Yen-denominated | Japan government and agencies
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	7,828	8,393
Total Unrealized Losses	1,811	1,696
Less than 12 months Fair Value	1,628	1,657
Less than 12 months Unrealized Losses	395	303
12 months or Longer Fair Value	6,200	6,736
12 months or Longer Unrealized Losses	1,416	1,393
Yen-denominated | Municipalities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	277	301
Total Unrealized Losses	59	58
Less than 12 months Fair Value	31	34
Less than 12 months Unrealized Losses	1	0
12 months or Longer Fair Value	246	267
12 months or Longer Unrealized Losses	58	58
Yen-denominated | Mortgage- and asset-backed securities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	54	58
Total Unrealized Losses	12	11
Less than 12 months Fair Value	1	0
Less than 12 months Unrealized Losses	0	0
12 months or Longer Fair Value	53	58
12 months or Longer Unrealized Losses	12	11
Yen-denominated | Public utilities
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	915	1,028
Total Unrealized Losses	77	82
Less than 12 months Fair Value	351	444
Less than 12 months Unrealized Losses	13	13
12 months or Longer Fair Value	564	584
12 months or Longer Unrealized Losses	64	69
Yen-denominated | Sovereign and supranational
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	55	60
Total Unrealized Losses	7	7
Less than 12 months Fair Value	0	0
Less than 12 months Unrealized Losses	0	0
12 months or Longer Fair Value	55	60
12 months or Longer Unrealized Losses	7	7
Yen-denominated | Banks/financial institutions
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	2,973	3,673
Total Unrealized Losses	285	365
Less than 12 months Fair Value	62	186
Less than 12 months Unrealized Losses	1	4
12 months or Longer Fair Value	2,911	3,487
12 months or Longer Unrealized Losses	284	361
Yen-denominated | Other corporate
Investments, Unrealized Loss Position [Line Items]
Total Fair Value	1,747	1,948
Total Unrealized Losses	245	294
Less than 12 months Fair Value	355	308
Less than 12 months Unrealized Losses	9	9
12 months or Longer Fair Value	1,392	1,640
12 months or Longer Unrealized Losses	$ 236	$ 285

XML

INVESTMENTS - Commercial Mortgage and Other Loans by Portfolio Segment (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 12,592	$ 12,801
Percent of total commercial mortgage and other loans	100.00%	100.00%
Allowance for credit losses	$ (232)	$ (274)
Total net commercial mortgage and other loans	12,360	12,527
Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 6,078	$ 6,114
Percent of total commercial mortgage and other loans	48.40%	47.80%
Allowance for credit losses	$ (114)	$ (112)	$ (65)	$ (54)
Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 1,653	$ 1,709
Percent of total commercial mortgage and other loans	13.00%	13.40%
Allowance for credit losses	$ (19)	$ (16)	(9)	(9)
Middle market loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 4,586	$ 4,677
Percent of total commercial mortgage and other loans	36.40%	36.50%
Allowance for credit losses	$ (99)	$ (146)	$ (149)	$ (129)
Other loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 275	$ 301
Percent of total commercial mortgage and other loans	2.20%	2.30%
Office | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 1,768	$ 1,807
Percent of total commercial mortgage and other loans	14.00%	14.10%
Office | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 356	$ 359
Percent of total commercial mortgage and other loans	2.80%	2.80%
Retail | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 335	$ 473
Percent of total commercial mortgage and other loans	2.70%	3.70%
Retail | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 254	$ 301
Percent of total commercial mortgage and other loans	2.00%	2.40%
Apartment/Multi-Family | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 2,550	$ 2,608
Percent of total commercial mortgage and other loans	20.30%	20.40%
Apartment/Multi-Family | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 583	$ 586
Percent of total commercial mortgage and other loans	4.60%	4.60%
Industrial | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 152	$ 157
Percent of total commercial mortgage and other loans	1.20%	1.20%
Industrial | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 445	$ 463
Percent of total commercial mortgage and other loans	3.50%	3.60%
Hospitality | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 818	$ 814
Percent of total commercial mortgage and other loans	6.50%	6.40%
Other | Transitional real estate loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 455	$ 255
Percent of total commercial mortgage and other loans	3.70%	2.00%
Other | Commercial mortgage loans
Participating Mortgage Loans [Line Items]
Commercial mortgage and other loans, gross	$ 15	$ 0
Percent of total commercial mortgage and other loans	0.10%	0.00%

XML

INVESTMENTS - Transitional Real Estate Loans by Key Credit Quality Indicators (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 12,592	$ 12,801
Transitional real estate loans
Financing Receivable, Credit Quality Indicator [Line Items]
2024	165
2023	226
2022	2,206
2021	2,295
2020	217
Prior	969
Total	6,078	$ 6,114
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	0
Transitional real estate loans | Loan to Value Ratio, 0.00% to 59.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	131
2023	86
2022	609
2021	507
2020	36
Prior	125
Total	1,494
Transitional real estate loans | Loan to Value Ratio, 60.00% to 69.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	34
2023	126
2022	496
2021	637
2020	18
Prior	552
Total	1,863
Transitional real estate loans | Loan to Value Ratio, 70.00% to 79.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	14
2022	883
2021	900
2020	83
Prior	47
Total	1,927
Transitional real estate loans | Loan-to-Value Ratio, 80.00% or greater
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	218
2021	251
2020	80
Prior	245
Total	$ 794

XML

INVESTMENTS - Commercial Mortgage Loans by Key Credit Quality Indicators (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 12,592	$ 12,801
Commercial mortgage loans
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	33
2022	0
2021	309
2020	45
Prior	1,266
Total	$ 1,653	$ 1,709
Weighted Average DSCR	2.30
2024	$ 0
2023	0
2022	0
2021	0
2020	0
Prior	0
Total	$ 0
Commercial mortgage loans | 2024
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	0.00
Commercial mortgage loans | 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.58
Commercial mortgage loans | 2022
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	0.00
Commercial mortgage loans | 2021
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.92
Commercial mortgage loans | 2020
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.26
Commercial mortgage loans | Prior
Financing Receivable, Credit Quality Indicator [Line Items]
Weighted Average DSCR	2.14
Commercial mortgage loans | Loan to Value Ratio, 0.00% to 59.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	$ 0
2023	33
2022	0
2021	309
2020	45
Prior	983
Total	$ 1,370
Weighted Average DSCR	2.57
Commercial mortgage loans | Loan to Value Ratio, 60.00% to 69.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	$ 0
2023	0
2022	0
2021	0
2020	0
Prior	30
Total	$ 30
Weighted Average DSCR	1.73
Commercial mortgage loans | Loan to Value Ratio, 70.00% to 79.99%
Financing Receivable, Credit Quality Indicator [Line Items]
2024	$ 0
2023	0
2022	0
2021	0
2020	0
Prior	120
Total	$ 120
Weighted Average DSCR	1.26
Commercial mortgage loans | Loan-to-Value Ratio, 80.00% or greater
Financing Receivable, Credit Quality Indicator [Line Items]
2024	$ 0
2023	0
2022	0
2021	0
2020	0
Prior	133
Total	$ 133
Weighted Average DSCR	0.52

XML

INVESTMENTS - Middle Market Loans by Key Credit Quality Indicators (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 12,592	$ 12,801
Middle market loans
Financing Receivable, Credit Quality Indicator [Line Items]
2024	66
2023	130
2022	591
2021	1,128
2020	658
Prior	1,136
Revolving Loans	877
Total	4,586	$ 4,677
2024	0
2023	0
2022	0
2021	27
2020	0
Prior	23
Revolving Loans	0
Total	50
Middle market loans | BBB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	17
2022	45
2021	123
2020	54
Prior	64
Revolving Loans	77
Total	380
Middle market loans | BB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	18
2023	60
2022	308
2021	408
2020	251
Prior	287
Revolving Loans	446
Total	1,778
Middle market loans | B Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	48
2023	53
2022	218
2021	547
2020	302
Prior	633
Revolving Loans	290
Total	2,091
Middle market loans | CCC Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	20
2021	50
2020	51
Prior	136
Revolving Loans	48
Total	305
Middle market loans | CC Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	10
Revolving Loans	0
Total	10
Middle market loans | C and Lower Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	6
Revolving Loans	16
Total	$ 22

XML

INVESTMENTS - Other Loans by Key Credit Quality Indicators (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Total	$ 12,592	$ 12,801
Other loans
Financing Receivable, Credit Quality Indicator [Line Items]
2024	5
2023	90
2022	175
2021	5
2020	0
Prior	0
Revolving Loans	0
Total	275	301
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	0
Revolving Loans	0
Total	0
Other loans | A Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	22
2022	94
2021	0
2020	0
Prior	0
Revolving Loans	0
Total	116
Other loans | AA Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	5
2021	5
2020	0
Prior	0
Revolving Loans	0
Total	10
Other loans | BBB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	5
2023	68
2022	0
2021	0
2020	0
Prior	0
Revolving Loans	0
Total	73
Other loans | BB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	76
2021	0
2020	0
Prior	0
Revolving Loans	0
Total	76
Middle market loans
Financing Receivable, Credit Quality Indicator [Line Items]
2024	66
2023	130
2022	591
2021	1,128
2020	658
Prior	1,136
Revolving Loans	877
Total	4,586	$ 4,677
2024	0
2023	0
2022	0
2021	27
2020	0
Prior	23
Revolving Loans	0
Total	50
Middle market loans | BBB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	17
2022	45
2021	123
2020	54
Prior	64
Revolving Loans	77
Total	380
Middle market loans | BB Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	18
2023	60
2022	308
2021	408
2020	251
Prior	287
Revolving Loans	446
Total	1,778
Middle market loans | B Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	48
2023	53
2022	218
2021	547
2020	302
Prior	633
Revolving Loans	290
Total	2,091
Middle market loans | CCC Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	20
2021	50
2020	51
Prior	136
Revolving Loans	48
Total	305
Middle market loans | CC Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	10
Revolving Loans	0
Total	10
Middle market loans | C and Lower Credit Rating
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0
2023	0
2022	0
2021	0
2020	0
Prior	6
Revolving Loans	16
Total	$ 22

XML

INVESTMENTS - Nonaccrual Loans (Details) - USD ($) $ in Millions	Mar. 31, 2024		Dec. 31, 2023
Financing Receivable, Past Due [Line Items]
Total	$ 12,592		$ 12,801
Total, nonaccrual status	910		718
Total, 90 days or more past due and still accruing	0		0
Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	6,078		6,114
Total, nonaccrual status	829		633
Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	1,653		1,709
Total, nonaccrual status	55		0
Middle market loans
Financing Receivable, Past Due [Line Items]
Total	4,586		4,677
Total, nonaccrual status	26		85
Other loans
Financing Receivable, Past Due [Line Items]
Total	275		301
Total, nonaccrual status	0		0
Current
Financing Receivable, Past Due [Line Items]
Total	11,585		12,050
Current | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	5,152		5,481
Current | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	1,598		1,676
Current | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	4,560		4,592
Current | Other loans
Financing Receivable, Past Due [Line Items]
Total	275		301
Less Than 90 Days Past Due
Financing Receivable, Past Due [Line Items]
Total	97		141
Less Than 90 Days Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	97		108
Less Than 90 Days Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	0		33
Less Than 90 Days Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	0		0
Less Than 90 Days Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	0		0
90 Days or More Past Due
Financing Receivable, Past Due [Line Items]
Total	910	[1]	610	[2]
90 Days or More Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	829	[1]	525	[2]
90 Days or More Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	55	[1]	0	[2]
90 Days or More Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	26	[1]	85	[2]
90 Days or More Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	0	[1]	0	[2]
Financial Asset, Past Due
Financing Receivable, Past Due [Line Items]
Total	1,007		751
Financial Asset, Past Due | Transitional real estate loans
Financing Receivable, Past Due [Line Items]
Total	926		633
Financial Asset, Past Due | Commercial mortgage loans
Financing Receivable, Past Due [Line Items]
Total	55		33
Financial Asset, Past Due | Middle market loans
Financing Receivable, Past Due [Line Items]
Total	26		85
Financial Asset, Past Due | Other loans
Financing Receivable, Past Due [Line Items]
Total	$ 0		$ 0

[1] As of March 31, 2024, there were no loans that were 90 days or more past due that continued to accrue interest.

[2] As of December 31, 2023, there were no loans that were 90 days or more past due that continued to accrue interest.

XML

INVESTMENTS - Allowance for Loan Losses by Portfolio Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	$ (274)
(Addition to) release of allowance for credit losses	(7)	$ (31)
Balance, end of period	(232)
Balance, beginning of period	(5)	(7)
(Addition to) release of allowance for credit losses	0	1
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(5)	(6)
Balance, beginning of period	0	0
(Addition to) release of allowance for credit losses	0	0
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	0	0
Balance, beginning of period	(295)	(223)
(Addition to) release of allowance for credit losses	(7)	(27)
Write-offs, net of recoveries	50	0
Change in foreign exchange	0	0
Balance, end of period	(252)	(250)
Transitional real estate loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(112)	(54)
(Addition to) release of allowance for credit losses	(2)	(11)
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(114)	(65)
Commercial mortgage loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(16)	(9)
(Addition to) release of allowance for credit losses	(3)	0
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	(19)	(9)
Middle market loans
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(146)	(129)
(Addition to) release of allowance for credit losses	(3)	(20)
Write-offs, net of recoveries	50	0
Change in foreign exchange	0	0
Balance, end of period	(99)	(149)
Other loans and loan commitments
Allowance for Loan Losses by Portfolio Segment [Roll Forward]
Balance, beginning of period	(16)	(24)
(Addition to) release of allowance for credit losses	1	3
Write-offs, net of recoveries	0	0
Change in foreign exchange	0	0
Balance, end of period	$ (15)	$ (21)

XML

INVESTMENTS - Other Investments (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Investment Holdings [Line Items]
Other investments		$ 6,677	$ 4,530
Policy loans
Investment Holdings [Line Items]
Other investments		203	214
Short-term investments
Investment Holdings [Line Items]
Other investments	[1]	3,341	1,304
Limited partnerships
Investment Holdings [Line Items]
Other investments	[2]	2,838	2,750
Real estate owned
Investment Holdings [Line Items]
Other investments		253	227
Other
Investment Holdings [Line Items]
Other investments		$ 42	$ 35

[1] Includes securities lending collateral

[2] Includes tax credit investments and asset classes such as private equity and real estate funds

XML

INVESTMENTS - Investments in Consolidated Variable Interest Entities (Detail) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		$ 70,130	$ 73,290
Commercial mortgage and other loans		12,360	12,527
Other investments		6,677	4,530
Asset derivatives		321	337
Assets		124,742	126,724
Liability derivatives		1,135	1,430
Liabilities		101,205	104,739
Liabilities, fair value		1,135	1,430
Variable Interest Entity, Consolidated
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		3,678	3,712
Commercial mortgage and other loans		9,947	10,150
Other investments	[1]	2,443	2,381
Asset derivatives	[2]	57	55
Assets		16,125	16,298
Liability derivatives	[2]	583	507
Liabilities		$ 583	$ 507

[1] Consists entirely of alternative investments in limited partnerships

[2] Consists entirely of derivatives

XML

INVESTMENTS - Investments in Variable Interest Entities Not Consolidated (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		$ 70,130	$ 73,290
Other investments		6,677	4,530
Assets		124,742	126,724
Variable Interest Entity, Not Consolidated
Variable Interest Entity [Line Items]
Fixed maturity securities, available-for-sale		6,486	6,424
Other investments	[1]	395	369
Assets		$ 6,881	$ 6,793

[1] Consists entirely of alternative investments in limited partnerships

XML

INVESTMENTS - Securities Lending Transactions Accounted for as Secured Borrowings (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		$ 3,366	$ 1,503
Gross amount of recognized liabilities for securities lending		3,366	1,503
Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,542	737
Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		33	19
Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		148	72
Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		643	675
Maturity Overnight and Continuous
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	824	766
Maturity Overnight and Continuous | Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	0	0
Maturity Overnight and Continuous | Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	33	19
Maturity Overnight and Continuous | Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	148	72
Maturity Overnight and Continuous | Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred	[1]	643	675
Maturity up to 30 Days
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,542	737
Maturity up to 30 Days | Japan government and agencies
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		2,542	737
Maturity up to 30 Days | Public utilities
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		0	0
Maturity up to 30 Days | Banks/financial institutions
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		0	0
Maturity up to 30 Days | Other corporate
Transfer of Certain Financial Assets Accounted for as Secured Borrowings [Line Items]
Securities Loaned, Including Not Subject to Master Netting Arrangement and Assets other than Securities Transferred		$ 0	$ 0

[1] The related loaned security, under the Company's U.S. securities lending program, can be returned to the Company at the transferee's discretion; therefore, they are classified as Overnight and Continuous.

XML

INVESTMENTS - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) investment	Mar. 31, 2023 USD ($) investment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Schedule of Investments [Line Items]
Held to maturity securities transferred to available for sale securities, number of investments | investment	0	0
Equity securities, FV-NI, unrealized gain (loss)	$ 71	$ (5)
Transitional real estate loan commitments	442
Middle market loan program unfunded amount	24		$ 24
Middle market loan commitments	787
Other loans commitments	5
Amortized Cost	16,694		17,824
Limited partnerships investment commitments	$ 2,200
Percentage that the lending policy requires that the fair value of the securities received as collateral be of the fair value of the loaned securities	102.00%
Percentage that the lending policy requires that the fair value of the unrestricted cash received as collateral be of the fair value of the loaned securities	100.00%
Securities Lending, Securities Received as Collateral	$ 4,500		4,300
Repurchase Agreements and Repurchase-to-Maturity Transactions Outstanding	0		0
Nonaccrual loans, interest income	0	0
Credit allowance	232		274
Financing receivable, before allowance for credit loss	12,592		12,801
Real estate owned, held-and-used			210
Real estate owned, held-for-sale			17
Depreciation expense	1
Accumulated depreciation	2
Other investments	6,677		4,530
Real estate owned
Schedule of Investments [Line Items]
Other investments	253		227
Transitional real estate loans
Schedule of Investments [Line Items]
Nonaccrual loans, no allowance	$ 383
Percent of total financing receivables	3.00%
Weighted-average interest rate before modification	8.30%
Weighted-average interest rate after modification	6.90%
Amortized cost of foreclosure or deed in lieu foreclosure	$ 31
Gains (loss) due to foreclosure	4
Amortized cost of financing receivable modified	210
Credit allowance	114	65	112	$ 54
Financing receivable, before allowance for credit loss	6,078		6,114
Transitional real estate loans | Potential Foreclosure or Deed-in-lieu Foreclosure
Schedule of Investments [Line Items]
Amortized cost of financing receivable in loan modification	601
Credit allowance	60
Financing receivable, before allowance for credit loss	598
Middle market loans
Schedule of Investments [Line Items]
Nonaccrual loans, no allowance	0		0
Credit allowance	99	$ 149	146	$ 129
Financing receivable, before allowance for credit loss	4,586		$ 4,677
Zero-credit-loss expectation | Japan government and agencies
Schedule of Investments [Line Items]
Amortized Cost	$ 15,900
CALIFORNIA | Commercial Mortgage and Transitional Real Estate Loans | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	20.00%
TEXAS | Commercial Mortgage and Transitional Real Estate Loans | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	15.00%
FLORIDA | Commercial Mortgage and Transitional Real Estate Loans | Mortgages
Schedule of Investments [Line Items]
Concentration Risk, Percentage	12.00%

XML

DERIVATIVE INSTRUMENTS - Summary of Balance Sheet Classification of Derivative Fair Value Amounts, as well as Gross Asset and Liability Fair Value Amounts (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Notional Amount	$ 52,919	$ 57,049
Derivative Asset, Fair Value	321	337
Derivative Liability, Fair Value	1,135	1,430
Cash flow hedges
Derivatives, Fair Value [Line Items]
Notional Amount	18	18
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	5	4
Cash flow hedges | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivatives, Fair Value [Line Items]
Notional Amount	18	18
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	5	4
Fair value hedges
Derivatives, Fair Value [Line Items]
Notional Amount	0	2,158
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	0	0
Fair value hedges | Foreign currency options
Derivatives, Fair Value [Line Items]
Notional Amount	0	2,158
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	0	0
Net investment hedge
Derivatives, Fair Value [Line Items]
Notional Amount	2,339	3,067
Derivative Asset, Fair Value	202	179
Derivative Liability, Fair Value	0	27
Net investment hedge | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Notional Amount	2,339	2,611
Derivative Asset, Fair Value	202	179
Derivative Liability, Fair Value	0	27
Net investment hedge | Foreign currency options
Derivatives, Fair Value [Line Items]
Notional Amount	0	456
Derivative Asset, Fair Value	0	0
Derivative Liability, Fair Value	0	0
Non-qualifying strategies
Derivatives, Fair Value [Line Items]
Notional Amount	50,562	51,806
Derivative Asset, Fair Value	119	158
Derivative Liability, Fair Value	1,130	1,399
Non-qualifying strategies | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivatives, Fair Value [Line Items]
Notional Amount	3,417	3,417
Derivative Asset, Fair Value	57	55
Derivative Liability, Fair Value	578	503
Non-qualifying strategies | Foreign currency swaps | Consolidated Entity Excluding Variable Interest Entities (VIE)
Derivatives, Fair Value [Line Items]
Notional Amount	1,200	1,200
Derivative Asset, Fair Value	24	31
Derivative Liability, Fair Value	0	0
Non-qualifying strategies | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Notional Amount	0	7,402
Derivative Asset, Fair Value	0	59
Derivative Liability, Fair Value	0	477
Non-qualifying strategies | Foreign currency options
Derivatives, Fair Value [Line Items]
Notional Amount	28,715	22,557
Derivative Asset, Fair Value	38	2
Derivative Liability, Fair Value	69	0
Non-qualifying strategies | Interest rate swaps
Derivatives, Fair Value [Line Items]
Notional Amount	17,230	17,230
Derivative Asset, Fair Value	0	11
Derivative Liability, Fair Value	$ 483	$ 419

XML

DERIVATIVE INSTRUMENTS - Gains (Losses) Recognized on Fair Value Hedging Relationships (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Total gains (losses) recognized for derivatives	$ (39)
Gains (losses) on derivatives excluded from effectiveness testing	(39)	[1]
Gains (losses) on derivatives included in effectiveness testing	0	[2]
Gains (losses) recognized for hedged items	0	[2]
Net realized gains (losses) recognized for fair value hedge	0
Fixed maturity securities | Foreign currency options
Derivative Instruments, Gain (Loss) [Line Items]
Total gains (losses) recognized for derivatives	(39)
Gains (losses) on derivatives excluded from effectiveness testing	(39)	[1]
Gains (losses) on derivatives included in effectiveness testing	0	[2]
Gains (losses) recognized for hedged items	0	[2]
Net realized gains (losses) recognized for fair value hedge	$ 0

[1] Gains (losses) excluded from effectiveness testing includes the forward point on foreign currency forwards and time value change on foreign currency options which are reported in the consolidated statements of earnings as net investment gains (losses). It also includes the change in the fair value of the interest rate swaptions related to the time value of the swaptions which is recognized as a component of other comprehensive income (loss).

[2] Gains and losses on foreign currency forwards and options and related hedged items are reported in the consolidated statements of earnings as net investment gains (losses). For interest rate swaptions and related hedged items, gains and losses included in the hedge assessment, premium amortization and time value amortization while the hedge items are still outstanding are reported within net investment income. The time value gains and losses for interest rate swaptions when the related hedged items are redeemed are reported in net investment gains (losses) consistent with the impact of the hedged item. For the three-month period ended March 31, 2023, gains and losses included in the hedge assessment on interest rate swaptions and related hedged items were immaterial.

XML

DERIVATIVE INSTRUMENTS - Schedule of Interest Rate Fair Value Hedges Hedged Items (Details) - Fixed maturity securities - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Carrying Amount of Hedged Assets/ (Liabilities)	[1]	$ 1,597	$ 1,692
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets/(Liabilities)		$ 161	$ 164

[1] The balance includes hedging adjustment on discontinued hedging relationships of $161 in 2024 and $164 in 2023.

XML

DERIVATIVE INSTRUMENTS - Derivatives and Hedging Instruments Gain (Loss) Summary (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative		$ (5)	$ 1
Unrealized foreign currency translation gains (losses) during period		(501)	(43)
Derivative and non-derivative hedging instruments, gain (loss) recognized in other comprehensive income, before tax	[1]	381	55
Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative	[2]	0	0
Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(215)	17
Reclassification Out Of Accumulated Other Comprehensive Income
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments, cash flow hedges, gains (losses) reclassified from accumulated other comprehensive income into earnings		(1)	(1)
Cash flow hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative	[1]	0	1
Cash flow hedges | Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative	[2]	0	0
Cash flow hedges | Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative	[3]	(1)	(1)
Cash flow hedges | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in other comprehensive income on derivative	[1]	0	1
Cash flow hedges | Foreign currency swaps | Variable Interest Entity, Consolidated | Net investment income
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative	[2]	0	0
Cash flow hedges | Foreign currency swaps | Variable Interest Entity, Consolidated | Net investment gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(1)	(1)
Fair value hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	(39)
Fair value hedges | Foreign currency options
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	(39)
Net investment hedge
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		44	87
Unrealized foreign currency translation gains (losses) during period	[1]	381	54
Net investment hedge | Foreign currency options
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	(3)
Unrealized foreign currency translation gains (losses) during period	[1]	0	0
Net investment hedge | Non-derivative hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		0	0
Unrealized foreign currency translation gains (losses) during period	[1]	236	25
Net investment hedge | Foreign currency forwards
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		44	90
Unrealized foreign currency translation gains (losses) during period	[1]	145	29
Non-qualifying strategies
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(258)	(30)
Non-qualifying strategies | Foreign currency swaps | Variable Interest Entity, Consolidated
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(88)	(27)
Non-qualifying strategies | Foreign currency swaps | Consolidated Entity Excluding Variable Interest Entities (VIE)
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		1	1
Non-qualifying strategies | Foreign currency options
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(41)	(19)
Non-qualifying strategies | Foreign currency forwards
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		17	(51)
Non-qualifying strategies | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		(147)	69
Non-qualifying strategies | Forward bond purchase commitment | Variable Interest Entity, Consolidated
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in income on derivative		$ 0	$ (3)

[1] Gains and losses on cash flow hedges and the change in the fair value of interest rate swaptions related to the time value of the swaptions in fair value hedges are recorded as unrealized gains (losses). Gains and losses on net investment hedges related to changes in foreign currency spot rates are recorded in the unrealized foreign currency translation gains (losses) line in the consolidated statements of comprehensive income (loss).

[2] Interest expense/income on cash flow hedges are recorded in net investment income. For interest rate swaptions classified as fair value hedges, the change in the time value of the swaptions is recognized in other comprehensive income (loss) and amortized into net investment income over its legal term. If the swaption is early terminated but the hedge item is still outstanding, the amortization of disposal amount of the swaptions is recorded in net investment income over the remaining life of the hedged items.

[3] Impact of cash flow hedges reported as net investment gains (losses) includes $1 of losses reclassified from accumulated other comprehensive income (loss) into earnings during the three-month period ended March 31, 2024, and $1 of losses during the three-month period ended March 31, 2023.

XML

DERIVATIVE INSTRUMENTS - Offsetting of Financial Assets and Derivative Assets (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets	$ 264	$ 282
Gross amount of liabilities offset in balance sheet	0	0
Net amount of derivative assets presented in balance sheet	264	282
Financial instruments, amount not offset	(38)	(96)
Derivative, collateral, obligation to return securities	(78)	(53)
Derivative, collateral, obligation to return cash	(148)	(130)
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement	0	3
Derivative asset, not subject to master netting arrangement	57	55
Derivative asset, fair value, gross asset including not subject to master netting arrangement	321	337
Net amount of derivative assets presented in balance sheet	321	337
Derivative asset, fair value, amount offset against collateral	57	58
Securities lending, gross amounts of recognized financial instruments	3,334	1,480
Securities lending, gross amounts offset in balance sheet	0	0
Securities lending, net amounts of assets presented in balance sheet	3,334	1,480
Securities lending, carrying value of financial instruments not offset in balance sheet	0	0
Securities lending, securities collateral, not offset in balance sheet	0	0
Securities lending, cash collateral, not offset in balance sheet	(3,334)	(1,480)
Securities lending, financial instruments, amount of assets offset against collateral	0	0
Gross amount of recognized assets	3,655	1,817
Gross amounts offset in balance sheet	0	0
Net amounts of assets presented in balance sheet	3,655	1,817
Carrying value of financial instruments not offset in balance sheet	(38)	(96)
Securities collateral, not offset in balance sheet	(78)	(53)
Cash collateral, not offset in balance sheet	(3,482)	(1,610)
Financial instruments, amount of assets offset against collateral	57	58
OTC - Bilateral
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets	264	271
Gross amount of liabilities offset in balance sheet	0	0
Net amount of derivative assets presented in balance sheet	264	271
Financial instruments, amount not offset	(38)	(85)
Derivative, collateral, obligation to return securities	(78)	(53)
Derivative, collateral, obligation to return cash	(148)	(130)
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement	0	3
Derivative asset, not subject to master netting arrangement	$ 57	55
OTC- Cleared
Offsetting Assets [Line Items]
Gross amount of recognized derivative assets		11
Gross amount of liabilities offset in balance sheet		0
Net amount of derivative assets presented in balance sheet		11
Financial instruments, amount not offset		(11)
Derivative, collateral, obligation to return securities		0
Derivative, collateral, obligation to return cash		0
Derivative asset, fair value, amount offset against collateral, subject to master netting agreement		$ 0

XML

DERIVATIVE INSTRUMENTS - Offsetting of Financial Liabilities and Derivative Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	$ 552	$ 923
Gross amount of assets offset in balance sheet	0	0
Derivative liability, fair value, amount not offset against collateral	552	923
Financial instruments, amount not offset	(38)	(96)
Derivative, collateral, right to reclaim securities	(58)	(400)
Derivative, collateral, right to reclaim cash	(456)	(426)
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	0	1
Derivative liability, not subject to master netting arrangement	583	507
Derivative liability, fair value, gross liability including not subject to master netting arrangement	1,135	1,430
Net amount of derivative liabilities presented in balance sheet	1,135	1,430
Derivative liability, fair value, amount offset against collateral	583	508
Securities lending, gross amounts of recognized financial instruments, offsetting liabilities	3,366	1,503
Securities lending, gross amounts offset in statement of financial position, offsetting liabilities	0	0
Securities lending, net amounts of financial instruments presented in balance sheet, offsetting liabilities	3,366	1,503
Securities lending, carrying value of financial instruments, liabilities not offset in balance sheet	(3,334)	(1,480)
Securities lending, securities collateral, liabilities not offset in balance sheet	0	0
Securities lending, cash collateral, liabilities not offset in balance sheet	0	0
Securities lending, financial instruments, amount of liabilities offset against collateral	32	23
Gross amounts of recognized financial instruments, offsetting liabilities	4,501	2,933
Gross amounts offset in statement of financial position, offsetting liabilities	0	0
Net amounts of financial instruments presented in balance sheet, offsetting liabilities	4,501	2,933
Carrying value of financial instruments, liabilities not offset in balance sheet	(3,372)	(1,576)
Securities collateral, liabilities not offset in balance sheet	(58)	(400)
Cash collateral, liabilities not offset in balance sheet	(456)	(426)
Financial instruments, amount of liabilities offset against collateral	615	531
OTC - Bilateral
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	69	504
Gross amount of assets offset in balance sheet	0	0
Derivative liability, fair value, amount not offset against collateral	69	504
Financial instruments, amount not offset	(38)	(85)
Derivative, collateral, right to reclaim securities	(31)	(381)
Derivative, collateral, right to reclaim cash	0	(37)
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	0	1
Derivative liability, not subject to master netting arrangement	583	507
OTC- Cleared
Offsetting Liabilities [Line Items]
Gross amount of recognized derivative liabilities	483	419
Gross amount of assets offset in balance sheet	0	0
Derivative liability, fair value, amount not offset against collateral	483	419
Financial instruments, amount not offset	0	(11)
Derivative, collateral, right to reclaim securities	(27)	(19)
Derivative, collateral, right to reclaim cash	(456)	(389)
Derivative liability, fair value, amount offset against collateral, subject to master netting agreement	$ 0	$ 0

XML

DERIVATIVE INSTRUMENTS - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Derivative, Notional Amount	$ 52,919	$ 57,049
Derivative, net liability position, aggregate fair value	1,000	1,200
Additional Collateral, Aggregate Fair Value	447
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ (5)
Maximum Length of Time Hedged in Cash Flow Hedge	3 years
Fair value hedges	$ 0
Fair value hedges of interest rate risk	0	$ 0
Senior notes | Interest rate swaps
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Derivative, Notional Amount	$ 1,200

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Assets:
Fixed maturity securities, available-for-sale	$ 70,130	$ 73,290
Equity securities	762	1,088
Other investments	3,341	1,304
Cash and cash equivalents	5,098	4,306
Asset derivatives	$ 321	$ 337
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other	Other
Total assets	$ 79,652	$ 80,325
Liabilities:
Liability derivatives	1,135	1,430
Total liabilities	1,135	1,430
Foreign currency swaps
Assets:
Asset derivatives	81	86
Liabilities:
Liability derivatives	583	507
Foreign currency forwards
Assets:
Asset derivatives	202	238
Liabilities:
Liability derivatives		504
Foreign currency options
Assets:
Asset derivatives	38	2
Liabilities:
Liability derivatives	69
Interest rate swaps
Assets:
Asset derivatives		11
Liabilities:
Liability derivatives	483	419
Government and agencies
Assets:
Fixed maturity securities, available-for-sale	20,814	22,600
Municipalities
Assets:
Fixed maturity securities, available-for-sale	2,210	2,298
Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	3,385	3,086
Public utilities
Assets:
Fixed maturity securities, available-for-sale	7,313	7,592
Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	490	537
Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	8,899	8,835
Other corporate
Assets:
Fixed maturity securities, available-for-sale	27,019	28,342
Level 1
Assets:
Fixed maturity securities, available-for-sale	19,976	21,700
Equity securities	603	840
Other investments	3,341	1,304
Cash and cash equivalents	5,098	4,306
Asset derivatives	0	0
Total assets	29,018	28,150
Liabilities:
Total liabilities	0	0
Level 1 | Foreign currency swaps
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0	0
Level 1 | Foreign currency forwards
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives		0
Level 1 | Foreign currency options
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0
Level 1 | Interest rate swaps
Assets:
Asset derivatives		0
Liabilities:
Liability derivatives	0	0
Level 1 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	19,976	21,700
Level 1 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 1 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 2
Assets:
Fixed maturity securities, available-for-sale	48,236	49,809
Equity securities	0	0
Other investments	0	0
Cash and cash equivalents	0	0
Asset derivatives	321	337
Total assets	48,557	50,146
Liabilities:
Total liabilities	1,135	1,430
Level 2 | Foreign currency swaps
Assets:
Asset derivatives	81	86
Liabilities:
Liability derivatives	583	507
Level 2 | Foreign currency forwards
Assets:
Asset derivatives	202	238
Liabilities:
Liability derivatives		504
Level 2 | Foreign currency options
Assets:
Asset derivatives	38	2
Liabilities:
Liability derivatives	69
Level 2 | Interest rate swaps
Assets:
Asset derivatives		11
Liabilities:
Liability derivatives	483	419
Level 2 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	838	900
Level 2 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	2,210	2,298
Level 2 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	2,526	2,314
Level 2 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	6,806	7,339
Level 2 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	462	507
Level 2 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	8,825	8,757
Level 2 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	26,569	27,694
Level 3
Assets:
Fixed maturity securities, available-for-sale	1,918	1,781
Equity securities	159	248
Other investments	0	0
Cash and cash equivalents	0	0
Asset derivatives	0	0
Total assets	2,077	2,029
Liabilities:
Total liabilities	0	0
Level 3 | Foreign currency swaps
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0	0
Level 3 | Foreign currency forwards
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives		0
Level 3 | Foreign currency options
Assets:
Asset derivatives	0	0
Liabilities:
Liability derivatives	0
Level 3 | Interest rate swaps
Assets:
Asset derivatives		0
Liabilities:
Liability derivatives	0	0
Level 3 | Government and agencies
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 3 | Municipalities
Assets:
Fixed maturity securities, available-for-sale	0	0
Level 3 | Mortgage- and asset-backed securities
Assets:
Fixed maturity securities, available-for-sale	859	772
Level 3 | Public utilities
Assets:
Fixed maturity securities, available-for-sale	507	253
Level 3 | Sovereign and supranational
Assets:
Fixed maturity securities, available-for-sale	28	30
Level 3 | Banks/financial institutions
Assets:
Fixed maturity securities, available-for-sale	74	78
Level 3 | Other corporate
Assets:
Fixed maturity securities, available-for-sale	$ 450	$ 648

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets and Liabilities Carried at Cost or Amortized Cost (Details) - USD ($) $ in Millions	Mar. 31, 2024		Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 6,677		$ 4,530
Assets:
Amortized Cost	16,694		17,824
Fixed maturity securities, held-to-maturity, fair value	18,245		19,657
Commercial mortgage and other loans	12,360		12,527
Commercial mortgage and other loans, fair value	12,017		12,217
Other investments carried at amortized cost	42	[1]	35	[2]
Other investments carried at amortized cost, fair value	42	[1]	35	[2]
Total financial instruments assets not carried at fair value	29,091		30,381
Assets fair value disclosure financial instruments carried at cost	30,304		31,909
Liabilities:
Other policyholders’ funds	5,831		6,169
Other policyholders' funds fair value disclosure	5,750		6,080
Notes payable	7,799		7,240
Notes payable, fair value disclosure	7,466		6,930
Total financial instrument liabilities not carried at fair value	13,630		13,409
Liabilities fair value disclosure financial instruments carried at cost	13,216		13,010
Government and agencies
Assets:
Amortized Cost	16,000		17,083
Fixed maturity securities, held-to-maturity, fair value	17,474		18,829
Municipalities
Assets:
Amortized Cost	248		266
Fixed maturity securities, held-to-maturity, fair value	285		307
Public utilities
Assets:
Amortized Cost	33		34
Fixed maturity securities, held-to-maturity, fair value	36		38
Sovereign and supranational
Assets:
Amortized Cost	391		418
Fixed maturity securities, held-to-maturity, fair value	431		462
Other corporate
Assets:
Amortized Cost	17		18
Fixed maturity securities, held-to-maturity, fair value	19		21
Policy loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	203		214
Equity method investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	2,838		2,750
Real estate owned
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	253		227
Level 1
Assets:
Fixed maturity securities, held-to-maturity, fair value	17,319		18,662
Commercial mortgage and other loans, fair value	0		0
Other investments carried at amortized cost, fair value	0	[1]	0	[2]
Assets fair value disclosure financial instruments carried at cost	17,319		18,662
Liabilities:
Other policyholders' funds fair value disclosure	0		0
Notes payable, fair value disclosure	0		0
Liabilities fair value disclosure financial instruments carried at cost	0		0
Level 1 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	17,319		18,662
Level 1 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 1 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 2
Assets:
Fixed maturity securities, held-to-maturity, fair value	926		995
Commercial mortgage and other loans, fair value	0		0
Other investments carried at amortized cost, fair value	42	[1]	35	[2]
Assets fair value disclosure financial instruments carried at cost	968		1,030
Liabilities:
Other policyholders' funds fair value disclosure	0		0
Notes payable, fair value disclosure	6,762		6,178
Liabilities fair value disclosure financial instruments carried at cost	6,762		6,178
Level 2 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	155		167
Level 2 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	285		307
Level 2 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	36		38
Level 2 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	431		462
Level 2 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	19		21
Level 3
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Commercial mortgage and other loans, fair value	12,017		12,217
Other investments carried at amortized cost, fair value	0	[1]	0	[2]
Assets fair value disclosure financial instruments carried at cost	12,017		12,217
Liabilities:
Other policyholders' funds fair value disclosure	5,750		6,080
Notes payable, fair value disclosure	704		752
Liabilities fair value disclosure financial instruments carried at cost	6,454		6,832
Level 3 | Government and agencies
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Municipalities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Public utilities
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Sovereign and supranational
Assets:
Fixed maturity securities, held-to-maturity, fair value	0		0
Level 3 | Other corporate
Assets:
Fixed maturity securities, held-to-maturity, fair value	$ 0		$ 0

[1] Excludes policy loans of $203, equity method investments of $2,838, and REO of $253, at carrying value.

[2] Excludes policy loans of $214, equity method investments of $2,750, and REO of $227, at carrying value.

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets by Pricing Source, Securities Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	$ 70,130	$ 73,290
Equity securities	762	1,088
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	19,976	21,700
Equity securities	603	840
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	48,236	49,809
Equity securities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,918	1,781
Equity securities	159	248
Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	603	800
Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	603	800
Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		216
Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0
Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0
Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		216
Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	159	72
Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	40
Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0	0
Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	159	32
Government and agencies
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	20,814	22,600
Government and agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	19,976	21,700
Government and agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	838	900
Government and agencies | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	20,481	22,500
Government and agencies | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	19,976	21,692
Government and agencies | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	505	808
Government and agencies | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	333	60
Government and agencies | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	333	60
Government and agencies | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Government and agencies | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		40
Government and agencies | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		8
Government and agencies | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		32
Government and agencies | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		0
Municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,210	2,298
Municipalities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,210	2,298
Municipalities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,943	1,426
Municipalities | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	1,943	1,426
Municipalities | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	267	256
Municipalities | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	267	256
Municipalities | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Municipalities | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		616
Municipalities | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		0
Municipalities | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		616
Municipalities | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale		0
Mortgage- and asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,385	3,086
Mortgage- and asset-backed securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,526	2,314
Mortgage- and asset-backed securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	859	772
Mortgage- and asset-backed securities | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,420	2,277
Mortgage- and asset-backed securities | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	2,420	2,277
Mortgage- and asset-backed securities | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	67	132
Mortgage- and asset-backed securities | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	27	27
Mortgage- and asset-backed securities | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	40	105
Mortgage- and asset-backed securities | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	898	677
Mortgage- and asset-backed securities | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Mortgage- and asset-backed securities | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	79	10
Mortgage- and asset-backed securities | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	819	667
Public utilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	7,313	7,592
Public utilities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	6,806	7,339
Public utilities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	507	253
Public utilities | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,680	4,570
Public utilities | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,680	4,570
Public utilities | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,126	2,677
Public utilities | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	3,126	2,677
Public utilities | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	507	345
Public utilities | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Public utilities | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	92
Public utilities | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	507	253
Sovereign and supranational
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	490	537
Sovereign and supranational | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	462	507
Sovereign and supranational | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	28	30
Sovereign and supranational | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	125	118
Sovereign and supranational | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	125	118
Sovereign and supranational | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	337	330
Sovereign and supranational | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	337	330
Sovereign and supranational | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	28	89
Sovereign and supranational | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Sovereign and supranational | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	59
Sovereign and supranational | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	28	30
Banks/financial institutions
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	8,899	8,835
Banks/financial institutions | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	8,825	8,757
Banks/financial institutions | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	74	78
Banks/financial institutions | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4,703	5,085
Banks/financial institutions | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4,703	5,085
Banks/financial institutions | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4,187	3,077
Banks/financial institutions | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	4,122	3,008
Banks/financial institutions | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	65	69
Banks/financial institutions | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	9	673
Banks/financial institutions | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Banks/financial institutions | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	664
Banks/financial institutions | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	9	9
Other corporate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	27,019	28,342
Other corporate | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	26,569	27,694
Other corporate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	450	648
Other corporate | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	21,282	18,092
Other corporate | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	21,282	18,088
Other corporate | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	4
Other corporate | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,526	4,440
Other corporate | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	5,277	4,210
Other corporate | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	249	230
Other corporate | Broker/other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	211	5,810
Other corporate | Broker/other | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	0	0
Other corporate | Broker/other | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	10	5,396
Other corporate | Broker/other | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, available-for-sale	$ 201	$ 414

XML

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy Levels of Assets by Pricing Source, Securities Carried at Amortized Cost (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	$ 18,245	$ 19,657
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	17,319	18,662
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	926	995
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Government and agencies
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	17,474	18,829
Government and agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	17,319	18,662
Government and agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	155	167
Government and agencies | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Government and agencies | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	17,474	18,829
Government and agencies | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	17,319	18,662
Government and agencies | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	155	167
Government and agencies | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	285	307
Municipalities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	285	307
Municipalities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	285	307
Municipalities | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Municipalities | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	285	307
Municipalities | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	36	38
Public utilities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	36	38
Public utilities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	36	38
Public utilities | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Public utilities | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	36	38
Public utilities | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	431	462
Sovereign and supranational | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	431	462
Sovereign and supranational | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	213	226
Sovereign and supranational | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	213	226
Sovereign and supranational | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Internal
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	218	236
Sovereign and supranational | Internal | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Sovereign and supranational | Internal | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	218	236
Sovereign and supranational | Internal | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	19	21
Other corporate | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	19	21
Other corporate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Third party pricing vendor
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	19	21
Other corporate | Third party pricing vendor | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	0	0
Other corporate | Third party pricing vendor | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	19	21
Other corporate | Third party pricing vendor | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed maturity securities, held-to-maturity, fair value	$ 0	$ 0

XML

FAIR VALUE MEASUREMENTS - Changes in Investments and Derivatives Carried at Fair Value Classified as Level 3 (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 2,029	$ 1,987
Net investment gains (losses) included in earnings	(4)	2
Unrealized gains (losses) included in other comprehensive income (loss)	(19)	45
Purchases	220	277
Issuances	0	0
Sales	0	0
Settlements	(142)	(129)
Transfers into Level 3	226	18
Transfers out of Level 3	(233)	(260)
Balance, end of period	2,077	1,940
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$ (2)	3
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net investment gains (losses)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), before Tax
Fixed maturity securities | Mortgage- and asset-backed securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 772	343
Net investment gains (losses) included in earnings	1	0
Unrealized gains (losses) included in other comprehensive income (loss)	(4)	3
Purchases	118	192
Issuances	0	0
Sales	0	0
Settlements	(28)	(120)
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	859	418
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	1	0
Fixed maturity securities | Public utilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	253	497
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	(10)	10
Purchases	60	0
Issuances	0	0
Sales	0	0
Settlements	(22)	(7)
Transfers into Level 3	226	18
Transfers out of Level 3	0	(168)
Balance, end of period	507	350
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Sovereign and supranational
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	30	37
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	(2)	0
Purchases	0	0
Issuances	0	0
Sales	0	0
Settlements	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	28	37
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Banks/financial institutions
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	78	159
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	(4)	2
Purchases	5	0
Issuances	0	0
Sales	0	0
Settlements	(5)	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	74	161
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Fixed maturity securities | Other corporate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	648	742
Net investment gains (losses) included in earnings	0	0
Unrealized gains (losses) included in other comprehensive income (loss)	1	30
Purchases	37	75
Issuances	0	0
Sales	0	0
Settlements	(3)	(2)
Transfers into Level 3	0	0
Transfers out of Level 3	(233)	(92)
Balance, end of period	450	753
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	0	0
Equity securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	248	209
Net investment gains (losses) included in earnings	(5)	2
Unrealized gains (losses) included in other comprehensive income (loss)	0	0
Purchases	0	10
Issuances	0	0
Sales	0	0
Settlements	(84)	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Balance, end of period	159	221
Changes in unrealized gains (losses) relating to Level 3 assets and liabilities still held at the end of the period included in earnings	$ (3)	$ 3

XML

FAIR VALUE MEASUREMENTS - Fair Value Measurement Inputs and Valuation Techniques (Details) $ in Millions		Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 70,130	$ 73,290
Equity securities		762	1,088
Total assets		79,652	80,325
Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		1,918	1,781
Equity securities		159	248
Total assets		2,077	2,029
Adjusted cost valuation technique | Level 3 | Private Financials
Fair Value Measurement Inputs and Valuation Techniques
Equity securities		159	248
Municipalities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		2,210	2,298
Municipalities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		0	0
Mortgage- and asset-backed securities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		3,385	3,086
Mortgage- and asset-backed securities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		859	772
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 859	$ 772
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Lower Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	85.28	84.81
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Upper Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	105.35	105.89
Mortgage- and asset-backed securities | Consensus pricing valuation technique | Level 3 | Weighted Average | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]	99.24	99.39
Public utilities
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 7,313	$ 7,592
Public utilities | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		507	253
Public utilities | Consensus pricing valuation technique | Level 3 | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale			$ 253
Public utilities | Consensus pricing valuation technique | Level 3 | Lower Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]		94.34
Public utilities | Consensus pricing valuation technique | Level 3 | Upper Limit | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]		102.99
Public utilities | Consensus pricing valuation technique | Level 3 | Weighted Average | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[1]		96.46
Public utilities | Discounted cash flow technique | Level 3 | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 507
Public utilities | Discounted cash flow technique | Level 3 | Lower Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0175
Public utilities | Discounted cash flow technique | Level 3 | Upper Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0225
Public utilities | Discounted cash flow technique | Level 3 | Weighted Average | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0208
Sovereign and supranational
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 490	$ 537
Sovereign and supranational | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		28	30
Sovereign and supranational | Consensus pricing valuation technique | Level 3 | Offered Quotes
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		28	30
Banks/financial institutions
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		8,899	8,835
Banks/financial institutions | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		74	78
Banks/financial institutions | Discounted cash flow technique | Level 3 | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		74	78
Other corporate
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		27,019	28,342
Other corporate | Level 3
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		450	648
Other corporate | Discounted cash flow technique | Level 3 | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale		$ 450	$ 648
Other corporate | Discounted cash flow technique | Level 3 | Lower Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0069	0.0069
Other corporate | Discounted cash flow technique | Level 3 | Upper Limit | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0388	0.0423
Other corporate | Discounted cash flow technique | Level 3 | Weighted Average | Credit Spreads
Fair Value Measurement Inputs and Valuation Techniques
Fixed maturity securities, available-for-sale, measurement input	[2]	0.0183	0.0206

[1] Represents prices for securities where the Company receives unadjusted broker quotes and for which there is no transparency into the providers' valuation techniques.

[2] Actual or equivalent credit spreads in basis points.

XML

DEFERRED POLICY ACQUISITION COSTS - Schedule Of Deferred Policy Acquisition Costs (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	$ 9,132	$ 9,239	$ 9,239
Capitalization	254		1,086
Amortization expense	(215)	(205)	(816)
Foreign currency translation and other	(352)		(377)
Balance, end of period	8,819		9,132
Aflac Japan | Cancer
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	2,971	3,035	3,035
Capitalization	72		317
Amortization expense	(49)		(184)
Foreign currency translation and other	(189)		(197)
Balance, end of period	2,805		2,971
Aflac Japan | Medical and other health
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	2,041	2,161	2,161
Capitalization	29		123
Amortization expense	(25)		(105)
Foreign currency translation and other	(129)		(138)
Balance, end of period	1,916		2,041
Aflac Japan | Life insurance
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	491	525	525
Capitalization	9		33
Amortization expense	(8)		(34)
Foreign currency translation and other	(32)		(33)
Balance, end of period	460		491
Aflac Japan | Other
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	56	55	55
Capitalization	0		8
Amortization expense	(1)		(3)
Foreign currency translation and other	(2)		(4)
Balance, end of period	53		56
Aflac U.S. | Life insurance
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	172	135	135
Capitalization	19		61
Amortization expense	(7)		(24)
Foreign currency translation and other	0		0
Balance, end of period	184		172
Aflac U.S. | Accident
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	917	904	904
Capitalization	32		151
Amortization expense	(36)		(138)
Foreign currency translation and other	0		0
Balance, end of period	913		917
Aflac U.S. | Disability
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	625	613	613
Capitalization	29		125
Amortization expense	(29)		(113)
Foreign currency translation and other	0		0
Balance, end of period	625		625
Aflac U.S. | Critical Care
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	1,336	1,304	1,304
Capitalization	39		173
Amortization expense	(38)		(141)
Foreign currency translation and other	0		0
Balance, end of period	1,337		1,336
Aflac U.S. | Hospital Indemnity
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	436	418	418
Capitalization	19		84
Amortization expense	(18)		(66)
Foreign currency translation and other	0		0
Balance, end of period	437		436
Aflac U.S. | Dental/Vision
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	86	88	88
Capitalization	4		10
Amortization expense	(4)		(12)
Foreign currency translation and other	0		0
Balance, end of period	86		86
Aflac U.S. | Other
Deferred Policy Acquisition Cost [Line Items]
Balance, beginning of period	1	$ 1	1
Capitalization	2		1
Amortization expense	0		4
Foreign currency translation and other	0		(5)
Balance, end of period	$ 3		$ 1

XML

POLICY LIABILITIES - Schedule of Changes in Present Value of Expected Net Premiums and Expected Future Policy Benefits (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Present value of expected future policy benefits:
Beginning balance		$ 132,131
Ending balance		123,453	$ 132,131
Net liability for future policy benefits		77,867	83,718
Aflac Japan | Cancer
Present value of expected premiums:
Beginning balance		17,509	19,298
Beginning balance at original discount rate		16,452	18,221
Effect of changes in cash flow assumptions			0	$ (165)
Effect of actual variances from expected experience			(46)	(315)
Adjusted beginning of period balance			16,406	17,741
Issuances		229	1,034
Interest accrual		97	412
Net premiums collected	[1]	(369)	(1,564)
Foreign currency translation		(1,041)	(1,170)
Other		0	(1)
Ending balance at original discount rate		15,322	16,452
Effect of changes in discount rate assumptions		895	1,057
Ending balance		16,217	17,509
Present value of expected future policy benefits:
Beginning balance		50,161	54,766
Beginning balance at original discount rate		43,626	47,677
Effect of changes in cash flow assumptions			0	(147)
Effect of actual variances from expected experience			(62)	(385)
Adjusted beginning of period balance			43,564	47,145
Issuances		232	1,059
Interest accrual		343	1,473
Benefit payments		(682)	(2,987)
Foreign currency translation		(2,757)	(3,064)
Other		0	0
Ending balance at original discount rate		40,700	43,626
Effect of changes in discount rate assumptions		5,689	6,535
Ending balance		46,389	50,161
Net liability for future policy benefits		30,172	32,652
Less: reinsurance recoverable		3,829	4,135
Net liability for future policy benefits after reinsurance recoverable		26,343	28,517
Aflac Japan | Medical and other health
Present value of expected premiums:
Beginning balance		14,697	16,714
Beginning balance at original discount rate		14,040	16,195
Effect of changes in cash flow assumptions			0	(470)
Effect of actual variances from expected experience			(52)	(137)
Adjusted beginning of period balance			13,988	15,588
Issuances		103	418
Interest accrual		77	334
Net premiums collected	[1]	(290)	(1,261)
Foreign currency translation		(888)	(1,038)
Other		0	(1)
Ending balance at original discount rate		12,990	14,040
Effect of changes in discount rate assumptions		535	657
Ending balance		13,525	14,697
Present value of expected future policy benefits:
Beginning balance		25,257	27,419
Beginning balance at original discount rate		25,023	27,566
Effect of changes in cash flow assumptions			0	(507)
Effect of actual variances from expected experience			(59)	(154)
Adjusted beginning of period balance			24,964	26,905
Issuances		105	432
Interest accrual		142	608
Benefit payments		(246)	(1,153)
Foreign currency translation		(1,582)	(1,769)
Other		0	0
Ending balance at original discount rate		23,383	25,023
Effect of changes in discount rate assumptions		(52)	234
Ending balance		23,331	25,257
Net liability for future policy benefits		9,806	10,560
Less: reinsurance recoverable		1,407	1,521
Net liability for future policy benefits after reinsurance recoverable		8,399	9,039
Aflac Japan | Life insurance
Present value of expected premiums:
Beginning balance		6,488	7,485
Beginning balance at original discount rate		6,258	7,284
Effect of changes in cash flow assumptions			0	43
Effect of actual variances from expected experience			(19)	(42)
Adjusted beginning of period balance			6,239	7,285
Issuances		58	335
Interest accrual		28	124
Net premiums collected	[1]	(226)	(1,017)
Foreign currency translation		(392)	(469)
Other		0	0
Ending balance at original discount rate		5,707	6,258
Effect of changes in discount rate assumptions		194	230
Ending balance		5,901	6,488
Present value of expected future policy benefits:
Beginning balance		29,731	31,954
Beginning balance at original discount rate		30,256	32,800
Effect of changes in cash flow assumptions			0	65
Effect of actual variances from expected experience			(20)	(51)
Adjusted beginning of period balance			30,236	32,814
Issuances		59	341
Interest accrual		146	625
Benefit payments		(516)	(1,415)
Foreign currency translation		(1,909)	(2,109)
Other		0	0
Ending balance at original discount rate		28,016	30,256
Effect of changes in discount rate assumptions		(767)	(525)
Ending balance		27,249	29,731
Net liability for future policy benefits		21,348	23,243
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		21,348	23,243
Aflac Japan | Other
Present value of expected premiums:
Beginning balance		1,088	1,256
Beginning balance at original discount rate		1,069	1,242
Effect of changes in cash flow assumptions			0	(12)
Effect of actual variances from expected experience			(5)	(15)
Adjusted beginning of period balance			1,064	1,215
Issuances		5	26
Interest accrual		4	20
Net premiums collected	[1]	(26)	(112)
Foreign currency translation		(66)	(80)
Other		0	0
Ending balance at original discount rate		981	1,069
Effect of changes in discount rate assumptions		14	19
Ending balance		995	1,088
Present value of expected future policy benefits:
Beginning balance		5,178	5,582
Beginning balance at original discount rate		5,444	5,940
Effect of changes in cash flow assumptions			0	(27)
Effect of actual variances from expected experience			(8)	(15)
Adjusted beginning of period balance			5,436	5,898
Issuances		7	32
Interest accrual		23	100
Benefit payments		(55)	(206)
Foreign currency translation		(345)	(380)
Other		0	0
Ending balance at original discount rate		5,066	5,444
Effect of changes in discount rate assumptions		(294)	(266)
Ending balance		4,772	5,178
Net liability for future policy benefits		3,777	4,090
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		3,777	4,090
Aflac U.S. | Life insurance
Present value of expected premiums:
Beginning balance		853	724
Beginning balance at original discount rate		909	799
Effect of changes in cash flow assumptions			0	61
Effect of actual variances from expected experience			(8)	(25)
Adjusted beginning of period balance			901	835
Issuances		66	181
Interest accrual		9	31
Net premiums collected	[1]	(37)	(137)
Foreign currency translation		0	0
Other		1	(1)
Ending balance at original discount rate		940	909
Effect of changes in discount rate assumptions		(66)	(56)
Ending balance		874	853
Present value of expected future policy benefits:
Beginning balance		1,764	1,526
Beginning balance at original discount rate		1,971	1,778
Effect of changes in cash flow assumptions			0	72
Effect of actual variances from expected experience			(11)	(32)
Adjusted beginning of period balance			1,960	1,818
Issuances		70	185
Interest accrual		19	68
Benefit payments		(29)	(105)
Foreign currency translation		0	0
Other		1	5
Ending balance at original discount rate		2,021	1,971
Effect of changes in discount rate assumptions		(246)	(207)
Ending balance		1,775	1,764
Net liability for future policy benefits		901	911
Less: reinsurance recoverable		15	15
Net liability for future policy benefits after reinsurance recoverable		886	896
Aflac U.S. | Accident
Present value of expected premiums:
Beginning balance		2,488	2,534
Beginning balance at original discount rate		2,630	2,760
Effect of changes in cash flow assumptions			0	(16)
Effect of actual variances from expected experience			(18)	(58)
Adjusted beginning of period balance			2,612	2,686
Issuances		111	323
Interest accrual		26	102
Net premiums collected	[1]	(117)	(473)
Foreign currency translation		0	0
Other		0	(8)
Ending balance at original discount rate		2,632	2,630
Effect of changes in discount rate assumptions		(173)	(142)
Ending balance		2,459	2,488
Present value of expected future policy benefits:
Beginning balance		3,109	3,098
Beginning balance at original discount rate		3,302	3,391
Effect of changes in cash flow assumptions			0	(11)
Effect of actual variances from expected experience			(21)	(75)
Adjusted beginning of period balance			3,281	3,305
Issuances		115	331
Interest accrual		32	127
Benefit payments		(125)	(464)
Foreign currency translation		0	0
Other		0	3
Ending balance at original discount rate		3,303	3,302
Effect of changes in discount rate assumptions		(233)	(193)
Ending balance		3,070	3,109
Net liability for future policy benefits		611	621
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		611	621
Aflac U.S. | Disability
Present value of expected premiums:
Beginning balance		1,652	1,635
Beginning balance at original discount rate		1,738	1,775
Effect of changes in cash flow assumptions			0	(51)
Effect of actual variances from expected experience			(10)	(29)
Adjusted beginning of period balance			1,728	1,695
Issuances		121	376
Interest accrual		16	62
Net premiums collected	[1]	(99)	(390)
Foreign currency translation		0	0
Other		(1)	(5)
Ending balance at original discount rate		1,765	1,738
Effect of changes in discount rate assumptions		(99)	(86)
Ending balance		1,666	1,652
Present value of expected future policy benefits:
Beginning balance		2,422	2,445
Beginning balance at original discount rate		2,541	2,636
Effect of changes in cash flow assumptions			0	(59)
Effect of actual variances from expected experience			(17)	(59)
Adjusted beginning of period balance			2,524	2,518
Issuances		128	392
Interest accrual		24	96
Benefit payments		(112)	(465)
Foreign currency translation		0	0
Other		0	0
Ending balance at original discount rate		2,564	2,541
Effect of changes in discount rate assumptions		(141)	(119)
Ending balance		2,423	2,422
Net liability for future policy benefits		757	770
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		757	770
Aflac U.S. | Critical Care
Present value of expected premiums:
Beginning balance		4,074	4,486
Beginning balance at original discount rate		4,416	5,050
Effect of changes in cash flow assumptions			0	(494)
Effect of actual variances from expected experience			(48)	(223)
Adjusted beginning of period balance			4,368	4,333
Issuances		221	493
Interest accrual		43	179
Net premiums collected	[1]	(139)	(580)
Foreign currency translation		0	0
Other		0	(9)
Ending balance at original discount rate		4,493	4,416
Effect of changes in discount rate assumptions		(412)	(342)
Ending balance		4,081	4,074
Present value of expected future policy benefits:
Beginning balance		11,290	11,489
Beginning balance at original discount rate		12,120	12,846
Effect of changes in cash flow assumptions			0	(592)
Effect of actual variances from expected experience			(60)	(271)
Adjusted beginning of period balance			12,060	11,983
Issuances		233	505
Interest accrual		128	524
Benefit payments		(228)	(893)
Foreign currency translation		0	0
Other		1	1
Ending balance at original discount rate		12,194	12,120
Effect of changes in discount rate assumptions		(1,092)	(830)
Ending balance		11,102	11,290
Net liability for future policy benefits		7,021	7,216
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		7,021	7,216
Aflac U.S. | Hospital Indemnity
Present value of expected premiums:
Beginning balance		1,107	1,220
Beginning balance at original discount rate		1,193	1,365
Effect of changes in cash flow assumptions			0	(142)
Effect of actual variances from expected experience			(14)	(73)
Adjusted beginning of period balance			1,179	1,150
Issuances		95	249
Interest accrual		11	45
Net premiums collected	[1]	(58)	(247)
Foreign currency translation		0	0
Other		(1)	(4)
Ending balance at original discount rate		1,226	1,193
Effect of changes in discount rate assumptions		(99)	(86)
Ending balance		1,127	1,107
Present value of expected future policy benefits:
Beginning balance		1,943	2,074
Beginning balance at original discount rate		2,076	2,300
Effect of changes in cash flow assumptions			0	(194)
Effect of actual variances from expected experience			(18)	(99)
Adjusted beginning of period balance			2,058	2,007
Issuances		99	258
Interest accrual		20	84
Benefit payments		(76)	(274)
Foreign currency translation		0	0
Other		0	1
Ending balance at original discount rate		2,101	2,076
Effect of changes in discount rate assumptions		(163)	(133)
Ending balance		1,938	1,943
Net liability for future policy benefits		811	836
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		811	836
Aflac U.S. | Dental/Vision
Present value of expected premiums:
Beginning balance		206	211
Beginning balance at original discount rate		217	231
Effect of changes in cash flow assumptions			0	(9)
Effect of actual variances from expected experience			(4)	(17)
Adjusted beginning of period balance			213	205
Issuances		18	44
Interest accrual		2	8
Net premiums collected	[1]	(10)	(39)
Foreign currency translation		0	0
Other		(1)	(1)
Ending balance at original discount rate		222	217
Effect of changes in discount rate assumptions		(14)	(11)
Ending balance		208	206
Present value of expected future policy benefits:
Beginning balance		478	488
Beginning balance at original discount rate		506	532
Effect of changes in cash flow assumptions			0	(14)
Effect of actual variances from expected experience			(5)	(22)
Adjusted beginning of period balance			501	496
Issuances		16	46
Interest accrual		5	21
Benefit payments		(14)	(59)
Foreign currency translation		0	0
Other		1	2
Ending balance at original discount rate		509	506
Effect of changes in discount rate assumptions		(35)	(28)
Ending balance		474	478
Net liability for future policy benefits		266	272
Less: reinsurance recoverable		0	0
Net liability for future policy benefits after reinsurance recoverable		266	272
Aflac U.S. | Other
Present value of expected premiums:
Beginning balance		277	110
Beginning balance at original discount rate		272	118
Effect of changes in cash flow assumptions			0	(9)
Effect of actual variances from expected experience			2	(2)
Adjusted beginning of period balance			274	107
Issuances		147	169
Interest accrual		3	6
Net premiums collected	[1]	(8)	(17)
Foreign currency translation		0	0
Other		(1)	7
Ending balance at original discount rate		415	272
Effect of changes in discount rate assumptions		6	5
Ending balance		421	277
Present value of expected future policy benefits:
Beginning balance		798	622
Beginning balance at original discount rate		769	624
Effect of changes in cash flow assumptions			0	(13)
Effect of actual variances from expected experience			2	(4)
Adjusted beginning of period balance			771	$ 607
Issuances		151	169
Interest accrual		10	33
Benefit payments		(17)	(48)
Foreign currency translation		0	0
Other		0	8
Ending balance at original discount rate		915	769
Effect of changes in discount rate assumptions		15	29
Ending balance		930	798
Net liability for future policy benefits		509	521
Less: reinsurance recoverable		2	0
Net liability for future policy benefits after reinsurance recoverable		$ 507	$ 521

[1] Net premiums collected represent the portion of gross premiums collected from policyholders that is used to fund expected future benefit payments.

XML

POLICY LIABILITIES - Schedule of Weighted-Average Interest Rate and Liability for Future Policy Benefit (Details)		Mar. 31, 2024	Dec. 31, 2023
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	3.90%	3.90%
Weighted-average interest, current discount rate	[1]	2.00%	1.80%
Weighted-average liability duration		13 years	13 years 1 month 6 days
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	2.50%	2.60%
Weighted-average interest, current discount rate	[1]	2.50%	2.30%
Weighted-average liability duration		24 years 8 months 12 days	24 years 10 months 24 days
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	2.10%	2.10%
Weighted-average interest, current discount rate	[1]	1.90%	1.70%
Weighted-average liability duration		16 years 3 months 18 days	16 years 3 months 18 days
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	3.80%	3.70%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		13 years 9 months 18 days	13 years 7 months 6 days
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	3.90%	3.90%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		8 years	8 years 1 month 6 days
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.30%	4.20%
Weighted-average interest, current discount rate	[1]	5.20%	5.30%
Weighted-average liability duration		5 years 7 months 6 days	5 years 7 months 6 days
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.60%	4.60%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		11 years 2 months 12 days	11 years 3 months 18 days
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.50%	4.40%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		9 years 3 months 18 days	9 years 3 months 18 days
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	4.30%	4.30%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		7 years 10 months 24 days	7 years 10 months 24 days
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	1.80%	1.80%
Weighted-average interest, current discount rate	[1]	2.30%	2.10%
Weighted-average liability duration		17 years 1 month 6 days	17 years 3 months 18 days
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Weighted-average interest, original discount rate	[1]	5.40%	5.40%
Weighted-average interest, current discount rate	[1]	5.30%	5.30%
Weighted-average liability duration		9 years 2 months 12 days	9 years 4 months 24 days

[1] The weighted-average interest rates are calculated using the reserve balances as the weights. No adjustments were made to observable market information.

XML

POLICY LIABILITIES - Reconciliation of Future Policy Benefits (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		$ 77,867	$ 83,718
Deferred reinsurance gain liability		161	175
Deferred Profit Liability - Limited-payment Contracts
Liability for Future Policy Benefit, Activity [Line Items]
Deferred profit liability - limited-payment contracts		1,734	1,806
Deferred reinsurance gain liability		910	1,012
Intercompany eliminations
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits	[1]	(4,598)	(5,017)
Corporate and other
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		3,842	4,225
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		30,172	32,652
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		9,806	10,560
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		21,348	23,243
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		901	911
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		611	621
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		757	770
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		7,021	7,216
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		811	836
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		266	272
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		3,777	4,090
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Future policy benefits		$ 509	$ 521

[1] Elimination entry necessary due to the internal reinsurance transactions with Aflac Re and to recapture a portion of policy liabilities ceded externally as a result of the reinsurance retrocession transaction. See Note 8 for additional details.

XML

POLICY LIABILITIES - Summary of Net Earned Premiums Recognized (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	$ 3,456	$ 3,688
Reinsurance ceded	(69)	(104)
Corporate and other
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	165	90
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	878	1,132
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	605	689
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	339	399
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	138	115
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	325	329
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	333	309
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	444	443
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	185	184
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	59	53
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	34	39
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Net earned premiums	$ 20	$ 10

XML

POLICY LIABILITIES - Summary of Interest Expense Related to Insurance Contracts Recognized (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	$ 576	$ 641
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	246	285
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	65	71
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	118	133
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	10	9
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	6	6
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	8	8
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	85	87
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	9	10
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	3	3
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	19	22
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Interest expense	$ 7	$ 7

XML

POLICY LIABILITIES - Summary of Undiscounted Expected Future Gross Premiums and Future Benefits and Expenses (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	$ 149,085	$ 156,494
Benefits and Expenses	182,776	193,058
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	55,096	59,169
Benefits and Expenses	61,876	66,427
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	35,735	38,583
Benefits and Expenses	37,277	39,884
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	11,637	12,677
Benefits and Expenses	39,439	42,541
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	2,824	2,719
Benefits and Expenses	3,367	3,260
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	9,097	9,095
Benefits and Expenses	4,551	4,548
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	5,819	5,776
Benefits and Expenses	3,210	3,177
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	20,008	19,886
Benefits and Expenses	20,712	20,626
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	4,985	4,922
Benefits and Expenses	3,058	3,025
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,161	1,162
Benefits and Expenses	729	726
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,646	1,781
Benefits and Expenses	6,923	7,448
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,077	724
Benefits and Expenses	$ 1,634	$ 1,396

XML

POLICY LIABILITIES - Summary of Discounted Expected Future Gross Premiums and Future Benefits and Expenses (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	$ 114,691	$ 121,753
Benefits and Expenses	123,453	132,131
Cancer | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	44,795	48,363
Benefits and Expenses	46,389	50,161	$ 54,766
Medical and other health | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	28,312	30,757
Benefits and Expenses	23,331	25,257	27,419
Life insurance | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	10,274	11,240
Benefits and Expenses	27,249	29,731	31,954
Life insurance | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,963	1,914
Benefits and Expenses	1,775	1,764	1,526
Accident | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	6,293	6,369
Benefits and Expenses	3,070	3,109	3,098
Disability | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	4,476	4,488
Benefits and Expenses	2,423	2,422	2,445
Critical Care | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	12,295	12,417
Benefits and Expenses	11,102	11,290	11,489
Hospital Indemnity | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	3,425	3,419
Benefits and Expenses	1,938	1,943	2,074
Dental/Vision | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	794	807
Benefits and Expenses	474	478	488
Other | Aflac Japan
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	1,391	1,512
Benefits and Expenses	4,772	5,178	5,582
Other | Aflac U.S.
Liability for Future Policy Benefit, Activity [Line Items]
Gross Premiums	673	467
Benefits and Expenses	$ 930	$ 798	$ 622

XML

POLICY LIABILITIES - Schedule of Changes in Other Policyholders' Funds (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Policyholder Account Balance [Line Items]
Other deposit type reserves		$ 293	$ 230
Total		5,831	6,169
Aflac Japan | Fixed Annuity
Policyholder Account Balance [Line Items]
Beginning balance	[1]	5,939	6,423
Premiums received	[1]	29	126
Transfers from WAYS conversions	[1]	61	229
Surrenders and withdrawals	[1]	(18)	(59)
Benefit payments	[1]	(110)	(419)
Interest credited	[1]	13	53
Foreign currency translation and other	[1]	(376)	(414)
Ending balance	[1]	$ 5,538	$ 5,939

[1] Aflac Japan fixed annuities

XML

POLICY LIABILITIES - Schedule of Other Policyholders' Funds by Guaranteed Crediting Rates (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder Account Balance, Weighted Average Crediting Rate		1.50%	1.50%
Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
At Guaranteed Minimum	[1]	$ 5,538	$ 5,939	$ 6,423
Cash Surrender Value	[1]	$ 5,457	$ 5,850
Lower Limit | Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Guaranteed Minimum Crediting Rates	[1],[2]	0.50%	0.50%
Upper Limit | Aflac Japan | Fixed Annuity
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Guaranteed Minimum Crediting Rates	[1],[2]	2.20%	2.30%

[1] Aflac Japan fixed annuities

[2] Weighted-average crediting rate of 1.5% at March 31, 2024 and December 31, 2023.

XML

POLICY LIABILITIES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Insurance [Abstract]
Effect of changes in discount rate assumptions during period, net of income taxes	$ 1,065	$ (2,794)

XML

REINSURANCE - Effect of Reinsurance on Premiums and Benefits and Claims (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Effects of Reinsurance [Line Items]
Direct earned premiums	$ 3,482	$ 3,738
Ceded premiums	(69)	(104)
Net earned premiums	3,456	3,688
Direct benefits and claims, excluding reserve remeasurement	2,082	2,256
Benefits and claims, excluding reserve remeasurement	2,066	2,203
Reserve remeasurement (gains) losses, direct	(57)	(53)
Reserve remeasurement gains (losses), ceded	1	0
Reserve remeasurement (gains) losses, assumed	0	0
Reserve remeasurement (gains) losses	(56)	(53)
Benefits and claims, net	2,010	2,150
All other
Effects of Reinsurance [Line Items]
Ceded premiums	(35)	(25)
Assumed premiums earned	14	23
Ceded benefits and claims	(15)	(27)
Assumed benefits and claims from other companies	4	10
Aflac Japan | Closed Block
Effects of Reinsurance [Line Items]
Ceded premiums	(34)	(82)
Assumed premiums earned	29	34
Ceded benefits and claims	(18)	(77)
Assumed benefits and claims from other companies	$ 13	$ 41

XML

REINSURANCE - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Effects of Reinsurance [Line Items]
Deferred reinsurance gain liability	$ 161	$ 175
Reinsurance recoverable	178	183
Reinsurance recoverable, allowance for credit loss	$ (4)	$ (10)

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Notes Payable (Details) - USD ($) $ in Millions		Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Notes payable and lease obligations		$ 7,912	$ 7,364
Finance lease obligations		6	6
Operating lease obligations		107	118
1.125% senior sustainability notes due March 2026
Debt Instrument [Line Items]
Notes payable and lease obligations		398	398
2.875% senior notes due October 2026
Debt Instrument [Line Items]
Notes payable and lease obligations		299	299
3.60% senior notes due April 2030
Debt Instrument [Line Items]
Notes payable and lease obligations		993	993
6.90% senior notes due December 2039
Debt Instrument [Line Items]
Notes payable and lease obligations		221	221
6.45% senior notes due August 2040
Debt Instrument [Line Items]
Notes payable and lease obligations		254	254
4.00% senior notes due October 2046
Debt Instrument [Line Items]
Notes payable and lease obligations		394	394
4.750% senior notes due January 2049
Debt Instrument [Line Items]
Notes payable and lease obligations		542	542
.300% senior notes due September 2025
Debt Instrument [Line Items]
Notes payable and lease obligations		82	87
.932% senior notes due January 2027
Debt Instrument [Line Items]
Notes payable and lease obligations		395	422
1.048% senior notes due March 2029
Debt Instrument [Line Items]
Notes payable and lease obligations		86	0
1.075% senior notes due September 2029
Debt Instrument [Line Items]
Notes payable and lease obligations		220	234
.500% senior notes due December 2029
Debt Instrument [Line Items]
Notes payable and lease obligations		83	88
.550% senior notes due March 2030
Debt Instrument [Line Items]
Notes payable and lease obligations		87	93
1.159% senior notes due October 2030
Debt Instrument [Line Items]
Notes payable and lease obligations		192	206
1.412% senior notes due March 2031
Debt Instrument [Line Items]
Notes payable and lease obligations		184	0
.633% senior notes due April 2031
Debt Instrument [Line Items]
Notes payable and lease obligations		197	211
.843% senior notes due December 2031
Debt Instrument [Line Items]
Notes payable and lease obligations		61	65
.750% senior notes due March 2032
Debt Instrument [Line Items]
Notes payable and lease obligations		136	145
1.320% senior notes due December 2032
Debt Instrument [Line Items]
Notes payable and lease obligations		139	148
.844% senior notes due April 2033
Debt Instrument [Line Items]
Notes payable and lease obligations		79	84
1.488% senior notes due October 2033
Debt Instrument [Line Items]
Notes payable and lease obligations		100	106
1.682% senior notes due March 2034
Debt Instrument [Line Items]
Notes payable and lease obligations		51	0
1.600% senior notes due March 2034
Debt Instrument [Line Items]
Notes payable and lease obligations		122	0
.934% senior notes due December 2034
Debt Instrument [Line Items]
Notes payable and lease obligations		64	69
.830% senior notes due March 2035
Debt Instrument [Line Items]
Notes payable and lease obligations		69	74
1.740% senior notes due March 2036
Debt Instrument [Line Items]
Notes payable and lease obligations		100	0
1.039% senior notes due April 2036
Debt Instrument [Line Items]
Notes payable and lease obligations		65	70
1.594% senior notes due September 2037
Debt Instrument [Line Items]
Notes payable and lease obligations		43	45
1.750% senior notes due October 2038
Debt Instrument [Line Items]
Notes payable and lease obligations		58	62
1.920% senior notes due March 2039
Debt Instrument [Line Items]
Notes payable and lease obligations		110	0
1.122% senior notes due December 2039
Debt Instrument [Line Items]
Notes payable and lease obligations		41	44
1.264% senior notes due April 2041
Debt Instrument [Line Items]
Notes payable and lease obligations		65	70
2.160% senior notes due March 2044
Debt Instrument [Line Items]
Notes payable and lease obligations		38	0
2.108% subordinated notes due October 2047
Debt Instrument [Line Items]
Notes payable and lease obligations		392	419
.963% subordinated bonds due April 2049
Debt Instrument [Line Items]
Notes payable and lease obligations	[1]	198	211
1.560% senior notes due April 2051
Debt Instrument [Line Items]
Notes payable and lease obligations		131	140
2.144% senior notes due September 2052
Debt Instrument [Line Items]
Notes payable and lease obligations		79	84
1.958% subordinated bonds due December 2053
Debt Instrument [Line Items]
Notes payable and lease obligations		197	210
2.400% senior notes due March 2054
Debt Instrument [Line Items]
Notes payable and lease obligations		130	0
Yen-denominated loan variable interest rate due August 2027
Debt Instrument [Line Items]
Notes payable and lease obligations		77	82
Yen-denominated loan variable interest rate due August 2029
Debt Instrument [Line Items]
Notes payable and lease obligations		166	178
Yen-denominated loan variable interest rate due August 2032
Debt Instrument [Line Items]
Notes payable and lease obligations		$ 461	$ 492

[1] Redeemed in April 2024

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Notes Payable (Details 2) - JPY (¥) ¥ in Billions	Mar. 31, 2024	Dec. 31, 2023
1.125% senior sustainability notes due March 2026
Debt Instrument [Line Items]
Debt instrument, interest rate	1.125%	1.125%
2.875% senior notes due October 2026
Debt Instrument [Line Items]
Debt instrument, interest rate	2.875%	2.875%
3.60% senior notes due April 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	3.60%	3.60%
6.90% senior notes due December 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	6.90%	6.90%
6.45% senior notes due August 2040
Debt Instrument [Line Items]
Debt instrument, interest rate	6.45%	6.45%
4.00% senior notes due October 2046
Debt Instrument [Line Items]
Debt instrument, interest rate	4.00%	4.00%
4.750% senior notes due January 2049
Debt Instrument [Line Items]
Debt instrument, interest rate	4.75%	4.75%
.300% senior notes due September 2025
Debt Instrument [Line Items]
Debt instrument, interest rate	0.30%	0.30%
Debt instrument, principal amount	¥ 12.4	¥ 12.4
.932% senior notes due January 2027
Debt Instrument [Line Items]
Debt instrument, interest rate	0.932%	0.932%
Debt instrument, principal amount	¥ 60.0	¥ 60.0
1.048% senior notes due March 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	1.048%
Debt instrument, principal amount	¥ 13.0
1.075% senior notes due September 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	1.075%	1.075%
Debt instrument, principal amount	¥ 33.4	¥ 33.4
.500% senior notes due December 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	0.50%	0.50%
Debt instrument, principal amount	¥ 12.6	¥ 12.6
.550% senior notes due March 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	0.55%	0.55%
Debt instrument, principal amount	¥ 13.3	¥ 13.3
1.159% senior notes due October 2030
Debt Instrument [Line Items]
Debt instrument, interest rate	1.159%	1.159%
Debt instrument, principal amount	¥ 29.3	¥ 29.3
1.412% senior notes due March 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	1.412%
Debt instrument, principal amount	¥ 27.9
.633% senior notes due April 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	0.633%	0.633%
Debt instrument, principal amount	¥ 30.0	¥ 30.0
.843% senior notes due December 2031
Debt Instrument [Line Items]
Debt instrument, interest rate	0.843%	0.843%
Debt instrument, principal amount	¥ 9.3	¥ 9.3
.750% senior notes due March 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	0.75%	0.75%
Debt instrument, principal amount	¥ 20.7	¥ 20.7
1.320% senior notes due December 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	1.32%	1.32%
Debt instrument, principal amount	¥ 21.1	¥ 21.1
.844% senior notes due April 2033
Debt Instrument [Line Items]
Debt instrument, interest rate	0.844%	0.844%
Debt instrument, principal amount	¥ 12.0	¥ 12.0
1.488% senior notes due October 2033
Debt Instrument [Line Items]
Debt instrument, interest rate	1.488%	1.488%
Debt instrument, principal amount	¥ 15.2	¥ 15.2
1.682% senior notes due March 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	1.682%
Debt instrument, principal amount	¥ 7.7
1.600% senior notes due March 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	1.60%
Debt instrument, principal amount	¥ 18.3
.934% senior notes due December 2034
Debt Instrument [Line Items]
Debt instrument, interest rate	0.934%	0.934%
Debt instrument, principal amount	¥ 9.8	¥ 9.8
.830% senior notes due March 2035
Debt Instrument [Line Items]
Debt instrument, interest rate	0.83%	0.83%
Debt instrument, principal amount	¥ 10.6	¥ 10.6
1.740% senior notes due March 2036
Debt Instrument [Line Items]
Debt instrument, interest rate	1.74%
Debt instrument, principal amount	¥ 15.0
1.039% senior notes due April 2036
Debt Instrument [Line Items]
Debt instrument, interest rate	1.039%	1.039%
Debt instrument, principal amount	¥ 10.0	¥ 10.0
1.594% senior notes due September 2037
Debt Instrument [Line Items]
Debt instrument, interest rate	1.594%	1.594%
Debt instrument, principal amount	¥ 6.5	¥ 6.5
1.750% senior notes due October 2038
Debt Instrument [Line Items]
Debt instrument, interest rate	1.75%	1.75%
Debt instrument, principal amount	¥ 8.9	¥ 8.9
1.920% senior notes due March 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	1.92%
Debt instrument, principal amount	¥ 16.5
1.122% senior notes due December 2039
Debt Instrument [Line Items]
Debt instrument, interest rate	1.122%	1.122%
Debt instrument, principal amount	¥ 6.3	¥ 6.3
1.264% senior notes due April 2041
Debt Instrument [Line Items]
Debt instrument, interest rate	1.264%	1.264%
Debt instrument, principal amount	¥ 10.0	¥ 10.0
2.160% senior notes due March 2044
Debt Instrument [Line Items]
Debt instrument, interest rate	2.16%
Debt instrument, principal amount	¥ 5.7
2.108% subordinated notes due October 2047
Debt Instrument [Line Items]
Debt instrument, interest rate	2.108%	2.108%
Debt instrument, principal amount	¥ 60.0	¥ 60.0
.963% subordinated bonds due April 2049
Debt Instrument [Line Items]
Debt instrument, interest rate	0.963%	0.963%
Debt instrument, principal amount	¥ 30.0	¥ 30.0
1.560% senior notes due April 2051
Debt Instrument [Line Items]
Debt instrument, interest rate	1.56%	1.56%
Debt instrument, principal amount	¥ 20.0	¥ 20.0
2.144% senior notes due September 2052
Debt Instrument [Line Items]
Debt instrument, interest rate	2.144%	2.144%
Debt instrument, principal amount	¥ 12.0	¥ 12.0
1.958% subordinated bonds due December 2053
Debt Instrument [Line Items]
Debt instrument, interest rate	1.958%	1.958%
Debt instrument, principal amount	¥ 30.0	¥ 30.0
2.400% senior notes due March 2054
Debt Instrument [Line Items]
Debt instrument, interest rate	2.40%
Debt instrument, principal amount	¥ 19.5
Yen-denominated loan variable interest rate due August 2027
Debt Instrument [Line Items]
Debt instrument, interest rate	0.38%	0.35%
Debt instrument, principal amount	¥ 11.7	¥ 11.7
Yen-denominated loan variable interest rate due August 2029
Debt Instrument [Line Items]
Debt instrument, interest rate	0.48%	0.45%
Debt instrument, principal amount	¥ 25.3	¥ 25.3
Yen-denominated loan variable interest rate due August 2032
Debt Instrument [Line Items]
Debt instrument, interest rate	0.63%	0.60%
Debt instrument, principal amount	¥ 70.0	¥ 70.0

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Summary of Lines of Credit (Details) - 3 months ended Mar. 31, 2024 ¥ in Millions, $ in Millions	USD ($)	JPY (¥)
$100 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 100.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	The rate quoted by the bank and agreed upon at the time of borrowing
100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	5 years
Line of credit facility, maximum borrowing capacity | ¥		¥ 100,000
Line of credit facility, amount outstanding | ¥		0
Line of credit facility, interest rate description	A rate per annum equal to (a) Tokyo Interbank Market Rate (TIBOR) plus, the alternative applicable TIBOR margin during the availability period from the closing date to the commitment termination date or (b) the TIBOR rate offered by the agent to major banks in yen for the applicable period plus, the applicable alternative TIBOR margin during the term out period
$1 billion line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	5 years
Line of credit facility, maximum borrowing capacity	$ 1,000.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	A rate per annum equal to, at the Company's option, either, (a) Secured Overnight Financing Rate (SOFR) for U.S. dollar denominated borrowings or TIBOR for Japanese yen denominated borrowings, in either case adjusted for certain costs, or (b) a base rate determined by reference to the highest of (1) the federal funds rate plus 1/2 of 1%, (2) the rate of interest for such day announced by the agent as its prime rate, or (3) SOFR for an interest period of one month plus 1.00%, in each case plus an applicable margin
$50 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 50.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	A rate per annum equal to, at the Parent Company's option, either (a) a rate determined by reference to SOFR for the interest period relevant to such borrowing or (b) the base rate determined by reference to the highest of (1) the lender's USD short-term commercial loan rate and (2) the federal funds rate plus 1/2 of 1%
$250 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 250.0
Line of credit facility, amount outstanding	$ 50.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
50.0 billion yen line of credit (Tranche 1)
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity | ¥		50,000
Line of credit facility, amount outstanding | ¥		0
Line of credit facility, interest rate description	Three-month yen TIBOR plus 75 basis points per annum
50.0 billion yen line of credit (Tranche 2)
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity | ¥		50,000
Line of credit facility, amount outstanding | ¥		0
Line of credit facility, interest rate description	Three-month yen TIBOR plus 75 basis points per annum
$25 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 25.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$15 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 15.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$300 thousand line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 0.3
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
900 million yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity | ¥		900
Line of credit facility, amount outstanding | ¥		0
Line of credit facility, interest rate description	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period
600 million yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity | ¥		600
Line of credit facility, amount outstanding | ¥		¥ 0
Line of credit facility, interest rate description	A rate per annum equal to the short-term prime lending rates of banks appearing on the website for the Bank of Japan on the first day of the applicable period
$30 million line of credit
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 30.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 75 basis points per annum
$400 million line of credit (Aflac Incorporated as borrower)
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 400.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 97 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 97 basis points per annum for Japanese yen-denominated borrowings
$400 million line of credit (Aflac Re Bermuda Ltd. as borrower)
Line of Credit Facility [Line Items]
Line of credit facility term	364 days
Line of credit facility, maximum borrowing capacity	$ 400.0
Line of credit facility, amount outstanding	$ 0.0
Line of credit facility, interest rate description	Three-month term SOFR plus a 10 basis point SOFR adjustment and an additional 68 basis points per annum for U.S. dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings
Lower Limit | 100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.28%
Lower Limit | $1 billion line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.08%
Upper Limit | $100 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	3 months
Upper Limit | 100.0 billion yen line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.45%
Upper Limit | $1 billion line of credit
Line of Credit Facility [Line Items]
Line of credit facility, commitment fee percentage	0.20%
Upper Limit | $50 million line of credit
Line of Credit Facility [Line Items]
Debt instrument, term	3 months

XML

NOTES PAYABLE AND LEASE OBLIGATIONS - Additional Information (Details) $ in Millions, ¥ in Billions	1 Months Ended	3 Months Ended
	Mar. 31, 2024 JPY (¥) series	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)
Debt Instrument [Line Items]
Number of Senior Notes Issued Through a Private Placement | series	5
Number of Senior Notes Issued Through a Public Offering | series	3
Interest expense on debt | $		$ 46	$ 47
Senior Notes Issued Through a Private Placement
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 75.0
Senior Notes Issued Through a Public Offering
Debt Instrument [Line Items]
Debt Instrument, Face Amount	48.6
1.600% senior notes due March 2034
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 18.3
Debt instrument, interest rate	1.60%			1.60%
1.740% senior notes due March 2036
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 15.0
Debt instrument, interest rate	1.74%			1.74%
1.920% senior notes due March 2039
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 16.5
Debt instrument, interest rate	1.92%			1.92%
2.160% senior notes due March 2044
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 5.7
Debt instrument, interest rate	2.16%			2.16%
2.400% senior notes due March 2054
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 19.5
Debt instrument, interest rate	2.40%			2.40%
1.048% senior notes due March 2029
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 13.0
Debt instrument, interest rate	1.048%			1.048%
1.412% senior notes due March 2031
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 27.9
Debt instrument, interest rate	1.412%			1.412%
1.682% senior notes due March 2034
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 7.7
Debt instrument, interest rate	1.682%			1.682%
Lines of credit
Debt Instrument [Line Items]
Debt instrument, debt default, amount | $				$ 0
Notes payable
Debt Instrument [Line Items]
Debt instrument, debt default, amount | $				$ 0

XML

SHAREHOLDERS' EQUITY - Reconciliation of Number of Shares of Common Stock (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Common Stock Issued [Roll Forward]
Balance, beginning of period	1,355,398	1,354,079
Exercise of stock options and issuance of restricted shares	1,082	933
Balance, end of period	1,356,480	1,355,012
Treasury Stock [Roll Forward]
Balance, beginning of period	776,919	738,823
Share repurchase program	9,276	10,348
Balance, end of period	786,202	749,060
Shares outstanding, end of period	570,278	605,952
Treasury Stock
Treasury Stock [Roll Forward]
Other purchases	457	347
Shares issued to AFL Stock Plan	(212)	(239)
Exercise of stock options	(55)	(48)
Other dispositions	(183)	(171)

XML

SHAREHOLDERS' EQUITY - Anti-Dilutive Share-Based Awards Excluded from Calculation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Anti-dilutive share-based awards	69	164

XML

SHAREHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	$ (5,520)	$ (6,429)
Other comprehensive income (loss) before reclassifications net of tax	550	(805)
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	(132)	(44)
Other comprehensive income (loss), net of tax	418	(849)
Balance, end of period	(5,102)	(7,278)
Unrealized Foreign Currency Translation Gains (Losses)
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(4,069)	(3,564)
Other comprehensive income (loss) before reclassifications net of tax	(597)	(54)
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	0	0
Other comprehensive income (loss), net of tax	(597)	(54)
Balance, end of period	(4,666)	(3,618)
Unrealized Gains (Losses) on Fixed Maturity Securities
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	1,139	(702)
Other comprehensive income (loss) before reclassifications net of tax	86	2,036
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	(133)	(45)
Other comprehensive income (loss), net of tax	(47)	1,991
Balance, end of period	1,092	1,289
Unrealized Gains (Losses) on Derivatives
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(22)	(27)
Other comprehensive income (loss) before reclassifications net of tax	(5)	0
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	1	1
Other comprehensive income (loss), net of tax	(4)	1
Balance, end of period	(26)	(26)
Effect of Changes in Discount Rate Assumptions
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(2,560)	(2,100)
Other comprehensive income (loss) before reclassifications net of tax	1,065	(2,794)
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	0	0
Other comprehensive income (loss), net of tax	1,065	(2,794)
Balance, end of period	(1,495)	(4,894)
Pension Liability Adjustment
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning of period	(8)	(36)
Other comprehensive income (loss) before reclassifications net of tax	1	7
Amounts reclassified from accumulated other comprehensive income (loss) net of tax	0	0
Other comprehensive income (loss), net of tax	1	7
Balance, end of period	$ (7)	$ (29)

XML

SHAREHOLDERS' EQUITY - Reclassifications Out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		$ 951	$ 123
Acquisition and operating expenses		(1,256)	(1,308)
Income tax (expense) or benefit		(291)	(154)
Net of tax		$ 1,879	$ 1,188
U.S. federal statutory income tax rate		21.00%	21.00%
Reclassification Out Of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net of tax		$ 132	$ 44
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized gains (losses) on available-for-sale securities
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		168	57
Income tax (expense) or benefit	[1]	(35)	(12)
Net of tax		133	45
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)		(1)	(1)
Income tax (expense) or benefit	[1]	0	0
Net of tax		$ (1)	$ (1)

[1] Based on 21% tax rate

XML

SHAREHOLDERS' EQUITY - Additional Information (Detail) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders Equity Note [Line Items]
Stock acquired under share repurchase program, shares	9,276	10,348
Common stock, share repurchase, dollar amount	$ 793	$ 732
Remaining common stock available for purchase under share repurchase authorizations	68,500
Share Repurchase Program
Stockholders Equity Note [Line Items]
Stock acquired under share repurchase program, shares	9,300	10,300
Common stock, share repurchase, dollar amount	$ 750	$ 700

XML

SHARE-BASED COMPENSATION - Stock Options Outstanding and Exercisable (Detail) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Options Outstanding - Stock Option Shares | shares	856
Options Outstanding - Weighted-Average Remaining Term (Yrs)	2 years 2 months 12 days
Options Outstanding - Aggregate Intrinsic Value | $	$ 45
Options Outstanding - Weighted-Average Exercise Price Per Share | $ / shares	$ 33.37
Options Exercisable - Stock Option Shares | shares	856
Options Exercisable - Weighted-Average Remaining Term (Yrs.)	2 years 2 months 12 days
Options Exercisable - Aggregate Intrinsic Value | $	$ 45
Options Exercisable - Weighted-Average Exercise Price Per Share | $ / shares	$ 33.37

XML

SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - Restricted Stock shares in Thousands	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Shares
Beginning Balance | shares	2,308
Granted | shares	1,213
Canceled | shares	(7)
Vested | shares	(1,337)
Ending Balance | shares	2,177
Weighted-Average Grant-Date Fair Value Per Share
Beginning Balance | $ / shares	$ 62.96
Granted | $ / shares	79.75
Cancelled | $ / shares	67.50
Vested | $ / shares	49.24
Ending Balance | $ / shares	$ 72.33

XML

SHARE-BASED COMPENSATION - Additional Information (Detail) - USD ($) shares in Thousands, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from stock options exercised		$ 5	$ 4
Tax benefit from exercise of stock options		$ 24	$ 17
Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, maximum number of shares issuable		75,000
Share-based compensation arrangement by share-based payment award, maximum number of shares issuable other than options and stock appreciation rights		38,000
Shares available for future grants under the long-term incentive plan		33,600
Long-term incentive plan awards, term (in years)		10 years
Long-term incentive plan awards, vesting period		3 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost not yet recognized, restricted stock awards		$ 74
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, shares		2,177		2,308
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition		1 year 10 months 24 days
Restricted stock awards, grants in period		1,213
Performance-based Vesting Condition | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost not yet recognized, restricted stock awards		$ 40
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number, shares		1,800
Restricted stock awards, grants in period	303

XML

BENEFIT PLANS - Net Periodic (Benefit) Cost Included in Acquisition and Operating Expenses (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Other Postretirement Benefits Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 0	$ 0
Interest cost	0	0
Expected return on plan assets	0	0
Amortization of net actuarial loss	0	0
Net periodic (benefit) cost	0	0
Japan | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	4	4
Interest cost	2	2
Expected return on plan assets	(2)	(2)
Amortization of net actuarial loss	0	0
Net periodic (benefit) cost	4	4
U.S. | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	0	4
Interest cost	9	11
Expected return on plan assets	(7)	(9)
Amortization of net actuarial loss	0	0
Net periodic (benefit) cost	$ 2	$ 6

XML

BENEFIT PLANS - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended
	Jan. 01, 2014	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Amount of years active employees have left to meet rule of 80 in order to be eligible for postretirement medical benefits	5 years
Amount of years left to meet 15 year service requirement for active employees age 55 or older to be eligible for postretirement medical benefits	5 years
Net periodic (benefit) cost, excluding service cost		$ 2	$ 2
Lower Limit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Health care plan, retirement age and years of service combined years for eligibility (rule of 80)	80 years
Health care plan, retirement age for eligibility, (in years)	55 years
Health care plan, number of years of service for eligibility	15 years
Japan | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions		6
U.S. | Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions		$ 0